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Abstract 
The objective of this thesis was to assess the impact of altering macronutrient 
intakes on hepatic lipid metabolism. Two separate studies were performed, with 
liver triglyceride content being the principal outcome of both. In the first study 32 
healthy and centrally overweight males were randomised to 2 periods, each of 2 
weeks, of either a high fructose or glucose intake in a non-crossover fashion. 
Isoenergetic status was maintained by providing foodstuffs during the first period, 
followed by a 6 week washout and then a second period of ad libitum 
overfeeding. In the second study 55 patients with biopsy proven non-alcoholic 
fatty liver disease were randomised to 3 months 5g a day of capsules containing 
either n-3 polyunsaturated fatty acid or oleic enriched sunflower oil.  
 
The main findings are summarised. High intakes of fructose and glucose in the 
isoenergetic period resulted in a stable weight, and no change in hepatic, serum 
and ectopic triglyceride content. There was a raised serum uric acid with fructose. 
During the hyperenergetic period there was a tendency for greater uric acid with 
fructose, whilst both groups had a matched weight gain, elevation of liver 
biochemistry and an increase in hepatic, serum and muscle triglycerides. Changes 
in liver biochemistry and triglycerides were associated with changes in weight. 
During both periods there was calorimetric evidence for a shift in whole body 
metabolism towards that reflective of a high carbohydrate intake. There was no 
alteration in renal function or cardiovascular haemodynamic parameters or 
consistent change in insulin resistance. 
 
The n-3 polyunsaturated versus oleic acid study resulted in significant alterations 
of serum fatty acid profiles between the groups, which were in line with the 
capsules’ contents. These changes however failed to translate, in the whole group, 
to any detected metabolic or hepatic changes beyond a reduction in serum 
triglyceride with n-3 polyunsaturated fatty acids. Only 43 of the 55 patients had 
elevated liver triglycerides on baseline MRI. Amongst this 43 there was a 
reduction in liver triglyceride with n-3 polyunsaturated fatty acids, but no other 
associated metabolic changes. 
 
The uric acid findings support the notion of fructose and glucose differing 
in their pre triose metabolism. There was however no differing outcomes in terms 
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of lipid synthesis or storage. There was a suggestion of reduced liver triglycerides 
with n-3 polyunsaturated fatty acids though this was an isolated result only found 
amongst those with a steatotic liver at baseline. Ultimately the exquisite 
sensitivity of the liver to nutrient intakes was highlighted by the 0.8% gain in 
weight in the fructose / glucose study resulting in a 24% increase in liver lipid. 
This affirms the notion that dietary energy intakes have a profound influence on 
hepatic metabolism, but there is no evidence from this thesis that this influence is 
macronutrient specific. In the future macronutrient comparisons need to be made. 
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Chapter 1. Introduction   
 
1.1. The function of adipose tissue 
 
Triglycerides comprise around 95% of dietary lipids and can be stored 
within the specialised storage organ adipose tissue, or within other organs, 
principally liver and muscle. Lipids play essential roles in energy storage, vitamin 
absorption, cellular membrane maintenance and cellular signalling. The fatty acid 
content of the body originates either from exogenous dietary sources or from 
endogenous synthesis. Circulating lipoprotein and chylomicron-bound lipids 
increase following an intake of lipid containing foodstuffs. Lipoprotein lipase 
breaks down the triacylglycerol (triglyceride) from these circulating complexes, 
releasing non-esterified fatty acids (NEFA) which are taken up into adipocytes, 
where they are esterified into triglyceride and stored. The high energy density of 
triglyceride (9kcal/g) means that it is a more efficient energy store than protein 
(4kcal/kg) or carbohydrates (3.75kcal/kg). During a period of energy demand 
which is greater than exogenous supply, the stored triglyceride is hydrolysed by 
hormone-sensitive lipase and re-mobilised back into the circulation as NEFA. 
These opposing actions of lipid storage and lipolysis are under strict hormonal 
control. The hormones adrenaline, adrenocorticotropic hormone (ACTH) and 
glucagon promote lipolysis, whereas insulin promotes lipid storage and 
esterification. This hormonal profile is ultimately influenced by metabolic need, 
metabolic reserves and stress. 
Traditionally adipose tissue was considered as being merely the major 
storage organ for triglyceride, and little significance was attributed to ectopic lipid 
storage in liver or muscle. This has radically changed over the past decade or so. 
Adipose tissue has emerged as a major endocrine organ, muscle lipids have been 
implicated in insulin resistance and hepatic lipid in altering local and whole-body 
metabolic and inflammatory status.  
Adipose tissue secretes over 100 differing factors including adipokines, 
steroid hormones, fatty acids, and prostaglandins. With the exception of 
adiponectin, these factors are all released in greater amounts with increasing 
adipose tissue volume. Adiponectin, a key regulatory factor, promotes insulin 
sensitLYLW\DQGȕ-oxidation. The reasons for the change in hormone and cytokine 
production rates by adipocytes with increasing adipose volume are uncertain, 
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though suggested roles include adipocyte hypertrophy and hyperplasia, chronic 
hypoxia due to relative vascular insufficiency, and mitochondrial dysfunction and 
oxidative stress (Kraemer and Shen 2006). There is emerging evidence for the 
existence of a biological limit to which a fat depot can expand, above which 
metabolic decompensation occurs (Christodoulides, Lagathu et al. 2009). 
Adipose tissue and ectopic lipid storage has been shown to be closely linked 
with inflammatory and immune function. Metabolic and immune systems are 
among the most fundamental requirements for survival. Energy excess or 
deficiency results in an impaired immune response (Hotamisligil and Erbay 
2008). Recent evidence suggests that the processes of metabolic and inflammatory 
responses may have co-evolved, as both processes are controlled by a single 
functional unit or organ termed the ‘fat body’ in primitive organisms such as the 
Drosophila melanogaster (Leclerc and Reichhart 2004). Indeed there remains a 
close association between metabolism and inflammation in the tissues of higher 
organisms. The principal metabolic cells (hepatocytes and adipocytes) are in close 
proximity to immune cells (macrophages, Kupffer cells, lymphocytes and 
dendritic cells). Indeed lymph nodes are embedded in adipose tissue. The 
adipocyte derived hormones, termed adipokines, influence not only adipocyte 
function in an auto- and paracrine fashion, but also are released systemically via 
the bloodstream to influence whole body metabolic and inflammatory pathways. 
As a result of this systemic release the anatomical location, and hence venous 
drainage paths, appears to critically determine the functional importance of 
adipose tissue. This has led to the portal/visceral hypothesis (Ronti, Lupattelli et 
al. 2006). There is much to support this theory and it will be frequently discussed 
in this thesis. In an elegant and simple study, Klein et al. assessed the metabolic 
outcomes following liposuction removal of over 30% of abdominal subcutaneous 
tissue (Klein, Fontana et al. 2004). Around a 6% body weight loss was achieved, 
though as a result of this selective weight loss visceral and muscle lipid contents 
remained unchanged 12 weeks later. There was a significant reduction in leptin 
(reflecting a reduction in adipocyte mass, though no alteration of systemic, 
hepatic or adipocyte insulin resistance or circulating mediators of inflammation. 
The long-term (7-17 years) follow up of this original study has been subsequently 
published and showed that long term weights were identical to those at 10 weeks 
and that long-term insulin resistance and lipid profiles remained unchanged from 
before liposuction (Mohammed, Cohen et al. 2008).  
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A criticism of these studies is that there is no control arm. Similar amounts 
of weight loss through lifestyle changes have however been repeatedly shown to 
improve all of these parameters (Blackburn 1995). The explanation for these 
findings is that lifestyle induced weight loss reduces the metabolically critical 
stores in visceral and ectopic stores as well as the relatively benign subcutaneous 
stores. The difference between these is their anatomical distribution, and hence 
venous drainage. The venous drainage of intra-abdominal, or visceral, adipocytes 
means that factors released are transported straight to the liver via the portal 
system. In comparison, the venous drainage from subcutaneous fat enters the 
wider systemic circulation. This theory is further reinforced by the observation 
that central obesity (apple shaped) results in greater cardiovascular risk than 
subcutaneous (pear shaped) obesity (Kannel, Cupples et al. 1991). To conclude, it 
is not so much how much adipose tissue you have, as where you have it. 
 
1.2. Overview of hepatic fatty acid metabolism in health 
The liver is the key organ in determining the metabolism and distribution 
of fatty acids. It is the source of endogenous synthesis and degrades or 
interconverts exogenous fatty acids. The resultant fatty acids may either be stored 
in the liver itself, or exported to adipose tissue and muscle. Hepatic fatty acid 
metabolism is dynamic with triglyceride turnover occurring every 2 days (Boberg, 
Carlson et al. 1972). As depicted in figure 1.1, hepatic fatty acids are derived from 
two sources: circulating fatty acids or endogenous de novo lipogenesis (DNL) 
which uses monosaccharides as its principal substrates. 
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Figure 1.1: Overview of hepatic fatty acid metabolism depicting intra and 
extra-hepatic influences including the roles of adipocytes, muscle and diet. 
Abbreviations used: DNL- de novo lipogenesis, SREBP-1C - sterol regulatory 
element binding protein-1c, VLDL - very low-density lipoprotein. Adapted from 
(Tamura and Shimomura 2005). 
 
Circulating fatty acids are either bound to lipoproteins or albumin. 
Lipoprotein-bound lipids, which include chylomicron complexes, are internalised 
into cells following the formation of a specific apolipoprotein-receptor complex. 
Dietary medium-chain triglycerides enter the portal circulation directly, whereas 
longer chain fatty acids enter the vascular circulation complexed with 
chylomicrons via the lymphatic system and the thoracic duct. 
Historically it was believed that in contrast to lipid-lipoprotein complexes, 
the albumin bound NEFAs are internalised into cells via simple and direct 
penetration of the plasma membrane. The recently discovered cluster 
differentiation protein 36 (CD 36) forms a pathway for hepatic fatty acid uptake 
which is upregulated by insulin and experimental models of NAFLD (Ge, Zhou et 
al. 2010; Larter, Chitturi et al. 2010)As a result NEFAs are the key fatty acid 
source for the liver with an uptake that is directly proportional to its delivery rate 
(Havel, Kane et al. 1970) and potentially increased by insulin resistance and 
NAFLD. The concentration of circulating NEFAs is dependent on their release 
from adipocytes and myocytes. This is regulated by hormone sensitive lipase, 
 20  
which is stimulated by adrenaline, and inhibited by insulin (Qureshi and Abrams 
2007). 
Insulin also acts to reduce circulating glucose concentrations by promoting 
its tissue uptake. Insulin resistance however results in increased circulating 
concentrations of insulin, and the principal hepatic fatty acid substrates, namely 
glucose and NEFA. As a result insulin resistance promotes hepatic lipogenesis as 
will be further discussed later. 
 Intra-hepatic fatty acids are cytotoxic (Gibbons, Wiggins et al. 2004) and 
so are further metabolised by three potential and separate processes: either beta-
oxidation, VLDL synthesis or intra-hepatic storage as triglycerides. In the 
presence of high energy demand, intra-hepatic fatty acids undergo oxidation to 
generate energy in the form of ATP. If there is a low energy demand then intra-
hepatic fatty acids are esterified into triglycerides and either stored in the 
hepatocyte or exported as VLDL.  
 
1. Oxidation 
 Within the mitochondria fatty acids in the form of acyl-CoA molecules are 
SURJUHVVLYHO\FOHDYHGE\ȕ-oxidation to generate ATP. The process is initiated at 
WKHFDUER[\OHQGDQGLQYROYHVWKHVXFFHVVLYHGLVUXSWLRQRIWKHOLQNEHWZHHQWKHĮ-
DQGȕ-3 carbon atoms (Lavoie and Gauthier 2006).  At the end of each cycle the 
chain is reduced by two carbon atoms, and one molecule of FADH2, NADH and 
acetyl CoA is produced. The acetyl-CoA is then further oxidised within the 
mitochondria via the citric acid cycle, while the FADH2 and NADH enter the 
electron-transport chain. The process is repeated until the whole chain is oxidised.  
 0LFURVRPDOĮDQGȦR[LGDWLRQRFFXUVZLWKLQWKHHQGRSODVPLFUHWLFXOXP
by members of the cytochrome P450 family.  They catalyse the oxidation of a 
variety of exogenous and endogenous compounds and play a relatively minor role 
in fatty acid oxidation. 
 
2. VLDL synthesis 
 The addition of a single glycerol molecule to three fatty acids forms a 
triglyceride. Triglycerides cannot freely cross hepatocyte membranes, and so are 
either stored within the hepatocyte itself, or are coated in lipoproteins, 
incorporated within VLDL, and exported into the systemic circulation. VLDLs are 
formed within the liver and are a complex fusion of lipoproteins (predominantly 
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Apolipoprotein B-100), lipids and phospholipids. VLDL secretion facilitates the 
transfer of intra-hepatic fatty acids to peripheral adipose stores (Gibbons, Wiggins 
et al. 2004). 
 
3. Storage within the hepatocytes 
The final option for fatty acids is of conversion to triglycerides and storage 
within the hepatic cytosol. Factors that directly promote hepatic triglyceride 
storage are poorly understood. Intra-hepatic storage appears to occur when fatty 
acid production exceeds the liver’s oxidation or exportation abilities (Gibbons, 
Islam et al. 2000; Lavoie and Gauthier 2006; Serviddio, Sastre et al. 2008).  
 
1.3. Introduction to Non-Alcoholic Fatty Liver Disease (NAFLD) 
Pathologically excessive intra-hepatic triglyceride storage, termed 
steatosis, may result from a variety of liver insults including alcohol, medication 
and hepatitis C.  The histological criteria for steatosis is the presence of 
triglyceride stored in more than 5% of hepatocytes (Hubscher 2006). Non-
alcoholic fatty liver disease (NAFLD) is diagnosed in the absence of clinical and 
histological evidence of such insults. Furthermore, NAFLD has characteristic 
histological patterns of lipid storage and injury, if present.  
The term NAFLD encompasses a spectrum of disorders. The majority of 
NAFLD patients are asymptomatic at presentation and hence present incidentally 
following a routine health check-up, or as part of an evaluation for another health 
process (Cortez-Pinto, Chatham et al. 1999). In these situations NAFLD may be 
suspected by the presence of abnormal blood liver function tests or liver 
appearance on radiology. The minority of NAFLD patients present with 
complications of advanced liver disease, such as a variceal bleed or ascites.  
 
1.4. NAFLD epidemiology 
1.4.1. Prevalence of NAFLD 
Accurate assessment of the prevalence of NAFLD is hampered by the lack 
of a cheap, non-invasive, accurate and widely available tool for disease screening 
and staging. Use of ‘liver function’ blood tests is extremely limited as they are 
normal in 80% of those with radiological evidence of steatosis (Browning, 
Szczepaniak et al. 2004), and they correlate poorly with the severity of injury and 
fibrosis (de Ledinghen, Combes et al. 2004). Radiology can establish the presence 
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of steatosis with reasonable accuracy, but it cannot reliably differentiate between 
the differing stages in the disease spectrum. As a result, routine clinical practice 
relies on a liver biopsy for disease staging, though its invasive nature means that it 
cannot be used in population based studies.  
The prevalence of any condition depends upon the cohort studied. 
Globally massive differences exist between population body habitus and lifestyle. 
As a consequence estimates of NAFLD prevalence vary from 9% to 37% (Ong 
and Younossi 2007). NAFLD is the most prevalent liver disease in the Western 
world (Clark 2006). The US-based third National Health and Nutrition 
Examination Survey (NHANES III) analysed liver function tests in 15,676 adults. 
A presumptive diagnosis of NAFLD was made following abnormal liver function 
test findings in the absence of an alternative explanation, although this method 
clearly underestimates true prevalence. This approach found that prevalence of 
presumed NAFLD was greatest during the fourth and sixth decades (Ruhl and 
Everhart 2003), and present in more men than women (9.3% vs. 6.6%, p=.002) 
(Clark, Brancati et al. 2003). These observed associations may be explained by 
the increasing obesity and insulin resistance with age, and that men are more 
prone to visceral than peripheral adiposity (Frith, Day et al. 2009).  
The largest population-based survey reported a prevalence of fatty liver 
disease at 34% in Dallas, USA (Szczepaniak, Nurenberg et al. 2005). 2,349 adults 
underwent hepatic lipid content assessment by proton magnetic resonance 
spectroscopy (1H MRS). Their cohort had a mean age of 45 years, 43% were 
obese, and there was a 6% rate of alcohol abuse.  
 
1.4.2. Natural history of NAFLD 
NAFLD appears to be a spectrum of related disorders as shown in figure 
1.2. The natural history and rate of progression through the various stages is 
contentious. There is evidence to support both progression and regression along 
the various stages, up until the development of hepatocellular carcinoma. 
Understanding to date is critically hampered by the absence of a study that has 
prospectively and systematically followed up a large cohort of NAFLD patients 
with a repeat liver biopsy after a pre-determined time interval. Several groups 
have presented ad-hoc case series, though the resultant data is difficult to 
interpret. 
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Figure 1.2.: The differing stages of NAFLD and estimates of their relative 
prevalence. Adapted from (Hubscher 2006).  
 
The population prevalence of NAFLD in the US is estimated to be 30% 
though the majority have simple fatty change, termed steatosis, i.e. the presence of 
increased fat without significant inflammation or fibrosis, whereas only 3-5% 
have NASH (Vernon, Baranova et al. 2011). Simple steatosis appears to have a 
low rate of progression to NASH. Consequently it is believed that the majority of 
NASH patients, i.e. those with fibrosis or liver injury, progress rapidly through the 
stage of simple steatosis due to a pro-inflammatory state (Ong and Younossi 
2007). A recent analysis of 545 NAFLD liver biopsies however has questioned 
this assumption, as steatosis severity was positively associated with the degree of 
lobular inflammation, fibrosis and NASH (Chalasani, Wilson et al. 2008). So a 
severe steatosis may drive an inflammatory state, an observation which is in direct 
conflict with the two separate and independent hit hypothesis. Multivariate 
analyses have demonstrated that independent clinical factors predictive of fibrosis 
on biopsy are age, body mass index (BMI), hypertension and insulin resistance 
(Argo and Caldwell 2009). 
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The elucidation of formal factors involved in the aetiology and prediction 
of progressive fibrosis development is an ongoing area of considerable scientific 
scrutiny. Argo et al. performed a recent systematic review of 10 studies 
comprising 221 patients that were assessed for histological progression in 
untreated NASH (Argo, Northup et al. 2009). 38% of patients with fibrosis 
develop progressive fibrosis, 41% have no progression, and 21% have fibrotic 
regression. Factors that were predictive for progressive fibrosis were age and the 
presence of fibrosis on the initial biopsy. Although some groups have previously 
shown metabolic features to be predictive for fibrosis (Ekstedt, Franzen et al. 
2006), this was not borne out in this systematic review. As a result of progressive 
fibrosis, between 9 and 20% of patients with fibrosis or liver injury develop 
cirrhosis (Ong and Younossi 2007). The 5 year rates of hepatocellular carcinoma 
or liver-related deaths in a Japanese study of NAFLD cirrhotic patients were 20% 
and 7% respectively (Hashimoto, Yatsuji et al. 2005)  .  
Most NAFLD patients do not have a liver-related mortality. As compared 
the general population, NAFLD patients do have an increased mortality with a 
standardised mortality rate of 1.57 as compared to the general population (Musso, 
Gambino et al. 2010).  This primarily originates from cardiovascular disease, 
followed by non-liver malignancy, with the third cause of death being liver-
related in 6% (Adams, Lymp et al. 2005; Ong, Pitts et al. 2008; Rafiq, Bai et al. 
2009). Indeed only 22% of NASH cirrhotic patients die from liver complications 
or receive a liver transplant (Ong and Younossi 2007). Ultimately NAFLD can be 
viewed as being primarily a metabolic as opposed to a hepatic disorder. 
Until recently the largest prospectively followed cohort of NAFLD 
patients came from Esktedt et al.’s work in Sweden (Ekstedt, Franzen et al. 2006). 
This cohort of 129 patients was consecutively followed up with a repeat liver 
biopsy after a mean of 13.7 years. Amongst the 58 patients with simple steatosis 
there was no increased mortality over that predicted. Furthermore, of these 58 
patients, only 8% developed bridging fibrosis, and none developed cirrhosis. 
Progression of liver fibrosis occurred in 41% and regression in 16%. Nine percent 
of the cohort developed cirrhosis over the study period. This led people to argue 
that simple steatosis had a very benign liver prognosis.  
A recent review compiled all the studies assessing mortality with a greater 
than 5 years follow-up (Angulo 2010). This entailed 2 recently published large 
cohorts (Rafiq, Bai et al. 2009; Soderberg, Stal et al. 2010). The average follow 
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up period for the 798 patients with simple steatosis and 342 patients with NASH 
was 15 years. The overall all cause mortality was 32.5% for simple steatosis and 
40.5% for NASH, which was not significantly different. There was however a 
significantly greater cirrhosis development rate (0.7% and 10.8%) and liver 
related death rate (0.9% vs. 7.3%) amongst those with NASH.  
From the above it appears that NAFLD patients as a whole are at an 
increased risk of cardiovascular disease, and those with NASH are at the greatest 
risk of liver morbidity and mortality.  
 
1.5. NAFLD Aetiology 
 
The pathophysiology of NAFLD is complex and not completely 
understood. Classically NAFLD was believed to result from ‘two hits’ (Day and 
James 1998). The first hit is the development of steatosis, whist the second hit is 
the development of inflammation and fibrosis in the steatotically primed liver. 
This has since been shown to be an overly simplistic approach as these two 
pathological processes are not distinct from each other and instead the concept of 
multiple parallel hits has been generated (Tilg and Moschen 2010). The 
complexity of the current model means that even the paper proposing multiple 
parallel hits is predominantly structured along the lines of the two hit hypothesis 
(Tilg and Moschen 2010), and so will this thesis for simplicity’s sake.  
 
1.5.1. 1st hit – Hepatic steatosis development 
 
It remains unclear as to what the origin is of the increased fatty acid stores. 
Donnelly et al. have performed the most in-depth lipid kinetic assessments in 
NAFLD to date, with liver biopsy fatty acid profiles performed after oral lipid 
isotope labelling (Donnelly, Smith et al. 2005). The subjects were viscerally obese 
and systemically insulin resistant, and they were fed oral lipid isotopes in 
conjunction with a four day low-fat (30%), high carbohydrate (55%, of which 
72% was mono or di-saccharides) diet. Fifty nine percent of hepatic triglycerides 
arose from NEFA, 26% from de novo lipogenesis (DNL), and 15% directly from 
recent diet intakes of fat. It is notable that most of the hepatic triglycerides 
appeared to have originated from peripheral or visceral adipocyte stores via 
NEFA, with a relatively small recent dietary fat contribution. This does not 
 26  
minimise the importance of diet intakes as ultimately the source of all of the 
lipogenic pathways is dietary.  
Interestingly the observed rate of DNL in NAFLD by Donnelly et al. was 
greater than previously described in healthy subjects (Schwarz, Linfoot et al. 
2003). Strikingly this increase in DNL rates was mainly in the fasted state, with a 
relative lack of post-prandial DNL stimulation. There are two potential 
interpretations of these observations. Firstly it may have purely resulted from the 
high carbohydrate diet consumed in the Donnelly protocol. Secondly it may be 
that the hepatic lipogenic capacity in NAFLD is persistently and maximally 
upregulated. If the latter is true then reducing DNL substrate availability, mainly 
glucose and fructose, may be a key step in NAFLD prevention or therapy. It was 
not possible to assess the specific influence of insulin in this study, though a 
blunted diurnal pattern in DNL has previously been noted in insulin-resistant 
subjects (Schwarz, Linfoot et al. 2003).  
There are however some limitations in interpreting the findings of this 
excellent study. Firstly, only 38% of hepatic triglycerides on biopsy had their 
source accounted for. Furthermore, there was no healthy control and so the 
findings may not be NAFLD-specific. Finally, as acknowledged by the authors, 
the DNL contribution to hepatic triglyceride was augmented by the high 
carbohydrate intake, and the low direct dietary contribution may in part reflect the 
low fat intake.  
Comparisons between NAFLD and healthy volunteer lipid kinetics have 
been made though in a less rigorous manner. Obese NAFLD patients have been 
shown to have rates of hepatic DNL 3-fold greater than slim healthy subjects, with 
a blunted post-prandial response also noted (Diraison, Moulin et al. 2003). 
Fabbrini et al. compared the rates of NEFA release from adipocytes into the 
circulation, and the rates of hepatic VLDL-triglyceride and VLDL-apoB100 
secretion, in 14 NAFLD patients and 14 age, sex, BMI and body fat percentage 
matched non-steatotic controls (Fabbrini, Mohammed et al. 2008). There was a 
greater NEFA release in NAFLD, but unfortunately no assessments of DNL were 
made. Interestingly there was a greater hepatic VLDL secretion rate with NAFLD 
which reached a maximal plateau. Indeed the rate of VLDL-apoB100, reflecting 
the number of VLDL particles secreted, was not different between the groups. So 
it appears that the capacity for the liver to export triglyceride had been exceeded 
in NAFLD.  
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Taken together these data suggest that NAFLD results from persistently 
elevated rates of DNL both in the fed and fasted state, greater NEFA delivery to 
the liver and impaired VLDL exportation. The influence of oxidation remains 
uncertain.  
The two key clinical associations with steatosis are insulin resistance and 
visceral obesity, and they underpin many of the above observations. Genetic 
status has also recently been implicated in NAFLD development. These factors 
will now be discussed.  
 
1.5.1.1.  Hepatic steatosis and insulin resistance  
 
Insulin drives an anabolic state by promoting lipid and carbohydrate 
storage and protein synthesis (Choudhury and Sanyal 2004). These actions are 
balanced by the actions of the catabolic hormones glucagon, adrenaline and 
growth hormone. The term ‘insulin resistance’ is generally used to describe an 
impaired ability to clear glucose from the systemic circulation into tissues. 
Clinically significant insulin resistance results in type 2 diabetes. However due to 
its plethora of actions, the term insulin resistance can be classified as being both 
tissue and action specific. It is standard to define insulin resistance by its 
carbohydrate as opposed to lipid or amino acid actions, and it is these actions that 
will be principally referred to in this thesis.  
The term ‘systemic insulin resistance’ refers to disruption of normal 
insulin mediated peripheral glucose uptake and utilisation such that 
normoglycaemia can only be achieved by an increase in insulin secretion to 
overcome the peripheral tissues resistance to the action of insulin. This can be 
assessed by measuring fasting glucose concentrations alone or in combination 
with insulin. It can also be assessed by determining the plasma glucose response 
to a glucose or insulin load. This is further discussed in the methods section. 
The term ‘hepatic insulin resistance’ refers to an impairment in 
suppressing fasting hepatic glucose production (Seppala-Lindroos, Vehkavaara et 
al. 2002). The rate of this is more difficult to assess, with no test available in the 
routine clinical arena. The most common assessment involves tracer labelled 
glucose infusions, as will be described in the methods chapter.  
Finally ‘adipocyte insulin resistance’ refers to the sensitivity of adipose 
tissue to insulin-mediated suppression of lipolysis. Lipolysis is the process 
 28  
whereby stored trigylycerides are hydrolysed into diacylglycerols (DAGs), then 
monoacylglcerols and finally into NEFAs and glycerol. Insulin potently inhibits 
the lipolytic actions of hormone sensitive lipase (HSL), adipose triglyceride lipase 
(ATGL) and monoacylglycerol lipase (MGL) (Lafontan 2008). Adipocyte insulin 
resistance is therefore assessed by the glycerol and NEFA response to insulin 
administration.   
The differentiation between these terms is a fundamental metabolic 
concept. Hepatic insulin resistance results in increased hepatic glucose production 
by reducing rates of glycogen synthesis in association with increased rates of 
glycogenolysis and gluconeogenesis (Choukem and Gautier 2008). In an attempt 
to maintain normoglycaemia there is a matched rise in pancreatic insulin 
secretion. So combined hepatic and systemic insulin resistance results in elevated 
circulating concentrations of both insulin and glucose. The hepatic consequences 
of insulin resistance are:  
 
1. Increased lipogenesis via insulin: Insulin directly up-regulates the transcription 
and proteolytic maturation of the transcription factor SREBP-1c. This action is 
independent of the insulin receptor (IRS-1) that mediates insulin’s glucose 
influence (Shimomura, Bashmakov et al. 1999; Sajan, Standaert et al. 2004). 
SREBP-1c induces a family of lipogenic genes within the liver including fatty 
acid synthase (FAS) (Dentin, Benhamed et al. 2006).  
 
2. Increased lipogenesis via hyperglycaemia: The elevated glycaemia directly up-
regulates nuclear translocation of carbohydrate responsive element-binding 
protein (ChREBP) (Ishii, Iizuka et al. 2004). CHREBP acts in synergy with 
SREBP-1c to further induce lipogenic gene expression and provide the precursors 
for lipogenesis by also inducing glycolytic gene expression (Denechaud, Dentin et 
al. 2008). 
 
3. Increased NEFA delivery to the liver: Adipocytes are normally exquisitely insulin 
sensitive (Reaven 1997). Adipocyte insulin resistance results in a reduced 
suppression of lipolysis, and thus an increased NEFA release into the circulation 
and hepatic uptake. Of note there appears to be no regulation of the rate of NEFA 
uptake by the liver.  
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4. Decreased VLDL excretion: Insulin attenuates apolipoprotein B, and hence 
VLDL, formation (Lewis, Uffelman et al. 1993). This impairs hepatic triglyceride 
exportation ability. The mechanism behind this frequently observed phenomenon 
has not been fully determined, though may it be occur via microsomal triglyceride 
transfer protein (MTP) down regulation (Lin, Gordon et al. 1995; Olofsson and 
Boren 2005). MTP is a critical determinant of triglyceride and apolipoprotein B 
incorporation into VLDL and its subsequent plasma excretion (Hussain, Shi et al. 
2003). MTP-specific inhibition reduces plasma triglycerides and VLDL, whilst 
increasing hepatic triglycerides (Chandler, Wilder et al. 2003).  
 
From the above actions it is clear that insulin resistance is a key factor in 
hepatic lipid balance and steatosis development. In response to a high 
carbohydrate intake, insulin resistant subjects have a much greater rate of hepatic 
DNL and reduced rate of muscle glycogen synthesis than insulin-sensitive 
controls (Petersen, Dufour et al. 2007).  
When rigorously assessed most non-diabetic NAFLD patients have sub-
clinical insulin resistance with evidence of impaired glucose peripheral uptake. 
Sub-clinical systemic and hepatic insulin resistance correlates strongly with intra-
hepatic steatosis (Seppala-Lindroos, Vehkavaara et al. 2002; Sakurai, Takamura et 
al. 2007; Korenblat, Fabbrini et al. 2008). Indeed hepatic insulin resistance can 
pre-date the development of systemic insulin resistance, but this is rarely assessed 
as it is both laborious and invasive (Kraegen, Clark et al. 1991). 
The above accepted, there is clearly more to NAFLD than purely being the 
hepatic consequence of insulin resistance. Most NAFLD patients do not have 
overt systemic insulin resistance i.e. type 2 diabetes, and only around 50% of type 
2 diabetics have NAFLD (Choudhury and Sanyal 2004; Targher, Bertolini et al. 
2007). 
 
1.5.1.2.  Hepatic steatosis and obesity  
 
Obesity is the most frequently observed clinical association with NAFLD, 
with studies reporting its presence in 25% to 93% of patients (Ong and Younossi 
2007). As previously discussed the anatomical distribution of adipose tissue 
determines its venous drainage and hence its metabolic effects. Using tracer 
methods, Nielsen et al. demonstrated a direct correlation between the degree of 
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visceral fat and the post-absorptive NEFA delivery to the liver (Nielsen, Guo et al. 
2004). Furthermore, a review of clinical and epidemiological studies 
demonstrated a direct association between visceral and hepatic fat content 
(Jakobsen, Berentzen et al. 2007).  
The association between visceral obesity and steatosis appears however to 
be more than just increased NEFA delivery. The key inflammatory regulators of 
hepatic metabolic homeostasis are primarily adipocyte derived, and are the pro-
LQIODPPDWRU\ F\WRNLQH 71)Į DQG WKH DQWL-inflammatory adipokine adiponectin 
(Tilg and Hotamisligil 2006). Visceral adiposity and NAFLD are independently 
FKDUDFWHULVHGE\DQLQFUHDVHG71)ĮDQGUHGXFHGDGLSRQHFWLQSURGXFWLRQ2IQRWH
this pattern not only induces a pro-inflammatory, but also an insulin-resistant, 
state (Schaffler, Scholmerich et al. 2005). To summarise, visceral adiposity results 
in an increased portal concentration of NEFA, a pro-inflammatory cytokine 
profile and insulin resistance. The influences of adiposity and insulin resistance on 
hepatic metabolism are therefore closely entwined. 
 
1.5.1.3.  Hepatic steatosis and genetics  
 
Recently a non-synonymous sequence variation I148M (rs738409) in the 
PNPLA3 gene has been shown to have a homozygous population prevalence of 
7.5%, and to confer NAFLD susceptibility (Romeo, Kozlitina et al. 2008). 
PNPLA3 is a 481-residue protein with in vitro lipase activity which is highly 
expressed in the liver (Lake, Sun et al. 2005). This association has been 
reproduced by several other groups. PNPLA3 status does not appear to influence 
systemic insulin resistance, but may exert its effect via limiting hepatic hydrolysis 
of triglycerides (He, McPhaul et al. 2009; Kantartzis, Peter et al. 2009; Romeo, 
Sentinelli et al. 2009). 
Recent data however shows that the presence of a mutated PNPLA3 
genotype adds little to clinical markers for predicting hepatic steatosis (Kotronen, 
Peltonen et al. 2009). Whereas there is evidence for greater liver injury with a 
mutated genotype, possibly via increased lipotoxicity (Sookoian, Castano et al. 
2009). The precise role and relevance of this mutation thus awaits full 
determination. 
This whole field has been widened following the recent publication of a 
genome wide association study in NAFLD (Chalasani, Guo et al. 2010). An 
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inheritability of NAFLD was placed at around 27% with three associations made 
with steatosis: variants near PNPLA3, NCAN and PPP1R3B and with 
inflammation or fibrosis, and in or near PNPLA3, NCAN, GCKR, LYPLAL1 but 
not PPP1R3B. As with all GWAS studies, more questions than answers were 
generated but it does provide a fascinating insight into the critical genetic and 
molecular pathways that may become future therapeutic targets. PPP1R3B region 
encodes for a protein that regulates glycogen breakdown. The role of LYPLAL1 
is unclear though it may have a role in triglyceride breakdown. NCAN encodes 
for an adhesion molecule.  
Interestingly GCKR encodes glucokinase regulatory protein (GKRP), 
which regulates glucokinase activity. The role of glycolysis in NAFLD will be 
discussed in full detail later. Glucokinase initiates glycolysis and hence glucose 
storage or disposal in the liver. A common variant in GKRP is the P466L mutant. 
This mutant has recently been shown to result in reduced regulation by 
physiological concentrations of F6P (Beer, Tribble et al. 2009). So there was 
increased GCK activity. This mutant therefore could result in increased rates of de 
novo lipogenesis, though there are no data to support or refute this at present.  
 
1.5.2. 2nd hit – Steatohepatitis development 
 
The presence of steatosis plus inflammation, cellular ballooning and/or 
fibrosis is termed non-alcoholic steatohepatitis (NASH). The processes implicated 
in NASH development include a pro-inflammatory cytokine profile, generation of 
reactive oxygen species, and decreased hepatic ATP production (Perez-Carreras, 
Del Hoyo et al. 2003).  
Mitochondrial dysfunction is centrally implicated in the development of 
NASH (Pessayre 2007). Re-entry of protons back into the mitochondria via 
ATPase is the final step in ATP generation by the electron transport chain. 
Uncoupling proteins (UCPs) bypass ATPase and hence the protons re-enter the 
mitochondria with energy generated as heat as opposed to ATP. Despite the 
discovery of UCP2 in 1997, its precise physiological role remains highly 
contentious (Yonezawa, Kurata et al. 2009).  
Animal models of NASH are characterised by a progressive reduction in 
hepatic ATPase activity and ATP concentrations, in association with an increase 
in UCP2 expression and markers of oxidative stress (Chavin, Yang et al. 1999; 
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Serviddio, Bellanti et al. 2008). Progressive histological clinical studies have been 
rarely done, though patients with NASH have greater hepatic oxidative stress and 
UCP2 expression than healthy controls (Serviddio, Bellanti et al. 2008).  
The aetiology and pathways behind these changes in NASH is uncertain, 
though increased UCP2 expression has been speculated as being an attempt to 
remove excess energy stores, or an attempt to minimise oxidative stress by 
limiting mitochondrial reactive oxygen species generation (Pessayre 2007; 
Serviddio, Bellanti et al. 2008). This uncoupled and ATP depleted state however 
leaves the liver vulnerable to external injuries (Caraceni, Bianchi et al. 2004). 
As previously mentioned, the balance of circulating pro and anti-
inflammatory cytokines plays a key role in hepatic metabolism and inflammatory 
status. These cytokines are mainly visceral adipocyte derived though may also be 
hepatically sourced. Hepatic production of pro-inflammatory cytokines is 
stimulated by oxidative stress and circulating pro-inflammatory cytokines (Day 
2006). 
As a result of this systemic inflammatory status oxidative stress can be 
detected in the plasma of NASH patients (Yesilova, Yaman et al. 2005; Madan, 
Bhardwaj et al. 2006). These observations have led to the search for systemic 
biomarkers of NASH and fibrosis as an alternative approach to the invasive liver 
biopsy (Guha 2009).  
 
1.6. Medical and weight loss therapy for NAFLD 
 
Several therapeutic strategies exist for this condition. To summarise, no 
therapy has been shown to fulfil the following criteria: effective, safe, and 
improves long-term prognosis. As of yet there is no approved medical therapy. 
Given the high prevalence and relatively benign prognosis for many, the potential 
for any toxicity is a major concern in what will need to be a long-term therapy. 
The experiences from the differing approaches are presented below: 
 
1.6.1. Lifestyle and weight loss therapy 
Diet and lifestyle influence NAFLD development primarily via their 
effects on visceral adiposity and insulin resistance and so are logically central to a 
NAFLD therapeutic strategy (Harrison and Day 2007). The American 
Gastroenterology Association recommends the first line strategy for overweight 
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NAFLD patients to be a target weight loss of 10% (AGA 2002). There is however 
scant clinical evidence to support this recommendation outside the bariatric 
surgery experience and in practice such weight loss is rarely achieved or 
maintained. To date there is liver biopsy data assessing the efficacy of weight loss 
from only 5 studies containing less than 150 patients (Bellentani, Dalle Grave et 
al. 2008). As a result there is inadequate data to define what the ideal macro- and 
micro-nutrient structure should be of such weight loss diets, or how much weight 
should be lost, and at what rate.  
A recent small trial of 21 NASH patients who prospectively underwent 
either direct dietetic review on 39 occasions in 12 months to promote a low 
energy and fat diet, behavioural strategies and exercise or no advice in the 
controls (Promrat, Kleiner et al. 2010). The intervention arm lost 9.8% of their 
original weight, and none in the control arm. Insulin sensitivity was unchanged, 
but there were greater reductions in the NAFLD activity score (NAS) in the repeat 
biopsies of the intervention as opposed to the control arm. Weight loss of more 
than 7% appeared to be the most beneficial. A previous uncontrolled study 
involved similarly highly intensive support but only managed to result in 3.3% 
weight loss (Huang, Greenson et al. 2005). There was some reduction in 
inflammation, but nil in steatosis or fibrosis. These data clearly describes the 
potential benefits and also the logistical difficulties in generating meaningful 
long-term weight loss in NAFLD patients.  
The experience of combined diet and exercise regimens is a little more 
encouraging, though again the studies frequently lack a control arm. Ueno et al. 
introduced energy restriction and increased activity by jogging in 25 patients for 
three months (Ueno, Sugawara et al. 1997). A mean reduction of BMI by 3kg/m2 
resulted in reduced steatosis on repeat biopsy. There have been several other 
lifestyle studies, though they have used indirect markers of liver content as 
opposed histological or 1H MRS evaluation, and so only limited conclusions can 
be deduced from them (Harrison and Day 2007). 
NAFLD has been frequently assessed in bariatric surgery patients. A liver 
biopsy is simple to perform at the time of surgery, and the vast majority have 
steatosis. The largest initial cohort was performed by Mathurin et al. who repeated 
liver biopsies in 121 patients 1 year following bariatric surgery (Mathurin, 
Gonzalez et al. 2006). There was a mean weight loss of 27kg over this year. 
Steatosis was significantly reduced, but alarmingly fibrosis increased. This same 
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group then presented similar data from a larger cohort of 381 patients followed up 
for 5 years (Mathurin, Hollebecque et al. 2009). This time there was evidence of 
improved steatosis and a non significant reduction in mean fibrotic score and it 
was shown that a lack of long-term histological improvement could be predicted 
by a failure in early improvement in systemic insulin resistance.  
Orlistat induces fat malabsorption. It results in no greater changes in 
NAFLD histological outcomes than weight loss from an energy restricted diet 
(Harrison, Fecht et al. 2009).. 
 
1.6.2. Promoting insulin sensitivity and antioxidants 
After addressing lifestyle and adiposity, the next logical approach is to 
promote insulin sensitivity. Thiazolidinediones (TZDs) act via peroxisome 
proliferator-DFWLYDWHG JDPPD 33$5Ȗ DJRQLVP WR GLUHFWO\ SURPRWH LQVXOLQ
sensitivity. TZDs induce fat store transfer from liver and muscles to peripheral 
adipocytes. Patients therefore gain peripheral weight, but become more 
systemically insulin sensitive. All three published randomised placebo controlled 
studies describe histological improvement with TZD therapy, and these findings 
are irrespective of whether the patient is diabetic or not (Belfort, Harrison et al. 
2006; Aithal, Thomas et al. 2008; Ratziu, Giral et al. 2008). Unfortunately the 
favourable effects on liver biochemistry and histology are not continuous with 
rosiglitazone as there are no additional improvements after the first year of 
treatment (Ratziu, Charlotte et al. 2010), it is not known if this is the same with 
pioglitazone which does appear to have importantly different biological activity. 
Furthermore, any improvements revert on the discontinuation of TZDs, and so in 
order to maintain the initial benefits TZDs would have to be long-term therapies 
(Lutchman, Modi et al. 2007). This is an issue as there are considerable concerns 
over the side effects of TZD therapy including congestive cardiac failure, fluid 
retention and osteoporosis (Rizos, Elisaf et al. 2009).  
The story has recently become even more interesting. Until very recently 
there was no histological data to support the use of antioxidants (Duvnjak, Lerotic 
et al. 2007). The latest TZD trial randomised 247 biopsy proven NASH patients to 
either 30mg per day of pioglitazone (a TZD), vitamin E (800IU per day), or 
placebo (Sanyal, Chalasani et al. 2010). Repeat biopsy was performed in 90% at 
96 weeks with the aim to re-assess histological injury. Pioglitazone did not fulfil 
the pre-determined histological primary end-point and so this can be interpreted as 
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a negative study.  The interpretation of this data however is fraught as many 
patients in the pioglitazone arm were recruited on the basis of having NASH, 
though on subsequent central pathologist review did not have adequate injury on 
their initial biopsy to justify their initial entry into the study. As a result it was 
impossible to demonstrate injury regression in those without injury at baseline. 
Fascinatingly vitamin E resulted in no side effects and 43% showed a reduction in 
liver injury to meet the primary end-point. This was opposed to 34% for 
pioglitazone and 19% for placebo. These vitamin E findings are currently being 
reproduced by other centres. Indeed there is some concerns re vitamin E safety 
with some highly controversial data suggesting that vitamin E intakes greater than 
400IU/day may be associated with an increased mortality (Miller, Pastor-Barriuso 
et al. 2005). 
1.6.3. Dyslipidaemia treatments 
&ORILEUDWH D 33$5Į DJRQLVW, does not improve liver histology after one 
year (Laurin, Lindor et al. 1996). The HMG CoA reductase inhibitor atorvastatin 
has been used in three small studies with a combined total of 56 patients 
(Duvnjak, Lerotic et al. 2007). There is evidence of histological improvement, but 
this needs to be reproduced in a placebo controlled large-scale setting before it 
becomes an accepted therapy.  
 
1.7. Interactions between diet and NAFLD 
Observations detailed below have lead many authors to speculate on the 
role of specific dietary macronutrient intakes as opposed to simply energy excess 
in the aetiology and treatment of NAFLD (Cave, Deaciuc et al. 2007; Sullivan 
2009). Ultimately all hepatic lipids originate from dietary intakes of carbohydrates 
or lipids. Furthermore, dietary contents have been shown to be powerful inducers 
and suppressors of the pathways central to hepatic fatty acid metabolism. 
 
1.7.1. Dietary history assessments in NAFLD  
Dietary assessments are frequently performed at the time of bariatric 
surgery but are poor indicators of long-term intake patterns. Such patients are 
keen to report and perform weight-loss promoting behaviour which commonly 
includes energy or macronutrient restriction. As a result only the non-bariatric diet 
history experience will be discussed here. There have been seven main studies 
comparing the diets of non-bariatric surgery NAFLD patients with that of healthy 
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controls (Musso, Gambino et al. 2003; Cortez-Pinto, Jesus et al. 2006; Zelber-
Sagi, Nitzan-Kaluski et al. 2007; Allard, Aghdassi et al. 2008; Thuy, Ladurner et 
al. 2008; Abid, Taha et al. 2009; Oya, Nakagami et al. 2010). The findings are 
summarised in table 1. Only two of these studies however have used body mass 
index (BMI) matched controls. The reliability of this data in terms of 
underreporting of nutrient intakes is not presented by any paper. It would appear 
to be an issue as the mean predicted energy intakes (Schofield formula (Schofield 
1985)) needed for a 30-59 year old weighing 85kg and a standard activity factor 
of 1.6 is 2960kcal/day in men and 2482kcal/day in women. This is not adjusted or 
accounted for in any of the assessments. 
 Table 1: Macronutrient intake patterns in NAFLD as compared to healthy 
controls. (Abbreviations used: SFA = Saturated fatty acid; MUFA = 
Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid. Significance 
determined at p<0.05, the symbol . means that there was no data supplied). 
 
Musso et al. analysed seven-day food records from 25 Italian patients with 
NAFLD (Musso, Gambino et al. 2003). These were compared with records from 
25 sex, age and BMI-matched healthy controls who had no evidence of NAFLD 
on liver enzymes and abdominal ultrasound. The individuals studied were trained 
to use dietary records, and their responses were analysed by published Italian food 
composition databases. The reported dietary intakes by the two groups were 
matched in terms of overall energy, total fat and carbohydrate intakes. The 
NAFLD patients however reported significantly greater intakes of daily saturated 
fatty acids (40g vs. 29g, p=.001), and reduced intakes of polyunsaturated fatty 
acids (10.3g vs. 13.4g, p=.019), and fibre (12.9g vs. 23.2g, p<.001).  
 Musso Cortez-
pinto 
Thuy Allard Abid Oya Zelber-
Sagi 
Weight (kg) 
BMI 
80 
26 
83 
31 
- 
28 
92 
32 
- 
30 
- 
25.0 
- 
30 
Reported  energy 
intake (kcal/day)  
2638 2253 2242 2151 2186 1952 2493 
Energy ļ ļ ļ ļ ļ ļ ļ 
Total Protein  ļ Ļ ļ ļ ļ ļ ļ 
Total Fat  ļ Ĺ ļ ļ ļ ļ ļ 
Total 
Carbohydrate  
ļ Ļ ļ ļ ļ ļ ļ 
SFA Ĺ Ļ . ļ . ļ ļ 
MUFA ļ Ĺ . ļ . - ļ 
PUFA Ļ ļ . ļ . - ļ 
n-3 PUFA . ļ . ļ . Ļ ļ 
n-6 PUFA . Ĺ . . . -  
Simple 
carbohydrates 
ļ ļ . ļ Ĺ - Ĺ 
Fibre Ļ ļ . ļ . - ļ 
Fructose . . Ĺ . . - . 
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Cortez-Pinto et al. used a semi-quantitative food frequency questionnaire 
(FFQ) to analyse food intakes over the preceding year in 45 NAFLD patients and 
856 controls in Portugal (Cortez-Pinto, Jesus et al. 2006). The controls were age 
and sex balanced to the patients, though were neither BMI-matched nor screened 
for the absence of NAFLD. A further issue was that the 82-item FFQ has not been 
adequately validated and was unpublished. The data was BMI-adjusted, although, 
as the unadjusted data was not presented, it is unclear as to what effect this had. 
The findings in part conflict with those of Musso et al. Again there was no 
difference in terms of energy intakes, but the NAFLD patients consumed less 
carbohydrates (243g vs. 262 g, p=0.003), a similar amount of fibre (24.1g vs. 
22.6, p=NS), a tendency to a greater amount of simple sugars (109g vs. 101g, 
p=NS), and a greater amount of total fat (79.7g vs. 73.0g, p<0.001). The fatty acid 
profile was assessed in greater detail than in the work by Musso et al., and 
identified a greater intake of n-6 polyunsaturated fatty acids (PUFAs) by the 
NAFLD patients (9.3g vs. 8.3g, p=0.003) and an identical combined long and 
short chain n-3 PUFA intake of 1.4g per day between the two groups.  
12 biopsy proven NAFLD patients and 6 opportunistically obtained and 
neither sex nor BMI matched healthy controls had a dietary history analysed by an 
undisclosed method (Thuy, Ladurner et al. 2008). Energy adjusted data was not 
presented. The groups had identical macronutrient intakes including glucose, 
though fructose intakes were significantly greater in the NAFLD patients. 
Allard et al. analysed 7 day food diaries and liver biopsy fatty acid profiles 
in 73 patients with elevated liver enzymes with a normal viral, genetic, 
autoimmune, medication and alcohol screen and hence assumed to represent 
NAFLD (Allard, Aghdassi et al. 2008). Seventeen had a normal biopsy, 18 simple 
steatosis and 38 had NASH. The NASH patients had a significantly greater BMI. 
There was no difference in macronutrient intakes between the three groups. 
Two Israeli studies have assessed general intakes but focused on the intake 
of simple sugars in NAFLD patients. Zelber-Sagi et al. identified 349 people 
randomly selected from the Israeli National Health and Nutrition Survey, who 
were all negative on screening for alcohol abuse, viral or drug induced liver 
disease (Zelber-Sagi, Nitzan-Kaluski et al. 2007). They then divided their cohort 
into 108 individuals who had evidence of NAFLD on ultrasound, and 241 who did 
not. The benefits of this approach were that it was community based, and that it 
excluded the principal non NAFLD liver diseases. The limitation was that the 
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NAFLD arm contained more men and a greater BMI. The investigators 
interviewed all of the subjects face-to-face using a semi-quantitative 111-itemed 
FFQ. Multivariate analyses adjusting for age, sex, BMI and total energy intake 
demonstrated greater intakes amongst the NAFLD cohort of sugars from soft 
drinks (odds ratio 1.45 (1.13-1.85), p=0.005) and a tendency for reduced intakes 
of n-3 PUFA  containing fish (odds ratio 0.73 (0.52-1.04), p=0.08).  
Abid et al. recruited 60 patients with abnormal liver biochemistry and a 
clinical and ultrasound diagnosis of NAFLD (Abid, Taha et al. 2009). Seven day 
food records and activity levels were compared to those of 30 age, sex and BMI 
matched controls. There was no difference between the groups in terms of overall 
energy intake, macronutrient contribution to energy intakes, or physical activity.  
The mean daily intake of added sugars was greater in the NAFLD patients at 75g 
vs. 30g (p<0.001) and the majority (43%) of this originated from sugar-sweetened 
soft drinks. Unfortunately although the controls had normal liver biochemistry, 
they were not further assessed for the absence of NAFLD. 
A Japanese group assessed for dietary factors predictive of NASH as 
opposed to simple steatosis. They compared 3 day food records of 18 patients 
with biopsy proven simple steatosis and 28 with NASH (Toshimitsu, Matsuura et 
al. 2007). Both arms had similar BMI profiles. Diets associated with NASH had a 
greater energy contribution from carbohydrates and sugars, and reduced protein, 
zinc and PUFA intakes.  
Finally another Japanese group compared intake patterns of nearly 800 
apparently healthy alcohol abstinent adults, with a normal ‘liver screen’ including 
viral studies, who they subdivided by gender and the presence or absence of a 
fatty liver on ultrasound scan (Oya, Nakagami et al. 2010). The subjects were 
recruited from a hospitals health check-up programme and dietary data collated by 
a Japanese foodstuff food frequency questionnaire. The percentage dietary energy 
contribution of all n-3 PUFAs, and EPA and DHA were lower in men with 
steatosis on ultrasound scan than those with a normal scan. There was no such 
difference amongst the women. These associations persisted after adjustments for 
age, waist and physical activity levels. There was however some energy 
underreporting in the patients with steatosis as despite having a greater BMI the 
men reported similar, if not lower, energy intakes and similar physical activity 
levels.  
 39  
Using an entirely different approach to the previous studies, Kechagias et 
al. performed a fascinating study by analysing the hepatic effects of short-term 
fast-food overfeeding with intakes twice that of normal and exercise restriction to 
less than 5,000 steps per day (Kechagias, Ernersson et al. 2008). Over 4 weeks 18 
healthy volunteers had a mean weight gain of 9.5%. Serum alanine transferase 
(ALT), a marker of hepatic injury, increased by 2.1-fold, and intra-hepatic lipid 
stores by 1.5-fold. Nutrient intakes prior to and during the intervention period 
were assessed by 3 day food diaries. The increases in ALT correlated with 
monosaccharide intakes, with no correlation with protein or fatty acids. There was 
no further sub analysis of the influence of individual macronutrients presented. As 
highlighted by my recent communication, this study however had several flaws 
(Johnston, Aithal et al. 2009). Firstly, pre-existing liver disease was not excluded 
from the cohort, and secondly the intervention lacked a control. Therefore the 
authors’ conclusions that the findings are directly attributable to fast-food are not 
tenable.  
In summary there is no dietary intake pattern that has been repeatedly 
shown to be characteristic for NAFLD. There are flaws in the data collection 
processes and degree of nutrient analyses in all of these studies, so a large scale 
and robustly performed study is urgently needed. The only macronutrients 
implicated in two or more studies are n-3 and n-6 PUFAs and simple 
carbohydrates and fructose. These limited observations form a key part of the 
background to this thesis. 
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1.7.2. Dietary assessment in NAFLD employing liver biopsy lipid analyses 
 
An alternative method to assess hepatic exposure to dietary fatty acids is to 
quantify liver biopsy fatty acid profiles. This process assumes that hepatic fatty 
acid profiles directly correlate with dietary intakes, and that the liver handles the 
different fatty acid subtypes in the same manner during health as in disease. 
Inflammation and oxidative stress could alter synthesis from precursors, or 
metabolism of complex lipids including peroxidation. Therefore any observations 
may be either cause or effect of the disease. The above assumptions accepted 
lipidomic analyses remain an interesting nutritional biomarker assessment 
technique in assessing the interactions of nutrients and hepatic fatty acid 
metabolism. The published data however has failed to produce a clear picture.  
Araya et al. analysed liver fatty acid profiles by gas liquid chromatography 
in 19 NAFLD patients and 11 non-BMI matched controls (Araya, Rodrigo et al. 
2004). The relative contribution of saturated and monounsaturated fatty acids did 
not significantly differ, whereas there was a significant reduction in total 
polyunsaturated fatty acids (PUFAs) in the NAFLD patients (18.7% vs. 33.0%, 
p<0.05). Within the polyunsaturated fatty acids, there was reduced n-3 PUFAs 
(1.6% vs. 7.2%, p<0.05), and reduced n-6 PUFAs (16.8% vs. 25.5%, p<0.05). The 
reduction in n-3 PUFAs was more marked than in the n-6, such that the n-6 to n-3 
PUFA ratio was greater in the NAFLD livers as opposed to the controls (11.5 to 1 
vs. 3.6 to 1, p<0.05). The difference in n-3 PUFA content was more marked in the 
longer chain fatty acids with a 5.2 fold reduction in DHA in the NAFLD livers.  
Puri et al. performed a similar analysis from 18 NAFLD patients and 9 
age, sex and BMI-matched controls (Puri, Baillie et al. 2007). An identical data 
pattern to that described by Araya et al. was generated in terms of the saturated, 
monounsaturated and polyunsaturated fatty acid profiles including n-3 and n-6 
PUFA. This study validated Araya’s prior work with a more rigorously selected 
control group. 
As previously described, Allard et al. analysed liver biopsy fatty acid 
profiles in 73 patients with elevated liver enzymes (Allard, Aghdassi et al. 2008). 
Patients with simple steatosis had greater n-6 PUFA content than those with 
normal biopsies, whilst NASH was characterised by a mild increase in 
monounsaturated fatty acid composition, and a marked long-chain n-3 PUFA 
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depletion. The combined EPA and DHA composition was 0.8% in normal 
biopsies, 0.4% in simple steatosis, and 0.2% in NASH.  
From the above studies the dietary trends in NAFLD patients appear to 
involve increased intakes of simple sugars, and sugar-sweetened drinks, as well as 
reduced intakes of PUFAs in particular n-3 PUFAs. These dietary observations 
have not been universally shown, though are supported by other observations. As 
a result this thesis will focus on fructose and glucose, the principal components of 
added sugars in drinks, and on n-3 PUFAs. 
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1.8. Polyunsaturated fatty acids  
 
1.8.1. Classification of polyunsaturated fatty acids (PUFAs) 
Thirty-five percent of total energy intake in the UK adult diet originates 
from fatty acids (Swan 2004). Fatty acids are classified by their number of double 
bonds, with saturated fatty acids possessing none, monounsaturated possessing 
one, and polyunsaturated fatty acids (PUFAs) possessing two or more cis double 
bonds, see 3.1. 
PUFAs are further sub-classified by the location of their first double bond 
starting from the methyl end of the chain. In n-3 PUFAs this double bond is at the 
third carbon-carbon bond from the methyl end, and is at the sixth bond for n-6 
PUFAs, see figure 1.3. These two types of PUFAs have distinct and commonly 
opposing physiological actions. The majority of dietary PUFA intake is in the 
forms of the 18-carbon linoleic acid (n-6) (LA), and the 18-FDUERQ Į-linolenic 
acid (n-3) (ALA).  
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Figure 1.3.: Names and structures of common 18-carbon chained saturated 
(stearic), monounsaturated (oleic), n-6 polyunsaturated (linoleic) and n-3 
polyunsaturated (Į- linolenic) fatty acids. Adapted from (Mann 2007). 
 
1.8.2. Dietary sources of n-3 PUFAs 
PUFAs are generated within the chloroplasts of the primary producers at 
the bottom of both the marine and terrestrial food chains. The primary producer in 
the marine world is phytoplankton. The PUFAs are absorbed, assimilated and 
passed directly up the food chain. The so-called ‘oily’ or pelagic fish, such as 
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mackerel, predominantly store oils in their fillets, whereas ‘white’ or demersal 
fish, such as cod, store oils in their liver.  
The handling of n-3 PUFAs differs in terrestrial food chains. Green-leaf 
vegetables generate a small but significant amount of short-chain PUFAs. This 
PUFA content is however not passed on and concentrated up the food chain, as 
microorganisms within the rumen of herbivorous ruminants hydrogenate PUFAs 
to saturated fatty acids. The herbivorous animal therefore may eat a relatively 
PUFA rich meal, but absorbs predominantly saturated fatty acids from its 
intestinal tract. Vegetable oils do contain a relatively high PUFA concentration, 
though this is principally only the short chain n-38)$ Į- linolenic (ALA) as 
opposed to the more biologically important long chain n-3 PUFAs such as 
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) found in fish.  
Intakes of PUFAs contribute only around 6% of adult dietary energy in the 
UK, with intakes of both long and short-chain n-3 PUFA ranging from 0.7g/day to 
greater than 4.5g/day (Swan 2004). It is however the long-chain PUFAs that are 
of principal interest. Givens and Gibbs recently analysed UK dietary intakes and 
sources for the long-chain EPA and DHA from published food disappearance 
databases (Givens and Gibbs 2008). They estimated that the average intake was 
244mg/day of EPA and DHA, and that 75% originates from fish, 6% from 
shellfish, 15% from meat, and 4% from eggs. There are no UK data assessing 
self-reported dietary intakes of long chain n-3 PUFAs. French self-reported data 
describes reported EPA and DHA intakes of 384mg per day (Astorg, Arnault et al. 
2004). 
 
1.8.2.1. Intake trends for PUFAs and the n-6 to n-3 ratio 
 
Given the frequently opposing n-6 and n-3 PUFA activities, the concept of 
an n-6 to n-3 PUFA ratio has emerged. Anthropological, nutritional and genetic 
data indicate that the human diet has changed significantly over the past 10,000 
years (Simopoulos 2006). The Paleolithic diet (400,000 to 45,000 years ago) 
contained mainly wild plant leaves, seeds, fish and animals with an estimated n-6 
to n-3 PUFA ratio of 1:1 (Eaton and Konner 1985). Intakes have gradually 
changed since then, though in the 150 years since the industrial revolution the 
onset of food technology and agribusiness has rapidly changed global fat intake 
patterns. Vegetable oil is a major modern industry, and domestic livestock now 
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have a very high cereal diet. United States foodstuff disappearance data describes 
an increase in the n-6 to n-3 PUFA ratio from 8.4 to 1 in 1935 to 10.6 to 1 in 1994 
(Kris-Etherton, Taylor et al. 2000). 
 
1.8.2.2. Determining adequacy of  long-chain n-3 PUFA intakes 
 
The short-chain n-3 PUFA alpha linolenic acid (ALA) is critical in 
maintaining the skin’s barrier function. Symptomatic deficiency with dermatitis, 
growth retardation and infertility is rare, occurring only in those with severe 
unresolved fat malabsorption and starvation (Bjerve, Fischer et al. 1987; 
Lauritzen, Hansen et al. 2001). No clinical features have been specifically 
ascribed to long chain n-3 PUFA deficiency (Benatti, Peluso et al. 2004), though 
the role of DHA in retinal and neuronal function is an area of intense current 
study (Hoffman, Boettcher et al. 2009). So in contrast to most other 
micronutrients, it is the benefits of an increased intake of long chain n-3 PUFAs 
as opposed to the prevention of deficiency that poses the primary interest. As a 
result of this unusual nutrient health status, the determination of adequacy of 
intakes is a highly contentious area and recommendations vary dependent upon 
the committees’ review dates, health priorities, and data interpretation, see table 2. 
Of importance, there are no toxicity or maximal intake recommendations. The 
recently estimated UK average intake of 244mg/day is below all bar one of the 
recommendations (Givens and Gibbs 2008). 
 
Country Year Recommended 
EPA + DHA intake 
Advisory body 
UK 1994 200 Department of Health (1994) 
Global 2003 500 WHO/ Food and Agriculture 
Organisation (WHO 2003) 
UK 2004 450 Scientific Advisory Committee on 
Nutrition/ Committee on Toxicity 
(Nutrition 2004) 
Global 2004 500 International Society for the Study of 
Fatty Acids and Lipids (Lipids 2004) 
USA 2005 270 Institute of Medicine (IOM 2005) 
Table 2: Recommended adult daily EPA and DHA intakes (mg/day) 
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1.8.3. Bioavailability of long chain PUFAs 
 
Long and short chain PUFAs are considered to be essential dietary 
components as they cannot be endogenously synthesised by the human body and 
so must be obtained from the diet. Absorbed PUFAs can however be inter-
converted. The conversion of the prevalent short chain ALA to the longer chain 
EPA and DHA occurs primarily within the endoplasmic reticulum of the liver. It 
involves a series of alternate desaturation and elongation reactions that 
respectively insert double bonds and 2-carbon units, see figure 1.4. From the base 
chain length of 18 carbons, chain lengths of 20, 22 or 24 carbons are subsequently 
formed. Identical enzymes catalyse these reactions for n-3 and n-6 PUFAs. As a 
result direct competition exists between these two metabolic pathways, dependent 
on enzyme and substrate availability. Tracer studies using 13C or 2H-labelled ALA 
demonstrate that 15-35% of dietary ALA is oxidised to form energy, and the 
fractional conversion of plasma ALA to DHA is less than 4% in males and around 
9% in female (Arterburn, Hall et al. 2006). This low conversion rate may be 
further reduced by EPA and DHA supplementation (Burdge, Finnegan et al. 
2003).  
Interestingly, retroconversion of DHA to EPA has been demonstrated, and 
occurs at a rate of 1.4% with a standard diet (Brossard, Croset et al. 1996), and up 
to 9.4% following a solely DHA supplemented diet of 1.6g per day for 6 weeks 
(Conquer and Holub 1997).  
The clear implications of this is that extremely high dietary intakes of 
ALA are required in order to replenish or maintain long chain n-3 PUFA intakes. 
This is better achieved by a diet rich in long-chain n-3 PUFAs or their direct 
supplementation.  
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Figure 1.4.: Desaturation and elongation of n-3 and n-6 polyunsaturated fatty 
acids.  Abbreviations: /$ /LQROHLF DFLG $/$ Į- Linolenic acid, ARA: 
Arachidonic acid, EPA: Eicosapentaenoic acid, DPA: Docosapentaenoic acid, 
DHA: Docosahexaenoic acid. Adapted from (Arterburn, Hall et al. 2006). 
 
1.8.4. Biological activity of PUFAs in relation to hepatic fatty acid metabolism 
 
PUFAs exert their physiological effects by modifying cellular wall 
function, eicosanoid production and balance, and gene transcription rates. The 
expression of cellular proteins is genetically determined, whereas the fatty acid 
content of cellular membranes is largely dependent on diet. Increasing EPA and 
DHA intakes have been shown to replace arachidonic acid (ARA) from membrane 
phospholipids of almost all cells in the body including platelets, neutrophils and 
hepatocytes (Benatti, Peluso et al. 2004). 
 
1.8.4.1. PUFAs and insulin resistance 
 
There remains considerable controversy as to whether PUFA status 
influences insulin resistance. No definitive mechanism behind any potential 
insulin sensitising effects has been widely shown as of yet. In rodents, fish oil has 
been shown to reduce skeletal muscle triglyceride content and hence improve 
whole-body insulin sensitivity (Klimes, Sebokova et al. 1993). Cultured human 
skeletal muscle cell line work has shown that EPA exposure increases cellular 
glucose uptake, via increased glucose transporter GLUT-1 expression, and 
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intracellular glucose oxidation (Aas, Rokling-Andersen et al. 2006). Ob/ob mice 
received a standard diet that was either enriched with 6% n-3 PUFA or not for 5 
weeks (Gonzalez-Periz, Horrillo et al. 2009). There was no difference in terms of 
chow intake or weight gain in the two groups. The PUFA enriched group down-
regulated hepatic FAS (a promoter of DNL) and up-UHJXODWHG33$5ĮDSURPRWHU
RIȕ-oxidation) and hence developed markedly less hepatic steatosis. Furthermore, 
n-3 PUFA supplementation up-regulated peripheral adipocyte expression of the 
insulin sensitising adipokine adiponectin. This was associated with an up-
regulation of the insulin sensitising PPARJ, insulin-receptors (IRS-1 and IRS-2) 
and glucose transporters (GLUT-4 and GLUT-2) in adipocytes and hepatocytes. 
The functional outcome of these changes was confirmed by improved systemic 
insulin sensitivity. 
Some epidemiological studies have shown a negative association between 
oily fish consumption and incident diabetes development. A Chinese group 
recently analysed fasted glucose, insulin and plasma phospholipid profiles in 180 
healthy individuals and 186 type 2 diabetics (Huang, Wahlqvist et al. 2009). 
Moderate associations were made between n-3 PUFA status and the homeostasis 
model assessment insulin resistance (HOMA-IR) with a correlation coefficient of 
-0.42. This suggests that greater intakes improve sensitivity, though such data 
needs to be interpreted with caution as oily fish consumption may merely be a 
marker for a healthier lifestyle.  
There have been very few large-scale interventional studies in either the 
healthy volunteer or clinical setting. A review evaluated 22 papers that assessed 
whether n-3 PUFAs influence glycaemic control in type 2 diabetes (De Caterina, 
Madonna et al. 2007). Four of these papers supplied more than 3g/day for more 
than a month to a combined total of only 78 patients. All showed significant 
plasma triglyceride reduction, whilst only one study showed an improvement in 
fasted insulin sensitivity.  
There have been a few published studies in the non-diabetic setting. 
Griffin et al. demonstrated no alteration in HOMA-IR values in 61 healthy adults 
after a 6 month diet containing around 1g of long chain n-3 PUFAs per day 
(Griffin, Sanders et al. 2006). 29 overweight women received 4.2g of EPA and 
DHA for 12 weeks with reductions in plasma triglycerides but no alteration in 
insulin sensitivity (Browning, Krebs et al. 2007).  
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Overall there is no convincing data that altering PUFA status influences 
systemic insulin sensitivity.  
 
1.8.4.2. PUFAs and immunomodulation 
 
Plasma membrane phospholipid PUFAs are substrates for cyclo-
oxygenases (COX-1 and 2), lipoxygenase (LOX) and cytochrome p450 
monoxygenases (Jump 2002). These enzymes produce the hormone-like 
eicosanoids including prostanoids, thromboxanes and leukotrienes. The most 
abundant and active precursor for these enzymes is the n-6 PUFA ARA, with EPA 
being the principally active n-3 PUFA. Eicosanoids influence platelet aggregation, 
inflammation, chemotaxis, vascular permeability and vasoconstriction. n-3 
PUFAs induce less COX and LOX eicosanoid production than n-6 PUFAs 
through three activities (Jump 2002): Firstly, they are less effective COX and 
LOX substrates than n-6 PUFAs. Secondly, their resultant eicosanoid products 
tend to have reduced biological activity. Finally, n-3 PUFAs enhance eicosanoid 
catabolism via peroxisomal degradation (von Schacky, Kiefl et al. 1993). The 
cytochrome p450 enzymes are a large and diverse group that oxidise fatty acids to 
produce eicosanoids, but also oxidise hormones and medication (Capdevila, Falck 
et al. 2000).  
The previously described systemic, and predominantly vascular, anti-
inflammatory effects of n-3 PUFAs are well described. There is abundant data 
describing n-3 PUFA modulation of hepatic vascular insults, such as 
ischaemia/reperfusion injury, an area critical to liver transplant practice (El-Badry, 
Graf et al. 2007). Furthermore there is some evidence that it modulates response 
to a chemical induced hepatitis (Schmocker, Weylandt et al. 2007). However their 
influence on hepatic lipid inflammatory status has been much less assessed. There 
is evidence that n-3 PUFAs improve the adiponectin-71)Į EDODQFH (Gonzalez-
Periz, Horrillo et al. 2009) and that this reduces hepatic steatotic necro-
inflammation (Svegliati-Baroni, Candelaresi et al. 2006). This paper is discussed 
in greater detail in section 1.9.5. Malinska et al. have recently developed a 
transgenic spontaneously hypertensive rat line that is characterised by NASH and 
n-3 PUFA depletion and an elevated n-6 to n-3 PUFA ratio (Malinska, Oliyarnyk 
et al. 2010). As to what is cause and what is effect is difficult to determine as 
there was no n-3 PUFA replacement. 
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1.8.4.3. PUFAs and gene expression 
n-3 PUFAs regulate intracellular, including intra-hepatic, gene expression 
rates and activity. Via intracellular receptors, they can either promote or inhibit 
gene transcription, or modify mRNA maturation or stability (Pegorier, Le May et 
al. 2004). The two main targets of n-3 PUFA hepatic gene modifications are the 
peroxisome proliferator-activated receptors (PPARs), and sterol regulatory 
element binding proteins (SREBPs).  
 
1.8.4.3.1. n-3 PUFAs and peroxisome proliferator-activated receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
nuclear receptors. They function as transcription factors regulating the expression 
of the peroxisomal genes which directly determine whole-body lipid and glucose 
metabolism. Four PPAR isoforms have been identified- D, E, G and J. n-3 PUFAs 
are natural ligands for the PPARD and PPARJ isoforms (Forman, Chen et al. 
1997). n-6 PUFAs function as very weak ligands, whereas saturated fatty acids 
exert no effect (Price, Nelson et al. 2000). 
PPARD is mainly expressed in the liver, kidney and heart. It activates fatty 
DFLGȕ-oxidation and lipoprotein synthesis. It therefore promotes hepatic fatty acid 
oxidation and exportation into the plasma (Semple, Chatterjee et al. 2006). The 
clinical outcome of PPARD agonism is well known as fibrate drugs are pure 
PPARD agonists. Fibrates are widely used to treat dyslipidaemia due to their 
triglyceride lowering and high-density lipoprotein cholesterol elevating effects. 
Their clinical benefit is modest, though they have been shown to reduce 
cardiovascular morbidity in diabetic patients and those with the metabolic 
syndrome (Staels, Maes et al. 2008). Fenofibrate has been shown to reduce 
steatosis in Zucker diabetic rats (Forcheron, Abdallah et al. 2009) 33$5Į DOVR
appears to modulate inflammation as knock-out mice have increased expression of 
LQIODPPDWRU\ F\WRNLQHV ZKLFK DUH UHGXFHG ZLWK WUHDWPHQW RI 33$5Į OLJDQG
replacement (Stienstra, Mandard et al. 2007). The clinical experience of hepatic 
outcoPHV IURP 33$5Į DJRQLVP LV OHVV LPSUHVVLYH WKDQ WKH URGHQW 7ZHOYH
PRQWKV WKHUDS\ZLWKFORILEUDWH D33$5ĮDJRQLVW UHVXOWHG LQQRELRFKHPLFDORU
histological improvement in 16 NASH patients (Laurin, Lindor et al. 1996).  
PPARJ is mainly expressed in white adipose tissue (Chui, Guan et al. 
2005). It promotes differentiation and proliferation of adipocytes via targeting 
fatty acid binding protein 4, lipoprotein lipase and adiponectin. PPARJ 
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stimulation results in reduced free fatty acid release from adipose tissue, and 
hence improves peripheral and hepatic insulin-sensitisation (Semple, Chatterjee et 
al. 2006). Thiazolidinediones  (TZDs) are a class of drugs that are powerful 
PPARJ agonists and widely used as insulin-sensitising agents in diabetic patients 
(Rohatgi and McGuire 2008). As previously discussed, TZDs have been shown to 
be beneficial therapies in NAFLD, though concerns remain over their safety. 
 
1.8.4.3.2. n-3 PUFAs and sterol regulatory element binding proteins (SREBPs) 
SREBPs are a group of transcription factors that directly enhance the 
transcription of more than 30 genes by binding to specific sterol regulatory DNA 
sequences (Horton, Shah et al. 2003). There are three main isoforms: SREBP-1a, 
SREBP-1c and SREBP-2.  
SREBP-1c is the most pathologically implicated isoform, and has been 
linked to increased rates of de novo lipogenesis with the development of 
dyslipidaemia, type 2 diabetes and hepatic steatosis (Ferre and Foufelle 2007). 
SREBP-1c knockout mice have reduced expression rates of lipogenic genes with 
resultant reduced plasma triglyceride concentrations (Liang, Yang et al. 2002). 
Whereas, SREBP-1c overexpression in transgenic mice have a 4-fold increase in 
FAS levels, and a 4-fold increase in hepatic triglyceride content (Horton, 
Goldstein et al. 2002). 
The formation of mature SREBPs is controlled by feedback inhibition. 
Factors central to this include intra-cellular levels of cholesterol, insulin, glucose 
and long-chain n-3 PUFAs (Loewen and Levine 2002). Short-chain n-3 PUFAs, 
such as ALA, exert only mild inhibition, whereas long chain n-3 PUFAs lower 
mRNA SREBP-1c levels by activating transcript delay (Worgall, Sturley et al. 
1998; Clarke 2001; Xu, Cho et al. 2002). Sekiya et al. demonstrated that EPA 
decreased SREBP-1c expression in the livers of leptin-deficient ob/ob mice 
(Sekiya, Yahagi et al. 2003). There was a consequential reduction in the 
expression of lipogenic genes including FAS, and a reduction in hepatic 
triglyceride content and insulin resistance. There is great interest in the therapeutic 
potential of SREBP based therapies for NAFLD (Ahmed and Byrne 2007). 
 
1.8.5. Summary of the observed biological activity of n-3 PUFAs 
7KHSURSRUWLRQDWHEDODQFHRI33$5ĮDQG65(%3-1c activities determines 
the relative rates of fatty acid oxidation and de novo lipogenesis (DNL). Pettinelli 
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et al. recently described strong correlations between hepatic long chain n-3 PUFA 
FRQWHQW DQG WKH 33$5Į  65(%3-1c ratio (r=0.48, p<0.02) in obese humans 
(Pettinelli, Del Pozo et al. 2009). The potential for n-38)$VWRDFWLYDWH33$5Į
and inhibit SREBP-1c results in a cascade of events up-regulating lipid oxidation, 
and down-regulating DNL. Furthermore PPARJ stimulation may promote insulin 
VHQVLWLYLW\ DQG WKLV LV IXUWKHU LPSURYHG E\ FRUUHFWLQJ WKH DGLSRQHFWLQ71)Į
balance. As a result n-3 PUFAs can be viewed as master switches to intracellular 
metabolism and promoters of pathways that would be predicted to reduce hepatic 
inflammation and steatosis. 
 
1.8.6. Animal models of NAFLD and n-3 PUFA supplementation 
The numerous rodent models of NAFLD and differing n-3 PUFA 
preparations have resulted in much study in this area assessing steatosis, gene 
expression, metabolic profile, fatty acid profiles and inflammatory status. A 
comprehensive review is therefore beyond the scope of this introduction. Three 
studies are worthy of in-depth discussion as they describe many of the prior 
discussed features: 
The leptin-deficient ob/ob mice are a well validated metabolic model of 
obesity, insulin resistance, and hepatic steatosis. Gonzalez-Periz et al. recently 
used this model in an elegant study (Gonzalez-Periz, Horrillo et al. 2009). They 
randomised mice to receive either a standard chow or chow supplemented with a 
modest dose of n-3 PUFAs for 5 weeks. There were no differences in terms of 
weight gain between the two groups. In the n-3 PUFA fed mice PPARD and 
PPARJ were up-regulated and the hepatic expression of FAS was reduced. 
Adipocyte expression of adiponectin was up-regulated, whilst there was no 
FKDQJH LQ 71)Į $V D UHVXOW KHSDWLF VWHDWRVLV ZDV DOOHviated, and insulin 
sensitivity improved.  
In a contrasting and fascinating protocol, Pachikian et al. have performed 
the only study, to the author’s knowledge, to date that assessed the hepatic effects 
of n-3 depletion (Pachikian, Neyrinck et al. 2008). Second-generation n-3 PUFA 
depleted mice were fed for 34 weeks following birth a standard chow with n-3 
PUFAs contributing either 2% or 9% of fatty acids. The n-3 PUFAs were 
predominantly short chain. The 2% fed mice had reduced weight gain, and 
identical amounts of visceral adipose tissue as compared to the repleted 9% fed 
mice. However the 2% mice developed a marked systemic insulin resistance and a 
 52  
1.5-fold increase in hepatic triglyceride content. The degree of hepatic steatosis 
correlated very strongly with the hepatic n-6 to n-3 triglyceride ratio (r2=0.87), 
though the authors were not able to identify the mechanisms behind these 
observations.  
In standard rats a high fat/high energy diet induced visceral obesity, 
LQFUHDVHG1()$VDQG71)ĮVXSSUHVVHGDGLSRQHFWLQDQGLQGXFHGKHSDWLFLQVXOLQ
resistance (Svegliati-Baroni, Candelaresi et al. 2006). These modifications 
resulted in a model of NAFLD with hepatic steatosis, oxidative stress, 
necroinflammation, apoptosis and ultimately fibrosis. This model was then used 
with or without n-3 PUFA supplementation. Supplementation stimulated hepatic 
33$5ĮH[SUHVVLRQDQGUHVWRUHGDGLSRQHFWLQDQG71)ĮP51$OHYHOV$VDUHVXOW
the n-3 PUFA supplementation halved the amount of hepatic steatosis and 
necroinflammation induced. 
 
1.8.7.  Hepatic incorporation of supplemented n-3 PUFAs 
Much of the prior data has originated from rodent studies. A key clinical 
question is whether supplemented PUFAs are incorporated within human livers, 
and what the time course is? There have been numerous serum and plasma 
incorporation studies which show maximal rate of changes of plasma 
phospholipid and erythrocyte n-3 PUFA content occur within 1 and 2 months of 
supplementation respectively (Arterburn, Hall et al. 2006). 
To the author’s knowledge, there is only one study that has quantified 
hepatic PUFA incorporation response to supplements. Senkal et al. randomised 40 
patients undergoing elective gastrointestinal surgery into two age, sex and weight 
matched groups. Each group received five days of an isoenergetic diet, with one 
group receiving 3.7g of EPA and DHA (Senkal, Haaker et al. 2005) and the an 
isoenergetic control diet. Intestinal and liver biopsies were taken at the time of 
surgery and thus there was no pre-randomisation histology. The EPA content in 
the supplemented patients’ liver and intestine was more than 3-fold greater than in 
the control group. It therefore is clear that hepatocyte phospholipid fatty acid 
patterns are likely to respond promptly and dramatically to supplementation of 
EPA and DHA. Therefore it is reasonable to expect that prolonged 
supplementation may result in altered hepatic metabolism.  
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1.8.8. Clinical trials of NAFLD and n-3 PUFA supplementation 
There have been six clinical studies assessing the effects of n-3 PUFA 
supplementation in patients with NAFLD or related disorders:  
1. 42 patients with presumed NAFLD were supplemented with 1g of EPA and DHA 
for 12 months (Capanni, Calella et al. 2006). The validity of the comparator has to 
be questioned as the 14 patients used as controls were those who had refused to 
take supplements. Steatosis was assessed by ultrasound scans using a 4-point 
graded scale. The control group had no changes on the scale, whereas 64% of the 
intervention group improved. The biochemistry worsened in their control group, 
whereas there were modest but significant reductions in the intervention group’s 
liver enzymes, fasting glucose and triglycerides. This study had several flaws. It 
used a very low dose of n-3 PUFA supplements in patients with limited evidence 
of NAFLD (no biopsy), and it lacked a true control. Diabetics were not excluded 
and so alteration in their glycaemic control could have compounded the results. 
The biochemical changes detected were small, though the majority had normal 
baseline liver biochemistry. Ultrasound scans were used despite being a poorly 
validated tool for quantifying liver steatosis. 
 
2. A Japanese group supplemented 23 biopsy-proven NAFLD patients to receive 
2.7g of EPA per day for 12 months (Tanaka, Sano et al. 2008). Liver function 
tests, serum inflammatory and oxidative stress markers were improved and weight 
remained stable. There was no control group, and so the natural history effects 
cannot be fully accounted for. Seven patients agreed to a post treatment repeat 
liver biopsy, which showed evidence of improved steatosis, injury, inflammation 
or fibrosis in 6 out of the 7. However the small numbers, and lack of placebo 
control limit interpretation of the findings. It is noteworthy that such positive 
findings occurred from a Japanese cohort, as their community’s n-3 PUFA intake 
is substantially greater than that in Western Europe and North America. 
 
3. An Italian group randomised 40 patients with a clinical diagnosis of NAFLD (no 
liver biopsy) to either an energy restricted diet or an energy restricted diet plus 2g 
PUFA per day for 6 months (Spadaro, Magliocco et al. 2008). In those taking the 
PUFAs there was evidence of increased systemic insulin sensitivity and reduced 
inflammatory profile, plasma triglycerides, and liver steatosis as assessed by liver 
ultrasound. There were no such changes in the controls. Interpretation of this 
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study again is limited. The EPA and DHA content of the capsules was not 
presented, and the diet plus PUFA arm appeared to lose more weight which is a 
confounding factor that was not adjusted for. 
 
4. A group from the United States have published the only negative study to date 
(Vega, Chandalia et al. 2008). 16 healthy volunteers with known hepatic steatosis 
noted on MR spectroscopy and normal liver function tests received 9g of fish oil 
per day for 8 weeks. The capsules contained 4.6g of EPA and 2.2g DHA. There 
were significant increases in plasma EPA and DHA concentrations and reductions 
in serum triglycerides. There was however no change in hepatic triglyceride 
content as assessed by proton MR spectroscopy. The authors had no explanation 
for their findings, though it is not certain that all the volunteers had NAFLD as 
they lacked a full exclusion of other liver pathology with no liver biopsy or 
presented alcohol intake. 
 
5. Twenty five patients with polycystic ovarian syndrome, 13 with steatosis on their 
baseline 1H MRS were randomised to either 3.3g/day of EPA and DHA or oleic 
enriched olive oil for 8 weeks in a double blind crossover design (Cussons, Watts 
et al. 2009). The treatment arm resulted in reductions in HTGC, plasma 
triglycerides, and blood pressure. The effect on HTGC was most noted in those 
with steatosis at baseline and non-significant in those without steatosis at baseline. 
There were no changes in liver biochemistry or C-reactive protein.  
  
6. A group from China assessed the largest cohort to date (Zhu, Liu et al. 2008). 134 
NAFLD patients with associated dyslipidaemia were randomised to 6g of seal oil 
for 24 weeks or placebo. There were no changes in weight, whereas there were 
significant improvements in liver biochemistry, serum triglycerides and 
ultrasound assessment of liver fat stores. Again this study is limited as there was 
no liver biopsy performed to confirm NAFLD, we are given no data on the fatty 
acid profile of the active or placebo capsules, the steatosis assessment is by 
ultrasound only, and the biochemical differences between the two groups were at 
best modest.  
 
These studies were recently entered into a meta-analysis (Parker, Johnson 
et al. 2011). Also include was a small Chinese study that it is not on pubmed nor 
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an abstract identifiable on the internet, and an ultrasound comparison of 6 versus 5 
patients which I view as being too small to worthy comment on (Sofi, Giangrandi 
et al. 2010). The negative paper by Vega and colleagues was not included in the 
meta-analysis. The meta-analysis demonstrated evidence for a significant 
reduction in liver fat but not transaminases with n-3 polyunsaturated fatty acids. 
The authors however acknowledged the small sample size, assessment 
heterogeneity, and lack of histological confirmation in these studies. Publication 
bias needs also to be remembered in such small studies. 
 
1.8.9. Safety of n-3 PUFA supplementation 
Up until recently there have been no clinical concerns regarding n-3 PUFA 
supplementation (Schmidt, Arnesen et al. 2005), although some recent 
epidemiological data has suggested a link between serum PUFA status and 
prostate cancer risk. Over 1,500 cases of prostate cancer were matched with over 
1,500 age, treatment and prostate cancer family history controls. Serum 
phospholipid analyses demonstrated that the highest quartile of serum DHA was 
associated with a 2.5 odds ratio of high grade prostate cancer as compared to the 
lowest quartile (Brasky, Till et al. 2011). There were no associations with EPA or 
n-6 fatty acids. The European Prospective Investigation into Cancer and Nutrition 
study (EPIC) is the second largest study to investigate this area. Prostate cancer 
risk was non-significantly increased in those with a high serum DHA, and high-
grade cancer risk was significantly increased with increased EPA (Crowe, Allen et 
al. 2008). These data seem to be alarming and the authors of both papers have no 
explanation for their findings. It bears remembering that no biological pathway for 
n-3 PUFA carcinogenesis has been identified (Brasky, Till et al. 2011), and that 
long-term n-3 PUFA supplementation has been undertaken in many interventional 
studies without an increased tumour rate noted. As a result it seems premature to 
issue warnings. 
 
1.8.10. Conclusion on n-3 PUFAs and NAFLD 
To conclude, there is emerging evidence to support the principles and practice 
of n-3 PUFA supplementation. NAFLD appears to be characterised by a relative 
deficiency of the long chain n-3 PUFAs when assessed in the diets, plasma and 
livers of patients, though these are not universal observations. Hepatic lipid 
metabolism appears to be potentially improved by n-3 PUFAs via the promotion 
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of insulin sensitivity, and beta-oxidation, combined with the reduction of 
lipogenic gene expression, and de novo lipogenesis rates and anti-inflammatory 
immunomodulation,. It bears remembering that not all of these effects have been 
conclusively demonstrated outside the hepatocyte cell line or animal model 
experience. Clinical studies in NAFLD have been performed, though the data 
regarding the precise role of n-3 PUFAs remains unclear.  
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Figure 1.5. Summary of the potential actions of n-3 PUFAs on hepatic fatty 
acid metabolism 
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1.9. Fructose 
 
1.9.1.Classification of dietary carbohydrates 
 
Carbohydrates are structurally classified according to their size, 
constituent monomers and the linkages between them. The number of monomeric 
units is termed the degree of polymerisation. Sugars have 1-2 monomers, 
oligosaccharides 3-9, and polysaccharides 10 or more.  
Carbohydrates can also be classified nutritionally into those which are 
absorbed in the small intestine, termed glycaemic carbohydrates, and 
carbohydrates that pass unabsorbed into the colon, termed dietary fibre. As a 
result it is the glycaemic carbohydrates that influence metabolism. The principal 
glycaemic carbohydrates are the monosaccharides glucose, fructose and galactose, 
the disaccharides sucrose and lactose, and starch. All of these glycaemic 
carbohydrates bar resistant starch are normally digested in the small intestine to 
form monosaccharides prior to their absorption and transfer to the liver via the 
portal vein.  
This thesis will only review the monosaccharides, as all carbohydrates are 
degraded to them prior to absorption. It is important to remember that prior to 
digestion monosaccharides may have originated from more complex 
carbohydrates.  
Galactose is an infrequent dietary component which undergoes the same 
glycolytic pathway as glucose, and hence has no intrinsic metabolic differences 
from glucose, see figure 1.6. Fructose and glucose do however differ in their 
metabolic handling. This will be the main focus for this section of the thesis.  
Glucose and fructose have the same molecular content of C6H1206, though 
their ring structures differ, see figure 1.6. Sucrose or table sugar, a disaccharide of 
fructose and glucose, is the main dietary source for both of these 
monosaccharides.  
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Figure 1.6.: The ring structures of galactose, glucose, fructose and sucrose 
 
1.9.2. Dietary origins of fructose 
 
Fructose is popularly regarded as being the ‘fruit sugar’. Although this is 
true, modern agricultural practices means that the current principal source of 
fructose is from table sugar or sucrose, and that fruit and fruit juices only 
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contribute just over 10%, see table 3.  The majority of data on fructose intakes 
originate from the USA, with no reliable UK data. 
In order to identify the dietary sources of fructose in the USA, Marriott et 
al. analysed the NHANES data collected from 1999 to 2004 (Marriott, Cole et al. 
2009). The NHANES survey analysed 24-hour dietary recall data collected by 
telephone from 25,165 children and adults. There are two limitations of this data 
for extrapolation to the UK. Firstly, it has been shown that the 24-hour dietary 
recall method underreports intakes by 15%, and that socially embarrassing (often 
fructose-rich) foodstuffs are the most underreported (Poslusna, Ruprich et al. 
2009). Secondly, the dietary records are at least 6 years old and of a USA source. 
As a result the findings may have underestimated the actual intakes at the time of 
data collection, and the intake patterns may not be reflective of current UK dietary 
patterns. The above accepted, the paper by Marriott et al is the most accurate 
source we currently have to identify the dietary origins of fructose. 
 
Food group 
 
Male (%) Female (%) 
Dairy  5.1 7.2 
Grain products 15.0 17.0 
Fruit and fruit products 9.4 12.1 
Vegetables and veg. products 2.5 2.8 
Sugars and sweets 8.5 10.8 
Beverages  55.1 46.1 
 
Table 3. Percentage contribution of differing food groups to total fructose 
dietary intakes in US adults aged 23-50 years (Marriott, Cole et al. 2009) 
 
Analysing table 3, it is clear that the main source of dietary fructose is 
from beverages, with fruit only providing just over 10% of intakes. The overall 
contribution of natural sources to fructose intakes was only 16%, the rest 
originating from added sources. The 95th centile for intakes of naturally sourced 
fructose was 19g per day. As the vast majority of fructose originates from added 
sources, the concern that vegetarianism may substantially increase fructose 
intakes does not seem valid. Indeed the fruit and vegetable intakes of vegetarians 
is only 44% greater than of non-vegetarians (Haddad and Tanzman 2003). 
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The mean fructose intake for males aged 19-30 years was 71g per day, with a 95th 
centile of 120g per day. The values for women of the same age were 55g and 
104g per day respectively. Fructose intakes on average contributed 9.1% to the 
total daily energy intake, and for males aged 19-30 years the mean contribution 
was 10.0%, with a 95th centile of 16.6%.  
There is no intake data for for individual sugars in the UK, but fructose 
intakes seem to be less than that reported in the US. The UK Department of 
Health presents data on the population’s intakes of NMES (non-milk extrinsic 
sugar) intakes, due to its greater cariogenic potential than lactose, as opposed to 
individual sugars. Sucrose is the principal dietary NMES, though not exclusively. 
According to the 2009 National Diet and Nutrition Survey (NDNS), the average 
UK 25-34 year old male consumes 73g per day of NMES (NDNS 2009). This 
provides 13.0% of total energy intake. It is unclear as to what the relative 
contribution of each sugar is to this total NMES, though it is notable that 55% 
originates from beverages, and 35% originates from sugar, preserves and 
confectionary. It is therefore highly likely that the majority of this is sucrose and 
its constituent components of fructose and glucose.  
There are two issues with the above data: 
a. Firstly, it bears remembering that the history of dietary sweetener 
consumption is slightly different in the USA than the UK. In the USA the 
contribution of high fructose corn syrup (HFCS) to the national dietary sweeteners 
increased from around 0% to around 35% in between 1960 and 1985 (Park and 
Yetley 1993). HFCS contains around 55% fructose to 45% glucose. The high 
fructose content of HFCS is a source of much concern in the USA, though there is 
no evidence that justifies this. HFCS acts metabolically the same as sucrose, 
which is 50% fructose and 50% glucose (Melanson, Zukley et al. 2007; Stanhope, 
Griffen et al. 2008). It also bears remembering that HFCS is only used as a 
sucrose replacement, and so it has no substantial impact on the overall intakes of 
glucose or fructose. HFCS is not added to foodstuffs in the UK where sucrose is 
the predominant sweetener.  
b. There is no such data presented on intakes of other simple sugars, 
presumably because there is less interest or concern over glucose than fructose. 
Though it begs the question as to whether a high fructose but low glucose intake 
is possible or whether their intakes tend to be equivalent. The majority of fructose 
and glucose originates from sucrose containing drinks and sweets with an even 
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glucose and fructose content. The foodstuffs with an uneven balance of fructose 
and glucose are fruit and vegetables. So intake patterns of fruit and vegetables 
could theoretically result in a difference in overall glucose and fructose intakes.  
The five main fruits and vegetables purchased in the UK and their fructose 
and glucose content are presented in table 4. Combining average weekly intakes 
with their composition results in a 30% greater fructose than glucose intake from 
fruit and vegetables. This absolute value is not reliable as it does not contain all 
fruits and vegetables, is purchase as opposed to consumption data, and the intake 
data source is old. Since 1998 the survey has been switched to the Expenditure 
and Food survey which collects data on money spent as opposed to amount of 
foods bought.  
Limitations withstanding, it does reinforce the notion that it is difficult to 
have an intake of fructose or glucose which markedly differs from the other. It 
bears remembering that fruit and vegetables only contribute 13% of total fructose 
intakes. So studies presenting an association between fructose intakes and an 
outcome may well have noted the same associations with glucose had they 
analysed / presented this data. Unfortunately in the absence of data this argument 
can neither be proven nor refuted. 
 
 Purchase per 
head per week (g) 
Fructose g (%) Glucose g (%) 
Banana  197 20.9 (10.6) 20.5 (10.4) 
Apple 173 14.2 (8.2) 6.4 (3.7) 
Tomato 85 1.4 (1.6) 1.3 (1.5) 
Orange 63 2.8 (4.4) 2.6 (4.2) 
Pear 49 3.7 (7.5) 1.3 (2.7) 
    
Potato  889 6.2 (0.7) 7.1 (0.8) 
Carrot 109 2.9 (2.7 ) 3.2 (2.9) 
Onion 103 2.7 (2.6) 3.2 (3.1) 
Cauliflower  93 0.8 (0.9) 0.9 (1.0) 
Cabbage  52 0.5 (1.0) 0.6 (1.1) 
    
Average  56.1 41.0 
 
Table 4. Weekly purchases in the UK of the five main fruit and the five main 
vegetables and their fructose and glucose content (purchase data from the 
National Food Survey (MAFF 1998), and composition data from McCance and 
Widdowson 6th edition (FSA 2002)). 
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1.9.2.1. Trends in fructose and glucose intakes 
 
Mintz’s fascinating account of the global history of sugar estimates that in 
the past 150 years there has been a 2,500% increase in UK sugar intakes (Mintz 
1986). Pre the 1850’s honey was the main dietary sweetener, though it was never 
mass produced and so access to any sweetener was very limited. At that time the 
main carbohydrates consumed were barley, wheat, oats and rye (Johnson, Segal et 
al. 2007). Historical food disappearance records describe that the average 
consumption of sugar per capita per year in England was 1.8kg in 1700, rising to 
8.1kg in 1800, and is currently 67.6kg (Johnson, Segal et al. 2007). This massive 
increase in consumption was largely due to the discovery of the New World. 
Sugar plantations were set up in the New World and West African slaves 
imported to work them. The subsequent industrialisation of agriculture, global 
transportation and ultimately food production has meant that foodstuffs such as 
cakes, biscuits and sugar-sweetened drinks are now widely and cheaply available. 
More recently the percentage of total energy intakes from added sugar rose from 
15% in 1965 to 18% in 1999-2000 (Duffey and Popkin 2008). This remained 
stable at 17% in 2003-2204.  
As already described, the use of HFCS in the USA has recently 
dramatically increased. Trend data for fructose itself (as opposed to sucrose or 
HFCS) is extremely limited. Studies analysing fructose intakes reported in the 
1988 to 1994 and 1999 to 2004 NHANES surveys describe gradual increases in 
intakes in fructose over time though these changes are dwarfed by greater 
increases in total daily carbohydrate and energy intakes (Vos, Kimmons et al. 
2008; Marriott, Cole et al. 2009).  
 
1.9.2.2. Recommended intakes of fructose and glucose  
 
There is no UK dietary reference value (DRV) for fructose, glucose or 
sucrose. The Department of Health advised upper limit for NMES is 10% of all 
dietary energy intake (DOH 1991). The WHO advises that less than 10% of all 
energy should originate from mono and disaccharides (WHO 2003). 
The lack of DRV for sucrose – a whole food with no micronutrient content 
and hence no nutritional value beyond energy provision has been repeatedly 
questioned (Ruxton 2003). The European Food Safety Authority (EFSA) drafted a 
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proposal for the DRV for carbohydrate and dietary fibre in late 2009, though it 
felt there was insufficient data to set an upper limit for sucrose intake.  
 
1.9.3. Metabolism of fructose and glucose 
 
All polysaccharides and disaccharides are hydrolysed to their constituent 
monosaccharides (principally glucose and fructose) by intestinal brush border 
enzymes prior to gastrointestinal absorption. Glucose is actively transported along 
with two sodium ions across the intestinal mucosa by the sodium-glucose co-
transporter 1 (SGLT1), whereas fructose undergoes passive facilitated transport 
by glucose transporter type 5 (GLUT5) (Wright, Martin et al. 2003). The lack of 
active transportation means that fructose malabsorption may occur either as a 
result of a GLUT5 deficiency (Born 2007) or following a dietary intake greater 
than can be passively absorbed (Rumessen and Gudmand-Hoyer 1986). Fructose 
malabsorption symptoms include abdominal distension, flatulence or diarrhoea. 
For reasons that are unclear, fructose absorption seems to be improved by the co-
consumption of glucose (Rumessen and Gudmand-Hoyer 1986). As a result 
complete fructose absorption has been shown to occur when 50g of fructose is 
taken with 50g of glucose, whereas only 68% is absorbed when 50g of fructose is 
consumed alone. In standard dietary situations fructose is not consumed in 
isolation, and at smaller doses than 50g. So the majority of intakes appear to be 
absorbed and the effects of fructose malabsorption, if any, on systemic 
metabolism in standard dietary conditions remain undetermined (Bizeau and 
Pagliassotti 2005). Absorbed glucose and fructose enter the portal circulation and 
hence are transported first to the liver before entering the systemic circulation. 
Their initial transference straight to the liver is critical to their outcome. 
The maintenance of normoglycaemia is one of the key components of 
homeostasis. The nervous system is not able to oxidise fatty acids and so relies 
predominantly on glucose as its energy source, whereas erythrocytes are entirely 
glucose energy dependent. Glycaemia depends upon the rate of glucose intake 
(absorption from the gut), tissue consumption (glycogen, amino acid and fatty 
acid synthesis, and glycolysis, citric acid cycle and the pentose phosphate 
pathway) and endogenous glucose production (glycogenolysis and 
gluconeogenesis). The liver is the central organ to these metabolic processes. 
Normoglycaemia is achieved via hormonal control of the above processes, with a 
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balance between the actions of insulin and insulin-like growth factors and the 
opposing glucagon, catecholamines, cortisol and growth hormone. As will now be 
discussed, hepatic metabolism of glucose is principally influenced by the degree 
of insulin sensitivity, and whether it is during the fasted (post-absorptive) state or 
during the fed (post-prandial) state. 
 
1. Normal glucose physiology: 
a. The fasted state 
In the fasted state the availability of glucose for intestinal absorption falls, 
and so endogenous production increases in order to prevent hypoglycaemia. 
Insulin levels drop and glucagon and catecholamines are produced. This initially 
results in glycogenolysis, however prolonged fasting (greater than 8 to 12 hours) 
depletes hepatic and muscle glycogen stores such that gluconeogenesis is 
initiated. The liver is the main organ involved in gluconeogenesis (some renal 
contribution occurs during prolonged fasting) and produces glucose from amino 
acids, glycerol and lactate. Ketone bodies are used in prolonged fasting. Of note, 
during fasting there remains a continuous basal secretion rate of insulin so as to 
prevent excessive hepatic glucose production. The term hepatic insulin sensitivity 
refers to the degree of reduction in hepatic glucose production in response to 
insulin. 
 
b. The fed state 
In the fed state the majority of serum glucose arises from dietary rather 
than endogenous source and the catabolic state of fasting reverts to an anabolic 
one. In response to luminal carbohydrates, the intestinal wall produces the incretin 
hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) (Baggio and Drucker 2007). These incretin hormones stimulate 
the pancreatic beta cells to release insulin before the glucose reaches the systemic 
circulation. A systemic glucose concentration greater than 3.3mmol/L further 
stimulates pancreatic insulin and amylin secretion (Cryer 2008). 
Insulin acts to reduce postprandial glucose via activating translocation of 
GLUT4 glucose transporters to the cell surface of skeletal muscle and adipose 
tissue. As a result, glucose enters the cells and due to an effect of insulin within 
the cells is stored intracellularly either as glycogen or triglycerides for subsequent 
release during a further post-prandial period. 
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2. Glucose physiology and systemic insulin resistance 
Systemic insulin resistance is characterised by fasting and postprandial 
hyperglycaemia due to the failure of glucose to enter insulin-dependent tissues 
and persistent endogenous production. This results from a reduction in cell surface 
GLUT4 transporter number and function (Karnieli and Armoni 2008). 
Consequently there is a reduction in glucose uptake by skeletal muscles and 
increased hepatic glucose output. Insulin also has indirect effects on glucose 
metabolism by suppressing adipose tissue lipolysis and modulating adipokine 
release (Bizeau and Pagliassotti 2005). As a result there is an initial rise in insulin 
secretion in an attempt to improve insulin-mediated responses followed by a 
subsequent fall in insulin secretion with pancreatic functional decline. These 
processes result in the development of a dysregulated hyperglycaemia, and 
ultimately type 2 diabetes which is characterised by systemic insulin resistance 
DQGORVVRISDQFUHDWLFȕ-cell function. 
 
1.9.4. The effects of fructose and glucose on insulin profiles and sensitivity 
 
In ex vivo KXPDQ VWXGLHV IUXFWRVH GLUHFWO\ LQGXFHV OHVV SDQFUHDWLF ȕ-cell 
stimulation than glucose (Curry 1989). Furthermore a fructose load has a very low 
glycaemic index of 23 and this further reduces the stimulus for insulin release 
compared to an identical glucose load (Teff, Elliott et al. 2004).  The reduced 
glycaemic index and insulin response to fructose, as opposed to glucose, in 
humans is unquestioned. However the long-term effects on systemic and hepatic 
insulin resistance in humans are much less clear.  
In rodents a high fructose or sucrose diet induces systemic and hepatic 
insulin resistance as well as hepatic steatosis (Thresher, Podolin et al. 2000). 
Unfortunately this study lacked a glucose comparator and so this cannot be 
viewed as a fructose or sucrose specific effect. Fructose appears to induce hepatic 
insulin resistance in both a direct and indirect manner. The binding of insulin to 
its receptor results in the phosphorylation of the intracellular portion of the 
receptor. Intracellular insulin receptor signalling is attenuated by c-Jun N-terminal 
kinase (JNK) (Tuncman, Hirosumi et al. 2006; Singh, Wang et al. 2009). High 
fructose diets in rodents increase hepatic JNK activity (Wei, Wang et al. 2005), 
which reduce post insulin-receptor signalling and hence result in hepatic insulin 
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resistance which is characterised by and greater hepatic glucose and fatty acid 
synthesis (Wei, Wang et al. 2007). These effects may be further compounded by 
fructose induced hepatic steatosis impairing hepatic insulin sensitivity. The 
association between these two states is well established, though whether hepatic 
steatosis is the result of insulin resistance, or whether hepatic steatosis causes 
insulin resistance remains unclear (Garg and Misra 2002).  
Clinical studies have attempted to reproduce these rodent findings. A key 
limitation in assessing many of these studies is that the control failed to match the 
intervention in terms of energy and carbohydrate content. The studies have also 
varied in terms of fructose doses, supplied diets, single dose versus long-term 
dietary changes, and subject factors such as obesity, pre-existing insulin 
resistance, age, and sex. Schaefer et al. performed a comprehensive literature 
review and found that the majority of these studies have failed to show any 
significant difference at all between fructose and glucose intakes on systemic 
insulin resistance (Schaefer, Gleason et al. 2009). There have been numerous 
short-term studies involving oral or intravenous carbohydrate loading. 
Astonishingly there are only three published long-term healthy volunteer (i.e. non-
diabetic) studies with an energy matched control that have assessed the influence 
of fructose or sucrose on fasted insulin sensitivity using a dynamic test. The 
findings of these papers will be discussed in chapter 4, but to summarise, both a 
high glucose and fructose intake impair insulin sensitivity. Fructose appears to 
result in greater insulin resistance though this has only been shown to be 
significantly different in a single study. 
 Using a longitudinal observational approach, several studies have assessed 
the influence of sugar-sweetened beverage consumption on incident diabetic 
development. Most have shown positive associations (Meyer, Kushi et al. 2000; 
Schulze, Manson et al. 2004; Montonen, Jarvinen et al. 2007; Palmer, Boggs et al. 
2008) whereas others have found none (Liu, Serdula et al. 2004). These papers are 
difficult to interpret however as the consumption of sugar sweetened beverages 
are accompanied by an unhealthy dietary and physical lifestyle. Also it is 
impossible to determine which sugar is responsible for these observations.  
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1.9.5. The differing hepatic metabolism of fructose and glucose 
Both fructose and glucose enter hepatic cells via the GLUT2 transporter 
(Leturque, Brot-Laroche et al. 2005). The metabolic outcome of hepatic fructose 
and glucose is dependent on the need for energy generation or storage as glycogen 
or triglycerides. In addition, fructose can undergo gluconeogenesis, the reverse 
does not occur.  
The key difference between fructose and glucose metabolism is the 
proportion which is metabolised within the liver or peripheral tissues (Schaefer, 
Gleason et al. 2009). 70-80% of intestinally absorbed glucose passes through the 
liver and circulates to peripheral tissues (Cherrington 1999). The reverse is true 
for fructose (DeFronzo, Ferrannini et al. 1978). This effect can be observed in 
clinical studies. Systemic plasma glucose rises by around 3mmol/ following a 
high glucose meal. Following an identical high fructose meal systemic plasma 
fructose rises by only 0.5mmol/l (Chong, Fielding et al. 2007; Teff, Grudziak et 
al. 2009). Indeed within 3 hours circulating fructose concentrations return to zero 
(Teff, Grudziak et al. 2009).  
The very high clearance rate from the circulation by the liver results from 
the high fructose affinity of fructokinase. This initiates fructose catabolism and 
the subsequent pathway lacks any feedback inhibition (Bizeau and Pagliassotti 
2005). Lower rates of hepatic glucose extraction occur as the metabolic pathways 
are strictly regulated and rate limited. Most of the glucose extracted is used for 
glycogen replenishment and catabolism via glycolysis. The “extra” carbohydrate 
extraction with fructose leads to increased glycogen formation as well as entering 
alternative hepatic pathways such as aerobic and anaerobic fructose catabolism 
and de novo lipogenesis (Stanhope, Schwarz et al. 2009). 
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Figure 1.7. Pathways of hepatic carbohydrate catabolism. Triose formation is 
highlighted in blue from fructose, and red from glucose. Subsequent triose 
catabolism resulting in the citric acid cycle, or the formation of lactate or VLDL, 
is highlighted in green.  
 
The first phase of glucose and fructose catabolism converts these 6 carbon 
structures to two 3-carbon trioses: glyceraldehyde-3-P and dihydroxyacetone-P. 
This process requires 2 ATP molecules. These trioses are interconvertible. 
Dihydroxyacetone-P is either catabolised to form glycerol or converted to 
glyceraldehyde-3-P. The second phase of catabolism involves the conversion of a 
triose to pyruvate, with 4 ATP molecules generated. Both of these phases occur in 
the cytosol.  
The overall outcome of both initial phases converts one 6 carbon glucose 
or fructose molecule to 2 pyruvate molecules (3 carbon) with the net production 
of 2 ATP molecules.  
C6H12O6 + 2 NAD+ + 2 ADP + 2 P -----> 2 CH3(C=O)COOH + 2 ATP + 2 NADH + 2 H+ 
 
The subsequent potential catabolic outcomes for pyruvate are either 
decarboxylation to acetyl CoA or anaerobic reduction to lactate. Any acetyl CoA 
formed either enters the citric acid cycle or forms triacylglycerol (triglyceride) via 
Acyl-CoA and glycerol. Following acetyl CoA entrance into the citric acid cycle 
hydrogen molecules are released and enter the electron-transport chain via NADH 
and FADH2. The transference of 2 pyruvate molecules into the citric acid cycle 
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and electron transport chain via acetyl CoA generates a further 34 ATP molecules. 
So the full catabolism of a single glucose or fructose molecule via the aerobic 
pathway has a net production of 36 ATP molecules. 
C6H12O6 +6O2 6CO2+6H2O + 36 ATP 
Anaerobic catabolism occurs either in the presence of inadequate tissue 
oxygen, or if the functional capacity of the mitochondria is exceeded. In anaerobic 
catabolism pyruvate is reduced to lactate. This occurs within the cytosol by lactate 
dehydrogenase and generates no further ATP. So the catabolism of a single 
glucose or fructose molecule via the anaerobic pathway has a net gain of only 2 
ATP molecules. Clearly aerobic catabolism is a much more energy efficient 
process. 
C6H12O6 2 CH3CHOHCOOH + 2 ATP 
The catabolic pathways for glucose and fructose are identical after the first 
phase – the formation of trioses. The key difference is that the enzymatic control 
of this initial critical phase differs between the two. Fructose enzymes lack the 
strict feedback inhibition present for glucose and so they differ in their rates of 
triose formation. This is central to their differing metabolic outcomes. In glucose 
catabolism (glycolysis) the second step forms glucose-6-phosphate (G6P) which 
has 3 possible outcomes: 
1. continue glycolysis via the formation of  fructose 1,6-bis phosphate 
2. entrance into the pentose phosphate pathway  
3. glycogen formation 
These first two potential outcomes are energy generating, whereas the 
latter is energy storing. Strict feedback control exists to ensure that there is a 
balance between these potential differing outcomes. This is achieved by the end 
products of the citric acid cycle (citrate and ATP) providing feedback inhibition 
on glucokinase and phosphofructokinase action.  
Glucokinase phosphorylates glucose to form glucose-6-phosphate. 
Fructose-6-phosphate (F6P) is then formed by phosphoglucose isomerise. F6P 
provides negative feedback inhibition on glucokinase by enhancing glucokinase 
regulatory protein (GKRP) mediated inhibition of glucokinase activity. So 
synthesis and accumulation of initial glycolytic intermediaries causes feedback 
inhibition on glycolysis. This is important physiologically as it prevents the 
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otherwise unregulated and excessive production of distal metabolites including 
triacylglycerol and lactate from glucose.  
Distal aerobic glycolytic metabolites, citrate and ATP, also provide 
feedback via phosphofructokinase. Phosphofructokinase forms fructose 1,6-bis 
phosphate from fructose-6-phosphate. The rate of this step is strictly regulated as, 
once formed, fructose 1,6-bis phosphate is irreversibly committed to undergoing 
glycolysis. Inhibition of phosphofructokinase results in an accumulation of F6P 
which switches off glucokinase via GKRP. As a result the presence of adequate 
cellular energy, in the form of ATP, prevents an excess of hepatic glucose 
catabolism. Glucose is either not metabolised at all and passes into the systemic 
circulation or is transferred to form glycogen. 
G6P and hence F6P is also formed by galactose or glycogen catabolism, 
and so feedback on phosphofructokinase affects glucose, galactose and glycogen 
identically. Fructose does not form F6P and fructose catabolism (fructolysis) 
differs in that it lacks any end-product feedback control. This lack of feedback 
control means that more fructose can enter the pathway than is needed for energy 
yielding metabolism. So a high concentration of fructose results in an abundance 
of triose and pyruvate formation greater than a comparative glucose concentration 
(Mayes 1993). This high pyruvate concentration exceeds the mitochondrial ability 
for it to undergo citric acid cycle and electron transport chain. The excess 
pyruvate therefore is shunted into alternative pathways either lactate, or glycogen 
or VLDL formation.  
The cut-off value for oral fructose intake which  exceeds the liver’s 
mitochondrial ability to handle pyruvate is undetermined. It is likely to vary and 
be dependent on metabolic needs (Mayes 1993). Clinical studies however do 
provide some evidence that support these notions of dysregulated fructose as 
opposed to glucose catabolism. Following a high fructose, as opposed glucose, 
load there is clear evidence of hepatic ATP depletion and increased hepatic 
pyruvate formation with resultant increased lactate, and triglyceride production: 
 
1. ATP depletion. 
The initial phase of fructose and glucose catabolism involves the 
formation of trioses at the expense of 2 ATP molecules. This initial ‘investment’ 
phase is normally subsequently ‘rewarded’ by further aerobic or anaerobic 
catabolism. ATP depletion occurs if this reward is not generated by further 
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catabolism, and may be compounded by further ATP utilisation for lactate to 
undergo gluconeogenesis or glycogenesis.  
31Phosphorus magnetic resonance spectroscopy (31P MRS) allows for 
frequent and accurate quantification of hepatic in vivo ATP, fructose-1-P and 
inorganic phosphate (Pi) concentrations (Solga, Horska et al. 2005). The intra-
observer correlation coefficient for interpreting the spectra is high at between 0.83 
and 0.92 (Solga, Horska et al. 2008). Several groups have given healthy 
volunteers a single large dose of fructose and assessed their hepatic response 
using 31P MRS (Terrier, Vock et al. 1989; Segebarth, Grivegnee et al. 1991; 
Boesch, Elsing et al. 1997; Cortez-Pinto, Chatham et al. 1999). A consistent, rapid 
and dramatic picture emerges from these studies. The first change to occur is a 
rise in the phosphomonoester (PME) peak, which represents a rise in fructose-1-P. 
This returns to normal within 20 minutes of the fructose administration. The next 
change to occur is approximately a 50% reduction in ATP levels from the baseline 
values. That Pi levels rise following the fall in ATP further reinforces the 
assumption that the ATP depletion is due to a net catabolism. These changes 
normalise within an hour in healthy volunteers, though are more prolonged in 
those with NAFLD (Cortez-Pinto, Chatham et al. 1999; Nair, V et al. 2003). 
ATP consumption within the liver results in an increased formation of 
adenine nucleotides. These are degraded to form uric acid (Tran, Yuen et al. 
2009). There is moderately convincing evidence that a high fructose intake results 
in hyperuricaemia and indeed gout as is discussed in chapter 5. 
 
2. Increased lactate production 
Brundin and Wahren performed an extraordinary and highly informative 
set of experiments (Brundin and Wahren 1993). In healthy volunteers they 
analysed blood samples taken from hepatic venous catheters before and after oral 
intakes of 75g of fructose or glucose. The findings are summarised in table 5. It is 
clear that hepatic release of monosaccharides was much smaller following 
fructose than glucose, indicating that the majority of the fructose was metabolised 
within the liver. This was reinforced by the greater hepatic release of pyruvate and 
lactate following oral fructose than glucose, suggesting increased rates of triose 
catabolism and anaerobic glycolysis.  
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 15 min post 
fructose 
15 min post 
glucose 
60 min post 
fructose 
60 min post 
glucose 
Fructose 638 . 659 . 
Glucose  788 5180 503 5653 
Pyruvate 249 3 317 107 
Lactate 1653 13 2316 501 
 
Table 5: Increases in hepatic venous concentrations of fructose, glucose, 
lactate and pyruvate as compared to baseline following consumption of either 
75g of fructose or glucose (units expUHVVHG DUH ȝPROPLQ (Brundin and 
Wahren 1993) 
 
Similar acute systemic elevations in lactate have also been described by 
other authors, though none have employed such invasive catheterisation 
techniques (Delarue, Normand et al. 1993; Chong, Fielding et al. 2007). Post-
prandial elevations in lactate synthesis have also been shown in long-term high 
fructose diet studies (Le, Faeh et al. 2006).  
 
3. Increased hepatic de novo lipogenesis and plasma triglyceride 
concentration 
The evidence that fructose results in greater rates of hepatic de novo 
lipogenesis (DNL) than glucose is limited. Two pathways have been suggested. 
Firstly, by greater rates of fructolysis than glycolysis resulting in increased 
triglyceride formation. Secondly, by up-regulating hepatic lipogenic transcription 
factors and enzymes such as carbohydrate responsive element binding protein-1c 
(CHREBP-1c) and fatty acid synthase (FAS) (Roglans, Vila et al. 2007; Koo, 
Wallig et al. 2008). These findings are widely reported, but the findings by 
Roglans et al. demonstrated an identical response to glucose.  
Faeh et al. demonstrated increased rates of DNL following fructose and 
energy overfeeding in healthy male volunteers, though the lack of adequate 
control failed to show that this was a fructose specific effect (Faeh, Minehira et al. 
2005). A fructose specific has been shown however in a single study, with an 
increase in DNL rates of 27% following a 10 week high glucose diet and by 75% 
following a matched 10 week high fructose diet (Stanhope, Schwarz et al. 2009). 
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 The key hepatic question from these observations that remains to be fully 
resolved is what is the consequence of the (possibly) increased DNL rate? This 
will now be discussed. 
 
1.9.6. Potential mechanisms for differing hepatic triglyceride synthesis rates 
between fructose and glucose 
1.9.6.1. A greater rate of de novo lipogenesis with fructose than glucose 
 
Potential outcomes of an increased DNL rate are either increased intra-
hepatic storage as triglyceride, catabolism via beta oxidation or exportation into 
the plasma as VLDL incorporated triglyceride, see figure 1.1. Rodent data 
describes increases in all three processes with a high fructose diet (Nagai, Nishio 
et al. 2002; Roglans, Vila et al. 2007). These three processes have been assessed 
to a limited extent in only a single clinical trial with an adequate control. 
A high fructose diet has previously been shown to elevate fasting plasma 
triglycerides, but only once in a study with an adequate and energy balanced 
control (Silbernagel, Machann et al. 2011). This did show an increased fasted 
triglyceride concentration following 4 weeks of fructose versus glucose, this 
however was the only significant difference between these two groups and 
therefore the significance of this isolated finding is uncertain. 
As opposed to fasted assessments, post-prandial assessments in the acute 
or long-term setting, have repeatedly demonstrated an elevated plasma 
triglyceride profile in comparison to a high glucose intake (Bantle, Raatz et al. 
2000; Teff, Elliott et al. 2004; Swarbrick, Stanhope et al. 2008; Stanhope, 
Schwarz et al. 2009).  
The aetiology of the post-prandial fructose induced hypertriglyceridaemia 
appears to be both the result of both increased production (DNL) and reduced 
clearance by lipoprotein lipase (LPL) (Chong, Fielding et al. 2007; Stanhope, 
Schwarz et al. 2009). The reduced post-prandial insulin release following fructose 
results in reduced LPL activation, and hence reduced lipolysis of chylomicrons 
and VLDLs and their removal from the circulation into adipocytes. To further 
substantiate the reduced LPL activation, circulating  NEFAs, a by-product of LPL 
lipolysis, are lower following a high fructose than glucose diet (Le, Ith et al. 2009; 
Stanhope, Schwarz et al. 2009).  
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The final critical difference between glucose and fructose metabolism is 
the ultimate storage location of the synthesised circulating VLDL. In their 
excellent and balanced study, Stanhope et al. demonstrated that a 10 week high 
fructose or high glucose diet resulted in identical amounts of weight gain at 
around 1.5kg (Stanhope, Schwarz et al. 2009). The increased adiposity was 
mainly subcutaneous following glucose and visceral following fructose. This 
adipose deposition pattern had never been previously assessed. A recent study that 
failed to show any differences between 4 weeks of 23% fructose or glucose in any 
parameter, bar fasted triglycerides, showed no such changes in subcutaneous 
versus visceral lipid deposition (Silbernagel, Machann et al. 2011). Ngo Sock et 
al. published the only other energy matched study comparing the lipid deposition 
patterns in the two key alternative organs to adipocytes – liver and muscle (Ngo 
Sock, Le et al. 2010). No difference was shown between glucose and fructose 
though there was greater IMCL deposition with glucose.  
The reasons behind these disparate findings are unclear as will be further 
discussed in chapter 4. Ex vivo human adipose tissue studies have demonstrated a 
greater LPL insulin sensitivity in subcutaneous adipose tissue than visceral (Fried, 
Russell et al. 1993). No mechanistic evidence was generated by Stanhope et al. 
and hence their explanation for the findings, that the greater circulating insulin 
with a high glucose diet resulted in preferential subcutaneous as opposed to 
visceral fatty acid deposition, can only be viewed as conjecture.  
 
1.9.6.2. The prebiotic nature of fructose acting on Toll-like receptor 4 
 
If the ability of the small bowel to passively absorb dietary fructose is 
exceeded then it enters the colon. This colonic entry has a prebiotic effect on the 
intestinal microflora. Dietary glucose has no prebiotic effects as it is actively 
absorbed and so does not enter the colon. In rodents a high fructose diet has been 
shown to increase portal endotoxin concentrations, with a high glucose diet 
having no such effect (Bergheim, Weber et al. 2008). This same paper 
demonstrated that the use of non-absorbable antibiotics (polymyxin B and 
neomycin) markedly reduced the steatosis resulting from a high fructose diet. No 
data was shown as to whether the antibiotics did reduce portal endotoxin levels, 
though the authors felt that they had discovered a further and novel pathway for 
fructose induced hepatic steatosis – via portal endotoxin release. 
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Toll-Like receptor 4 (TLR4) is a complex expressed on the surface of the 
hepatic macrophage kupffer cells. TLR4 complexes are activated by portal 
endotoxin and result in a pro-inflammatory reaction that results in hepatic injury 
and fibrosis (Rivera, Adegboyega et al. 2007). Following this initial paper the 
same group compared dietary carbohydrate intakes with plasma endotoxin and 
hepatic TLR4 mRNA in 12 biopsy proven NAFLD patients and 6 healthy controls 
(Thuy, Ladurner et al. 2008). As expected there was a close correlation between 
the concentration of circulating endotoxin and the expression of TLR4 mRNA, 
whereas there was no correlation between fructose intakes and either plasma 
endotoxin concentrations or hepatic TLR4 mRNA.  
Following this negative paper, the same group further explored the 
potential links between fructose, endotoxin, TLR4 and hepatic steatosis. TLR4 
wild-type and knock-out mice were randomised to water or fructose in their drinks 
(Spruss, Kanuri et al. 2009). The authors claim that they demonstrated a link 
between hepatic steatosis, TLR4 status and a fructose-specific effect. 
Unfortunately there are many limitations in this paper as highlighted in my letter 
to the authors (Johnston, Macdonald et al. 2010). TLR4 status has a clear 
influence on overall hepatic metabolism and thus limits the utility of the 
assessment model. Furthermore, the two diets of chow with either water or water 
plus 30% fructose were not matched in terms of carbohydrate, energy or prebiotic 
intake. As a result it is not possible to determine whether the observed changes are 
fructose, energy or prebiotic specific. Additionally, there is a weight gain disparity 
between the fructose fed TLR4 wild-type and knock-out groups and consumption 
data are not presented. Finally, there appeared to be no difference in the response 
to a high fructose diet dependent on TLR4 status when the paper’s findings are 
analysed relative to each groups’ control. This intriguing and attractive area of 
work therefore needs further study before any definitive conclusions can be 
drawn. 
 
1.9.7. High fructose diet as an animal model of NAFLD 
A high fructose diet is an established rodent model for NAFLD inducing 
insulin resistance, obesity, hepatic steatosis, lobular inflammation, fibrosis and 
necrosis with acidophil bodies (Ackerman, Oron-Herman et al. 2005; Anstee and 
Goldin 2006). It has been shown to be a better model for inducing steatosis and 
lobular inflammation than a high fat diet (Kawasaki, Igarashi et al. 2009), though 
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the inflammatory changes are not entirely predictable. The key limitations in 
translating rodent dietary observations to clinical studies are that rodent and 
human hepatic metabolism differs, and the doses used in rodent studies are 
typically much greater than that observed or tolerated in human diets.  
Fructose contributes 10% of energy to an average male diet, with a 95th 
centile contribution of 17% (Marriott, Cole et al. 2009), whereas rodent model 
studies can supply as much as 70% of energy originating from fructose 
(Kawasaki, Igarashi et al. 2009). When such a high proportion of dietary intakes 
originate from a single macronutrient there is a risk of deficiencies of other macro 
or micro-nutrients. Some elegant and relatively low dose fructose studies have 
however shown that it can be a model for NAFLD. Roglans et al. supplied rats 
with drinks containing either water, or 10% fructose or 10% glucose on top of 
standard chow for 2 weeks (Roglans, Vila et al. 2007). There were identical 
intakes of sugars between the fructose and glucose arms. Similar weight changes 
were observed in all three arms as the glucose and fructose fed rats compensated 
for the energy containing drinks by eating less chow. There was no difference in 
terms of systemic insulin resistance, whereas there was a 1.8-fold increase in 
hepatic triglyceride content in the fructose group with a non-significant increase 
in the glucose group. Histological assessment of liver injury was not performed in 
this study, though it is clear that a relatively low intake of fructose as opposed to 
glucose did result in greater hepatic steatosis.   
 
1.9.8. High fructose diet and prior clinical experience of hepatic fatty acid 
metabolism 
 As presented in section 1.8.1., NAFLD diets have been frequently 
characterised by a high fructose intake. Ouyang et al. further explored these 
fructose observations (Ouyang, Cirillo et al. 2008). They took dietary histories in 
6 biopsy proven NAFLD patients and 6 healthy volunteers with a normal liver 
biopsy. Both the cases and controls were matched in terms of age, sex and BMI. 
The daily fructose beverage intake was 91g in the NAFLD patients and 43g in the 
control arm (p<0.05). A murine hepatocyte cell line was next exposed to differing 
concentrations of fructose. Fructokinase was shown to be upregulated in terms of 
its activity and expression by the addition of fructose in a dose-dependent manner. 
This demonstrated that hepatic fructokinase can be viewed as a biomarker of 
hepatic exposure to fructose. The group then quantified fructokinase mRNA in 
 77  
their two human liver biopsies. In comparison to the normal livers, hepatic 
fructokinase mRNA expression was increased by more than 2-fold, and fatty acid 
synthase (FAS) was increased by more than 3-fold in the NAFLD livers. This 
confirms the dietary histories and shows that the NAFLD livers had been exposed 
to and metabolised more fructose than the healthy BMI matched control livers. 
This however does not prove a causal nor fructose-specific relationship as glucose 
intakes were not assessed or presented. 
  There are relatively few clinical studies that have compared fructose 
versus glucose outcomes on hepatic metabolism and so they will be repeatedly 
referred to. In order to minimise repetition they will be individually discussed 
below: 
 Professor Luc Tappy’s group (Lausanne, Switzerland) have performed 
five of the prior six studies that have assessed the hepatic metabolic consequences 
of a high fructose diet (HFrD) in healthy volunteers. The studies are all very 
similar in design, though difficult to interpret. Unfortunately five out of the six 
lack either an energy or carbohydrate matched control. All of the studies provide 
fructose in drinks consumed in addition to food intakes. They involve a random 
crossover between the arms with a washout period of 2-4 weeks. Only one 
(negative) study presents baseline data including weights (Le, Faeh et al. 2006). 
This is critical as it is impossible to determine the adequacy of the washouts, or 
the absolute changes with the interventions. Instead the post intervention findings 
in the other four papers are compared with the findings post a control period 
where food is supplied. This ‘control’, ‘weight maintenance’, or ‘isoenergetic’ 
arm also has no weight maintenance or metabolic data presented and so it is 
impossible to be certain that there is not some underfeeding and hence metabolic 
alteration occurring in this comparator arm. Furthermore the fructose fed group 
consumes the same control diet plus additional fructose. The resultant energy 
difference between the fructose-fed and control group is around 800-1,000kcal per 
day. It is therefore theoretically possible that the results merely reflect energy 
overfeeding (with fructose) versus energy underfeeding. As a consequence it is 
impossible to state that the effects observed are fructose specific. 
 A further major issue is that the supplied food results in carbohydrate 
overfeeding providing 50-55% of the energy. The mean carbohydrate contribution 
to total energy intake in UK men is 43.0±7.3% (SD) with the 97.5% centile at 
56.1% (NDNS 2009). So the control group are not consuming a standard 
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carbohydrate intake. Finally, there is no mention of investigator blinding in any of 
the protocols. The six papers by this Lausanne group led by Luc Tappy are 
presented below: 
1. The first study involved 7 healthy and slim male volunteers with a mean 
body fat of 16.5% (Faeh, Minehira et al. 2005). Both groups consumed an 
identical isoenergetic diet for 6 days with or without 3g/kg of fructose per day. At 
the end of the 6 days body weights were greater with the HFrD than the energy 
reduced control, though with no differences in systemic insulin resistance. 
Interestingly, hepatic insulin resistance was induced, and hepatic de-novo 
lipogenesis and fasting triglycerides increased by 588% and 79% respectively. 
2. A similar protocol was observed where 8 healthy men and 8 healthy 
women received an isoenergetic diet for 6 days with or without 3.5g/kg per day of 
fructose (Couchepin, Le et al. 2008). Very similar post intervention period 
differences were shown in terms of systemic and hepatic insulin resistance in the 
men, though no differences were observed in the women despite greater fasted 
plasma triglycerides. In the men there was greater plasma ALT (a marker of 
hepatic injury) following the high fructose and energy period. The authors were 
uncertain as to the reason behind the differing responses between the sexes. They 
speculated as to whether this may be a result of differing hormonal profiles, body 
composition or hepatic metabolism. No further study has compared the influence 
of sex on the hepatic insulin sensitivity response to a HFrD. 
3. Two further studies have assessed hepatic lipid content using proton MR 
spectroscopy. The first took 7 healthy slim males with a low fructose intake, who 
consumed 18% fructose in addition to their baseline intakes for 4 weeks (Le, Faeh 
et al. 2006). There was no control group though baseline data were presented. 
There was an increase in fasting plasma triglycerides, lactate and reduced 
ketogenesis as evidenced by reduced beta-hydroxybutyrate. Insulin sensitivity and 
hepatic and muscle steatosis were assessed at baseline and weeks 1 and 4. There 
were no significant changes noted in these parameters. This could be explained by 
compliance or sample size issues. Weight gain was minimal at 0.3%, which is 
surprising as the fructose supplied 18% extra energy for 4 weeks. Carbohydrate 
and lipid oxidation rates were unchanged at week 4. As foods were not supplied 
and dietary intakes not presented, it would appear that there was either 
considerable dietary adaptation or non-compliance. The number of volunteers was 
very small at 7. 
 79  
4. The group clearly also felt that their prior study had limitations as they 
essentially repeated the study, this time with a larger cohort, greater fructose dose 
and shorter intervention period. 16 healthy slim men with a first degree relative 
with type 2 diabetes, and 8 men with no such family history, took 7 days of a high 
fructose diet providing 35% of their energy needs followed by a standard diet (Le, 
Ith et al. 2009). The energy difference between the two groups was again around 
810kcal per day, and as a result there was a 1.3% weight difference at the end of 
the study between the groups. In comparison to the low energy ‘controls’, the high 
fructose diet resulted in a 78% increase in hepatic lipids, and 5% increase in 
fasting hepatic glucose output. These changes were more marked in those with a 
family history of type 2 diabetes than those without. The reason for this is unclear. 
There are no baseline data to allow us to compare these two groups. Comparing 
the post-intervention data for the ‘control’, the 16 volunteers with a family history 
of type 2 diabetes had greater body weight and fat, greater hepatic lipid content, 
and were more systemically insulin resistant than the 8 healthy volunteers. There 
was no difference in terms of hepatic insulin resistance. It is therefore impossible 
to speculate as to which of these factors resulted in an increased susceptibility to 
the HFrD.  
5. Fructose overfeeding was compared with fat or fructose and fat 
overfeeding in healthy slim men (Sobrecases, Le et al. 2010). An isoenergetic 
diet, with no baseline data, was compared with 35% energy overfeeding with 
fructose for 7 days, and 30% energy overfeeding with fat for 4 days, and 35% 
energy overfeeding with fructose and 30% energy overfeeding with fat combined 
for 4 days. This extraordinary design meant that the groups all differed in 
macronutrients, energy and duration too. As a result little can be reliably inferred 
from it. The combined fat and fructose resulted in a greater increase in hepatic 
triglyceride content (HTGC) than fat or fructose alone, but the influence of the 
greater energy supply cannot be discounted for. 
6. The above studies lacked any true control and so cannot be viewed as 
being fructose specific. The final study performed by the same group addressed 
this issue and was published after the initiation of my study (Chapter 2). Ngo 
Sock et al. performed a 7day 35% fructose versus 35% glucose study versus a 
control diet in 11 healthy males (Ngo Sock, Le et al. 2010). Unfortunately there 
are the same issues with the data presentation of this study. There was only a 2-3 
week washout period employed between three arms, and no baseline data. 
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Furthermore the absolute HTGC values are not presented, despite being the 
primary outcome measure. Instead the mean log HTGC (no units) is presented 
graphically post intervention, so it is very unclear as to what the units of HTGC 
were.  
The cohort recruited had a BMI between 19 and 25 and were insulin 
sensitive (HOMA-IR of 1.0). Significant increases in the fructose and glucose 
treatments were seen for HTGC (52% vs. 58%), IMCL (49% vs. 84%), and 
VLDL (59% vs. 31%). As expected, carbohydrate oxidation increased in both. 
Curiously there was an identical increase in lactate and uric acid in both 
treatments and a similar reduction in NEFAs and beta-hydroxybutyrate. There is 
no comment on the outcome of systemic insulin resistance whilst hepatic insulin 
resistance reduced in both. The authors state that the HTGC changes in this study 
are smaller (52% versus 79%) than they have previously found with similar 
(uncontrolled) fructose overfeeding (Le, Ith et al. 2009), and that the inter-
individual variability may have been a factor. As a result the authors do not 
conclude that glucose and fructose have the same hepatic lipid outcomes. 
Since the onset of my current work a group separate from Luc Tappy’s 
published another related paper. This paper was in many ways well designed and 
presented, with the investigators being blinded to the randomisation process 
(Silbernagel, Machann et al. 2011). The cohort however was small at 10 in each 
arm and also of mixed sex that may have added another factor. 150g of fructose or 
glucose was consumed three times a day. Food was not supplied, but they were 
instructed to consume a diet containing 50% carbohydrates, 35% fat and 15% 
protein and the physical activity factor was fixed at 1.6. The cohort was evenly 
balanced at study entry. They were relatively slim with a mean BMI of 25.9kg/m2 
and low body fat of around 23%. As a result they were insulin sensitive (mean 
HOMA-IR of around 1.7) and had a low initial HTGC (around 1.5%).   
 There were no interim visits and unfortunately the two arms seemed to 
differ markedly in their energy intakes during the intervention period. The 
fructose group’s weight change was only 0.2±0.6kg (SEM) (p=0.40), indeed 
several seemed to lose weight. Weight gain seemed to be universal in the glucose 
arm as the changes were +1.7±0.4kg (p=0.001). So as a result the fructose arm 
appears to be isoenergetic and the glucose hyperenergetic. It is an interesting 
study, though the marked difference in weight gain between the two groups 
significantly hampers any real interpretation. Ultimately the only changes that 
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differed from baseline in either arm (including uric acid or NEFA) were an 
elevated fasting triglyceride with fructose, and an increased HOMA-IR with 
glucose. There were no changes that were different between the two arms. 
There was a non-significant increase in HTGC of 34% as compared to the 
baseline value in the fructose arm and 33% in the glucose arm, though the wide 
variation in responses meant that neither of these changes was significantly 
different from the baseline values. The changes in IMCL were again non-
significant at +24% and -6% respectively.  
 There is one final paper that is worthy of a mention though it did not 
assess hepatic lipid content (HTGC). Stanhope et al. randomised 32 (obese men 
and post-menopausal women who were older than prior studies (mean age 54), to 
10 weeks of drinks providing 25% of predicted energy needs as either fructose or 
glucose. Compliance and weight gain were matched equally between the arms. 
The study protocol was metabolically exhaustive and involved 2 weeks of 
baseline inpatient stay within the unit, 8 weeks as an outpatient and a final 2 
weeks as an inpatient. There was no crossover. During the initial pre-intervention 
2 weeks, weight was maintained by provided food that had a very low fructose 
(1.5%) and glucose (2.9%) content. The next 8 weeks were then as an outpatient 
with ad libitum food intakes but with no sugar-containing drink bar the fructose or 
glucose which was mixed with water. The same inpatient food was then finally 
consumed during the last 2 weeks with the fructose or glucose. These details are 
critical to interpreting the study. Pre-study habitual food intakes are not presented, 
though there was clearly a washout of all monosaccharides before the intervention 
started and of the non supplemented monosaccharide for two weeks pre repeat 
assessment. This approach meant that very real changes in intakes could be 
assured, though it compared the outcomes of dramatic changes in monosaccharide 
intakes from around 2% to 30% during the outpatient phase. Beyond these 
observations there are little other critical comments that can be directed towards 
this excellent and blinded paper. 
 Glucose had no influence on systemic insulin sensitivity, whereas fructose 
impaired sensitivity by 17% as assessed by a 3 hour oral glucose tolerance test 
and by deuterated glucose disposal. 24-hour circulating triglycerides increased by 
18% with fructose and by 3% with glucose. These changes were in association 
with increased postprandial DNL and reduced postprandial lipoprotein lipase 
(LPL) activity (non-significant). The authors attribute the LPL changes to lower 
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postprandial insulin concentrations. Ectopic lipid storage was only assessed by CT 
scans of the umbilical region to determine subcutaneous and visceral fat content. 
Weight changes were the same in both groups though fructose resulted in greater 
increases in visceral adiposity (14.0% vs. 3.2%) and abdominal subcutaneous 
adiposity too (7.3% vs. 4.6%). It therefore is unclear as to where the weight was 
deposited following glucose, though one assumes that it was in peripheral adipose 
stores. This is supported by the findings in the gluteal subcutaneous fat biopsies. 
Indeed lipogenic and lipid desaturation gene expression increased following 
glucose and was unchanged or reduced following fructose. Interestingly the 
DGLSRVH WLVVXH DGLSRQHFWLQ 71)Į EDODQFH ZDV ZRUVHQHG IROORZLQJ JOXFRVH DQG
improved witK IUXFWRVH 8QIRUWXQDWHO\ WKHUH ZDV QR V\VWHPLF 71)Į RU
adiponectin data presented. 
 In conclusion there is a conundrum. The single best and most long-term 
paper has demonstrated changes in all the factors associated with hepatic steatosis 
namely insulin resistance, visceral adiposity and increased DNL. However it 
failed to assess hepatic lipid content. No other controlled paper has shown all of 
these findings or that hepatic lipid content is increased following a high fructose 
intake. The aim was therefore to reproduce many of the key features of the paper 
by Stanhope et al. and to avoid some of the others’ pitfalls.  
 
1.9.9. Conclusions on fructose and glucose on hepatic fatty acid metabolism 
 
 The hepatic metabolism of fructose and glucose primarily differ as a result 
of their hepatic extraction rates. This is summarised in figure 1.8. Fructose results 
in a greater hepatic production of lactate and lipids, and increased hepatic insulin 
resistance and visceral adiposity. Compiling all the mechanisms previously 
described, fructose may result in greater hepatic steatosis than glucose by: 
 
1. increasing de novo lipogenesis, both through substrate provision and by 
upregulation of lipogenic factors. 
2. increasing visceral adiposity resulting in increased portal NEFA delivery to the 
liver 
3. inducing hepatic insulin resistance either by stimulating hepatic JNK activity and 
thus impairing post insulin-receptor signalling, or as a potential consequence of 
hepatic steatosis itself. 
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4. acting as an intestinal prebiotic resulting in greater portal endotoxin induced 
TLR4 activation. There is as yet however very limited evidence for this pathway. 
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Figure 1.8: Comparative overview of proposed fructose (blue) and glucose 
(red) metabolism. Hepatic effects are shown in green and systemic effects in 
yellow. (DNL = de novo lipogenesis; TG = triglyceride; IR = insulin resistance; 
VLDL = Very Low Density Lipoprotein; SAT LPL = Subcutaneous adipose tissue 
lipoprotein lipase; VAT TG = visceral adipose tissue triglyceride.) 
 
 This hypothesis that a high fructose diet (HFrD) may induce steatosis is 
further supported by the following observations: 
a. Biomarker and self-reported food intake patterns describe greater fructose 
intake patterns in NAFLD patients than matched controls. 
b. That a HFrD (albeit often a very HFrD) is a reliable rodent model for 
NAFLD  
c. That a HFrD has been shown to increase hepatic triglyceride content, 
though this has not been shown to be a fructose-specific effect.  
d. A single study demonstrating that a HFrD as opposed to glucose results in 
greater insulin resistance, visceral adiposity and DNL. 
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 This thesis aims to explore the impact of intakes of differing 
macronutrients on hepatic lipid metabolism. Given the background data described 
I chose to assess outcomes following altered intakes of fructose and n-3 PUFAs. 
Two studies were performed, both with the primary outcome measure of hepatic 
triglyceride content, whilst additional explanatory measures were also assessed.  
 A high fructose intake was compared with a high glucose intake in healthy 
overweight male volunteers, whilst the use of n-3 PUFA supplements were 
compared with oleic enriched sunflower oil supplements in patients with biopsy 
proven NAFLD. The fructose versus glucose study is detailed in chapters 3 to 5 
and the n-3 PUFA study is detailed in chapter 6.  
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Chapter 2. Methods 
 
2.1. Energy predictions 
The determination of resting energy expenditure (REE) by formulae is 
controversial and fraught with challenges. This is particularly an issue in the 
obese. The Schofield equation is widely employed, and uses the criteria of gender, 
age and weight to determine resting energy expenditure (Schofield 1985). The 
formula originates from a database of a combination of prior published studies. 
The result is both a strength and a weakness, with over 60% of the data on men 
aged between 10 to 60 years originating from Italian studies published between 
1936 and 1942. There are therefore concerns that the Schofield database does not 
reflect that observed in modern populations, and there have been observations that 
the energy requirements of Italians appear to differ from that of Northern 
Europeans.(Shetty, Henry et al. 1996)  
The metabolic rate of adipose tissue is lower than that of lean tissue. As a 
result, it has been shown that REE increases in a non-linear fashion with weight, 
with a slower increase in men weighing more than 75kg.(Horgan and Stubbs 
2003) As a result linear formulae tend to over predict energy needs in the 
overweight or obese. This is a particular problem when using the Schofield 
equation, and there is little data to support its use in the obese 
setting.(Frankenfield, Roth-Yousey et al. 2005) 
As a result Henry re-appraised the prior published energy requirements 
data in 2005.(Henry 2005) New predictive formulae were generated using height 
as an additional criterion to those of Schofield. The combination of weight and 
height results in an improved, but still imperfect, proxy for adiposity. The basal 
metabolic rate predicted by the Henry formula results in a 1-4% lower value in 
overweight young men than the Schofield equation. These equations have been 
assessed in the overweight male setting by 2 further groups, both of which have 
shown the formulae to be more accurate than the Schofield formula. (Ramirez-Zea 
2005; Weijs 2008) 
The Henry formulae for men are 
18 - 29 years:   REE = 14.4 x W + 313 x H + 113  
30 - 59 years:   REE = 11.4 x W + 541 x H - 137  
Where W is weight in kilograms, and H is height in meters, and REE is kcal/day 
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The determination of total energy expenditure (TEE) requires adjustment 
for the activity of the subject. Using doubly labeled water, Tooze et al. described a 
mean physical activity factor of 1.7 in overweight and obese middle-aged 
men.(Tooze, Schoeller et al. 2007) Subjects’ physical activity was assessed using 
the self-completed short version of the International Physical Activity 
Questionnaire (IPAQ) at the initial screening assessment (Hagstromer, Oja et al. 
2006). The IPAQ was developed in the late 1990s by a multi-national group, 
supported by the WHO. The short version of the IPAQ is quick and simple to 
administer and has been shown to correlate acceptably with objective evidence of 
physical exercise.(Mader, Martin et al. 2006) It assesses physical activity levels 
during the preceding seven days and generates a low, moderate or high activity 
score.  
 
2.2. Indirect calorimetry 
Direct calorimetry determines total energy expenditure (TEE) by 
measuring heat loss in a thermally sealed chamber and thus estimating heat 
production. Indirect calorimetry quantifies resting energy expenditure (REE) by 
measuring respiratory oxygen consumption and carbon dioxide production. REE 
is converted to TEE by: 
TEE = (REE + diet induced thermogenesis) x activity factor 
 
Diet induced thermogenesis varies little in most physiological 
circumstances and impacts little on the determination of TEE.  
Resting energy release arises from the oxidation of stored macronutrients: 
Substrate + O2  CO2 + H2O + Heat 
 
The amount of respiratory oxygen consumed (VO2), and carbon dioxide 
exhaled (VCO2) are measured by the calorimeter. The ratio between VCO2 and 
VO2 is termed the respiratory quotient (RQ), and reflects substrate oxidation. 
Oxidation of each of the main macronutrients results in a predictable amount of 
oxygen consumption and carbon dioxide production. The complete oxidation of 
glucose consumes 6mol of O2 and produces 6mol of CO2. As a result the RQ is 
1.0. The RQs for lipid and protein oxidation are 0.69 and 0.81 respectively 
(Haugen, Chan et al. 2007).  
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Using indirect calorimetry substrate oxidation rates can be calculated by the non-
protein equations of Peronnet and Massicotte (Peronnet and Massicotte 1991): 
Carbohydrate oxidation (g/min):  4.585 * VCO2 – 3.226 * VO2   
Fat oxidation (g/min):   1.695 * VO2 – 1.701 * VCO2 
These calculations assume that there is no accumulation or excretion from 
the body of a metabolic intermediary or end-product other than those in the 
equation, namely CO2, water or heat. Such states of accumulation or excretion can 
exist however, and include lipogenesis, gluconeogenesis, ketogenesis and lactate 
formation (Frayn 1983).  As a result, net carbohydrate oxidation rates generated 
by the above equations during periods of de novo lipogenesis also include the rate 
of conversion of glucose to fatty acids. This elevates the observed RQ, as the RQ 
of lipogenesis is 5.6. Furthermore, during lipogenesis calculated lipid oxidation 
values can become negative, the apparent negative rates of fat oxidation 
quantitatively represents net rates of fat synthesis.  
The gluconeogenic oxidation of lactate and pyruvate do not influence the 
calculations as the Cori cycle does not involve gaseous exchange. Protein 
oxidation resulting in gluconeogenesis consumes CO2 whilst producing no O2, 
though this process is rare in the absence of a very high protein diet or diabetes 
(Livesey and Elia 1988).  This has no influence on lipid oxidation rates and only a 
minimal influence on carbohydrate oxidation rates (Frayn 1983). Ketogenesis may 
need to be taken into account when studying subjects undergoing prolonged 
fasting. The formation of lactate may influence acid-base balance and hence 
displace CO2 from bicarbonate stores. This effect is most important in anaerobic 
exercise studies. Any influence however is very small in the absence of rapid 
changes in blood lactate concentrations (Frayn 1983). 
During an insulin clamp a steady state of plasma glucose is achieved. As a 
result, the glucose infusion rate is assumed to equal the whole body glucose 
disposal rate (G total). During the clamp procedure the rate of glucose oxidation (G 
ox) can be determined by indirect calorimetry. As a result the rate of non-oxidative 
glucose disposal (predominantly glycogen storage) can be calculated as: 
G
 non-ox = G total – G ox 
 
2.3. Satiety assessment 
There is a very large inter-subject variability in reported satiety and energy 
during periods of routine intake or following a dietary intervention. Visual 
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analogue scales (VAS) are widely used in to monitor satiety and its changes. 
Subjects are asked to mark along a line as to where their response fits between 
two opposing statements. The main advantage of this is its ease of design, but the 
interpretation is difficult as they cannot be assumed to measure the absolute 
intensity of a sensation. For example, a mark at 30mm along a line does not 
necessarily infer that the sensation is half as intense as a mark at 60mm.  
 
2.4. Whole body dual energy X-ray absorptiometry (DEXA)  
This technique was originally developed to quantify bone mineral density, 
though it has been extended to assess a whole body’s bone, fat and lean tissue 
mass.  X-rays produced by tungsten tubes result in photons of differing energies 
passing through the body which are quantified by filters in a sequential and planar 
projection. The molecular compositions of fat, lean tissue and bone result in 
differing absorption and scattering patterns for low and high energy photons. 
From these characteristic patterns the relative proportions of these tissues can be 
determined (Brownbill and Ilich 2005). Regional, as opposed to compartmental, 
data can be generated as only a single plane is assessed. As a result no 
differentiation is possible between fat content within the abdominal visceral and 
subcutaneous spaces. Cross-sectional CT or MRI images are needed to reliably 
assess compartmental compositions.  
There is no true gold standard in vivo method for analysing body 
composition. The correlation between whole body MRI taken at 10mm slices and 
DEXA was excellent, with an r2 of 0.95 (Vogt, Ruehm et al. 2007). The analysis 
of MRI data is extremely laborious and the investigation expensive. DEXA scans 
are the most commonly performed body composition assessment modality due to 
their speed of assessment and analysis, cost and low radiation exposure. There are 
however four potential limitations to the use of DEXA: the use of ionising 
radiation, the influence of hydration status, size of the absorption field, and its 
failure to distinguish overlying tissues types.  
The dose of ionising radiation supplied varies slightly according to the size of 
the individual, though it is small at around 0.2µSv (Bezakova, Collins et al. 1997). 
The annual background exposure dose is greater than 1000µSv and so the 
procedure results in a minimal increase. The failure of DEXA to measure body 
water does however limit its accuracy. A five percent change in the water content 
of the lean body mass alters DEXA derived estimates of whole body fatness by 1-
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2.5% (Lohman, Harris et al. 2000). Such variations are rare in healthy and stable 
conditions, and so in this setting the influence of hydration is negligible 
(Pietrobelli, Wang et al. 1998). The limbs of severely overweight individuals can 
fall outside the scanning area of the DEXA scanner, and overlapping of body parts 
increases thickness in those regions (Brownbill and Ilich 2005). The filters cannot 
distinguish between three tissue types in the same area. So when fat and lean 
tissue overlies bone the values cannot be directly resolved and have to be 
interpolated. The above accepted it is an acceptably reliable, safe and reproducible 
assessment. 
 
2.5. Quantifying insulin resistance 
 
2.5.1. Homeostasis model assessment of insulin resistance (HOMA) 
This is a simple assessment of insulin resistance in the overnight fasted 
state from a single blood test. It assumes a dynamic and functional feedback 
between the liver and pancreatic Beta cells. Insulin concentrations reflect Beta cell 
response to plasma glucose concentrations, whereas hepatic glucose production is 
regulated by the insulin concentration. As a result a high glucose concentration 
and hence HOMA value primarily reflects fasted hepatic resistance to insulin-
mediated reduction in gluconeogenesis. 
The formula is: 
HOMA = {[fasting insulin (µIU/ml)] * [fasting glucose (mmol/l)]} / 22.5. 
(Matthews, Hosker et al. 1985) 
 
The denominator of 22.5 is employed as a normalising factor; as the 
product of normal fasting plasma insulin (5 U/ml) and normal fasting plasma 
glucose (4.5mmol/l) is 22.5. Hence a healthy HOMA is approximately 1.0, and 
the higher the value the more resistant the individual. Though due to lack of 
standardised insulin assay techniques the inter-assay values means that it is not 
possible to define cut off points for insulin resistance. The other main issue with 
the use of HOMA is its low reproducibility of around 23% (Sarafidis, Lasaridis et 
al. 2007).  
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2.5.2. Adipose tissue insulin resistance (Adipo-IR) 
Recently the quantification of a fasted adipose insulin resistance index has 
been described, based on feedback between insulin and adipose tissue lipolysis via 
hormone sensitive lipase (Gastaldelli, Cusi et al. 2007). Adipo-IR correlates with 
hepatic fat (r=0.54) (Gastaldelli, Harrison et al. 2009). The formula is: 
Adipo-IR = Free fatty acids (mmol/L) x fasted plasma insulin (pmol/L). 
 
2.5.3. Hyperinsulinaemic euglycaemic clamp 
This technique is recognised as being the ‘gold standard’ for determining 
whole body glucose sensitivity to insulin in vivo (Muniyappa, Lee et al. 2008). It 
differs from the HOMA assessment in that it mimics the postprandial, as opposed 
to fasted, state and also it predominantly assesses tissue sensitivity to insulin-
mediated glucose uptake as opposed to hepatic sensitivity to insulin-mediated 
regulation of gluconeogenesis.  
The delivery of exogenous insulin, as opposed to relying on endogenous 
insulin production, increases its reproducibility over homeostasis models and 
glucose tolerance tests. The clamp procedure can be used to quantify sensitivity to 
several of insulin’s actions beyond that of whole body glucose disposal. Adipose 
tissue sensitivity to insulin-mediated lipolysis can be assessed by free fatty acid 
concentrations during the procedure. Hepatic insulin sensitivity and glucose 
output can be determined with the addition of a glucose tracer, as will be 
discussed further. Finally, the combination with indirect calorimetry facilitates the 
quantification of glycogen synthesis (i.e. non-oxidative glucose disposal) as 
previously described. 
Determining systemic insulin sensitivity by use of a hyperinsulinaemic 
euglycaemic clamp 
Using the protocol described by DeFronzo et al. (DeFronzo, Tobin et al. 
1979), exogenous insulin is delivered as a loading bolus over 10 minutes followed 
by a constant infusion at a pre-determined dose. A stable plasma glucose 
concentration is maintained by the simultaneous infusion of glucose. The delivery 
of a high insulin concentration mimics the postprandial state and is assumed to 
fully suppress endogenous glucose production. As a result of the suppression of 
endogenous production, the rate of exogenous glucose supplied equals the rate of 
whole body glucose disposal at steady state plasma glucose (M). M is typically 
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normalised to fat free mass as glucose uptake can only occur in these tissues 
(Ferrannini and Mari 1998).    
From the above it is clear that the determination of the timing of ‘steady 
state’ is critical to the analysis of the data generated. Two approaches can be 
taken, either defining an arbitrary time point towards the end of the clamp study, 
or by taking data from a period of objective stability more than an hour into the 
clamp (Muniyappa, Lee et al. 2008). The objective criteria proposed include a 
period greater than 30 minutes during which the coefficient of variation of plasma 
glucose, plasma insulin, and glucose infusion rate (GIR) is less than 5%. The 
latter approach is more rigorous, though may not be achieved during every clamp. 
Determining adipocyte insulin sensitivity 
Insulin suppresses lipolysis in adipocytes via inhibition of hormone-
sensitive lipase and thus reduces circulating plasma NEFA concentrations. The 
relative reduction in plasma NEFA concentrations following insulin delivery 
during a clamp can thus be used to assess adipocyte insulin sensitivity. 
Determining hepatic insulin sensitivity 
This was performed by using a stable glucose isotope dilution technique 
during basal and insulin stimulated periods. The addition of a label to 
exogenously delivered glucose enables differentiation of the origin of circulating 
glucose from exogenous and endogenous sources.  
Deuterated glucose is a stable isotope of glucose containing 2H as opposed 
to the naturally occurring 1H. The differing atomic masses of 2H and 1H glucose 
facilitate their individual quantification by mass spectrometry. The location of the 
isotopic label in the glucose molecule determines which metabolic pathways the 
tracer enters post glucose catabolism. Dideuterated glucose with deuterium in the 
6th position ([6,6-2H2]) was selected as it is less susceptible to intermediary step 
analyses than the 2nd or 3rd position, and hence estimates total glucose turnover 
with greater accuracy (Choukem and Gautier 2008). The rate of appearance (Ra) 
of [6,6-2H2] is its rate of infusion, and hence at steady glucose state the proportion 
of [6,6-2H2] dideuterated glucose amongst total glucose facilitates estimations of 
endogenous glucose production.  
There are 3 main assumptions made about the behaviour of tracer glucose: 
1. The tracer is treated and distributed the same as unlabelled glucose. 
2. At steady state the rate of tracer infusion is proportional to its disposal. 
3. The tracer is not recycled  
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The first two assumptions have been shown to be essentially valid (Wolfe RR 
2004). However, recycling has been shown to occur. Labeled glucose can be taken 
up peripherally and metabolised to pyruvate and then lactate. The labeled lactate 
can then return back to the liver and re-form glucose. The resultant endogenous, 
hepatically synthesised, glucose will be labeled and circulate in the plasma as 
either ([6,6-2H2]) or ([3,3-2H2]) glucose. As a result some of the products of this 
recycling and endogenous re-synthesis are indistinguishable from exogenous 
labeled glucose. The magnitude of this effect is not believed to be great 
(Finegood, Bergman et al. 1987), though it results in an underestimate of the rate 
of hepatic glucose production.  
Equations of Steele: 
The most commonly used equations to determine hepatic insulin 
sensitivity are the equations of Steele (Steele 1959). These equations rely on the 
assumptions that there is only a single compartment of distribution and that it has 
a constant volume. Several authors have questioned these assumptions (Cobelli, 
Mari et al. 1987; Finegood, Bergman et al. 1987), though these original equations 
remain the most widely used (Choukem and Gautier 2008).  
C* + C
Ra*
Rd*
Ra Rd
 
Figure 2.1. Depiction of a one compartment model (adapted from (Choukem 
and Gautier 2008)). Ra: rate of appearance of unlabelled (hepatic + exogenous 
sources) glucose. Ra*: rate of appearance of tracer glucose. C: unlabelled plasma 
glucose concentration. C*: labeled plasma glucose concentration. Rd: rate of 
disappearance of unlabelled glucose. Rd*: rate of disappearance of tracer glucose. 
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As depicted above in figure 2.1., during steady-state conditions, the 
combined rate of glucose appearance (Ra + Ra*) equals its combined 
disappearance rate (Rd + Rd*). Furthermore, the ratio of labeled to unlabeled 
plasma glucose (C* / C) also reflects the relative rate of the labeled tracer infusion 
to the rate of endogenous glucose production. So the equations of Steele for 
hepatic glucose production (HGP) are: 
HGP = TIR / (C* / C)  
Where TIR is tracer infusion rate. The greater the HGP the more resistant 
the liver is to the effects of insulin. HGP can be further related to plasma insulin 
to form a hepatic insulin resistance index (Matsuda and DeFronzo 1999). 
Hepatic insulin resistance index = 1 / (HGP x plasma insulin) x 100 
It bears remembering that the liver is not the only glucose-producing organ during 
fasting conditions. The renal contribution is at least 5% (Choukem and Gautier 
2008).  
Modifications to the equations of Steele: 
In the postabsorptive (fasted) state there is essentially no glycolysis of 
glucose within the liver, and therefore all hepatically produced glucose enters the 
circulation. A one-compartmental model can therefore be used in this setting. 
However as previously discussed, in the presence of glucose and insulin 
administration glucose is disposed of in muscle and liver either by oxidation or by 
non-oxidation (glycogen formation). This results in a non-static volume of 
distribution during a clamp.  
 
If ‘A’ is the amount of tracer (C* in figure 2.1.) and ‘B’ is the amount of tracee (C 
in figure 2.1.), then the enrichment ‘E’ is: 
E = A/B 
If we determine values at a specific time (t) DQGFKDQJHVDVįWKHQ 
į$t/ įt = Et į%t/įt) + Bt į(t įt) (equation 1) 
 
&KDQJHVLQWKHWRWDODPRXQWRIWUDFHHZLWKLQDSRROį%tRYHUDWLPHSHULRGįt) 
are equal to the differences between its rate of entry (Ra) and disappearance (Rd): 
 
į%t įt = Ra – Rd (equation 2) 
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&KDQJHVLQWKHWRWDODPRXQWRIWUDFHUZLWKLQDSRROį$tRYHUDWLPHSHULRGįt) 
are equal to the rate that it is infused (F) minus the rate that it leaves the pool 
(RdE): 
 
į$t įt = F – RdE (equation 3) 
combining equations 3 and 1: 
Et į%t/įt) + Bt į(t įt) = F – RdE 
Combining this with equation 2: 
Et (Ra – Rd) + Bt į(t įt) = F – RdE 
Hence 
Ra = [F- Bt į(t įt)] / Et 
 
As glucose tracee and tracer do not mix instantaneously additional factors need to 
be added, where ‘p’ is the fraction of the total pool that does not rapidly mix, and 
the total extracellular glucose space is ‘V’. As a result the amended formula is: 
 
Ra = [F- pV ((C2 + C1)/ 2) * ((E2 – E1) / (t2 – t1))] / ((E2 + E1) / 2) 
 
Where C is concentration, E enrichment and t is time at two time points (1 and 2). 
The commonly used value for p is 0.65 (Cowan and Hetenyi 1971), and 25% of 
body weight for V (Rebrin, Steil et al. 1999). 
 
A large volume of exogenous glucose is typically infused during a glucose clamp 
which results in a fall in glucose enrichment. The problem of negative values for 
glucose production can be avoided by the addition of tracer to the exogenous 
glucose infused, a so-called ‘hot infusion’ protocol (Finegood, Bergman et al. 
1987) (Levy, Brown et al. 1989). Such an approach was used by Powrie et al. who 
developed a formula for Ra (hepatic glucose production) (Powrie, Smith et al. 
1992): 
 
Ra = (F / Ep(t)) + (Evar * Ivar(t)) / Ep(t)) – ((p*V*G(t)į(S(t) įW(S(t))  
 
Where F is the glucose tracer constant infusion rate, Ep(t) is the plasma enrichment 
at time t, Evar is the enrichment of the variable glucose solution used during the 
 95  
clamp, Ivar(t) is the infusion rate of that solution, and G is the prevailing glucose 
concentration. 
,WZLOOEHQRWHGWKDWDWVWHDG\VWDWHWKHYDOXHIRUį(S(t) is zero and hence Ra is 
the sum of infusion divided by enrichment of the constant and variable solutions. 
From this, endogenous (hepatic) glucose production = Ra – exogenous glucose 
infusion rate 
 
2.6. MRI and MRS 
In order for a nucleus to be observable by magnetic resonance (MR) it must 
have a non-zero spin, i.e. an odd number of protrons such as 1H, 13C, 19F, 23Na, and 
31P. Hydrogen is the most naturally abundant element (99.98%) and hence 1H 
produces the most intense MR signals. As a result 1H is the most frequently used 
element for MR imaging and spectroscopy assessment, and most systems 
incorporate their own 1H receiver. Additional receivers need to be added within 
the magnet if other nuclei such as 13C or 31P are to be assessed. 
The basic principles of MR involve a series of steps. An object is first placed 
within a powerful and homogenous external magnetic field. The nuclei within the 
object thus align themselves parallel or anti-parallel to the field. A brief pulse of 
radiofrequency (RF) energy is then applied tangential to the magnetic field 
polarity. This pulse decreases the longitudinal magnetisation and increases the 
transverse magnetisation, and so the nuclei are displaced. Once the RF pulse is 
stopped there is a period of relaxation when the excited and displaced nuclei re-
align themselves to their original position. The signal generated by this re-
alignment is detected by a coil as free induction decay (FID). The FID is assessed 
at multiple moments during the relaxation period and hence its exponential 
reduction can be plotted as intensity versus time. This FID data undergoes Fourier 
transformation, by computer analysis, generating either an image (MR imaging 
(MRI)) or a frequency spectrum (MR spectroscopy).  
In MR spectroscopy the spectra are plotted on a graph with frequency in parts 
per million (ppm) on the x-axis and spectral amplitude on the y-axis. See figure 3. 
The spectroscopic peaks generated have four principle characteristics: 
A. resonance frequency (ppm), i.e. their position on the x-axis.  
B. height 
C. width 
D. peak area 
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Figure 2. Typical 1H MRS spectroscopic image with the main water peak and the 
smaller methylene lipid peak. 
 
It is the peak area which yields relative measurements of the concentration 
of each nucleus. Furthermore, each nucleus can be identified by its own unique 
and specific resonant frequency. These frequencies however are slightly modified 
by the molecular structure, or environment, of the compound that the nucleus is 
in. This frequency modification process is termed chemical shift, and it results 
from neighbouring electrons forming a cloud which ‘shield’ the nuclei from the 
overall magnetic field. The hydrogen in water (H-O) bond are less shielded than 
the hydrogen in lipids (H-C) bond, and so the hydrogen nuclei in water rotate at a 
higher resonant frequency than those in lipids (Mehta, Thomas et al. 2008). This 
difference in resonant frequency means that hydrogen within water can be 
separately identified and quantified to that within lipids etc. 
This separation effect can be intentionally maximised to improve the 
resolution of the differing spectra peaks. Improved resonance frequency 
separation, and reduced signal-to-noise ratio of spectra can be achieved by 
increasing the strength of the external magnetic field, improving the homogeneity 
of the magnetic field through shimming, and by repeating the excitation sequence 
so that multiple spectra are combined and analysed. As a result compounds with 
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close spectral frequencies can separated, and compounds with tissue 
concentrations as low as 0.1-1 mmol/L can be detected (Roden 2007). 
The final issue is the spatial localisation of the origin of the signals 
received. This is achieved by applying static and/or pulsed gradients along the 
magnetic field. This change in gradient within the field allows for a change in 
frequency of the signal and hence localisation. In MR imaging this facilitates the 
generation of cross sectional or even 3D images of the human body.  
 
2.6.1. Proton magnetic resonance spectroscopy (1H MRS) of liver 
Non-invasive in vivo hepatic fat quantification by 1H MRS involves the 
evaluation of the two main hydrogen-containing peaks, namely water and lipid 
(Szczepaniak, Nurenberg et al. 2005). There is a strong correlation between the 
liver fat quantification of histology by a pathologist and 1H MRS data, with 
correlation coefficients ranging from 0.88 and 0.93 (Thomsen, Becker et al. 1994; 
Cotler, Guzman et al. 2007). However it is important to remember that a strong 
correlation between assessment techniques does not mean that they quantify the 
same factors or generate similar absolute values. Pathologists quantify liver 
biopsy fat content as the percentage of hepatocytes with visible fat droplets, 
whereas 1H MRS determines the fractional volume of fat within the liver 
(Schwenzer, Springer et al. 2009). As a result the values determined by 1H MRS 
are consistently lower than histopathological values (Cotler, Guzman et al. 2007; 
McPherson, Jonsson et al. 2009). Confusion can arise over this as both techniques 
generate scores with percentages as their value. The absolute values for both 
techniques have been shown to differ by a factor of  approximately 1.8 (Longo, 
Pollesello et al. 1995).  
A value of 5.56% has been described as the upper limit of normal for 1H 
MRS determined hepatic triglyceride count (Szczepaniak, Nurenberg et al. 2005). 
This value was derived from being the 95th percentile value from assessments in 
345 subjects in Dallas, USA, with no risk factors for fatty liver disease. The 
subjects had a BMI less than 25kg/m2, low self-reported alcohol consumption, no 
history of liver disease, normal plasma transaminase enzyme levels, and no 
impaired glucose tolerance or diabetes. It was assumed that none of these 
individuals would have increased liver fat stores and so the 95th percentile was an 
appropriate cut-off value. This assumption cannot be fully maintained given the 
absence of a confirmatory normal liver biopsy, accurate alcohol history, and that 
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15% of the cohort were Hispanic – an ethnicity with a high rate of steatosis. It 
therefore seems plausible that more than 5% of the cohort had steatosis, and that 
the true cut-off value for steatosis is somewhat less than 5.56%. A large scale 
study with comparative assessment with liver biopsy data would be helpful to 
clarify this, though this may never be performed. 
Ignoring the interpretation of the absolute value generated by 1H MRS 
assessment of hepatic triglyceride count, it is clear that it is a useful assessment 
tool as it is both non-invasive and reproducible. The inter-examination co-
efficient of variation assessed by removing volunteers from the scanner and 
repositioning them and the voxel is excellent at 7.0% (Thomas, Hamilton et al. 
2005).  
Recently Johnson et al. furthered 1H MRS assessment of liver fat by 
identifying and defining the individual resonant frequencies of differing fatty acid 
functional groups (Johnson, Walton et al. 2008). This was done by generating a 
highly homogenous field, and by suppressing the water peak to increase the 
resolution within and adjacent to the lipid peak. Formulae were generated for 
determining the indexes of fatty acid saturation, unsaturation and polyunsaturation 
within human liver in vivo. This work was done firstly by in vitro analysis of oils 
with a known fatty acid composition, followed by in vivo analysis of 27 lean and 
obese volunteers using a 1.5 Tesla (T) scanner. There was no correlation data 
presented for the in vitro lipid chromatography versus 1H MRS work, and there 
was no comparative assessment with another assessment modality performed in 
the in vivo studies. As a result the paper produced no direct evidence to validate 
what may or may not become a useful non-invasive hepatic lipid profile 
assessment tool. 
The formulae generated by Johnson et al. involve the signal amplitudes of 
the described fatty acid peaks: 
Unsaturated index =  (Allylic + Diallylic) / (Allylic + Diallylic + Methylene + Methyl) 
Saturated index = 1 - (Allylic + Diallylic) / (Allylic + Diallylic + Methylene + Methyl) 
Polyunsaturated index =  Diallylic / (Allylic + Diallylic + Methylene + Methyl) 
 
2.6.2. Proton magnetic resonance spectroscopy (1H MRS) of calf muscle 
Triglyceride is stored in two compartments within muscle: intra- and 
extra-myocellular. Interest in intra-myocellular triglyceride content (IMCL) arises 
as its metabolites appear to impair insulin sensitivity (Hulver and Dohm 2004). 
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Extra-myocellular lipid (EMCL) appears to be relatively biologically inert. The 
main proton signal from muscle is from water, though following water 
suppression the main peak is lipid, and EMCL and IMCL are closely opposed but 
can be separately identified (see figure 4) and modeled for. Unlike the liver, 
movement due to respiration is not an issue. The reproducibility of these findings 
for IMCL is acceptable with a coefficient of variation of 13% using 1.5 T scanner 
(Torriani, Thomas et al. 2005), which would be predicted to be even more 
reproducible with 3T.  
 
 
Figure 4. Proton magnetic resonance spectroscopy (1H MRS) of calf soleus 
muscle. Peaks d and b are IMCL (methyl and methylene respectively) Peaks c and 
a are EMCL (methyl and methylene respectively). 
 
2.6.3. Phosphorus magnetic resonance spectroscopy (31P MRS) of liver 
31P has a 100% natural abundance, however it has a much lower sensitivity 
relative to 1H at 6.6% versus 100% respectively (Roden 2007). It results in sharp 
peak lines over a wide chemical shift range (broad x-axis). External 31P volume 
coils are rare i.e. coils integrally built into the scanner external magnetic system. 
Such external volume coils generate a voxel as per 1H MRS. Commonly, as with 
the Sir Peter Mansfield Magnetic Resonance Centre, a 31P surface coil has to be 
placed over the region of interest and its correct positioning confirmed by imaging 
prior to data collection. The limitation of this approach is that signal intensity has 
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been shown to reduce with a greater distance between the coil and the region of 
interest (Meyerhoff, Karczmar et al. 1990), i.e. subcutaneous muscle and fat 
overlying the liver. As a result it is the ratios between parameters, as opposed to 
their absolute values, which are commonly presented. The tissue detection limit of 
31P MRS in the liver is however reported to be excellent at around 0.1 mmol/l. 
The signals that are detected by 31P involve 4 main spectral groups as shown in 
figure 5.  
 
Figure 5. 31P MRS of the liver demonstrating spectral peaks for the 
phosphomonoesters (PME) PE and PC,  the phosphodiesters (PDE) GPE and 
GPC, inorganic phosphate (PLDQG$73ȖĮDQGȕ 
 
A major limitation in the interpretation of 31P MRS spectral data is that the 
PME and PDE peaks are not specific to one compound as they represent a 
heterogeneous mix of compounds with a phosphomonoester or phosphodiester 
bond, such as phospholipids and sugar phosphates (Solga, Horska et al. 2005). 
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PME rises following the administration of fructose, and this is attributed to the 
generation of fructose-1-phosphate (Boesiger, Buchli et al. 1994). 
The reproducibility of 31P MRS liver data has never been analysed in a large 
scale study. Sijens et al. repeated the analysis in six volunteers on differing days 
in a 2 Tesla scanner (Sijens, Dagnelie et al. 1998). The nature of the subject 
preparation and analysis time was not described. The intra-subject variability of 
the spectral peaks assessed by a single analyser ranged from 10-16%.  
 
2.7. Finometer  
The finometer provides continuous non-invasive beat to beat monitoring of 
haemodynamic status. It measures systolic and diastolic blood pressure, heart rate, 
inter beat interval, cardiac output, stroke volume, left ventricular ejection time, 
total peripheral resistance, and baroreflex sensitivity. Digital artery pulse 
waveforms are tracked by an infrared photo-plethysmograph built into a finger 
cuff. It uses a volume clamp method whereby inflation of the finger cuff opposes 
arterial pressure on a beat-to-beat basis to maintain a constant finger volume.  
The algorithmic equations used from the finger generated assessments derive 
intra-arterial and pressures and hence cardiac function non-invasively. As such it 
is clearly a highly useful assessment tool. Though being non-invasive it makes 
many assumptions about the cardiac and vascular compliance of the individual. 
As a result the true validity of using a finometer is in tracking intra-individual 
changes than for the absolute values it generates (Owen, Priestman et al. 2009). 
Digital artery pressure tends to be lower than brachial artery pressure due to 
progressive arterial narrowing. The finometer remodels and reconstructs the 
digital pressures into a brachial pattern by using a return-to-flow measurement 
from an additional brachial cuff (Bogert and van Lieshout 2005). As a result the 
difference in mean arterial pressure is 2 mmHg between brachial artery catheter 
pressures and finometer derived pressures (Guelen, Westerhof et al. 2008).  
The finometer also comprises Modelflow algorithms to reconstruct a central 
aortic waveform (Wesseling, Jansen et al. 1993). The model assumes the presence 
of a normal aorta and aortic valve, and the absence of pulmonary or abdominal 
hypertension.  Modelflow model uses the parameters of gender, age, height and 
weight to calculate aortic pressures and cardiac function. The waveform is 
integrated to generate stroke volume, and cardiac output is computed as the 
product of stroke volume and heart rate. Total peripheral resistance is computed 
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as a function of mean arterial pressure and cardiac output. In a recent head-to-
head comparison of cardiac thermodilution versus 3 non-invasive cardiac output 
algorithms, the Modelflow performed the best with an observed bias between the 
two assessments of 0.33 l/min (de Wilde, Geerts et al. 2009).  
The above accepted there clearly are several assumptions made by a finometer 
on the cardiovascular health of the individual. The machine itself is also not 
externally calibrated pre each assessment. It is however highly reproducible with 
an intra-individual variation  in stroke volume of 3% and less than 1% variation in 
blood pressure at assessments performed at least a week apart (Voogel and van 
Montfrans 1997).  
 
2.8. Serum spectrophotometry  
This was used to quantify serum creatinine, alkaline phosphatase, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), gamma 
glutamyltransferase (GGT), uric acid, free fatty acids and triglycerides using 
enzyme based assays for the fructose versus glucose study. In brief samples are 
first mixed with a reagent appropriate for each clinical parameter. The 
combination is then homogenised by a mixing palette. The spectrometer is a 
tungsten-halogen white bulb which transmits light to the sample mixture. Light 
that passes through this is then separated by a chromator into pre-determined 
wavelengths which are then focused onto the photometer to quantify the amount 
of light at each wavelength.  
Each reagent has its own pre-determined absorbing wavelength. As the 
amount of absorbance is proportional to the sample concentration, the comparison 
between the fraction of light that passes through a reference and test solution 
allows the spectrophotometer to be quantitative.  
The use of a bichromatic analysis further strengthens the quantitative 
reliability. One wavelength is selected to be within the absorption range, whereas 
another is outside this. This minimises any errors caused by sample turbidity 
(Gavella 1988). 
The ABX Pentra 400 system (Horiba Medical, Montpelier, France) is well 
validated with the company reporting co-efficient of variations (CoV) for the 
repeated use of the reagents of less than 3%, they also report a correlation 
coefficient of greater than r2=0.99 with another commercial reagent. 
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2.9. Statistical analyses 
All raw data were initially entered onto excel spreadsheets, and the data entry 
re-checked. Formulae were employed within Excel, where necessary, to generate 
further data such as body mass index etc. The raw and transformed data was then 
transferred into SPSS version 17.0 and databases formed and analysed. All data 
are presented as the mean ± standard deviation (SD) unless stated otherwise. 
Comparisons between baseline values were done by the independent samples T 
test. The Student’s T test was used for paired data. All studies involved two 
groups. Analysis of the significance of change between the two groups at two 
paired assessments was done by an independent samples T test of the absolute 
change between the two assessments in both groups. Associations were assessed 
for by 2-tailed Pearson correlations. Discrete data was analysed by Chi squared 
analyses. Repeated measures over time were assessed by a repeated measures one-
way ANOVA with a Greenhouse-Geisser correction. 
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Chapter 3. Whole body effects of a high fructose versus high glucose diet 
 
3.1. Introduction 
The rate of hepatic synthesis of trioses from monosaccharides undergoes 
strict feedback inhibition when glucose is involved, which is absent for fructose, 
as previously described in 1.10.3.2. This has led to speculation that fructose may 
lead to greater amounts of post triose metabolic products than glucose. Such 
products include lactate from anaerobic glycolysis, citric acid from aerobic 
glycolysis and triacylglycerols. The determination of which of these potential end 
products predominates is dependent on whole body metabolic status and insulin 
resistance profile. So data on whole body status is presented in this chapter, and 
insulin resistance in chapter 4 and hepatic effects in chapter 5.  
Healthy overweight males were randomised to a high fructose or high 
glucose diet for two separate periods of 2 weeks, firstly in an energy balanced 
(isoenergetic) setting and subsequently in an energy overfeeding (hyperenergetic) 
setting. The monosaccharides were consumed mixed with water four times a day 
and provided 25% of predicted energy requirements. The differing energy periods 
were achieved by firstly providing all food to be consumed and secondly by 
subjects consuming the monosaccharides in addition to their habitual intakes. 
The assessment processes were identical pre and post each intervention 
period. Specific to this chapter, assessments of weight and satiety were 
undertaken to assess energy intakes. Cardio-renal outcomes were assessed by 
serum creatinine and Finometry, a non-invasive beat to beat assessor of 
haemodynamic status. Indirect calorimetry assessed whole body substrate 
oxidative status. 
3.2. Method 
The following is an overview of the method for the data described in 
chapters 3, 4 and 5. 
3.2.1. Recruitment protocol 
The study was recruited for by a variety of methods. Firstly, e-mail invites 
were sent to all overweight male subjects on the local research databases of 
interested future volunteers. Secondly, a purchase order list was obtained from 
Royal Mail, and 2,100 men living in close proximity to the research facility were 
sent a covering letter and study flier. Thirdly, the study was advertised on the free 
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classified website ‘gumtree’. Finally, posters were placed around the university’s 
medical school. 
All interested subjects made contact with the investigator themselves and 
were sent the volunteer information sheet version 2.0 (dated 19/10/2009). 
Interested volunteers were then screened for their suitability by telephone and 
then by clinical review. 
The aim was to recruit young men who were healthy, weight stable, 
centrally overweight with no evidence of liver or renal disease, or diabetes. The 
subjects also had to have a relatively ‘standard’ carbohydrate intake, and a low 
intake of fructose from drinks. As a result the study inclusion criteria were: 
Inclusion criteria 
1. Body mass index 25-32 
2. Waist > 94 cm 
3. Age 18-50 years 
4. Male 
Exclusion criteria 
1. Active health problems requiring ongoing medical review, or chronic 
treatment. 
2. Evidence of metabolic or viral liver disease as screened for by hepatitis B 
and C serology, and plasma ferritin.  
3. Alcohol intake greater than 21 units per week  
4. Abnormal full blood count, liver or renal function tests 
5. Evidence of diabetes with a random glucose greater than 11.0mmol/L. 
6. Evidence of cardiovascular disease – abnormal electrocardiogram or blood 
pressure greater than 140/80 mmHg. 
7. Reported weight change greater than 3 kg in prior 3 months  
8. Regular high intensity physical activity (total energy requirements are difficult 
to reliably predict in such individuals) 
9. Contraindications to MRI or DEXA scanning (standard departmental 
screening protocols employed) 
10. Intolerance to a test drink containing 50g of fructose  
11. Symptoms of functional bloating or irritable bowel syndrome (as these may 
be exacerbated by a subsequent high fructose intake) 
12. Vegetarianism (their normal and supplied food intake would differ from non-
vegetarians) 
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13. Normal daily fructose intake from drinks greater than that in 500ml of coca 
cola (26g). 
14. Abnormal carbohydrate contribution to energy in the baseline diet – defined 
as greater than 2 standard deviations from the mean. Taking the National Diet 
and Nutrition Survey 2002 data for men aged 25-34, this equates to 
carbohydrates intakes contributing less than 36% or greater than 59% (Swan 
2004).  
 
3.2.2. Recruitment phase 
During an initial face to face meeting potential subjects were screened for 
the above criteria. The protocol was discussed and informed consent taken in 
those subjects who were willing and appropriate. Such subjects then underwent 
physical examination, anthropometric assessment, resting electrocardiography and 
non-fasted venesection. The subjects were randomised in a double blind fashion to 
receive 25% of their predicted total energy expenditure (TEE) from either fructose 
or glucose. 
The subjects then prospectively completed three day food records (one 
weekend and two weekdays). These were analysed for the percentage contribution 
to energy from macronutrients and fructose. The results of this and screening tests 
were reviewed prior to a subject’s formal study inclusion. 
Figure 1. Study time-frame with time in weeks along the bottom and food 
intakes and visits (overleaf). 
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3.2.3. First assessment period 
  The study was divided into two interventional periods, both lasting 14 
days, with an intervening six week washout period. During both periods the 
sugars were supplied in food-grade sachets and dissolved in water taken four 
times a day with food. During the first interventional period the supplemented 
sugars were taken in a carefully energy balanced setting with the explicit aim of 
weight maintenance. In order to achieve this all foodstuffs consumed during this 
period were provided. Weight and satiety were monitored after one week and 
energy intakes modified if necessary in order to ensure weight maintenance 
throughout the 2 week period. The energy from the provided foodstuffs and 
sugars combined comprised 55% from carbohydrate, 15% from protein and 30% 
from fat. The macronutrient profiles are presented in table 4. These proportions 
are a modest deviation from the average intakes of men aged 24-34 years in the 
UK of 48%, 16% and 36% respectively (Office for National Statistics and Food 
Standards Agency. Department of Health 2003), and are the same proportions 
used in prior related studies (Bantle, Raatz et al. 2000; Le, Ith et al. 2009; 
Stanhope, Schwarz et al. 2009). Further to this the foodstuffs were designed to be 
reasonably ‘healthy’ with an average of 3 portions of fruit or vegetables a day, a 
total salt content lower than the national male average of 11g per day (FSA 2008), 
and a saturated fatty acid content within the recommended range of 11% of total 
energy provision (SACN 2008).  
Four food plans were devised with differing energy contents energy, 
which in the absence of the supplementary sugars provided 2,000, 2,200, 2,400 or 
2,600 kcal per day. Subjects were allocated the food plan whose energy content 
most closely approximated their requirements. The food plans were designed and 
nutrient profile analysed with ‘Microdiet’ software (Downlee Systems Ltd., 
Salford, UK). The differing food plans had minimal foodstuff deviation between 
them with the differing energy values primarily originating from portion sizes. 
Subjects reviewed and agreed the food plans, and minor modifications were made 
for a handful of volunteers based on their preferences. These modifications 
resulted in minimal deviation from the standard plan. The supermarket delivered 
the foods to the volunteer’s home on four occasions. All deliveries were received, 
though on occasion the supermarket substituted the ordered product for an 
alternative similar product due to stock-related issues.  
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Detailed written instructions as to what to consume at which meal on 
which day were provided. Additional sugar or sugar-sweetened drinks were 
forbidden, and the subjects were asked to not drink more than 2 units of alcohol 
per day. The subjects started to consume the provided foods on the day before the 
first assessment, and consumed identical foods on the day before the week 2 
assessment. 
 
3.2.4. Washout period 
 Previously, 3-5 weeks following a high fructose diet had been reported as 
adequate an adequate washout period (Faeh, Minehira et al. 2005; Abdel-Sayed, 
Binnert et al. 2008; Le, Ith et al. 2009). A washout period of six weeks was 
chosen for this study. During this period subjects were asked to maintain their 
habitual food intakes and lifestyles  
 
3.2.5. Second assessment period  
During the second period the same amount and type of monosaccharide 
was consumed by each subject, though this time in addition to their routine food 
intakes. The only dietary restriction during the second assessment period was to 
consume less than 2 units of alcohol per day. On the days prior to the main 
assessments similar food intakes were encouraged. The subjects were asked to 
maintain stable physical activity during the study period.  
 
3.2.6. Assessment visit protocols 
At each of the main study assessments the subjects first underwent early 
morning fasted MRI and MR spectroscopy in the Sir Peter Mansfield MR centre. 
On the same day they then walked the short distance to the physiology laboratory, 
voided urine, were weighed and then rested for 30 minutes. They then underwent 
20 minutes of indirect calorimetry and Finometry measurement. Finally 
venesection was performed; satiety visual analogue scales self-completed and 
then 20 out of the 32 subjects left the physiology laboratory having been provided 
with breakfast. Twelve subjects remained fasted and underwent a 
hyperinsulinaemic euglycaemic clamp. This procedure is described later on. 
The mid-study assessments involved a brief fasted visit to the laboratory for 
weighing, compliance and side effect discussions, self completion of satiety visual 
analogue scales and venesection.  
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3.3. Power calculation: 
The primary outcome measure was a change in liver triglyceride content. 
In a previous study, mice randomised to consume ad libitum 10% fructose drinks 
for 2 weeks developed 80% greater liver triglyceride concentrations than those 
drinking 10% glucose or water (Roglans, Vila et al. 2007). This occurred in the 
absence of weight differences between the groups.  
Stanhope et al. conducted a 10-week 25% fructose diet which resulted at 
10 weeks in a 25% increase in abdominal visceral adiposity, and a 21% increase 
as compared to glucose. No assessment was made of liver fat stores. Prior MRI 
studies by Thomas et al. have shown a strong correlation between abdominal 
visceral fat and liver fat stores (Thomas, Hamilton et al. 2005). Using the 
formulae generated by Thomas' paper, the changes in visceral fat in Stanhope’s 
paper correspond to a 145% absolute increase in liver fat, and a 124% increase 
relative to glucose. No pre 10 week abdominal visceral adiposity data was 
generated by Stanhope’s study.  
Prior to the present study’s development only one large-scale study had 
assessed the hepatic effects of a high fructose diets in human volunteers. As 
compared to the baseline diet, 35% fructose energy overfeeding for 7 days 
increased liver fat stores by 79% in slim but mildly insulin resistant volunteers, 
and by 76% in slim insulin sensitive volunteers (Le, Ith et al. 2009).  
Provision of greater energy from monosaccharides than 25% was felt to 
make it very difficult to achieve an isoenergetic period. A two-week intervention 
duration was selected as metabolic changes including insulin resistance and 
hypertriglyceridaemia were detected in the Stanhope paper at 2 weeks (ectopic 
lipids were not measured then). Indeed this same group continues to recruit for a 
further fructose versus glucose study providing 25% energy or less for 2 weeks 
(ClinicalTrials.gov NCT01103921) with a primary outcome measure of 24 hour 
triglycerides and secondary measure of insulin sensitivity. As a result of the above 
the duration of 2 weeks was chosen, with the monosaccharides providing 25% of 
energy. 
Power was calculated with a predicted 75% increase in liver triglyceride 
count in the fructose group and no change in the glucose group. Using a two-sided 
p-value of 0.05 and power of 80%, 29.1 participants were the minimum required. 
A baseline steatosis of 4.4% and standard deviation of 3.18 was assumed, as 
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shown in prior 1H MRS assessments of 375 overweight white male volunteers 
(Browning, Szczepaniak et al. 2004).  
3.4. Study approval, registration and timelines 
The study was approved by the University of Nottingham Medical School 
Research ethics committee; reference number D/10/2009 on 04/11/2009. It was 
approved by the Nottingham University Hospitals NHS trust Research and 
Development committee on the 11/01/2010, with the identification number of 
09GA017. The study was registered on the ClinicalTrials.gov website with the 
identifier NCT01050140 on the 14th of January 2010. The study started on the 14th 
of April 2010 and finished on the 13th of December 2010.  
3.5. Randomisation process and provision of randomised monosaccharide  
It was a double blind study. Enrolled subjects’ age, initials, weight and 
monosaccharide dose were entered into the Nottingham Clinical Trials Unit online 
randomisation package. Non-stratified simple randomisation was employed using 
varied block sizes and the outcome communicated via automatic e-mail with 
sterile services in the Nottingham University Hospital’s clinical trials Pharmacy 
Department. There the food-grade glucose or fructose was then weighed and 
placed in sealed sachets with the subjects’ name on. The sachets were labeled as 
containing either fructose or glucose (not which one) with instructions to consume 
four times a day mixed with water. The sachets were collected pre study initiation 
and two weeks’ worth given to the subjects following their first main assessment 
of both periods.  
As a result of the above, the only individuals aware of the randomisation were 
the team in sterile services and Clinical Trials Unit. Both glucose and fructose 
were fine white powders and tasted similarly sweet. As it was not a crossover 
study there was no potential for subjects to compare the tastes.  
 
3.6. The protocols for data presented within this chapter: 
3.6.1. Physical assessment of body composition 
Weight was measured using a SECA medical calibrated digital weighing 
scale and height by an Avery beam stadiometer. Body surface area was 
determined using the Mosteller formula (Mosteller 1987). Waist circumference 
was measured halfway between the lower border of the ribs and the iliac crest in a 
horizontal plane. Hip circumference was measured at the widest point over the 
buttocks. 
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3.6.2. DEXA assessment of body composition 
Whole body DEXA assessments were done at baseline and not repeated as 
significant changes in weight and composition were not predicted. Subjects were 
screened for contraindications for DEXA scanning such as recent radiation 
exposure and the presence of foreign objects. A signed consent form was taken 
and the subjects then rested on the base of a Lunar Prodigy DEXA (GE Medical 
Systems, Bedford, UK) whilst the scintillation counter swept down the body 
cranio-caudally. Quality assurance tests (coefficient <2%) were performed using a 
phantom block with known attenuation before the subjects were assessed. All 
subjects fitted into the screening area of the machine. Specific precautions were 
not taken regarding hydration, though all assessments were done in the fed state. 
3.6.3. Energy predictions 
The Henry modified Schofield formulae were used to predict resting 
energy expenditure (REE), and an activity factor determined by the short form of 
the International Physical Activity Questionnaire (IPAQ). An activity factor of 1.5 
was ascribed to those with a low IPAQ score, an activity factor of 1.6 to those 
with a moderate IPAQ score, and an activity factor of 1.7 to those with a high 
IPAQ score. The total energy expenditure (TEE) was calculated and subjects were 
ascribed one of the pre-determined food plans designed in phase 1 to provide 75% 
of predicted TEE  (see table 4 for the precise macronutrient breakdown of each 
plan). This was reviewed after one week and if weight or satiety changes implied 
an incorrect plan allocation then it was switched for the subsequent week. The 
amount of fructose or glucose supplied provided 25% of this predicted TEE. 
3.6.4. The assessment of the energy and macronutrient content of habitual 
intakes and foodstuffs supplied  
The subjects were taught how to complete 3 day food records. The records 
were of two weekdays and one weekend day before study enrolment. The 
completed records were analysed using ‘Microdiet’ software (Downlee Systems 
Ltd., Salford, UK). Microdiet is a nutrient analysis software package that 
incorporates UK based nutrient data of with the ability to edit and add additional 
foodstuffs as needed. Nutrient content of foodstuffs not within the database was 
obtained from food labels and published values. The subjects’ reported intakes of 
energy, macronutrient contribution to energy intake and fructose contribution to 
energy intake were then determined.  
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The Microdiet software was also used to design the food plans for the two 
weeks when the subjects received food. The food plans primarily differed in 
portion size as opposed to foodstuff or macronutrient content.  
3.6.5. Satiety assessment  
Five 100mm horizontal lines were printed with the responses ‘never’ to 
the left and ‘all the time’ to the right. Above each line the following statements 
were written: ‘Over the last week I have enjoyed my food’, ‘Over the last week I 
have felt full of food’, ‘Over the last week I have felt satisfied by food’, ‘Over the 
last week I have felt hungry’, ‘Over the last week I have lacked energy’. The 
subjects marked their responses on these five lines at all four main study 
assessments and both mid-study assessments. They did so unsupervised and any 
significant changes from the prior week were then discussed. Quantification was 
done by measuring the distance from the left of the line.  
3.6.6. Indirect calorimetry  
Resting pulmonary VO2 and VCO2 exchange was measured in rested, 
awake subjects lying supine on a bed. It was measured in a fasted state with 24 
hour prior abstinence of stimulants such as caffeine and alcohol. Air was collected 
via a ventilated canopy and analysed by a Gas Exchange Monitor (GEM; Nutren 
Technologies Ltd, Manchester, UK). The entire GEM system was calibrated every 
month by an alcohol burn, and the gas analysers were calibrated pre each 
measurement by gases of known composition. All measurements were done for 20 
minutes, with the first 5 minutes discarded from analysis. 
3.6.7. Finometer assessment of rested cardiovascular status 
Cardiovascular status was non-invasively assessed by Finometry, as 
described in section 2.7. The Finometer provides beat to beat monitoring of 
haemodynamic status. Subjects were fasted rested supine for 15 minutes. A 
Finometer PRO (Finapres Medical Systems, Netherlands) was used according to 
the manufacturer’s standard operating procedure. Briefly, the subjects’ age, sex 
and weight were entered and then at each subject’s assessment an identical upper 
arm cuff, wrist box and middle finger cuff were placed.  
Height correction was made between the level of the heart and the finger 
cuff. The machine was then started for a couple of minutes until the ‘physiological 
measurements’ were classified as ‘great’ or ‘excellent.’ Further correction for the 
pressure gradient between the brachial and radial pulse was based on return-to-
flow calibration. Fifteen minutes of data was then generated, stored and exported 
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via the manufacturer’s ‘Beatscope Easy v01.02’ software for a visual review prior 
to transfer to an Excel spreadsheet.  
Subjects were asked to lie still, though movement did occur and it did 
appear to temporarily distort data. This was despite the manufacturer stating that 
the addition of a height correction unit facilitates the automatic correction for 
hydrostatic pressure changes due to movement in hand position relative to the 
heart. As a result the presence of temporarily distorted data was reviewed by 
inspection of the ‘Beatscope Easy v01.02’ image of pulse, blood pressure and 
cardiac output. In Excel the average findings of the final ten minutes were 
computed once any distorted data (infrequent) was removed.  
3.6.8. Blood sample handling (identical in chapters 4 and 5) 
Whole blood was sampled either from the antecubital fossa for overnight 
fasted values, or from retrogradely placed cannulae during a hyperinsulinaemic 
euglycaemic clamp. Blood was placed in an SST tube with no additives for 
quantification of liver biochemistry, insulin, creatinine, and uric acid. Blood was 
placed in a lithium-heparin tube with no additives for the quantification of 
triglycerides and deuterated glucose enrichment. For NEFA analysis 75µl of 
EGTA-glutathione and 5µl of tetrahydrolipstatin were added to lithium-heparin 
tubes in order to prevent ongoing in vitro lipolysis (Krebs, Stingl et al. 2000).  
SST tubes were stored for 30 minutes to allow for sample clotting pre-
centrifugation, whereas the lithium-heparin tubes were shaken so as to allow 
mixing with the additive and centrifuged instantaneously. These samples were 
centrifuged for 10 minutes at 4000 rpm and at 4oC. The resultant plasma or serum 
was separated from the red blood cells, placed in labeled eppendorf vials and 
frozen at –80oC prior to analysis. 
3.6.9. Serum spectrophotometry  
This protocol generated data for this chapter as well as chapters 4 and 5. 
The serum creatinine, alkaline phosphatase, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), uric acid, C 
reactive protein, non-esterified fatty acids and triglycerides were quantified by bi-
chromatic light absorbance using spectrophotometry with the ABX Pentra 400 as 
previously described. Validated calibrations were carried out with each reagent 
change, and following each 60 subject samples with both normal (healthy range) 
and pathological (unhealthy range) calibrators as provided by the company. The 
resultant coefficient of variations from these repeatedly assessed calibrator 
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samples performed at the time of the sample analyses were excellent and ranged 
from 0.4% to 2.0%, and the absolute values generated were very close to their 
target value.  
3.6.10.  Adrenaline and noradrenaline analysis 
The protocol followed the principles as previously described (Forster and 
Macdonald 1999). Samples were thawed, mixed and centrifuged at 3000rpm for 5 
minutes. Into a scintillation vial 100µl of internal standard, 500µl of the sample, 
250µl of ammonia buffer (containing diphenyl borate-ethanolamine complex) and 
1 ml of heptane solution (containing tetra-octyl ammonium bromide and 1% 
octanol) were added. This was vortex mixed and centrifuged at 3000rpm for 5 
minutes. 750µl of the top organic layer was pipetted and added to 380µl of octan-
1-ol and 40µl of 400mM acetic acid. This mixture was again vortexed and 
centrifuged. The acid droplet was removed from the base of the tube. The mixture 
underwent HPLC with a pump flow rate of 0.2 ml/min at 2000 – 3000psi and the 
electrochemical detector potential set at 0.65V. The column was a Phenomenex 
Hypersil / Hyperclone C18 100mm x 2.0mm internal diameter. The detector 
output was measured on a Spectra Physics SP4290 integrator. Calculations were 
done as per the manufacturer’s standard operating procedures.  
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3.7. Results 
3.7.1. Cohort demographics 
There were 15 subjects in the fructose group and 17 in the glucose group. 
The study was designed to have 10 subjects in each group undergoing the 
assessments without a hyperinsulinaemic euglycaemic clamp, and 6 with the 
clamp.  One subject in the fructose group was not able to tolerate the 
hyperinsulinaemic euglycaemic clamp though continued with the study in the 
non-clamp setting. This transference from the clamp to non-clamp setting was 
inadequately adjusted for by the randomisation package and hence the imbalance 
of 15 versus 17 occurred.  
All the subjects were overweight with body mass indices (BMI) ranging 
from 25.9 to 32.2. Body fat percentage, as measured by a whole body DEXA, 
ranged from 26.8 to 45.0%. This indicates that the increased weight primarily 
originated from excess adipose tissue, as opposed to muscle. The two groups were 
well matched in all parameters bar waist to hip ratio which was slightly greater in 
the glucose group. 
 Fructose 
(n=15) 
Glucose 
(n=17) 
Significance 
(p) 
Age  35±11 33±9 0.60 
Weight (kg) 96.8±7.4 93.9±8.7 0.32 
BMI (kg/m2) 30.0±1.4 28.9±1.7 0.07 
Body fat (%) 34.5±4.6 33.9±4.2 0.70 
Waist (cm) 103.8±4.9 103.3±5.2 0.77 
Waist > 102cm 11/15 11/17 0.60 
Waist : hip ratio 1.02±0.03 1.04±0.02 0.02 † 
 
Table 1. Subject pre-study initiation characteristics, mean ± SD. † = p<0.05 
between the groups  
 
3.7.2. Energy requirements and monosaccharide dose 
The two groups were matched in terms of their predicted energy 
requirements and hence energy supplied in the first period and monosaccharide 
amount provided during both periods. 
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Table 2. Subject energy requirements and supplemented monosaccharide 
quantity, mean ± SD. (REE = resting energy expenditure) 
 
3.7.3. Subjects’ self reported food intake  
Data from the three day food records of the subjects’ pre study is 
presented in table 3, with no significant differences between the two groups. The 
pattern of macronutrient contribution to overall energy intakes was similar to that 
described amongst men aged 19-64 in the UK: fat 34.2±4.5%, carbohydrate 
46.8±6.6%, protein 14.7±2.4%, alcohol 4.3%, saturated fat 13.0±2.5% (NDNS 
2009). The cohort tended to have a lower alcohol intake and a higher fat intake 
than the national average. There are no UK data on fructose intakes. The intake of 
salt was similar in both groups at 9.3±2.8 g/day in the fructose group, and 8.1±4.2 
g/day in the glucose group.  
 
Table 3. Total energy intakes and its percentage macronutrient origin in the 
subjects’ ordinary diets as analysed by Microdiet software from three day 
food records, mean ± SD.  
 
Assuming that weight was stable during the period of the three day records 
then the above reported energy intakes should equate to total energy expenditure 
(TEE). The TEE was calculated by combining an activity factor with the two 
measures of resting energy expenditure (REE), namely the Schofield formula and 
indirect calorimetry. The observed associations of reported energy intakes and 
these two measures of TEE were reasonable at r=0.50 (p<0.01), and r=0.52 
(p<0.01) respectively. However the absolute values for the reported energy intake 
 Fructose 
(n=15) 
Glucose 
(n=17) 
p 
Predicted REE (kcal/day) 2003±165 1974±158 0.62 
Activity factor 1.63±0.09 1.65±0.10 0.55 
Supplemented monosaccharide during both 
periods (g/day) 
217.6±16.1 215.5±13.7 0.70 
Total energy provided during 1st period 
(kcal/day) 
3276±260 3243±204 0.70 
 Total 
energy 
(kcal/day) 
Fat  Carbo 
hydrate  
Protein  Alcohol  Saturated 
fat  
Fructose  
All 2835±375 38.4±4.1 43.9±4.4 16.1±2.4 2.0±2.1 14.3±2.0 5.4±2.1 
Fructose  2724±282 37.3±3.9 44.2±4.3 17.0±2.2 1.7±1.7 14.2±1.6 6.1±2.2 
Glucose 2932±427 39.3±4.3 43.7±4.6 15.3±2.4 2.4±2.4 14.5±2.4 4.8±1.9 
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were lower than these predictions of TEE. Indeed 3 subjects were classified as 
low energy reporters (daily energy less than 1.2 times the Schofield predicted 
BMR).  These subjects were split between the groups.  
The energy profile of food supplied during the first period is presented in 
table 4. The food alone component had a very similar macronutrient profile to the 
three day records, although it tended to be greater in terms of fat and protein 
contribution and lower in terms of carbohydrate and fructose contribution. The 
combination of food plus drink resulted in a high overall carbohydrate intake and 
a 25% difference in energy contribution from fructose between the groups. The 
average fructose energy contribution during the first period in those randomised to 
additional glucose was 2.3% overall.  This is a lower contribution than their 
normal intakes of 4.8%. The mean sodium intake was slightly greater than the 
subjects’ ordinary diets at 4039mg/day (range 3294 to 4329). 
Food 
plan 
name 
No. 
subjects 
on plan 
Food or 
food plus 
drink 
Total 
energy 
(kcal/ 
day) 
Fat  Carbohy
drate 
Prote
in  
Alco
hol  
Satura
ted fat  
Fructose 
in fructose 
group 
Fructose 
in 
glucose 
group 
‘2000’ 1 Food alone 2045 37.3 43.5 19.3 0 15.2 3.3 3.3 
Food + drink 2667 29.8 54.4 15.4 0 12.2 27.6 2.5 
‘2200’ 7 Food alone 2248 39.5 42.1 18.5 0 15.3 3.3 3.3 
Food + drink 2933 31.6 56.3 14.8 0 12.2 27.6 2.5 
‘2400’ 6 Food alone 2431 40.4 41.7 18.0 0 15.5 3.1 3.1 
Food + drink 3200 32.3 52.1 14.4 0 12.4 27.5 2.3 
‘2500’ 3 Food alone 2513 40.3 42.0 17.8 0 15.5 3.0 3.0 
Food + drink 3333 32.2 52.5 14.2 0 12.4 27.4 2.3 
‘2600’ 15 Food alone 2595 40.2 42.3 17.5 0 15.6 3.0 3.0 
Food + drink 3467 32.2 52.9 14.0 0 12.5 27.4 2.3 
Average   Food alone 2444 40.0 42.2 17.9 0 15.5 3.1 3.1 
Food + drink 3259 32.0 52.8 14.3 0 12.4 27.5 2.3 
 
Table 4. Energy intakes and their mean percentage macronutrient origin in 
the food supplied during the first period by food plans including the 
contribution of fructose in the fructose and glucose groups 
 
3.8. Intervention outcomes 
3.8.1. Tolerability/side effects 
 There were no subject drop outs, and all six study assessments were 
attended by all. There were no procedure or investigation related incidents. One 
subject reported headaches during the first period. These were ascribed to his self-
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enforced concurrent caffeine restriction and resolved when he increased his 
caffeine intake back to his baseline level (glucose group). All other reported 
symptoms were gastrointestinal in origin. Such symptoms were more common 
with fructose than glucose, as shown on table 5, p=0.08. Most symptoms were 
mild and only two subjects were sufficiently troubled to contact the lead 
investigator in between study visits to discuss them. One was regarding 
constipation during the first period, which may well be attributed to the change in 
food intake during this period. The other subject was in the fructose group and 
was significantly troubled by bowel frequency. This was partially alleviated by 
modifying the monosaccharide consumption pattern though tended to persist 
throughout both two week periods. 
 Fructose 
(n=15) 
Glucose 
(n=17) 
Frequency 6 1 
Constipation 0 1 
Wind / gurgling 3 2 
Bloating / pain 2 2 
Nausea 1 0 
Any GI symptom 8 4 
 
Table 5. Gastrointestinal side effects reported during the study. 
 
3.8.2. Changes in weight and metabolism between the two baseline 
assessments 
The absolute change at the second baseline assessment as compared to the 
first of all principal variables measured for chapters 3, 4, and 5 is presented in 
table 6. There were no significant differences, or trends, in terms of weight, 
ectopic lipids, serum triglycerides, insulin resistance, renal and liver function, and 
whole body oxidative metabolism. Indeed no subject had a second baseline weight 
that differed by more than 3.5% from their first baseline weight, and 27 out of the 
32 had a repeat weight within 2% of the first.  
Amongst all the subjects there was a significant change in only one factor, 
NEFA, and near significance for uric acid (p=0.052). Between the groups there 
was a trend for a difference in uric acid only.  
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 All Fructose Glucose Significance 
between 
groups (p) 
Weight (kg) 0.33±1.37 0.59±1.7 0.09±1.0 0.32 
Resting energy expenditure 
(kcal/day) 
-39.6±114.1 -72.0±130.8 -11.0±91.7 0.13 
Respiratory quotient (RQ) 0.05±0.038 0.0003±0.31 0.010±0.04 0.50 
Lipid oxidation (mg/kg/min) -0.16±0.31 -0.20±0.35 -0.13±0.29 0.54 
Carbohydrate oxidation 
(mg/kg/min) 
0.48±0.51 0.44±0.54 0.51±0.50 0.78 
Hepatic triglyceride (%) 0.15±2.09 0.25±1.88 0.07±2.30 0.81 
Intra-myocellular lipid (%) 0.01±2.26 0.23±1.96 -0.18±2.55 0.62 
Extra-myocellular lipid (%) -0.54±3.13 0.42±3.37 -1.39±2.72 0.10 
Triglycerides (mmol/L) -0.14±0.56 -0.18±0.63 -0.10±0.50 0.68 
HOMA-IR 0.32±1.22 0.25±1.52 0.38±0.91 0.76 
Glucose disposal (mg/kg/min) -0.14±1.11 -0.23±0.86 -0.05±1.40 0.80 
Noradrenaline (nmol/L) -0.07±0.62 -0.01±0.69 -0.13±0.57 0.60 
Adrenaline (nmol/L) -0.04±0.17 -0.04±0.19 -0.04±0.17 0.97 
Non-esterified free fatty acids 
(mmol/L) 
-59±161* -34±149 -80±171 0.44 
&UHDWLQLQHȝPRO/ -1.8±5.6 -0.9±6.8 -2.5±4.5 0.43 
8ULFDFLGȝPRO/ -20.6±57.6 0.2±64.2 -38.9±45.4 0.054 
Alkaline phosphatase (IU/L) -1.6±6.2 -1.1±7.4 -2.1±5.0 0.66 
Alanine transaminase (U/L) -1.7±9.0 -4.3±9.3 0.7±8.3 0.12 
Aspartate transaminase (U/L) -1.4±5.2 -2.2±5.6 -0.8±4.9 0.45 
Gamma glutamyl 
transpeptidase (U/L) 
-1.9±6.5 -2.2±4.2 -1.7±8.2 0.82 
 
Table 6. The absolute change within the entire cohort and each group at the 
second baseline assessment compared to the first baseline assessment, mean ± 
SD. (*=p<0.05) 
 
3.8.3. Weight changes during the study  
The changes in weight reflected the differing energy statuses of the two 
periods, with weight maintenance during the first period and gain during the 
second, see table 7 and figure 1. During the first period 26 volunteers maintained 
their weight within 1kg of their baseline weight. Four volunteers lost more than 
1kg and 2 gained more than 1kg. In order to maintain stable weights, the food 
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plans were increased after the week 1 visit by 200kcal/day in two volunteers and 
reduced by 200kcal/day in two volunteers. 
During the second period both groups gained significant amounts of 
weight at both weeks one and two. By week two weight increased by +1.03±1.37 
kg in the fructose group (p=0.01) and by +0.57±1.00 kg in the glucose group 
(p=0.03). There was no significant difference between the groups in terms of the 
amounts of change. 
 
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
1st 
period  
baseline 95.3±8.1 96.8±7.4 93.9±8.7 0.32  
0.84 
0.62 
week 1 95.3±8.2 96.9±7.6 93.9±8.7 
week 2 95.1±8.1 96.6±7.2 93.8±8.9 
2nd 
period  
baseline 95.6±8.4 97.4±8.1 94.0±8.6 0.26  
0.63 
0.29 
week 1 96.2±8.6** 98.1±8.3* 94.5±8.3* 
week 2 96.4±8.5** 98.4±8.3* 94.6±8.5* 
 
Table 7. The subjects’ weight (kg) during the study, mean ± SD. (*=p<0.05, 
**=p<0.01 compared to baseline value in that group.) 
week 1 week 2 week 1 week 2
-1.0
-0.5
0.0
0.5
1.0
1.5
fructose
glucose
1st period                         2nd period
*
*
*
*
kg
Figure 1. The change in weight from baseline during the two study periods, 
mean ±SEM. (*=p<0.05 from baseline in that group) 
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3.8.4. Satiety outcomes 
a. First period  
The self completed visual analogue scale responses during the first period 
for subject’s satiety, energy and food enjoyment are presented in table 8. The 
baseline responses were essentially identical between the groups except that the 
glucose group reported less food satisfaction. It is however the change in response 
as opposed to the absolute value that is of greater interest. Overall the subjects 
reported increased fullness and reduced hunger during this first period despite 
weight maintenance. The degree of change was small and matched between the 
groups.  
 
Over the last week I 
have… 
 All  Fructose   Glucose  Difference 
between 
groups at 
baseline 
(p) 
Sig of 
absolute 
change 
between 
groups (p) 
Enjoyed my food baseline 70±14 72±15 69±13 0.54  
0.18 week 2 73±16 69±20 76±9* 
Felt full of food baseline 62±19 66±17 59±20 0.30  
0.69 week 2 69±18* 72±13 67±22 
Felt satisfied by food baseline 71±14 76±11 67±14 0.04†  
0.13 week 2 73±11 74±11 72±12 
Felt hungry baseline 39±19 34±19 41±21 0.37  
0.73 week 2 23±17** 21±14* 26±19 
Felt I lacked energy baseline 31±19 25±18 35±19 0.12  
0.58 week 2 26±18 18±10 34±20 
 
Table 8. Visual analogue scale responses during the first period to the 
statement: ‘Over the last week I have...’ (A score of 0 = never, whereas a 
score of 100 = all of the time), mean ± SD. (*=p<0.05, **=p<0.01 compared to 
baseline value in that group. † = p<0.05 difference between the groups at 
baseline.) 
 
b. Second period  
Baseline responses in the second period were not matched. The fructose 
group reported significantly greater food enjoyment and satisfaction, and a lower 
hunger and sense of lacking energy, see table 9. The reasons for this are unclear, 
though again what is more important is the change in values during the period 
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itself. Despite weight changes there were minimal changes in responses, and these 
were even more blunted than during the first period. During both periods there 
were no significant associations between change in weight and changes in visual 
analogue scale responses. 
Of note, hunger levels reduced in the glucose group during the second 
period (p=0.042), whereas there was no change in the fructose group. The 
interpretation of this isolated finding is uncertain as there were no changes in 
satisfaction, fullness or energy in this group.  
 
Over the last week 
I have… 
 All 
subjects 
Fructose  Glucose Difference 
between 
groups at 
baseline 
(p) 
Sig of 
absolute 
change 
between 
groups (p) 
Enjoyed my food baseline 71±11 76±12 67±9 0.01†  
0.83 week 2 74±13 79±11 69±14 
Felt full of food baseline 63±16 67±17 60±15 0.25  
0.60 week 2 65±16 69±15 60±16 
Felt satisfied by 
food 
baseline 70±10 74±10 66±10 0.03†  
0.92 week 2 70±11 75±12 67±9 
Felt hungry baseline 34±17 27±14 41±17 0.02†  
0.06 week 2 33±20 31±23 34±17* 
Felt I lacked 
energy 
baseline 32±19 24±19 40±17 0.02†  
0.45 week 2 34±19 28±20 40±16 
 
Table 9. Visual analogue scale responses during the second period to the 
statement: ‘Over the last week I have...’. (A score of 0 = never, whereas a 
score of 100 =all of the time) , mean ± SD. (*=p<0.05 compared to baseline 
value in that group. † = p<0.05 difference between the groups at baseline.) 
 
3.8.5. Renal outcomes 
The fasted serum creatinine data at each main visit are presented in table 
10. There were no significant changes during the study or differences between the 
groups.  
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  All 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
First period 
creatinine  
Baseline 90±11 91±14 89±8 0.52  
0.84 Week 2 89±11 90±12 88±9 
Second 
period 
creatinine 
Baseline 88±12 91±14 86±9 0.33  
0.25 Week 2 87±12 88±14 86±11 
7DEOH)DVWHGVHUXPFUHDWLQLQHȝPRO/EHIRUHDQGDIWHUWZRZHHNVRID
high fructose or glucose intake, mean ± SD. 
 
3.8.6. Whole body oxidative metabolism outcomes 
 The baseline oxidative metabolic values were matched between both 
groups, see table 11. The baseline respiratory quotient values were relatively low 
reflecting the subjects’ habitual low carbohydrate and high fat intakes, and the 
overnight fast. The initial resting energy expenditure value was strongly 
associated with the Henry modified Schofield equation prediction of the basal 
metabolic rate, r = 0.51, p=0.003.  
After two weeks during both periods there was an increase in the 
respiratory quotient value and the carbohydrate oxidation rates. This reflected the 
increased intakes of carbohydrate. These changes were very similar between the 
periods, though there was a greater rise in carbohydrate oxidation rates during the 
second period than the first, reflecting the greater energy overfeeding and 
lipogenesis.  
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  Whole cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
baseline 
values (p) 
Absolute 
change 
between 
groups (p) 
VO2 1st period 
(ml/kg*min) 
Baseline 226±31 227±35 225±27 0.87  
0.24 Week 2 227±25 223±25 230±25 
VO2 2nd period 
(ml/kg*min) 
Baseline 220±27 217±31 223±24 0.49  
0.73 Week2 225±26*  222±31 226±21 
VCO2 1st period 
(ml/kg*min) 
Baseline 164±24 165±27 164±21 0.90  
0.27 Week 2 171±22* 168±20 174±23* 
VCO2 2nd period 
(ml/kg*min) 
Baseline 161±21 157±25 164±17 0.37  
0.45 Week2 171±26*  170±27* 171±25 
RQ 1st period Baseline 0.726±0.034 0.725±0.037 0.726±0.031 0.94  
0.93 Week2 0.756±0.058** 0.755±0.050 0.758±0.066* 
RQ 2nd period Baseline 0.731±0.032 0.725±0.032 0.736±0.033 0.38  
0.45 Week2 0.763±0.064* 0.767±0.014* 0.759±0.073 
Resting energy 
expenditure 1st 
period (kcal/day) 
Baseline 1531±208 1537±240 1525±182 0.88  
0.23 Week 2 1544±167 1517±167 1567±168 
Resting energy 
expenditure 2nd 
period (kcal/day) 
Baseline 1491±186 1465±213 1514±161 0.46  
0.63 Week2 1532±179  1519±214 1543±148 
Lipid oxidation 
1st period 
(mg/kg/min) 
Baseline 1.11±0.19 1.09±0.20 1.12±0.19 0.86  
0.96 Week 2 0.98±0.26* 0.96±0.25 1.00±0.28* 
Lipid oxidation 
2nd period 
(mg/kg/min) 
Baseline 1.12±0.24 1.14±0.22 1.10±0.25 0.99  
0.56 Week2 0.94±0.29** 0.89±0.23** 1.00±0.32 
Carbohydrate  
oxidation 1st 
period 
(mg/kg/min) 
Baseline 0.355±0.239 0.353±0.274 0.356±0.212 0.97  
0.65 Week2 0.736±0.531** 0.724±0.453 0.746±0.610* 
Carbohydrate 
oxidation 2nd 
period 
(mg/kg/min) 
Baseline 0.396±0.214 0.345±0.216 0.425±0.216 0.41  
0.77 Week2 0.866±0.526** 0.849±0.462 0.882±0.602* 
 
Table 11. Whole body oxidative metabolism before and after two weeks of a 
high fructose or glucose intake, mean ± SD.  
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3.8.7. Cardiovascular outcomes 
3.8.7.1. Haemodynamic outcomes 
The resting cardiovascular function outcomes as assessed by a Finometer are 
presented in table 12. No variable changed significantly from the baseline. There 
was a trend during both periods for systolic and diastolic pressures to remain 
unchanged with fructose and to reduce with glucose. This trend was non-
significant however even when the absolute changes during both periods are 
combined, (p=0.15 for combined systolic changes).  
 
 All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
Heart rate 1st period 
(bpm) 
Baseline 65.5±8.9 64.3±9.8 66.5±8.2 0.51  
0.08 Week 2 65.6±9.7 62.2±9.9 68.5±8.8 
Heart rate 2nd period 
(bpm) 
Baseline 66.0±8.0 63.0±8.9 68.6±6.2 0.04†  
0.65 Week2 66.3±8.4 63.9±6.7 68.5±9.3 
Systolic pressure 
(mmHg) 1st period 
Baseline 123.2±10.3 120.8±9.9 125.3±10.5 0.22  
0.62 Week 2 122.2±9.0 120.5±8.7 123.6±9.2 
Systolic pressure 
(mmHg) 2nd period 
Baseline 126.2±10.5 123.3±10.8 128.7±9.8 0.16  
0.22 Week2 124.5±7.8 123.7±7.0 125.3±8.6 
Diastolic pressure 
(mmHg) 1st period 
Baseline 71.7±6.7 71.4±6.8 72.0±6.8 0.82  
0.43 Week2 70.7±6.2 71.3±7.0 70.2±5.6 
Diastolic pressure 
(mmHg) 2nd period 
Baseline 72.6±6.5 72.5±7.1 72.6±6.2 0.98  
0.49 Week2 72.1±4.7 72.9±3.5 71.5±5.6 
Cardiac output 1st 
period (l/min) 
Baseline 7.12±1.21 6.95±1.28 7.26±1.17 0.48  
0.31 Week 2 7.37±0.99 6.98±0.74 7.71±1.08 
Cardiac output 2nd 
period (l/min) 
Baseline 7.11±1.19 6.82±1.08 7.36±1.25 0.21  
0.30 Week 2 7.41±1.39 7.36±0.89 7.45±1.75 
Stroke volume 1st period 
(ml) 
Baseline 110±17 110±20 110±15 0.96  
0.88 Week2 114±14 114±14 113±15 
Stroke volume 2nd 
period (ml) 
Baseline 108±15 109±13 108±17 0.84  
0.15 Week2 112±15 116±14 108±16 
Total peripheral 
resistance 1st period 
(dyn.s/cm5) 
Baseline 769±226 762±292 775±154 0.88  
0.24 Week 2 745±100 784±79 710±105 
Total peripheral 
resistance 2nd period 
(dyn.s/cm5) 
Baseline 801±157 825±145 780±169 0.43  
0.21 Week 2 769±167 760±89 777±216 
 
Table 12. Resting, fasted cardiovascular haemodynamic parameters before 
and after two weeks of a high fructose or glucose intake, mean ± SD. 
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3.8.7.2. Adrenergic outcomes 
During the first period, a high fructose intake resulted in reduced resting 
adrenaline concentrations with no change in noradrenaline. With glucose there 
was no change in adrenaline whereas there was a reduced noradrenaline 
concentration during the first period. There were no significant changes in the 
second period. 
 
  All Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
Adrenaline 1st 
period 
baseline 0.30±0.17 0.32±0.15 0.29±0.18 0.72  
0.01 week 2 0.26±0.14* 0.25±0.11* 0.28±0.17 
Adrenaline 
2nd period 
baseline 0.26±0.09 0.27±0.11 0.25±0.06 0.59  
0.08 week 2 0.25±0.08 0.23±0.08 0.27±0.08 
Noradrenaline 
1st period 
baseline 1.31±0.55 1.16±0.50 1.44±0.56 0.16  
0.04 week 2 1.15±0.41* 1.18±0.46 1.15±0.38* 
Noradrenaline 
2nd period 
baseline 1.25±0.48 1.17±0.57 1.31±0.39 0.42  
0.10 week 2 1.28±0.63 1.07±0.46 1.47±0.71 
 
Table 13. Fasted, resting plasma adrenaline and noradrenaline 
concentrations (nmol/L) before and after two weeks of a high fructose or 
glucose intake, mean ± SD. 
 
3.9. Discussion  
Summary of the findings 
The intervention resulted in only one difference between the groups. 
During the first, isoenergetic, period plasma adrenaline and noradrenaline 
concentrations differed between the groups. This isolated finding failed to 
translate itself into any changes in haemodynamic profile and so its significance 
appears limited. In both groups there was an increase in carbohydrate oxidation 
rates, consistent with increased carbohydrate intakes; and in the second, 
hyperenergetic, period there was weight gain in both groups, consistent with 
energy overfeeding. 
The two groups were well matched at baseline and for their exposure to 
the intervention. The waist to hip ratios differed between the two groups, though 
the absolute numerical difference was small. Further to this there was a tendency 
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for a greater body mass index in the fructose group. These surrogate markers of 
adiposity were not reflected in DEXA determined total body adiposity. Indeed 
there is no evidence that this impacted on the study as there were no differences in 
the metabolic and cardiovascular variables measured at baseline. The fructose 
group reported greater abdominal and diarrhoeal symptoms. During the first 
period weight was maintained whereas the sense of fullness increased and hunger 
decreased. There was calorimetric evidence for a shift in whole body metabolism 
towards a pattern reflective of a high carbohydrate intake. There was no alteration 
in renal function or cardiovascular haemodynamic parameters. A high fructose 
intake resulted in reduced resting adrenaline concentrations with no change in 
noradrenaline. With glucose there was no change in adrenaline whereas there was 
a reduced noradrenaline concentration during the first period. 
The washout period resulted in a return to baseline levels in all parameters 
measured bar NEFAs, though the reduction in NEFAs at the start of the second 
assessment was matched in both groups. 
During the second period weight increased equally in both groups and 
there was minimal change in satiety measures. Again there was evidence for a 
shift in whole body metabolism to that representative of a high carbohydrate 
intake, with increased carbohydrate and reduced lipid oxidation rates, with no 
differences between the groups. There was no alteration in renal, cardiovascular 
haemodynamic or catecholamine profiles.  
3.9.1. Issues with the design of the study  
Certain issues need to be addressed prior to interpreting the data as a 
whole. Compliance needs to be considered as a potential issue in this outpatient / 
community dietary intervention. The next issue is the phenotype of the cohort, and 
as to whether they are representative of the general population or a clinically 
relevant sub-group. The final issue is whether the washout period was adequate 
such that the two intervention periods can be viewed as being truly separate 
assessments. 
a. Compliance with the study 
The subjects appeared to be well motivated.  All visits were attended and 
no drop outs occurred. Direct observation of monosaccharide and food 
consumption was only possible at study visits. There are no biomarkers specific 
for intakes of monosaccharides, though a few assessments can be used to infer 
compliance in this study. These are weight change, serum triglycerides and rates 
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of fasted carbohydrate oxidation. Due to the isoenergetic nature of the first period 
these ‘compliance’ assessments are only feasible during the second hyperenergetic 
period. In this period the energy content in the monosaccharides was greater than 
that normally consumed in drinks by the subjects, and so one would expect 
weight, carbohydrate oxidation and serum triglycerides to increase. This occurred 
in 25, 27 and 23 out of the 32 subjects respectively. Overall 2 failed to have either 
of these features present during the second period and 3 had only 1 feature 
present. They were evenly split between the groups. Neither of these assessment 
processes was designed, nor wholly reliable, as compliance monitors. The above 
suggests that compliance can be assumed to be acceptable overall.  
b. The cohort’s phenotype 
  The cohort was explicitly recruited on the basis of them being centrally 
overweight healthy men who were not vegetarian, did not drink excessive alcohol, 
and drank small volumes of sugar-sweetened drinks. These factors will now be 
discussed in turn. 
 The health screen identified active health problems requiring ongoing 
medical review, or chronic treatment, and screened for previously unidentified 
diabetes, liver, renal or cardiac disease as well.  The primary research question was 
to ascertain the hepatic effects of a high monosaccharide intake and so liver 
biochemistry had to be normal and the presence of hepatic disease including 
viruses, haemochromatosis, or alcohol abuse were actively screened for.  
In order to classify as being centrally overweight the target measurements were a 
body mass index (BMI) between 25 and 32kg/m2 with a waist circumference 
greater than 94cm, a predictor of increased coronary heart disease risk (Han, Lean 
et al. 1996). The addition of a minimum waist circumference helped to exclude 
individuals whose elevated BMI originated primarily from increased muscle as 
opposed to adipose tissue. This simple process was chosen as it was felt to be easy 
to understand and reproduce. Significantly overweight individuals were excluded 
due to the ethics of modestly overfeeding them and the feasibility of performing 
MRI based assessments. Central (visceral) obesity drives systemic and hepatic 
insulin resistance. Le et al. previously demonstrated an increased metabolic 
response to fructose in an overweight and insulin resistant cohort compared to a 
healthy weight and insulin sensitive cohort. A waist greater than 94cm is an 
independent and more powerful  predictor for metabolic risk than waist to hip 
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ratio or body mass index (Wang, Rimm et al. 2005) and a useful predictor of 
coronary artery risk (Han, Lean et al. 1996). 
Gonadal hormones influence carbohydrate metabolism. As these differ 
between men and women and vary with the menstrual cycle, women were 
excluded. Furthermore, women had previously been shown to be more resistant to 
the metabolic changes induced by fructose (Bantle, Raatz et al. 2000; Couchepin, 
Le et al. 2008; Stanhope, Schwarz et al. 2009). Recently a further paper has 
explored this in greater detail (Tran, Jacot-Descombes et al. 2010). Given the 
differing body sizes and composition of men and women these are very difficult 
studies to do as it is unclear if the amount of monosaccharide in gender 
comparative studies should be uniform, or weight or lean mass adjusted. Tran et 
al. compared outcomes in age and BMI matched men and women, but not weight 
or body fat percentage matched. The amount of fructose consumed was dependent 
on fat free mass and hence was significantly smaller in the female than the male 
group. The influence of this on the findings is difficult to fully account for. The 
insulin, lactate and uric acid response was smaller in women than men. There was 
lower tracer-labeled fructose enrichment into VLDL with women and a failure to 
suppress lipid oxidation. This supports the theory that women may be less 
vulnerable to fructose induced lipid disorders, though of course they also received 
less fructose. 
 Vegetarians were excluded from the present study as their requirements 
for differing foodstuffs than omnivores would have added another potentially 
confounding or complicating variable. In order to minimise the potential for 
symptomatic monosaccharide malabsorption, subjects were screened for pre-
existing gastrointestinal symptoms or an intolerance to a test drink containing 50g 
of fructose.  
  Self reported alcohol consumption greater than 21 units a week was used 
as an exclusion factor. The reliability of such volunteer supplied information has to 
be questioned. This exclusion was not mentioned in the volunteer information 
sheet and so potential recruits were not forewarned. Liver biochemistry was also 
checked pre study enrolment. Ultimately the reliable exclusion of alcohol excess is 
impossible, though this mirrors the clinical setting that this translational study was 
designed to address. During the study periods alcohol consumption was allowed at 
two units a day and nil for 24 hours pre a study visit. It was felt that complete 
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abstinence would in some subjects have resulted in the study being as much an 
assessment of the washout from alcohol as a ‘wash-in’ of monosaccharides.  
Another difficult assessment issue was that of baseline fructose 
consumption. The enzymes that initiate hepatic fructose metabolism, fructokinase 
and aldolase, are induced by fructose exposure (Koo, Wallig et al. 2008; Ouyang, 
Cirillo et al. 2008). Clearly the metabolic response to a high fructose diet may 
differ between high and low-baseline consumers. The clinical evidence to support 
this hypothesis however only comes from a single and very small study (Stirpe, 
Della Corte et al. 1970). In that study the postprandial uric acid concentration 
following consumption of 1g/kg of fructose in the fasted state was measured for 2 
hours following normal food intakes, a 2 week low fructose intake and a 3 week 
high fructose intake in a patient with gout and the child of a patient with gout. The 
increase in postprandial uricaemia reflected the preceding fructose intake. This 
data has never been replicated. Nonetheless the aim was to exclude high baseline 
fructose consumers. A complete dietary assessment was not practical prior to 
enrolment of each subject, and there are no data to help identify which cut-off 
value should be used. The total monosaccharide dose supplied in the present study 
was equivalent to that present in 2 litres of cola per day. A pragmatic approach 
taken was to exclude those with daily sugar sweetened beverage consumption 
greater than 500ml of cola. Again this exclusion was not mentioned in the 
volunteer information sheet and so they were specifically not forewarned prior to 
reporting their standard intake patterns. 
 The subjects were clearly a select group, though representative of a 
substantial proportion of the UK male adult population. Indeed 48% of UK adult 
males have both a waist greater than 94cm and a BMI between 25 and 35kg/m2 
(HSE 2006), and 72% drink less than 21 units of alcohol a week (Alcohol 2010). 
c. Effects and adequacy of the washout phase. 
Many prior studies of fructose lack an energy control. As a result it 
remained unclear as to whether much of the previously published data could be 
attributed to a high fructose or high energy intake. Glucose was chosen as the 
energy comparator as it is a similar macronutrient with the same energy density. 
The study was not a crossover design. This was specifically designed so as 
to facilitate the comparison of a high fructose or glucose intake in an energy 
balanced and overfeeding setting. The reason for this was that most of the prior 
data generated had been hyperenergetic and no study had previously compared the 
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findings in both settings. It was anticipated that only limited changes may occur 
during the isoenergetic phase and so a crossover of two isoenergetic phases may 
have generated limited outcome differences. It was also felt that if the study was 
merely a crossover of two hyperenergetic periods then the outcomes could only be 
viewed as a consequence of fructose versus glucose in combination with energy 
overfeeding and not directly attributable to the macronutrient. The approach 
decided upon facilitated the exploration of both energy settings. The limitation of 
this approach is that inter-monosaccharide outcome comparisons are not as robust 
as the inter-energy setting comparisons as they were comprised of differing 
individuals.  
The first period for each subject was the isoenergetic phase as this was 
predicted to induce less of a metabolic challenge. It was then followed by six 
weeks ‘washout’ and then the hyperenergetic phase. No prior study has published 
with repeated baseline assessments and so it was not possible to be certain that a 
six week duration of the ‘washout’ would be truly adequate. As a result, all of the 
analyses were repeated at the baseline of the second period. Hence the final issues 
that need to be addressed are whether the washout phase was adequate and 
whether the two groups had truly returned to their baseline ‘metabolic state’.  
In comparison between the two baseline assessments there were no 
differences in terms of weight, ectopic lipids, serum triglycerides, insulin 
resistance, renal and liver function, and whole body oxidative metabolism. There 
was a significant difference in NEFAs in both groups and a trend for lower uric 
acid in the glucose group, though this did not reach statistical significance. The 
interpretation of the biological/clinical significance of these isolated findings is 
not possible. As a result it seems likely that the washout was adequate and that the 
two baseline assessments were reflective of each other.  
3.9.2. Subject specific issues 
3.9.2.1. Phenotypic profile  
 The cohort had a mean age of 34 years. The mean body mass index was at 
the upper end of the recruitment range (25-32) at 29.4kg/m2 as potential recruits 
with a relatively low body mass index tended to not have a waist greater than 
94cm.  
The DEXA body composition scans confirmed that the subjects were 
correctly identified as having increased adiposity as opposed to muscle bulk. The 
two groups were closely matched for all anthropometric factors bar waist to hip 
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ratio which was mildly greater in the fructose group. The two groups did not 
differ in terms of their baseline metabolic profile and so this was not felt to be 
significant. 
In light of their baseline findings the cohort cannot be classified as entirely 
‘healthy’ and a more accurate statement would be that they were without ‘obvious 
end-organ disease detectable in routine clinical practice’. As will be discussed in 
the next chapters the cohort’s central adiposity was associated with relative 
baseline insulin resistance, dyslipidaemia and steatotic livers. They were all 
screened to exclude high blood pressure, and although they had a high resting 
cardiac output it was reflective of their weight. 
3.9.2.2. Baseline nutrient intake 
The groups were well matched in terms of their self reported energy 
consumption patterns pre study entry.  The use of three day food diaries 
commonly results in energy underreporting. Low energy reporting has been 
defined as reported energy intakes less than 1.2 times the respondent’s Schofield 
equation predicted basal metabolic rate. This was demonstrated in 33.6% of the 
Whitehall cohort (Brunner, Stallone et al. 2001), and was more prevalent amongst 
the obese and those with a lower employment status. The rate in the present study 
was 3 out of 32 and so clearly better than the Whitehall cohort but still remains 
imperfect. The source of this low energy reporting discrepancy is impossible to 
individually determine. During the monitoring period subjects may fail to 
document all of their intakes or alternatively actively, or unintentionally, restrict 
food  intake (Friedenreich, Slimani et al. 1992). Either way it is likely that more 
socially embarrassing, or so called ‘unhealthy’, foodstuffs are either avoided or 
underreported during assessments. This limits the reliability of such data. 
However, food frequency questionnaires and 24-hour recall interviews which can 
be used as alternatives do not adequately overcome this issue. 
The above accepted, the energy intake data reported by this cohort were 
strongly associated with their predicted total energy expenditure. This implies that 
the data were reliable. Furthermore the pattern of macronutrient contribution to 
energy was similar to that found in the recent UK NDNS survey which also 
gathered data by food diaries (NDNS 2009). One cannot expect too precise a 
similarity with the NDNS data as our cohort was not fully representative of the 
general adult male population. The lower alcohol consumption in this cohort will 
in part reflect that consumption greater than 21 units a week was an exclusion 
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criterion, though it may also reflect a subject’s reluctance to report a high alcohol 
intake for fear of removal from the study. The cohort had a greater fat intake than 
the NDNS male data.  
3.9.3. Nutrient and energy intakes during the first ‘isoenergetic’ period 
In order to maintain energy intakes (hence weight), and to standardise 
intakes during the first period of two weeks, all food was supplied direct to the 
volunteers’ homes. To avoid underreporting, I did not use 3 day food records. 
Instead standard predictive formulae were used to predict REE which were 
modestly associated with their subsequently measured fasted REE at baseline 
(r=0.51, p=0.003).  
Energy provision from food and supplements combined was on average 
3259kcal/day, range 2720-3485, which resulted in a non-significant weight 
change of - 0.18kg (range of -2.2kg and + 1.3kg) (p=0.21). The maintenance of 
weight during the first period means that the data for the groups can be viewed as 
originating from an ‘isoenergetic’ phase. This is in stark contrast with the marked 
weight gain that occurred during the second ‘hyperenergetic’ phase.  
An issue surrounding food delivery in the isoenergetic period was that of 
what macronutrient ratios to supply. There were two options. First, foodstuffs 
with standard macronutrient ratios and content such that the addition of 
monosaccharide drinks resulted in an overall high carbohydrate intake. Second, 
supply food with an abnormally low carbohydrate (hence high protein and fat 
content) such that standard overall ratios were maintained once the drinks were 
factored in. It was felt preferable to provide an overall high monosaccharide 
intake, resulting from standard foods in combination with the drinks, than a 
standard monosaccharide intake, resulting from nonstandard foods and the drinks. 
The use of nonstandard foods would have been as much an intervention as the 
addition of the monosaccharide drinks. Thus the foods aimed to provide 40% of 
energy from fat, 40% from carbohydrate and 20% from protein. The resultant 
averages from foodstuffs alone of 40.0%, 42.2% and 17.9% mimicked the 
subjects’ own intakes of 38.4%, 43.9% and 16.1% respectively. With the addition 
of the monosaccharide drinks the total intake patterns were 32.0%, 52.8% and 
14.3%. So it was a high carbohydrate, low fat and protein intake.  
The content of the supplied foodstuffs for sodium and saturated fatty acids 
were within the guidelines (FSA 2008; SACN 2008), as deviation from these may 
themselves have resulted in metabolic or cardiovascular changes. 
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3.9.4. Nutrient and energy intakes during the second ‘hyperenergetic’ period 
During the second period the subjects were advised to continue with their 
normal food intakes in terms of pattern and content and to take the 
monosaccharide drinks four times a day. I requested subjects to avoid any alcohol 
binges during this period. During both periods they were instructed to continue 
with their normal physical activities. 
As a result the subjects were energy overfed by up to 25%, depending on 
dietary compensation, by a monosaccharide (217g/day) for 14 days. This resulted 
in an average weight gain per week of 0.4%. The degree of compliance to the 
foodstuffs and supplements is difficult to be certain of, though it is possible to 
compare this rate with prior published data. 
Carbohydrate overfeeding has been previously shown to induce less 
energy storage and weight gain than fat overfeeding. This was attributed to greater 
increases in rates of energy expenditure and substrate oxidation (Horton, Drougas 
et al. 1995). Indeed the doubling of carbohydrate oxidation rates in this current 
study demonstrates that a large proportion of the dietary carbohydrates supplied 
were not used for energy storage, whereas the reduction in lipid oxidation rates 
will have meant that a greater proportion of the dietary fat will have been 
available for storage. Frustratingly a lot of the carbohydrate overfeeding literature 
presents changes in oxidative and hormonal profiles as opposed to weight. As a 
result there are few data on the weight effects of carbohydrate overfeeding for 
periods of around two weeks. The outcomes in the studies involving ad libitum 
fructose or simple sugar (sweets) overfeeding are presented below in table 14. The 
current findings are actually of greater weight gain per week than previously 
published as compared with similar amounts of overfeeding.  
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 Carbohydrate Energy 
overfeed 
(%)  
Duration of 
overfeeding 
(weeks) 
Mean weight 
gain per 
week (%) 
Le et al. 2006 Fructose 18 4  0.07 
Silbernagel et al. 2011  Fructose or glucose 23 4 0.3 
Johnston et al.  
(Present study) 
fructose or glucose 25 2 0.4 
Stanhope et al. 2009  Fructose or glucose 25 8 0.2 
Perez-Pozo et al. 2010  Fructose 30 2 0.35 
Claesson et al. 2009  Sweets ~50 2 0.6 
Table 14. Current and prior published rates of weight gain with simple 
carbohydrate overfeeding with type of carbohydrate, amount and duration of 
overfeeding. (Note I have estimated the degree of energy overfeeding in the 
paper by Claesson by using the Henry modified Schofield formula and an 
activity factor of 1.6) 
 
The interpretation of weight changes is aided in the papers by Perez-Pozo 
and Stanhope by their presentation of dietary intakes pre and during the 
intervention. The absolute increase in overall energy intakes were 24% (30% 
supplied) and 8.4% (25% supplied) respectively. A reduction in voluntary 
carbohydrate intake was the main source of accommodation in the Perez-Pozo 
paper; no such data were available from Stanhope. This reduction in alternative 
carbohydrates would have been predicted given the sweetness of fructose and 
glucose. The weight changes in this current study are almost identical to the 
Perez-Pozo study and so one can speculate that similar modifications occurred. 
Repeat body composition analyses were not performed in this study and so it is 
therefore not known what the increased weight during the hyperenergetic period 
represents. Horton and colleagues overfed obese subjects with 50% energy for 
two weeks with mixed complex and simple carbohydrate foodstuffs  (Horton, 
Drougas et al. 1995). The resultant weight gain was approximately two thirds fat 
mass and one third fat free mass. This makes sense as in the presence of energy 
excess carbohydrates are converted to lipids by de novo lipogenesis as will be 
discussed later.  
 
 137  
3.9.5. Changes in self reported satiety  
During the first period of the present study, subjects were supplied unfamiliar 
foodstuffs, to be consumed at specific meals. Most important, only 75% of their 
energy intakes were from solid foods. So, there were concerns that satiety may 
change and this in turn may affect outcomes during this or the subsequent 
hyperenergetic period.  I chose low energy-dense foodstuffs specifically, and 
monitored satiety with visual analogue scales. Satiety is notoriously difficult to 
assess. It was not a major outcome measure and I wanted to be able to detect 
major changes. 
There were no differences between the two groups in terms of their changes 
in visual analogue scale (VAS) satiety parameters or weights during the study 
periods and so I believe that energy intakes were similar between groups. There 
has been a suggestion that fructose may induce a reduced satiety. Over a 24 hour 
period there was a reduced rise in serum insulin and leptin concentrations and 
blunted reduction in ghrelin with intakes of 30% fructose compared to 30% 
glucose (Teff, Grudziak et al. 2009). The authors concluded that this may result in 
differing long-term satiety levels and intake patterns. These short term differences 
in satiety hormone profiles have never been reproduced, and differences in long-
term satiety have not been found (Monsivais, Perrigue et al. 2007), indeed the 
current data also refute this hypothesis.  
The changes in VAS satiety responses were small, though greater in the first 
than second period. This small change in the first period implies that the overall 
food energy, content and pattern of consumption were not dramatically altered 
from the subject’s habitual intakes. Interestingly during this period subjects 
reported increased fullness and reduced hunger despite no significant weight 
change. This discrepancy between reported changes in satiety and weights may 
reflect the supplied foods’ low energy density, or that the food was predominantly 
taken in a traditional regular three times a day meal pattern. It seems unlikely that 
abdominal bloating due to malabsorption of the monosaccharide drinks may have 
been mis-interpreted as fullness, as this should only have occurred with fructose. 
During the second period energy intakes were increased, with marked weight 
gain, though the changes in satiety and food satisfaction were minimal. This 
implies that the subjects adapted the additional monosaccharides into their normal 
intakes and did not ‘sense’ their overall increased energy intakes. Whether liquids 
fail to trigger satiety sensations as well as occurs with solid food is an area of 
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intense debate and scrutiny with protagonists on both sides of the fence (Malik, 
Schulze et al. 2006; Drewnowski and Bellisle 2007). The popular opinion 
however is that satiety is less well stimulated by drinks and this may explain the 
discrepancy between increased energy intakes, increased weight gain and the 
minimal effect on satiety noted in the second period.  
The subjects reported an increased sense of fullness during the energy 
balanced period and no change during energy overfeeding. The only difference 
between the two assessment periods was the food consumed with the 
monosaccharide drinks. This implies a lack of awareness of energy overfeeding 
from monosaccharide drinks, and an energy-independent effect on the sensation 
of fullness with the supplied foods. This latter effect probably resulted from the 
relative low energy density of the supplied foodstuffs.  
 
3.9.6. Side effects 
The volunteers were warned about gastrointestinal side effects. During the 
first period the supplied food was divided into three main meals with additional 
snacks which could be taken whenever the subject chose. This facilitated the 
taking of the monosaccharide drinks four times a day in combination with food in 
order to help reduce the incidence of malabsorption. Studies where fructose is 
taken ad libitum continuously throughout the day have reported a high incidence 
of symptomatic malabsorption that resulted in 9 out of 83 subjects withdrawing 
from a two week study and a further 22 reporting diarrhoea, abdominal cramps or 
flatulence (Perez-Pozo, Schold et al. 2010). Most of the symptoms in the present 
study were mild in nature and resulted in no drop outs. The majority of side 
effects occurred during the first period when both the monosaccharides and 
foodstuffs were different from habitual intakes.  
 
3.9.7. Renal outcomes 
Monosaccharides are not known to have renal interactions though the 
protocol may have altered hydration status by two opposing mechanisms. Firstly, 
the monosaccharides were consumed with around 2 liters of fluid a day, and 
secondly any malabsorption induced diarrhoea may have resulted in dehydration. 
The creatinine values were therefore primarily assessed to monitor hydration and 
safety. No changes were either predicted or occurred.  
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3.9.8. Whole body oxidative metabolism 
Oxidation involves the utilisation of oxygen to convert carbon based 
nutrients into carbon dioxide, water and heat. The data generated by indirect 
calorimetry represents gas exchange in the lungs and thus originates from the 
whole body, as opposed to a specific organ. The main oxidative organs in the 
fasted and rested state are the liver, brain and skeletal muscle. 
The complete oxidation of glucose results in a greater respiratory quotient 
(RQ) than for lipid or protein. An increased RQ and carbohydrate oxidation rate 
and reduced lipid oxidation rate are features of carbohydrate and energy 
overfeeding (Horton, Drougas et al. 1995; McDevitt, Poppitt et al. 2000). Short 
term studies have not previously shown a differing oxidative response to 96 hours 
of 50% fructose or glucose and energy overfeeding (McDevitt, Poppitt et al. 
2000).  
In this current study there were no differences in oxidative response 
between glucose and fructose although there was a significant increase in the RQ 
during both periods and a marked increase in carbohydrate oxidation and 
reduction in lipid oxidation rates. During the second period plasma triglyceride 
concentrations increased, and there were greater changes in lipid and carbohydrate 
oxidation rates than in the first period.  
The intervention periods resulted in a whole body oxidative metabolic 
status reflective of a high carbohydrate intake. There was no difference between a 
high fructose or glucose intake, and the greater changes noted during the second 
period are presumably due to the concurrent energy overfeeding. 
 
3.9.9. Cardiovascular outcomes 
3.9.9.1. Background 
In rats a high fructose diet (66% of all energy), as compared to standard 
chow, resulted in similar weight changes though an increased blood pressure 
(Hwang, Ho et al. 1987). Such changes do not progress after 5 weeks, implying 
that in rodents there is a plateau after a relatively short period of time (Sharma, 
Okere et al. 2007).  
Human data on the effects of fructose on BP are scant and it remains 
uncertain as to whether any changes occur. There are epidemiological data to 
support a link, with a 1.36-fold risk  for blood pressure being greater than 140/90 
mmHg in those with fructose intakes greater than the median 74g per day (Jalal, 
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Smits et al. 2010) and  1.87-fold risk for a blood pressure greater than 160/100 
mmHg. These data were adjusted for multiple factors including demographics, 
energy intake, salt intake and activity.  
However, the mechanism of such a potential hypertensive effect is unclear. 
It has been proposed to be due to a reduced vasodilatatory response following 
fructose and an increased adrenergic stimulation. Insulin induces splanchnic and 
skeletal muscle vasodilatation (Vollenweider, Tappy et al. 1993), and so the 
reduced insulin response following fructose may contribute to the reduced 
systemic vasodilatation noted following oral ingestion of fructose as opposed to 
glucose (Brundin and Wahren 1993; Brown, Dulloo et al. 2008). Such insulin-
induced vasodilatation would be expected to induce hypotension. Fructose is 
proposed to induce hypertension through inhibition of endothelial nitric oxide 
production and activation of the renin-angiotensin system (Schwarz, Acheson et 
al. 1992; Tran, Yuen et al. 2009). The proposition that fructose may impact on 
blood pressure via adrenaline has to be questioned however as the magnitude of 
changes in adrenaline previously reported are unlikely to be clinically significant. 
Though the only study with a glucose control published to date has shown a 
greater acute noradrenaline response with glucose than fructose in young 
normotensive individuals (Jansen, Penterman et al. 1987). 
These data have recently been summarised by Tran et al. (Tran, Yuen et al. 
2009) Figure 2 is adapted from their paper, it bears remembering that these 
pathways originate from extremely high dose rodent studies, which may not 
translate into clinical experience.  
    Fructose 
 
Ĺ Oxidative stress      Ĺ8ULFDFLG 
 
    Ĺ,QVXOLQUHVLVWDQFH 
    DQGĻLQVXOLQDHPLD 
  
Ļ Insulin mediated      Ĺ9DVRFRQVWULFWRUV 
Vasoconstriction  
 
    Ĺ(QGRWKHOLDOG\VIXQFWLRQDQG 
    Ĺ%ORRGSUHVVXUH 
 
Figure 2. Proposed mechanism of fructose induced hypertension. (Adapted 
from (Tran, Yuen et al. 2009)) 
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3.9.9.2. Prior short term clinical studies 
One study has reported a 3mmHg greater rise in systolic blood pressure 
immediately post fructose consumption than following glucose or water, (Brown, 
Dulloo et al. 2008), whereas a subsequent paper found no such change (Bidwell, 
Holmstrup et al. 2010). The paper by Brown and colleagues used continuous 
measurements by task force monitor, which employs the same non-invasive 
principles as a finometer. In contrast, the Bidwell paper only measured the acute 
cardiovascular responses in ten volunteers at six time points, and they compared 
the responses following glucose and sucrose (45% glucose, 55% fructose) as 
opposed to pure fructose. 
Brown et al. studied 15 healthy slim normotensive adults who consumed 
60g of fructose or glucose or water in a single blind fashion (Brown, Dulloo et al. 
2008). The mean rise in systolic pressures over the subsequent 120 minutes was 
around 1mmHg for water and glucose and over 4mmHg for fructose. A similar 
pattern was noted in the diastolic pressures. The increase in pressures with 
fructose was attributed to a rise in heart rate and cardiac output with no change in 
total peripheral resistance (TPR). Glucose also increased heart rate and cardiac 
output, though TPR fell such that pressures were relatively unchanged. The 
authors concluded that the difference in pressure was primarily due to the changes 
in TPR and that this was due to differing insulin and catecholamine responses, 
though no such confirmatory data were collected.    
 
3.9.9.3. Prior long-term clinical studies 
Three prior long-term high fructose diet studies have only crudely and 
discretely assessed cardiovascular status with a resting automatic cuff 
sphygmomanometer (Swarbrick, Stanhope et al. 2008; Stanhope, Schwarz et al. 
2009; Silbernagel, Machann et al. 2011). No changes in systolic or diastolic 
pressures occurred in their overweight but normotensive cohorts.  
The paper by Perez-Pozo et al. is the only other long-term paper to 
intensively assess the cardiovascular response to fructose (Perez-Pozo, Schold et 
al. 2010). They measured ambulatory 24 hour blood pressure in 74 middle-aged 
overweight normotensive men pre and post 2 weeks of a high fructose diet. There 
was a 7±2mmHg rise in systolic pressures and a 5±2mmHg rise in diastolic 
pressures during the day and a smaller rise during night time. Unfortunately this 
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paper lacked a nutrient control and so the changes could solely be attributed to 
energy (excess of 618kcal for 14 days) or carbohydrate overfeeding. In an attempt 
to demonstrate that this was a fructose-specific effect however the comparative 
group consumed fructose and allopurinol. Both groups had similar changes in 
weight, insulin and lipid profiles, though the fructose and allopurinol group had a 
significantly blunted change in systolic and diastolic blood pressures of 2.1 vs. 6.9 
mmHg and 1.0 vs. 4.7 mmHg respectively. The authors offered no specific 
mechanism for these effects beyond reduced uric acid production (-ȝPRO/YV
ȝPRO/+HDUWUDWHZDVDOVRLQFUHDVHGin the fructose alone group, though no 
catecholamines were analysed to facilitate the interpretation of this.  
 
3.9.9.4. Current cardiovascular findings 
The use of finometry paired with adrenergic analyses in this study allowed 
for an in-depth assessment of cardiovascular function. The cohort gave no history 
of cardiac disease and had a normal resting blood pressure and ECG at screening.  
Finometry was not performed at screening. Most of the finometry 
parameters are not routinely assessed and hence do not have widely accepted 
normal range values. The mean basal cardiac output was 7.12 L/min (normal is 4-
8 L/min) with 5 subjects having elevated readings. The normal range for cardiac 
output is contentious given the influence of body size. The cardiac index has been 
developed to adjust for the effect of body size. It is the cardiac output divided by 
body surface area in metres2 with a normal range of  3.0 to 4.2 L/min/m2 (Greim, 
Roewer et al. 1997). Using the Mosteller formula for body surface area, only one 
subject had an elevated cardiac index at entry and so the cohort can be viewed as 
having normal cardiac function. Again there were no significant differences in the 
absolute values or changes between the groups in their cardiac index values.  
There were no significant changes in cardiovascular function as assessed 
by a finometer during the study or between the groups. The non-significant trends 
found however did reproduce prior data. Systolic and diastolic pressures remained 
essentially unchanged with fructose whereas there was a tendency for a reduction 
with glucose. During the first period there was a non-significant trend for greater 
TPR with fructose and a fall in TPR with glucose as previously reported. Though 
cardiac output was unchanged with fructose and increased with glucose (p=0.31), 
and so pressures were similar between the groups. During the second period, there 
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again was no evidence of any difference between fructose or glucose or change 
with them.  
In contrast to the lack of cardiovascular parameter changes there were 
alterations in catecholamine profiles during the first period, with reductions in 
adrenaline with fructose and noradrenaline with glucose. The aetiology of these 
changes is impossible to determine as mechanistic data were not collected. 
Changes could result either from alterations in rates of synthesis or clearance. Of 
note, the findings were in direct contrast to that previously published where  there 
was a greater acute noradrenaline response with glucose than fructose in young 
normotensive individuals (Jansen, Penterman et al. 1987). As the primary 
stimulus for the reported noradrenaline changes is believed to be circulating 
insulin concentrations, the overnight fast will have resulted in a differing and 
blunted response than the acute postprandial state. The lack of ‘end-organ’ 
cardiovascular changes also means that interpretation of these adrenergic findings 
is limited. 
Ultimately the lack of changes observed during this study is overwhelmingly 
convincing, though there remains the possibility of a type 2 error. The 
cardiovascular assessments were not formally part of the study power process, and 
they were done in the fasted, as opposed to fed, state and only whilst rested. . The 
number of subjects consuming fructose in this current paper (15) were however 
similar to that reported by Brown (15) and by Perez-Pozo (36). This current study 
may have involved assessments at an inappropriate time point. The hypothesis of 
Brown et al. is that differing endocrine responses to fructose and glucose drive the 
differing cardiovascular responses. Such endocrine differences are greater in the 
fed than fasted state. The greater than 10 hours fast may have resulted in a blunted 
or absent cardiac and/or endocrine memory of the previously ingested 
monosaccharide. Indeed the two papers with positive cardiac outcomes have 
measured parameters in the immediate postprandial or semi-continuously 
postprandial (sipping) state (Brown, Dulloo et al. 2008; Perez-Pozo, Schold et al. 
2010). Another alternative is that resting may have blunted any adrenergic 
responses. The positive nocturnal findings of Perez-Pozo would argue against 
that, but that paper lacked a control and may merely reflect energy overfeeding. 
Finally the lack of long-term changes may be a true finding. Further studies need 
to assess this area using continuous ambulatory monitoring and comparing 
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fructose with another energy matched carbohydrate control to see if this is truly a 
fructose specific effect.  
 
3.10. Conclusions 
This study demonstrated no differences in whole body metabolism between 
a high fructose and a high glucose diet. The energy overfeeding period induced 
weight gain, as predicted, and both periods increased carbohydrate oxidation rates 
implying an increased intake of carbohydrates.  
 
There are several strengths of this study: 
1. The strict inclusion criteria resulted in a sharply defined cohort.  
2. The balance of energy and macronutrient profiles between the two groups 
meant that the monosaccharides were the only factor that differed between them.  
3. The food provided had a very similar macronutrient profile to habitual intakes.  
4. The creation of two energy settings facilitated the comparison of the effects of 
energy intakes on outcomes. 
5. The repeat baseline assessments ensured that a true washout had occurred.  
6. The assessment of satiety and self reported ‘energy’ ensured that these did not 
compound the outcomes.  
7. The comprehensive assessment process facilitated a global metabolic 
assessment.  
 
 I acknowledge some limitations in this study design: 
1. The sharply defined cohort means that these findings cannot be extrapolated 
out of the overweight healthy male population. 
2. The lack of cross-over between the groups weakens analyses between the 
monosaccharides. 
3. The relatively short-term nature of the intervention means that an effect with a 
longer dietary alteration cannot be excluded.  
4. The haemodynamic assessments were only made in the fasted and rested state.  
5. The monosaccharides were provided as their constituent powders as opposed to 
as a whole foodstuff. This resulted in a nutrient or metabolic comparison as 
opposed to that of dietary patterns. There is however no evidence that fructose 
differs in its metabolic outcomes when provided as a hexose from when bound to 
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glucose in sucrose (McDevitt, Poppitt et al. 2000; Stanhope, Griffen et al. 2008; 
Tappy, Le et al. 2010).  
 
In comparison to prior studies this study is the first to provide all 
foodstuffs and so achieved the strictest control over total intakes. This was also 
the first energy-controlled long-term cardiovascular study. This study adds to the 
growing body of appropriately controlled work which reports that there is no 
difference between fructose and glucose in terms of whole body metabolism, 
impact on satiety or potential for weight gain. The differences in weight between 
the two periods clearly highlight the impact of energy overfeeding on obesity. 
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Chapter 4. The responses to a high fructose versus high glucose diet in terms 
of insulin resistance, and non-hepatic lipid content 
 
4.1. Introduction 
These data are derived from the Study fully described in chapter 3. This 
chapter focuses on the impact of a high fructose or high glucose diet on insulin 
resistance, and plasma and myocellular lipid contents.  
In brief, healthy overweight males were randomised to a high fructose or 
glucose diet for 2 weeks firstly in an energy balanced (isoenergetic) setting and 
subsequently in an energy overfeeding (hyperenergetic) setting. The 
monosaccharides were consumed mixed with water four times a day and provided 
25% of predicted energy requirements. The differing energy periods were 
achieved by firstly providing all food to be consumed and secondly by subjects 
consuming the monosaccharides in addition to their habitual intakes. 
The assessment processes were identical pre and post each intervention 
period. Specific to this chapter, the 32 subjects underwent fasted proton magnetic 
resonance spectroscopy (1H MRS) of their calf and fasted serum was analysed for 
triglyceride, non-esterified fatty acids, glucose and insulin. A subset of 12 subjects 
underwent a hyperinsulinaemic euglycaemic clamp with indirect calorimetry 
repeated during the clamp. 
4.2. Protocols for the methods employed in this chapter 
4.2.1. Hyperinsulinaemic euglycaemic clamp 
Subjects were fasted overnight and rested supine. They were initially 
delivered a loading bolus dose of 4mg/kg of deuterated glucose [6, 6-2H2] (CK 
Gas Products Ltd, Hook, Hampshire, UK). This was followed by a continuous 
LQIXVLRQ DW ȝJNJPLQ IRU WKH UHVW RI WKH VWXG\ 7KH GHXWHUDWHG JOXFRVH ZDV
delivered at a concentration of 20mg/ml made up in sodium chloride 0.9% (Baxter 
Healthcare Ltd., Norfolk, UK). This infusion was started 2 hours pre the initiation 
of the insulin glucose clamp and continued at the same post-loading rate for the 
full 5 hours throughout the visit.  
A 20 gauge catheter (Becton Dickinson, Helsingborg, Sweden) was 
inserted retrogradely into a dorsal hand vein, and the hand placed in a warmed air 
box (550C) in order to arterialise the venous samples. The difference in blood 
glucose concentrations between arterial and arterialised sampling is minimal at 
0.1±0.3mmol/l due to shunting reducing tissue uptake (Liu, Moberg et al. 1992). 
A slow running infusion of 0.9% saline was used to maintain catheter patency. 
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Blood samples were drawn via a 3-way tap, with the first 1ml being discarded to 
avoid dilution with saline. The arterialised plasma samples were taken at baseline 
and every 30 minutes during the clamp for the measurement of tracer 
concentration and free fatty acids.  
25 units of insulin (Human Actrapid, Novo Nordisk, Bagsværd, Denmark) 
was mixed with 48 ml of 0.9% saline (Baxter Healthcare Ltd., Norfolk, UK) and 
2ml of the subject’s venous blood. This infusion was started following the 2 hour 
loading of deuterated glucose following the protocol described by DeFronzo et al. 
(DeFronzo, Tobin et al. 1979). Priming and maintenance insulin infusion rates 
were calculated based on body surface area (DeFronzo, Tobin et al. 1979) to 
provide 30 mU/min/m2 in a 3 hour single step clamp. Arterialised plasma glucose 
concentrations were measured every 5 minutes during the clamp (YSI 2300, 
Yellow Springs Incorporated, Ohio, USA), and maintained at 4.5mmol/L by a 
concurrent, variable rate infusion of 20% glucose (Baxter Healthcare Ltd., 
Norfolk, UK) with 1g (1%) of deuterated glucose spiked into the bag. The 
addition of deuterated glucose in the 20% clamp glucose generates what is termed 
a ‘hot’ glucose infusion protocol. This ‘hot’ protocol reduces inter-subject 
variation and improves the physiological plausibility of the endogenous glucose 
production data (Finegood, Bergman et al. 1987).  
The insulin dose was selected to mimic the postprandial response in mildly 
insulin resistant subjects. The target plasma glucose concentration was chosen at 
4.5mmol/l, as it was predicted to be the mean fasting concentration. Indirect 
calorimetry was performed for 20 minutes in every hour during the clamp by the 
same methods as previously described in section 3.6.5. 
4.2.2. Insulin quantification by radioimmunoassay 
This technique incubates a fixed concentration of labelled antigen tracer 
with a limited amount of antiserum such that only a limited proportion of the 
tracer is antibody bound. Unlabeled antigen is then added at known and increasing 
concentrations. The amount of bound tracer decreases as the concentration of 
added unlabeled antigen increases. This is due to competition between the labelled 
tracer and the unlabeled antigen for the limited amount of antibody binding sites. 
The fraction of bound to free antigen is then counted at each unlabeled antigen 
concentration and hence the amount of unknown antigen can be calculated from 
the resultant curve. 
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The Millipore Human Insulin assay was utilised with 125I-labeled Human 
Insulin and a Human Insulin antiserum to determine the level of Insulin in serum. 
The manufacturer’s protocol was followed. Briefly, six glass tubes had 1.0mL of 
assay buffer and serial dilXWLRQVRI WKHVWDQGDUGDGGHG7KHQȝ/RIK\GUDWHG
125I-,QVXOLQZDVDGGHGWRDOOWXEHVȝ/RI+XPDQ,QVXOLQDQWLERG\ZDVSLSHWWHG
to all tubes except the total count tubes. The mixture was vortexed, covered and 
incubated overnight at room temperature. The next day 1.0mL of cold (4°C) 
precipitating reagent was added to all tubes (except total count tubes), the mixture 
vortexed and incubated for 20 minutes at 4°C. This was then centrifuged for 20 
minutes at 2,000g. A firm pellet was formed and the supernatant decanted. The 
tubes were then counted in a gamma counter for 1 minute and the concentration of 
insulin calculated by using an automated data reduction procedure. 
4.2.3. Deuterated glucose quantification by gas chromatography mass 
spectrometry 
50µl of plasma was first mixed with 10µl of internal standard (methyl 
glucopyranose 50µg/ml). The addition of the internal standard means that a 
characteristic spectrum is subsequently formed and the peak of interest is then 
divided by the internal standard peak to ensure that losses are accounted for. Next 
300µl of ice cold absolute ethanol was added to the mixture to deproteinise it. 
This mixture was spun down and the supernatant removed. A tenth of the 
supernatant was evaporated under N2 at 90oC to form a dried solid residue. To this 
residue 50µl of pyridine and hydroxylamine (25mg/ml) was added to form an 
oxime group. This was then incubated at 70oC for 45 minutes and allowed to cool 
slightly. 50µl of BSTFA (1% TMCS) was added and it was incubated at 70oC 
again for 45 minutes.  
This was then injected in a gas chromatography mass spectrometer at 
240oC for up to 240 minutes. The glucose peak tended to come off at 10 to 12 
minutes. An enrichment curve was generated by making up 0.5%-5% deuterated 
glucose standards.  The internal standard peak was at 261. Unlabelled glucose 
peak was represented by a peak at 319 and deuterated glucose by a peak at 321. 
Two glucose peaks for each sample were obtained both with excellent enrichment 
curve correlation with the deuterated glucose standards of r2 of 0.9662 and 
0.9905. As the enrichment curve was slightly better using the 2nd peak, analyses 
just focus on this peak.  
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4.2.4. 1H MRS calf data collection 
MRI of the right calf was performed to identify the soleus muscle. A 
20x20x50mm3 voxel was positioned within the soleus muscle and an image was 
stored so that the voxel could be similarly placed at subsequent visits. Spectra 
were obtained from this voxel using a STimulated Echo Acquisition Mode 
(STEAM) sequence with the following parameters: echo/repetition time 13/7000 
ms, bandwidth 2000 Hz, 1024 samples. 16 averages were collected with water-
suppression applied and 2 without. 
4.2.5. 1H MRS calf data analysis 
Water-suppressed spectra were individually phase corrected and realigned 
using jMRUI (Java-based MR user interface) (Naressi, Couturier et al. 2001) 
before averaging. Residual water peaks at approximately 4.75ppm were removed 
to simplify lipid quantisation using a HLSVD filter (Poullet, Sima et al. 2007). To 
determine the relative IMCL to EMCL contribution to the lipid peaks, the 
Advanced Magnetic Resonance Metabolite (AMARES) algorithm within jMRUI 
was then used to quantify individual metabolite signals. The protocol devised by 
Torriani et al. was then followed (Torriani, Thomas et al. 2005). Briefly, prior 
knowledge was fitted into the analysis algorithm as follows: 
a. the IMCL -CH3 had a fixed resonance of 0.9ppm 
b. the EMCL -CH3 had a fixed resonance of 1.1ppm 
c. the IMCL -CH2 had a fixed resonance of 1.3ppm 
d. the EMCL –CH3 had a fixed resonance of 1.5ppm 
The first and zeroth order phase corrections were fixed to zero, and peaks 
were assumed to have a Gaussian shape. All resonances were fitted to ensure no 
contamination from neighbouring peaks were included, however only peak areas 
from the methylene groups were used for analysis. In order to calculate absolute 
lipid percentages (%IMCL and %EMCL), the total lipid (integrated peak areas 
from 1.7-0.5ppm in Matlab) to water ratio was determined from the non water 
suppressed spectra (as described earlier for liver). The IMCL and EMCL to water 
ratios are then found by relating the total lipid areas (IMCL(CH3) + EMCL(CH3) 
+ IMCL(CH2) + EMCL(CH2) calculated from the water suppressed data in 
AMARES ) to the total lipids to water ratio (calculated in MATLAB). To convert 
the methylene to water ratios to absolute values a correction was applied as 
described in equation 1 substituting with T2H2O=31ms, T2IMCL=89ms, 
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T2EMCL=78ms, Tw  JPO DQG ȡtg = 65.2mmol/ml (Szczepaniak, Babcock et 
al. 1999).  
4.2.6. Statistical analyses 
All data are tabulated as the mean ± standard deviation (SD). Comparisons 
between baseline values were done by the independent samples T test. The 
Student’s T test was used for paired data. Analysis of the significance of change 
between the two groups at two paired assessments was done by an independent 
samples T test of the absolute change between the two assessments in both 
groups. Repeated measures over time were assessed by a repeated measures one-
way ANOVA with a Greenhouse-Geisser correction. Associations were assessed 
for by 2-tailed Pearson correlations. Any negative rates of endogenous glucose 
production data were transformed to a rate of zero.  
 
4.3. Results 
4.3.1. Fasted insulin resistance 
No subject had a fasted glucose greater than 6.0mmol/L. There was 
evidence of fasted insulin resistance according to HOMA, with the mean baseline 
HOMA value of the whole cohort at study entry being 3.28 (range 1.45-3.85).  
In the whole cohort, concentrations of both insulin and glucose rose in the 
first period and were relatively unchanged in the second. As a result fasting 
insulin resistance increased in the first but not the second period.  
Comparing the two groups, blood glucose concentrations rose in the 
fructose group during both periods and tended to remain the same or fall in the 
glucose group. In contrast the trends for insulin were similar between the groups. 
As a result there was a difference in terms of insulin resistance between the two 
groups, with a significant increase in HOMA noted during the first period with 
fructose (+23±29%, p=0.005) and not with glucose (+7±23%, p=0.45). Due to 
technical issues, fasted glucagon was analysed in 14 fructose and 16 glucose 
samples. There were no changes during the study. 
 151  
 
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
absolute 
change 
between 
groups (p) 
Glucose 1st period 
(mmol/L) 
Baseline 4.58±0.34 4.50±0.20 4.65±0.42 0.20  
0.12 Week 2 4.68±0.37 4.71±0.29* 4.64±0.44 
Glucose 2nd period 
(mmol/L) 
Baseline 4.58±0.38 4.45±0.29 4.73±0.43 0.60  
0.10 Week 2 4.59±0.35 4.60±0.29 4.60±0.41 
Insulin 1st period 
(mIU/L) 
Baseline 16.1±5.5 17.9±5.1 14.6±5.6 0.09  
0.11 Week 2 17.9±6.9** 20.8±6.8* 15.4±6.2 
Insulin 2nd period 
(mIU/L) 
Baseline 17.7±6.6 19.5±7.4 16.2±5.6 0.16  
0.82 Week 2 17.0±5.4 18.6±5.6 15.6±5.0 
HOMA 1st period Baseline 3.28±1.16 3.58±1.04 3.02±1.24 0.19  
0.03 “ Week 2 3.71±1.40** 4.34±1.39** 3.15±1.19 
HOMA 2nd period Baseline 3.61±1.35 3.83±1.52 3.41±1.19 0.39  
0.47 Week 2 3.48±1.19 3.83±1.31 3.17±1.00 
Glucagon 1st 
period (pg/ml) 
baseline 50.0±13.6 53.5±15.3 47.0±11.6 0.20  
0.30 week 2 49.8±11.4 51.5±12.8 48.3±10.1 
Glucagon 2nd 
period (pg/ml) 
baseline 50.8±11.0 53.9±11.8 47.8±9.5 0.12  
0.79 week 2 51.6±12.2 55.2±14.1 48.4±9.5 
 
Table 1. Blood glucose and serum insulin and glucagon concentrations before 
and after the consumption of a high fructose or glucose diet for two weeks, 
mean ± SD. (In comparison to the baseline value, *=p<0.05, **=p<0.01, 
***=p<0.001. Absolute change between groups, “=p<0.05) 
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Figure 1. Changes in HOMA values (units arbitrary), mean ± SEM. (** 
p<0.01 in comparison to baseline value in that group) 
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4.3.2. Postprandial systemic insulin sensitivity  
4.3.2.1. The degree that the 12 subjects undergoing the hyperinsulinaemic 
euglycaemic clamp were representative of the entire group  
A self selected subgroup of 12 subjects underwent further assessment with 
a hyperinsulinaemic euglycaemic clamp to assess postprandial systemic insulin 
sensitivity. In terms of clinical features they were however representative of the 
whole cohort, and the 6 who underwent a clamp and took fructose were no 
different to the 6 who underwent a clamp and took glucose, see table 2. 
  
 Difference 
from rest of 
group (p) 
Difference 
between clamp 
groups (p) 
Age (years) Whole 34±10  
0.61 
 
 
0.64 
Clamp fructose 36±10 
Clamp glucose 39±11 0.19 
Weight (kg) Whole 95.3±8.1  
0.91 
 
 
0.48 
Clamp fructose 95.6±10.5 
Clamp glucose 91.7±7.5 0.24 
BMI (kg/m2) Whole 29.4±1.7  
0.73 
 
 
0.23 
Clamp fructose 29.2±1.4 
Clamp glucose 28.0±1.9 0.07 
Body fat (%) Whole 34.2±4.4  
0.45 
 
 
0.13 
Clamp fructose 35.4±3.1 
Clamp glucose 32.2±3.6 0.23 
Waist (cm) Whole 103.6±5.0  
0.99 
 
 
0.63 
Clamp fructose 103.6±4.7 
Clamp glucose 101.8±5.9 0.33 
Waist : hip ratio Whole 1.03±0.03  
0.47 
 
 
0.62 
Clamp fructose 1.04±6.7 
Clamp glucose 1.05±0.03 0.15 
Total energy 
provided during 1st 
period (kcal/day) 
Whole 3259±229  
0.57 
 
 
0.88 
Clamp fructose 3210±322 
Clamp glucose 3233±190 0.77 
Supplemented 
monosaccharide 
during both 
periods (g/day) 
Whole 216.5±14.7  
0.93 
 
 
0.78 
Clamp fructose 216.0±19.1 
Clamp glucose 213.3±12.3 0.57 
Weight change 1st 
period (%) 
Whole -0.19±0.87  
0.78 
 
 
0.79 
Clamp fructose -0.28±0.98 
Clamp glucose -0.41±0.62 0.49 
Weight change 2nd 
period (%) 
Whole 0.83±1.2  
0.70 
 
 
0.47 
Clamp fructose 1.01±0.02 
Clamp glucose 0.49±0.91 0.46 
 
Table 2. Comparisons of the fructose and glucose clamp groups, mean ± SD. 
(n=6 in both) with the rest of the cohort in terms of demographics, 
anthropometry, food and monosaccharide supplied and weight changes. 
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The clamp assessed 12 did not differ from the full 32 subjects in their 
HOMA values, though there were no significant changes noted, see table 3.  
 
   Mean ±SD Difference 
from rest 
of group 
(p) 
Difference 
between clamp 
groups (p) 
First 
period 
Baseline  Whole  3.28±1.17   
 
0.93 
Clamp fructose  2.91±0.96 0.40 
Clamp glucose 2.98±1.59 0.49 
Week 2 Whole 3.71±1.40   
 
0.11 
Clamp fructose 3.97±1.21 0.62 
Clamp glucose 2.80±1.09 0.08 
Second 
period 
Baseline Whole 3.60±1.35   
 
0.51 
Clamp fructose 3.57±1.35 0.94 
Clamp glucose 3.02±1.45 0.25 
Week 2 Whole 3.48±1.19   
 
0.25 
Clamp fructose 3.94±1.58 0.30 
Clamp glucose 2.97±1.14 0.25 
 
Table 3. Comparisons of the fructose and glucose clamp groups (n=6 in both) 
with the rest of the cohort in terms of fasted insulin resistance as assessed by 
the HOMA, mean ± SD. 
 
4.3.2.2. The degree of metabolic stability achieved during the clamp 
procedures 
 
4.3.2.2.1. Maintenance of stable glycaemia 
Arterialised blood glucose concentrations during the clamps were tightly 
controlled at 4.5mmol/L throughout the clamp and did not differ between the 
groups. 
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Figure 2. Arterialised blood glucose concentrations during the entire 180 
minute hyperinsulinaemic euglycaemic clamp.  
 
Whole body glucose disposal was measured during the final hour (t=120-
180minutes) and the arterialised blood glucose concentrations during this 
assessment period are presented in table 4. There were no differences between the 
groups and the mean coefficient of variation of the glucose values was acceptable 
at less than 6.0% in all bar one of the forty eight assessments.  
 
   Arterialised 
glucose 
(mmol/L) 
Difference 
between 
groups (p) 
Coefficient 
of variation 
(%) 
Difference 
between 
groups (p) 
First period Baseline Fructose 4.48±0.09 0.76 4.45±2.71 0.23 
Glucose 4.47±0.06 2.98±0.80 
Week 2 Fructose 4.43±0.04 0.21 3.22±1.30 0.30 
Glucose 4.47±0.04 2.54±0.77 
Second 
period 
 
Baseline Fructose 4.45±0.06 0.23 3.08±0.63 0.22 
Glucose 4.48±0.02 2.60±0.62 
Week 2 Fructose 4.45±0.03 0.61 2.88±0.80 0.77 
Glucose 4.46±0.04 2.77±0.45 
Table 4. Whole arterialised blood concentrations during the final hour of a 
three hour hyperinsulinaemic euglycaemic clamp, mean ± SD.  
 
4.3.2.2.2. Maintenance of stable insulinaemia 
The insulin values at each time point in all four clamp assessments are 
presented below. Some caution needs to be employed as unfortunately not every 
time period is fully represented by all 12 subjects due to sample misplacement. It 
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is however clear that a steady state of insulinaemia was achieved at all visits by 30 
minutes and that it persisted at the same concentration throughout the 180 minute 
study.  
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Figure 3 a-d. Serum insulin concentrations during a 180 minute 
hyperinsulinaemic euglycaemic clamp (units are mIU/L), mean ± SEM. A, 
baseline assessment during first period. B, week 2 assessment during first 
period. C, baseline assessment during second period. D, week 2 assessment 
during second period.  
 
The insulin concentrations during the last hour are presented in table 5. 
Again due to sample misplacement the data is not complete and so caution needs 
to be exercised, there was however no differences between the groups or between 
the assessments. 
 
  All (n=12) Fructose 
(n=6) 
 
Glucose 
(n=6) 
Difference 
between 
groups (p) 
First period Baseline 86.8±12.5 89.1±11.6 84.9±14.3 0.65 
Week 2 77.9±9.3 82.2±9.2 73.6±8.0 0.15 
Second period Baseline 82.1±12.0 85.5±13.9 79.3±10.6 0.42 
Week 2 83.8±15.9 80.8±8.1 86.8±22.0 0.58 
  
Table 5. Arterialised serum insulin concentrations during the final hour of a 
three hour hyperinsulinaemic euglycaemic clamp (units are mIU/L), mean ± 
SD.  
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4.3.2.3. Oxidative response to the hyperinsulinaemic euglycaemic clamp 
In all 12 subjects, the clamp mimicked the postprandial oxidative state 
seen after a carbohydrate rich meal, with increases in respiratory quotient and 
carbohydrate oxidation rates and reduced lipid oxidation rates, see table 6. There 
was no difference between the groups in terms of the baseline or final values.   
  Change in RQ Change in 
carbohydrate 
oxidation rate  
Change in lipid 
oxidation rate  
First period Baseline 0.077±0.066** 74±60** -29±26** 
Week 2 0.051±0.063* 49±63* -21±24* 
Second period Baseline 0.074±0.066** 71±63** -26±23** 
Week 2 0.091±0.073** 86±67* -36±27** 
 
Table 6. Absolute changes in the respiratory quotient (RQ), carbohydrate 
and lipid oxidation rates (mg/min) at 150 minutes from baseline of the 
hyperinsulinaemic euglycaemic clamp in all 12 subjects combined, mean ± 
SD. (*=p<0.05, **=p<0.01) 
 
4.3.2.4. Glucose disposal during the hyperinsulinaemic euglycaemic clamp 
The rate of whole body glucose disposal during the clamp period is 
presented in figures 4a-d below. The groups were the same at all time points. 
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Figures 4 a-d. Whole body glucose disposal (M value) during a 180 minute 
hyperinsulinaemic euglycaemic clamp (mg/kg/min), mean ± SEM. A, baseline 
assessment during first period. B, week 2 assessment during first period. C, 
baseline assessment during second period. D, week 2 assessment during 
second period.  
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The average values of glucose disposal (mg/min/kg) for the last hour of 
the clamp (120-180 minutes) are presented in table 7. The baseline values for both 
periods were similar. There was a tendency for insulin-mediated whole body 
glucose disposal to lower during the intervention periods, though this was not 
significant either within the whole cohort or within the groups.  
 
Table 7. Average whole body glucose disposal (M value) during the 120 to 
180 minute of a hyperinsulinaemic euglycaemic clamp (mg/kg/min), mean ± 
SD. 
 
When combined together the 48 individual M values presented in table 7 
were moderately associated (r=-0.45, p=0.002) with the HOMA value generated 
at the same assessments, as presented in figure 5.  
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Figure 5. The association between fasted HOMA (arbitrary units) and the 
mean M value from t=120 to 180 minutes (mg/kg/min).  
 
  All (n=12) Fructose  
(n=6) 
Glucose 
(n=6) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 4.76±1.66 4.50±1.84 5.01±1.59 0.62  
0.58 Week 2 4.27±1.25 4.21±1.42 4.33±1.20 
Second period Baseline 4.62±1.43 4.27±1.39 4.96±1.51 0.43  
0.55 Week 2 4.10±1.06 3.98±1.11 4.23±1.10 
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4.3.3. Fasted and postprandial hepatic glucose production 
  Rates of fasting hepatic glucose production were unaltered during the 
study. There was a tendency for it to increase with overfeeding but this was not 
significant, see table 8. 
 
  Whole 
cohort 
(n=12) 
Fructose 
(n=6) 
Glucose 
(n=6) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
First period baseline 2.00±1.34 2.07±1.31 1.93±1.49 0.87  
0.58 week 2 1.96±1.13 1.71±0.71 2.20±1.47 
Second period baseline 2.20±0.69 2.51±0.81 1.90±0.41 0.13  
0.89 week 2 2.45±1.72 2.82±2.27 2.07±1.00 
 
Table 8. Basal hepatic glucose output pre initiation of the hyperinsulinaemic 
euglycaemic clamp (mg/kg/min), mean ± SD. 
 
By the end of the clamp hepatic glucose production was not fully 
suppressed, see table 9. The mean reduction of the basal rates by the end of the 
clamp was 48%, with no differences between the groups.  
 
Table 9. End of hyperinsulinaemic euglycaemic clamp (170-180 minutes) 
hepatic glucose output (mg/kg/min), mean ± SD. 
 
As hepatic glucose production was not fully suppressed then the adjusted 
glucose disposal (M values) are presented in table 10.  
 
  All (n=12) Fructose  
(n=6) 
Glucose 
(n=6) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 1.10±0.68 1.02±0.68 1.17±0.73 0.73  
0.47 Week 2 1.29±1.52 0.91±1.08 1.66±1.90 
Second period Baseline 0.98±0.75 1.09±0.80 0.87±0.75 0.64  
0.33 Week 2 1.08±1.08 0.89±0.94 1.28±1.27 
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Table 10. Average whole body glucose disposal (M value) during the 120 to 
180 minute of a hyperinsulinaemic euglycaemic clamp (mg/kg/min), adjusted 
for endogenous glucose production during 170 to 180 minutes, mean ± SD. 
 
4.3.4. Oxidative and non-oxidative glucose disposal 
At the end of the hyperinsulinaemic euglycaemic clamp the rates of whole 
body oxidative glucose disposal were unaltered, though there was a trend for a 
reduction during the first period and an increase during the second period, see 
table 11.  
 
Table 11. Rate of glucose oxidative disposal at the end (150 minutes) of the 
hyperinsulinaemic euglycaemic clamp, (mg/kg/min), mean ± SD. 
 
There was a significant reduction in non-oxidative glucose disposal during 
the period of overfeeding though there was no difference between the groups.  
 
  All (n=12) Fructose  
(n=6) 
Glucose 
(n=6) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 3.7±2.0 3.5±2.2 3.8±2.0 0.76  
0.44 Week 2 3.0±2.1 3.3±1.3 2.7±2.8 
Second period Baseline 3.7±1.6 3.2±1.2 4.2±1.9 0.32  
0.30 Week 2 3.0±1.4 3.1±01.0 2.9±2.0 
  All (n=12) Fructose 
(n=6) 
Glucose 
(n=6) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 2.5±1.4 2.2±1.6 2.8±1.2 0.51  
0.70 Week 2 1.9±0.9 1.4±0.9 2.3±0.6 
Second period Baseline 2.3±1.4 2.3±1.4 2.3±1.4 0.98  
0.58 Week 2 2.9±1.6 3.2±1.6 2.6±1.7 
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Table 12. Rate of glucose non-oxidative disposal  at the end (150 minutes) of 
the hyperinsulinaemic euglycaemic clamp, (mg/kg/min), mean ± SD. 
 
4.3.5. Fasted serum triglycerides 
Fasted hypertriglyceridaemia (>1.8mmol/L) at study entry was present in 9 
subjects (5 fructose, 4 glucose). There was a mild increase in fasted triglycerides 
in the first period though this was not significant. In the second period there was a 
significant, though matched, increase in both groups.  
 
 
Table 13. Fasted serum triglycerides (mmol/L), mean ± SD. (*=p<0.05, 
**=p<0.01 within that group from baseline) 
 
  All (n=12) Fructose 
(n=6) 
Glucose 
(n=6) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 2.2±1.3 2.3±1.6 2.2±1.2 0.97  
0.48 Week 2 2.4±1.2 2.8±1.5 2.0±0.8 
Second 
period 
Baseline 2.3±1.0 1.9±1.2 2.6±0.8 0.26  
0.87 Week 2 1.2±1.0* 0.8±0.5 1.6±1.2 
  All (n=32) Fructose  
(n=15) 
Glucose 
(n=17) 
Baseline 
difference 
between 
groups (p) 
Absolute 
change 
between 
groups (p) 
First period 
 
Baseline 1.45±0.62 1.45±0.67 1.44±0.58 0.97  
0.65 Week 1 1.52±0.62 1.47±0.53 1.55±0.70 0.73 
Week 2 1.48±0.79 1.38±0.60 1.57±0.94 0.51 0.35 
Second 
period 
Baseline 1.31±0.59 1.27±0.48 1.34±0.67 0.72  
0.98 Week 1 1.63±0.70* 1.60±0.68* 1.66±0.73 0.81 
Week 2 1.65±0.72** 1.62±0.71 1.68±0.74** 0.84 0.91 
 161  
baseline week 2 baseline week2
0.0
0.5
1.0
1.5
2.0
fructose
glucose
**
1st period                     2nd period
m
m
o
l/L
 
Figure 6. Fasted serum triglyceride (mmol/L) within the groups, mean±SEM. 
 
During the first period there was neither much of a change in weight or 
triglycerides. The change in triglycerides during the second period was associated 
with change in weight (r=0.44, p=0.01). 
 
4.3.6. Intra-myocellular lipid (IMCL) 
Intra-myocellular lipid (IMCL) was relatively unchanged in the first 
period, and significantly increased in the second period. There were no differences 
between the groups.  
 
  Whole 
cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
1st period baseline 8.5±3.2 8.8±4.1 8.3±2.1 0.64  
0.34 week 2 8.8±3.2 8.4±3.0 9.2±3.4 
2nd period baseline 8.5±2.9 9.0±3.3 8.1±2.4 0.36  
0.51 week 2 9.9±2.7* 9.9±2.6 9.8±2.9 
 
Table 14. Intra-myocellular lipid (IMCL) percentage content of the soleus 
muscle, mean ± SD. (In comparison to the baseline value, *=p<0.05) 
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Figure 7. Intra-myocellular lipid content (IMCL) during the study, mean ± 
SEM. 
 
4.3.7. Extra-myocellular lipid (EMCL) 
The subjects were well matched in terms of their EMCL content, see table 
15. There were no changes noted during the study. 
 
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
absolute 
change 
between 
groups (p) 
1st period baseline 10.8±4.4 10.6±4.4 11.0±4.5 0.78  
0.71 week 2 10.1±3.5 10.1±3.6 10.1±3.5 
2nd period baseline 10.3±4.6 11.0±4.6 9.6±4.6 0.41  
0.19 week 2 10.2±4.4 9.9±4.6 10.4±4.3 
 
Table 15. The influence of two weeks of high fructose or glucose intakes on 
extra-myocellular lipid (EMCL) percentage content of the non-dominant 
soleus muscle, mean ± SD.  
 
4.3.8. Non-esterified fatty acids 
NEFA concentrations fell during the first period with fructose and were 
unchanged with glucose. There were identical reductions noted in both groups 
during the second period.  
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Table 16. Fasted non-esterified fatty acids (mmol/L), mean ± SD. (*=p<0.05 
within that group from baseline) 
 
4.3.9. Fasted adipose tissue insulin resistance 
Fasted adipose tissue insulin resistance was unaltered during the first 
period, whereas sensitivity increased during the second with both fructose and 
glucose. 
 
Table 17. Fasted adipose tissue insulin resistance (Adipo-IR = NEFA 
(mmol/L) x fasted plasma insulin (pmol/L)), mean ± SD. (*=p<0.05 within 
that group from baseline) 
 
4.3.10. Serum non-esterified fatty acid concentrations during the 
hyperinsulinaemic euglycaemic clamp  
 
NEFA concentrations fell markedly during the hyperinsulinaemic 
euglycaemic clamps, with no difference between the groups at any visit. There 
were no significant changes noted during the intervention periods either (p=0.47, 
and p=0.82 respectively).  
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 410±96 415±80 405±110 0.78  
0.17 Week 2 376±134 334±120* 409±140 
Second 
period 
Baseline 354±126 387±139 325±110 0.17  
0.90 Week 2 308±127 337±139 282±113 
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Baseline 
difference 
between 
groups (p) 
absolute 
change 
between 
groups (p) 
First period Baseline 46.2±20.8 47.7±17.5 45.0±23.7 0.72  
0.72 Week 2 46.2±24.4 46.3±23.0 46.1±26.3 
Second 
period 
Baseline 42.7±20.8 48.1±25.6 38.0±14.7 0.18  
0.90 Week 2 36.6±20.1* 41.6±23.5 32.2±16.1 
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Figures 8 a-d. Systemic concentrations of non-esterified free fatty acids 
(NEFAs) during a 180 minute hyperinsulinaemic euglycaemic clamp 
(mmol/L), mean ± SEM. A, baseline assessment during first period. B, week 2 
assessment during first period. C, baseline assessment during second period. 
D, week 2 assessment during second period.  
 
4.4. Discussion 
4.4.1. Summary of the findings 
The intervention resulted in only one difference between the groups. 
During the isoenergetic period fructose induced a greater state of fasted insulin 
resistance than glucose. The interpretation of this isolated finding is therefore 
limited, though as will be discussed, it has been previously reported. 
The subset who underwent the hyperinsulinaemic euglycaemic clamp was 
representative of the whole study cohort. Stable glycaemia and insulinaemia were 
maintained during the clamp. The postprandial state was mimicked in terms of 
circulating insulin concentrations (see below); reduction in hepatic glucose 
production, and the whole body oxidative response reflected that seen after a high 
carbohydrate meal. 
During the isoenergetic first period, fasted insulin resistance worsened 
with fructose due to an increase in both glucose and insulin concentrations. There 
was an associated tendency for a reduction in whole body glucose disposal (M 
value), though this was non-significant and not different between the groups. 
Hepatic glucose production and non-oxidative glucose disposal did not change 
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during the period or differ between the groups. Fasted serum triglycerides and 
ectopic lipid stores within the myocytes (IMCL) and outside them (EMCL) were 
unaltered. NEFA concentrations were unaltered by glucose and reduced by 
fructose. There was no change in fasted or postprandial adipose tissue insulin 
sensitivity.  
During the hyperenergetic second period, there was no change in fasted 
insulin resistance and a tendency, as in the first period, for reduced whole body 
glucose disposal (M value) which was similar in both groups. Hepatic glucose 
production was unaltered and there was a similar trend for a reduction in non-
oxidative glucose disposal in both groups. Fasted serum triglycerides rose to a 
matched extent in both groups as did IMCL with no change in EMCL. NEFA 
concentrations tended to fall in both groups to a similar extent. Fasted adipose 
tissue insulin resistance fell to a matched extent in both groups with no changes in 
postprandial adipose tissue insulin sensitivity, though the amount of insulin 
delivered so effectively suppressed NEFAs that reliable discrimination between 
the groups was not feasible. 
4.4.2. Fasted steady-state insulin sensitivity 
Insulin directs the major glucose homeostasis processes, namely 
endogenous production and tissue uptake. Maintenance of normoglycaemia is 
needed for the adequate function of the central nervous system, which uses 
glucose almost exclusively as its energy substrate. During the fasted state the level 
of glycaemia is primarily determined by the rate of hepatic glucose production as 
opposed to peripheral tissue uptake. Elevated fasting glycaemia or insulinaemia 
are indicative of a failure of adequate feedback between the liver and insulin and 
hence predominantly hepatic insulin resistance (DeFronzo and Tripathy 2009).  
The background to the HOMA is discussed in the methods section. 
Briefly, it is a function of fasted insulin and glucose concentrations with higher 
values representing greater resistance. As such it is a measure of fasted insulin 
resistance, though its poor reproducibility means that it is a relatively crude 
assessment. Due to its methodological ease the HOMA assessment has however 
been frequently assessed following a high fructose diet. Not all studies present 
their HOMA values, but the calculated findings based on the insulin and glucose 
data are presented below in table 18. Some caution needs to be employed in 
interpreting this table. The data by Ngo Sock and Bantle are limited as there are 
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no baseline values and so the final data comparisons are made either with a 
‘weight maintenance’ or glucose group respectively.  
 
Table 18. Fasted insulin resistance data in studies comparing fructose vs. 
glucose or starch. Arrows indicate changes in parameters from baseline. 
(glu=serum glucose, ins=serum insulin). A double arrow indicates a greater 
absolute change than the comparator, (* = p<0.05, ** =P<0.01, *** 
=p<0.001). N.B.: Johnston is the current study 
 
Comparisons between differing groups’ HOMA values are not valid or 
reliable due to major differences between insulin assays. Looking at the trends, 
the first observation is that fasted glucose increases following a high fructose diet, 
and falls following a high glucose diet in all prior studies bar the Silbernagel 
paper. Insulin concentrations rose following a high fructose or glucose diet in all 
prior studies with baseline data presented. As a result HOMA increased with both 
fructose and glucose in every prior study, and the magnitude was greater with 
fructose in all bar the Silbernagel paper. It bears remembering the unbalanced 
weight changes in the Silbernagel paper of +0.2kg and +1.7kg with fructose and 
glucose respectively. 
This current study repeated all of these previous findings during the first 
period which contained provided foods in an isoenergetic environment. These 
changes resulted in increases in HOMA in both groups, though this was markedly 
greater in the fructose group (p=0.03). These changes cannot be attributed to 
changes in weight or calf lipid as these both remained stable during this first 
period. During the second hyperenergetic period of this study there was a non-
significant rise in fasted glucose in the fructose group (p=0.19) and a fall in the 
glucose group. As a result HOMA values remained identical with fructose during 
this period and fell with glucose though these trends were non-significant. 
 Comparator 
to fructose 
Duration 
(weeks) 
Foodstuff 
provided / 
ad libitum 
Hyper / 
iso-
energetic 
Baseline 
HOMA 
value 
Fasted changes 
following fructose 
 
Fasted changes 
following comparator 
 
Glu         Ins HOMA Glu     Ins HOMA 
Swanson starch 4  provided iso  Ĺ- . . Ļ- . . 
Ngo Sock glucose 1  provided hyper  Ĺ- Ĺ- ĹĹ ĺ Ĺ- Ĺ 
Silbernagel glucose 2  ad lib hyper 1.8 Ĺ Ĺ- Ĺ Ĺ- Ĺ ĹĹ 
Bantle glucose 6  provided iso  Ĺ ĺ Ĺ ĺ ĺ ĺ 
Stanhope glucose 10  ad lib hyper 3.1 Ĺ Ĺ ĹĹ Ļ Ĺ- Ĺ 
Johnston 1st 
period 
glucose 2  provided iso 3.3 Ĺ Ĺ ĹĹ Ļ- Ĺ- Ĺ- 
Johnston 2nd 
period 
glucose 2  ad lib hyper 3.6 Ĺ- Ļ- ĺ Ļ- Ļ- Ļ- 
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Overall, when data from both periods are combined, there was a significant rise in 
HOMA with fructose and no change with glucose. 
It is not possible to be certain as to why these differing trends were noted 
between the two periods. The first period was much more strictly regulated and so 
the results can be viewed as being more scientifically robust, the second period 
was deliberately less controlled in an attempt to mimic a ‘real life’ less ‘rat in a 
cage’ styled experiment. This lack of control may however be responsible for the 
unexpected findings. Indeed the findings during the first period reflect those of 
Stanhope and colleagues’ whereas the second period does not. During the first 
period identical foodstuffs were consumed during the 24 hours prior to both of 
these assessments, and both groups consumed identical food in the intervening 
period. During the hyperenergetic period the precise intakes pre each assessment 
and during the intervention period are unknown. Insulin sensitivity is very 
sensitive to variation in preceding food intakes, and as a result the insulin 
resistance assessments are harder to interpret in this period. Ultimately there are 
no significant changes in the second period and so little should be deduced from 
the trends. 
The findings in the first period and previously of an increased fasting 
glucose with a high fructose diet and reduced fasting plasma glucose with a high 
glucose diet could either be explained by increased endogenous glucose 
production (hepatic insulin resistance), or by reduced glucose tissue uptake 
(systemic insulin resistance). Fasted endogenous glucose production, as assessed 
by the labelled hyperinsulinaemic euglycaemic clamp, did not alter and so it 
would appear that the changes evolved from tissue uptake rates.  
4.4.3. Findings during the hyperinsulinaemic euglycaemic clamp 
In the postprandial state the primary function of insulin is to limit 
endogenous glucose production and to prevent hyperglycaemia by appropriate 
rates of tissue uptake of glucose. The challenge with postprandial assessments is 
that they require a standardised exogenous perturbation of the glucose/insulin 
balance.  
The background to the hyperinsulinaemic euglycaemic clamp was 
described in the methods section. Briefly, whole body insulin sensitivity is 
determined by the rate of exogenous glucose infusion required to maintain 
normoglycaemia in response to a fixed level of exogenously supplied insulin. It 
assumes that there is no residual hepatic glucose production and hence the rate of 
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exogenous supply represents the rate of whole body glucose disposal. This was 
not the case in our cohort. This failure to fully suppress hepatic glucose 
production is likely to reflect the relatively low dose of insulin administered and 
the pre-existing insulin resistance of the cohort. Adjusting for this did not alter the 
glucose disposal conclusions of no difference between fructose and glucose. The 
vast majority (80-90%) of this disposal is to the skeletal muscle (Thiebaud, Jacot 
et al. 1982) , and so what is principally assessed is the rate of insulin-mediated 
skeletal glucose uptake. Furthermore, the relative rates of oxidative and non-
oxidative disposal can be determined by the addition of carbohydrate oxidation 
rates during this period as assessed by calorimetry. 
Due to resource availability such assessments were performed in only 12 
subjects out of the full cohort of 32. These 12 were representative of the full 
cohort in terms of characteristics, anthropometry and baseline HOMA values.  
The chosen target glucose concentration during the clamp was 4.5mmol/L which 
effectively maintained fasted normoglycaemia, as their mean fasted glucose 
concentrations were 4.66±0.47mmol/l and 4.54±0.43mmol/L at the first and 
second baseline assessments.  
The baseline serum insulin concentration was around 14miU/L, and during 
the clamp there was a 6-fold increase in circulating insulin concentrations to 
around 80miU/L. Such changes are similar to those found postprandially in 
insulin resistant obese male subjects (Parra, Martinez de Morentin et al. 2005). As 
a result the procedure mimicked the postprandial insulinaemic response in a 
standardised way whilst maintaining euglycaemia and without the potential 
confounding of inter-subject food substrate absorption variability. To reinforce the 
notion that the clamp reproduced the postprandial state, the exogenous delivery of 
glucose and insulin resulted in an increased respiratory quotient (RQ) as 
compared to baseline values. This elevation in RQ reflects the rise in carbohydrate 
oxidation rates and a reduction in lipid oxidation rates during the three hour clamp 
period. There were no significant differences between the groups in the oxidation 
rates or their changes either within or between the assessments. There was a 
tendency for there to be a greater rise in carbohydrate oxidation during the second 
period’s week 2 clamp though this was not significant (p=0.10). Such an increase 
could be attributed to the carbohydrate and energy overfeeding that occurred 
during the second period resulting in a system that was primed to cope with 
carbohydrate delivery.  
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The presented glucose disposal (M values) were calculated as the mean M 
value during the final hour (t=120-180). During this period the mean arterialised 
glucose values and insulin concentrations were at a relatively steady state and did 
not differ between the assessments or between the two groups. Overall the 
robustness of the insulin, glucose and M value balances generated facilitates a 
direct comparison of whole body insulin sensitivity between both groups and 
between visits.  
4.4.3.1. Baseline findings of systemic glucose disposal 
Previous studies with larger cohorts of overweight individuals have shown 
M values to be negatively associated with body fat (r=-0.80) (Holt, Wild et al. 
2007), and with HOMA (r=-0.47) (Ruige, Mertens et al. 2006). So the M values 
were predicted to be low in our overweight cohort, and the current association 
with HOMA (r=-0.45) reflects that of prior experience. 
There is no agreed cut-off M value to categorise an individual as being 
insulin resistant. A large European study performed euglycaemic clamps in 1,146 
nondiabetic, normotensive Caucasian men and women (Ferrannini, Natali et al. 
1997). The insulin dose was 1mU/min/kg body weight. No glucose disposal value 
suggestive of insulin resistance was generated, though the mean value amongst 
slim men was 7.1mg/kg/min. There were 376 overweight men with a mean BMI 
28.8±3.9 (SD), and a body fat percentage of 33%. The mean M value in this 
cohort was 5.5±2.2mg/kg/min. The current study’s baseline value is 
4.8±1.7mg/kg/min. The M value for Ferrannini and colleagues, corrected for fat 
free mass (FFM), was 8.2mg/kgFFM/min, which is comparable to the current 
baseline value of 7.2mg/kgFFM/min. Such corrections for fat free mass are useful 
when comparing glucose disposal values between cohorts. 
 
4.4.3.2. Changes in postprandial insulin sensitivity  
Overall there was a tendency for a decreased insulin sensitivity with a 
reduction in the M value during both periods, though the absolute changes were 
small and not significant in the first (p=0.17) or second (p=0.16) period. It is 
worth remembering that this was not the study’s primary outcome measure and 
hence it was not specifically powered for such assessments. Using the baseline 
standard deviation value of 1.66mg/kg/min, the study had 80% power to detect a 
difference of 2.7mg/kg/min with 12 subjects, and if all 32 had undergone the 
clamp then it would have had 80% power to detect a difference of 1.6mg/kg/min. 
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During the second period the absolute difference in change between the two 
groups was 0.44mg/kg/min. As such these assessments are markedly 
underpowered, the resultant data is non-significant, and any further interpretation 
needs to be done guardedly.  
There are no prior published data comparing a high fructose versus high 
glucose diet on systemic insulin resistance using a hyperinsulinaemic euglycaemic 
clamp. Other groups have however assessed the non-fasted insulin resistant state. 
Bantle et al. measured glucose and insulin excursions at nine time-points over a 
24 hour period during standardised meals after 42 days of a high fructose or 
glucose diet (Bantle, Raatz et al. 2000). There was no baseline analysis and so we 
can only compare the resultant post intervention data between the groups as 
opposed to the changes from baseline. There was no difference in mean hourly 
plasma glucose concentrations at 139 vs. 141mmol/L/hr, whereas the glucose diet 
had a higher insulin mean concentration at 4243 vs. 3486 pmol/L/hr.  
Stanhope assessed insulin sensitivity by a 75g oral glucose tolerance test at 
baseline and after 9 weeks of a high fructose versus high glucose diet. As 
compared to the baseline there were no changes in the resultant 4 hour curves with 
glucose consumption but there were significantly greater insulin and glucose 
excursions following fructose. So either the ability of insulin to mediate tissue 
glucose uptake or suppress hepatic production, or both, was impaired with 
fructose. The addition of (15g 6,6,D2 glucose) within the 75g of glucose aided this 
discrimination. The 6,6,D2 is retained in the glucose if the glucose is not oxidised, 
whilst more than 90% is lost to tissue water during glycolysis. This allows the 
determination of the proportion of plasma glucose that undergoes glycolysis 
within the whole-body. This can be further transferred to an insulin sensitivity 
index by comparing the 2H2O (a marker for glycolysis) area under the curve 
(AUC) over the insulin AUC. Whole body glycolytic insulin sensitivity was 
unchanged by a high glucose intake and reduced following a high fructose intake. 
No direct comments can be made about hepatic insulin sensitivity, but this is 
implied by the associated fasted HOMA, as previously discussed. 
The above assessments both differ from a clamp in that the perturbation in 
homeostasis originates from exogenous oral food or glucose as opposed to insulin. 
There is one study that used an insulin challenge. An intravenous insulin tolerance 
test was performed in 15 healthy volunteers who consumed a standard diet with 
either 1000kcal per day from fructose or glucose in drinks for a week (Beck-
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Nielsen, Pedersen et al. 1980). There was identical weight gain in both groups. No 
changes in insulin sensitivity occurred with glucose, and there was a 25% 
reduction with fructose. The aetiology of these changes was not determined, 
though there was an observed reduction in insulin binding to monocytes, and so 
the authors speculated about insulin receptor modulation. 
To conclude, previous data suggests that systemic postprandial insulin 
sensitivity worsens with fructose and is unchanged with glucose. These were not 
the findings in this current study, where non-significant similar reductions in 
systemic postprandial insulin sensitivity were found in both groups.  
4.4.3.3. Hepatic insulin sensitivity  
  In the basal fasted state there was no change in hepatic glucose output 
with isoenergetic feeding and a non-significant trend for greater output following 
hyperenergetic feeding. As insulin was not administered in this basal state this 
trend may merely reflect the energy overfeeding itself. In the ‘postprandial’ end of 
clamp period hepatic glucose output was incompletely suppressed. This facilitated 
discrimination between the two groups in terms of the degree of suppression. 
Suppression (hepatic insulin sensitivity) was not altered during the interventions, 
though tended to be greater with fructose than glucose. 
The effects of fructose versus glucose on hepatic insulin sensitivity have 
only once been previously assessed (Ngo Sock, Le et al. 2010). On that occasion 
there was a non-significant trend for a reduced sensitivity, with no differences 
between the two groups.  
4.4.3.4. Non-oxidative glucose disposal and glycogen synthesis  
The rate of non-oxidative glucose disposal approximates to the rate of 
glycogen synthesis. Indirect calorimetry measures whole body net carbohydrate 
loss, which includes the following processes: oxidation of exogenous and 
endogenous glucose and oxidation of glycogen without passage through 
extracellular glucose (Tappy and Schneiter 1997). Non-oxidative glucose disposal 
(NOGD) is the difference between systemic glucose disposal and carbohydrate 
oxidation. The potential outcomes include synthesis of glycogen, lactate or lipid 
(DNL). The latter two are quantitatively small and so NOGD corresponds to 
glycogen accumulation in either muscle or liver (Fery, Plat et al. 1999).  
Insulin resistance is characterised by a low NOGD, possibly influenced by 
a high IMCL (Yokoyama, Mori et al. 2008). There was no change in IMCL or 
NOGD in the first period and an increased IMCL and a reduction in NOGD in the 
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second. It is unclear if the reduced NOGD is due to the increased IMCL as there 
was no association between the changes in these parameters (r=-0.17, p=0.6).An 
alternative explanation is that the overfeeding resulted in greater repletion of 
glycogen stores and hence glucose disposal occurred via other mechanisms.  
4.4.4. Serum triglycerides 
The triglycerides were measured in the overnight fasted state. This is both 
a strength and a weakness. A fasted sample is taken in a standardised setting and 
hence should be more reproducible than a non-fasted sample. The utility however 
of the fasted triglyceride content to predict cardio-metabolic risk has recently been 
questioned. As a result this area is highly contentious. Serum triglycerides 
areindependently predictive of cardiovascular events when assessed in the non 
fasted state, whereas fasted triglycerides remained dependent on traditional 
cardiac risk factors (Bansal, Buring et al. 2007). This study was designed to focus 
on the hepatic effects of a high fructose versus glucose intake, Fructose has been 
proposed to stimulate hepatic triglyceride synthesis and so it should also increase 
fasted serum triglycerides. Postprandial lipid assessments would have been 
interesting to have performed but they would not have addressed the primary 
research questions and were not feasible given the constraints of all the 
investigations that were undertaken.  
A significant proportion of the cohort studied had evidence of 
dyslipidaemia at study entry with 9 subjects (5 in fructose group and 4 in glucose) 
having fasted serum triglycerides above the normal reference range 
(>1.8mmol/L). Weight was maintained during the first period and this was 
matched by an overall stable serum triglyceride concentration. During the second 
period there was a significant increase in triglycerides, though the amount of 
change was identical between the groups (p=0.91).  
In opposition to previous findings medium-term high fructose versus 
glucose studies, this current study failed to demonstrate any significant changes in 
fasted serum triglycerides from the baseline values with fructose, see table 19. Of 
note the two papers which did report significant increases in serum triglycerides 
did not show any associated changes in hepatic triglyceride content. The findings 
in the second period mirror that of Stanhope and colleagues, with a significant 
increase with glucose and not with fructose. 
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Table 19. Current and previously reported changes in fasted triglyceride 
serum concentrations following intakes a high fructose or glucose diet. (- = 
not significant, * = p<0.05 as compared to baseline value) (Johnston is the current 
study) 
Interpretation of several of these studies is limited given the absence of 
adequate controls in terms of energy or sugar as has been discussed. The reason 
behind the increase in triglycerides during the second period in this current study 
appears to be primarily the greater energy and/or carbohydrates supplied as there 
was a significant association between weight change and triglycerides (r=0.44, 
p=0.01). Without the addition of tracers it is impossible to fully ascertain fluxes in 
lipid kinetics. The association with energy excess seems to have also been a factor 
in the prior studies as those with weight gain all had an increase in fasted 
triglycerides. 
The paper by Silbernagel is difficult to interpret due to the significant 
weight discrepancy between the two groups. The rise in fasted triglycerides in the 
fructose group with no change in the glucose group was the only finding that 
differed between their groups, for which the authors offered no explanation. If I 
ignore this paper then the three prior medium term studies have generated 
opposing and conflicting fasted findings. The two studies however that have 
compared triglyceride data in the postprandial as opposed to fasted state (Bantle 
and Stanhope) have shown a greater postprandial triglyceride response following 
fructose than glucose.  
The aetiology of the differences in the postprandial as opposed to fasted 
state is believed to be due to increased production by de novo lipogenesis and 
reduced insulin excursion with fructose resulting in a lower activation of adipose 
tissue lipoprotein lipase (LPL) (Stanhope and Havel 2009). In the Stanhope paper 
 Duration 
(weeks) 
Foodstuffs 
provided / ad 
libitum 
Hyper / 
iso-
energetic 
Weight 
change 
(kg) 
Fructose 
 
Comparator 
 
Bantle 6  Provided Iso -1.4 Ļ- ĻĻ 
Silbernagel 2  ad libitum Hyper +0.9 Ĺ ĺ 
Ngo Sock 1 Provided Hyper ? Ĺ Ĺ- 
Stanhope 10  ad libitum Hyper +1.6 Ĺ- Ĺ 
Johnston 1st period 2  Provided Iso -0.2 Ļ- Ĺ- 
Johnston 2nd period 2  ad libitum Hyper +0.8 Ĺ- Ĺ 
 174  
fasted LPL and DNL rates were unchanged as compared to baseline rates in both 
groups. In the postprandial phase however DNL was increased 27% with glucose 
and 75% with fructose. In conjunction postprandial LPL excursions were 
increased by 20% with glucose and reduced by 5% with fructose. The resultant 
differences in postprandial triglyceride concentrations were relatively modest at 
an increase of 3% from glucose and 18% from fructose.  
The prior major contribution to the understanding of DNL in the acute 
setting comes from Chong and colleagues (Chong, Fielding et al. 2007). They 
assessed the acute lipaemic responses to a single high fructose or glucose meal. 
The absolute difference in DNL contributions at 240 minutes from fructose or 
glucose was minimal with ~ 0.05% of the labelled fructose forming de novo fatty 
acids and ~ 0% with glucose. 
To summarise, fasted serum triglycerides were unchanged during the 
isoenergetic period and rose in both groups during the hyperenergetic period to a 
matched extent. Changes in weight could partially explain the changes in the 
hyperenergetic period. 
 
4.4.5. Extra-Myocellular Lipid (EMCL) 
The extra-myocellular lipid (EMCL) content is quantified as part of the 
process of determining IMCL content. EMCL is of limited metabolic interest as it 
is ectopic lipid stored within adipocytes which are interspersed between muscle 
fibres. As it is not within the myocytes it appears to have no specific metabolic 
function and merely reflects the total body adiposity (Machann, Haring et al. 
2004). Changes in total body adiposity were not assessed during the study, but 
they were unlikely to change much due to the minimal changes in total body 
weight (–0.19% in 1st period and +0.83% in the 2nd). As expected there were no 
significant changes in EMCL throughout the study. 
 
4.4.6. Intra-Myocellular Lipid (IMCL) 
The association between IMCL and insulin resistance is firmly established, 
though the mechanism remains yet to be fully determined. IMCL is an early 
marker for the development of insulin resistance (Schrauwen-Hinderling, 
Hesselink et al. 2006). Myocytes lack the ability to perform de novo lipogenesis, 
and so an increased IMCL content is the result of either increased circulating fatty 
acid delivery or reduced oxidation. It is not believed that the triglycerides 
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themselves mediate the insulin resistance, but that this is done through 
intermediary metabolites (Machann, Haring et al. 2004). 
The current data appear to support these observations and theories. During 
the first assessment period the baseline IMCL value was not associated with 
HOMA from the same assessment (r=0.06), or the clamp derived M value 
(r=0.02), or serum triglycerides. During this period changes in HOMA, M value, 
weight, serum triglycerides, NEFA and lipid oxidation were also not associated 
with changes in IMCL.  
During the second period there was an increase in IMCL in the absence of 
a change in systemic insulin resistance as measured by the clamp and HOMA. 
There was however a weak association (r=0.36, p=0.04) between changes in 
IMCL and changes in HOMA during this period. There was no such association 
with changes in weight, serum triglycerides or lipid oxidation rates.  It is possible 
however that given time the increases in IMCL may have subsequently resulted in 
systemic insulin resistance, but that the time-frame was too short for this to 
develop.   
 
4.4.7. Serum NEFAs 
Concentrations of fasted NEFAs were relatively unchanged by glucose 
and reduced by fructose overfeeding. Direct assessments of lipolytic rates were 
not made. Previous acute overfeeding work has shown a similar reduction in 
NEFAs with no change in glycerol following fructose administration (Chong, 
Fielding et al. 2007). The authors proposed that the reduced NEFA concentrations 
reflect reduced spill-over of LPL derived fatty acids with fructose compared with 
glucose. LPL activity was not quantified in this study and so this is merely 
speculation, though it would explain the NEFA differences between the two 
groups.  
DeFronzo’s group has recently described adipose tissue insulin resistance 
(Adipo-IR) as the function of insulin and NEFA in the fasted non dynamic state 
(Gastaldelli, Cusi et al. 2007). Insulin mediates suppression of lipolysis via 
hormone sensitive lipase and this formula indirectly assesses this activity via 
circulating NEFA concentrations. The greater the value the less sensitive the 
adipocytes are to insulin. There were no changes during the first period whereas 
both groups demonstrated an improved sensitivity in the second period to a 
matched extent.  
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Adipose insulin sensitivity was further assessed during the clamp. Infusion 
of insulin resulted in a marked reduction in circulating NEFAs to a matched 
extent in both groups and with no change as a result of the intervention. Though 
the magnitude of the reduction is likely to have minimised any potential to 
discriminate between the two groups. It is noteworthy that despite both organs 
receiving the same insulin concentrations, there was a much greater response to 
exogenous insulin infusion from the adipocytes than from the liver. This was 
expected as endogenous insulin is delivered via the portal vein to the liver where 
there is a significant first pass effect. As a result the liver is normally exposed, and 
hence responds, to much greater concentrations of insulin than the rest of the 
body.  
 
4.5. Conclusions 
There were no convincing differences in terms of insulin resistance or 
non-hepatic lipid profiles resulting from a high fructose as opposed to a high 
glucose intake. In contrast, energy overfeeding resulted in increased serum 
triglycerides and intra-myocellular lipids, and reduced adipose tissue insulin 
resistance.  
There are several strengths specific to this chapter: 
1. Insulin resistance was assessed in a variety of states including systemic (fasted 
and postprandial), hepatic and adipose tissue.  
2. This was the first study to assess the effects of fructose versus glucose on 
systemic insulin resistance with the gold standard assessment, hyperinsulinaemic 
euglycaemic clamp.  
3. The clamp procedure reproduced the postprandial state in terms of circulating 
insulin concentrations and oxidative changes.  
4. The concurrent assessment of IMCL facilitated interpretation of any changes in 
insulin resistance.  
 
I acknowledge some weaknesses specific to this chapter: 
1. The hyperinsulinaemic euglycaemic clamp was only performed in a representative 
subset of the entire group, and the study was not specifically powered for these 
assessments.  
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2. The increase in IMCL during the hyperenergetic period without any change in 
insulin resistance may be interpreted that the duration of the intervention was too 
short.  
3. All assessments, bar insulin resistance, were made in the fasted state.  
4. There were no assessments made of lipid kinetics, LPL activity or DNL rates. 
Indeed the study would have benefited from postprandial lipaemic assessments as 
it is in this state that differences between fructose and glucose have been most 
reliably reported.  
 
This chapter refutes prior assertions that there is a significant difference between 
fructose and glucose on insulin resistance and non hepatic lipid stores. Further 
work is necessary to assess the lipaemic outcome in the postprandial state. 
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Chapter 5. The hepatic effects of a high fructose versus high glucose diet 
 
5.1. Introduction 
These data are derived from the method fully described in chapter 3. This 
final chapter of this study focuses on the primary outcome measure, namely the 
impact of a high fructose or high glucose diet on hepatic metabolism. 
In brief, healthy overweight males were randomised to a high fructose or 
glucose diet for 2 weeks firstly in an energy balanced (isoenergetic) setting and 
subsequently in an energy overfeeding (hyperenergetic) setting. The 
monosaccharides were consumed mixed with water four times a day and provided 
25% of predicted energy requirements. The differing energy periods were 
achieved by firstly providing all food to be consumed and secondly by subjects 
consuming the monosaccharides in addition to their habitual intakes. 
The assessment processes were identical pre and post each intervention 
period. Specific to this chapter, the 32 subjects underwent fasted hepatic proton 
and phosphorus magnetic resonance spectroscopy (1H MRS and 31P MRS), and 
fasted serum was analysed for liver biochemistry, C-reactive protein, and uric 
acid.  
 
5.2. Protocols for methods employed in this chapter 
5.2.1. 1H MRS liver data collection 
This collection protocol is the same for this chapter and chapter 6. 
Measurements of hepatic triglyceride content (HTGC) were obtained using a 
Philips Achieva 3.0 Tesla, whole body system (Philips Medical Systems). A 
transmit/receive body coil was used. Transverse images through liver and 
abdomen were acquired during a single breath-hold (duration = 14.4s) using a T1-
weighted Turbo Field Echo (TFE) sequence with the following parameters: in 
plane resolution= 2mm2, Field Of View (FOV) = 382x400mm2, with 36, 7mm 
slices in the foot-to- head direction, repetition time (TR) = 3.1s, echo time 
(TE)=1.5ms.  
Following image acquisition a 27 cm3 spectroscopic volume of interest 
(voxel) was positioned in the right lobe of the liver. The voxel avoided major 
blood vessels, intrahepatic bile ducts, and the lateral margin of the liver as 
previously described (Szczepaniak, Nurenberg et al. 2005). A screen shot was 
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stored at each visit to enable repositioning of the voxel in the same location at 
subsequent visits.  
For estimation of total fat percentages in liver, MR spectra were collected 
using a respiratory triggered Point RESolved Spectroscopy (PRESS) sequence 
(Bottomley 1987) with the following parameters: TR = 5000ms, Number of 
samples = 1024, bandwidth=2000Hz. In order to account for possible changes in 
signal relaxation times (the time over which signal dephases) with changes in fatty 
composition, 24 spectra were acquired with TE=40ms, 8 spectra with TE=50ms, 8 
spectra with TE=60ms and 8 spectra at TE=70ms. 
 
5.2.2. 1H MRS liver data analysis 
Spectra were individually phase corrected and realigned using jMRUI 
(Java-based MR user interface) (Naressi, Couturier et al. 2001) before averaging 
across each echo time. The water and methylene proton peak areas at each echo 
time were determined using in-house software built in Matlab (Mathworks, 
Matick, United States). In order to calculate the absolute HTGC percentage, a 
correction to account for spin-spin relaxation (T2) and to convert to absolute 
%HTGC was calculated as follows: 
 %HTGC = 100(ZRTw) / (ZRTw ȡtg ȡH2O) (DH2O / Dtg))) 
 
where Z = (exp(-TE/T2H20))/(exp-(TE/T2TG)) is the T2 correction factor for 
the measured HTGC/water ratio (R) at TE=40ms, Tw is the fractional mass of 
tissue water (Tw=0.711g/ml (Longo, Pollesello et al. 1995)ȡtg (=70.35mmol/ml 
(Szczepaniak, Babcock et al. 1999) DQG ȡH2O (=111.11mmol/ml (Szczepaniak, 
Babcock et al. 1999)) are the density of protons in 1ml of triglyceride and water 
respectively and Dtg (=0.9g/ml (Szczepaniak, Babcock et al. 1999)) and DH2O 
(=1g/ml (Szczepaniak, Babcock et al. 1999)) are the density of triglyceride and 
water respectively.  
T2 values, for both water and methylene, were calculated for each 
individual subject using the peak areas (S) at each echo time (TE) and the 
following equation: 
S = S0 exp(-TE/T2) 
where S0 is the un-relaxed signal (a constant). T2 is the gradient of a graph of ln 
(S) against (-TE).   
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5.2.3. Liver volume analysis 
The data was collected during a single breath hold. The image sequences 
were weighted by the tissue’s T1 relaxation via application of a pulse at 180 
degrees to the field at the beginning of the sequence. A three dimensional turbo 
field echo (3D-TFE) acquisition mode was used to gain an entire image out of a 
single sequence. The planar resolution of each T1-weighted image was 
2.08x2.08mm with 7mm slice thickness. Thirty six slices were acquired per 
analysis. Data was acquired from voxels measuring 2.08x180mm. The repetition 
time (TR) between sequence acquisitions was 3.11 ms with total scan time of 14.4 
seconds. Images were individually analysed by drawing the hepatic outline in 
Analyze9 software which summated the image areas to calculate the hepatic 
volumes.  
5.2.4. 31P data collection 
For measurement of 31P metabolite levels, a single loop 
(diameter=140mm) coil tuned to 3T 31P frequency, was positioned over the liver 
of the subject. A 1H MR image (acquired on the 1H body coil) was acquired to 
ensure the coil was positioned well over the liver (based on a 1H visible marked 
placed in the centre of the coil) and for positioning of the voxel for 31P MRS 
completely within the liver, as near to the coil as possible. Again, a screen shot 
was stored to aid positioning at the same location in subsequent visits. 31P data 
were acquired using a respiratory triggered Image Selected In vivo Spectroscopy 
(ISIS) localization with optimized proton decoupling and Nuclear Overhauser 
Effect (NOE) and the following parameters: TR=5000ms, 2048 samples, 
Bandwidth=3000Hz, 96 averages.  
5.2.5. 31P data analysis 
Spectra were truncated to 1024 points to reduce noise level before line 
broadening (12Hz Lorentzian) and phase correction in JMRUI. Spectral peaks for 
phosphoethanolamine (PE), phosphocholine (PC), glycerophosphorylcholine 
(GPC), glycerophosphoethanolamine (GPE), phosphoenolpyruvate (PEP), 
nicotinamide adenine dinucleotide (NAD) and uridine diphosphate (UDP) were 
WKHQILWWHGWRVLQJOHW/RUHQW]LDQOLQHVKDSHVLQ$0$5(6Ȗ-$73DQGĮ-ATP were 
fitted to two double peaks (doublets) with prior knowledge constraining the line 
widths and amplitudes to be equal for each peak in the doublet, as well as setting 
the doublet VSOLWWLQJ WR +] ȕ-ATP was fitted to three peaks with prior 
knowledge giving an amplitude ratio of 1:2:1 with line widths equal and 
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frequency shift =20Hz. The inorganic phosphate peak was fitted to two 
unconstrained peaks since separation can occur when there is a pH gradient 
between the intra- and extracellular compartments. Metabolite concentrations are 
routinely given as a ratio to each other since no internal reference exists for 31P 
spectra. The GPE and GPC peaks were combined as phosphodiesters (PDE) and 
the PE and PC were combined as phosphomonoesters (PME). 
There are no 31P metabolite findings which are characteristic for NAFLD 
(Cortez-Pinto, Chatham et al. 1999).  The largest case series published to date (85 
patients) demonstrated that there are progressive changes in PME/ATP, PDE/ATP 
and PDE/PME ratios with worsening liver disease (Menon, Sargentoni et al. 
1995). Using 31P MRS acute fructose loading has been shown to temporarily 
deplete human liver of ATP and increase Pi for 40 minutes post an intravenous 
bolus (Boesch, Elsing et al. 1997). As a result the absolute values and the 
following ratios are presented: PME/ATP, PDE/ATP, PDE/PME and ATP/Pi. 
5.2.6. Liver biochemistry and CRP  
This was as previously described in 3.5.7 and 3.5.8. 
5.2.7. Statistical analyses 
All data are presented as the mean ± standard deviation (SD). 
Comparisons between baseline values were done by the independent samples T 
test. The Student’s T test was used for paired data. Analysis of the significance of 
change between the two groups at two paired assessments was done by an 
independent samples T test of the absolute change between the two assessments in 
both groups. Associations were assessed for by 2-tailed Pearson correlations. 
5.3. Results 
5.3.1. Hepatic triglyceride content (HTGC) 
In one subject the repeat baseline assessment at the start of the second 
period was not performed due to failure of the magnetic coil, the baseline value 
was carried over from the first visit. The groups were well matched for HTGC at 
baseline of both periods, see table 1. The mean HTGC at the first assessment was 
7.6%. Indeed 17 of the 32 had steatosis using the recognised 1H MRS cut-off 
value of 5.5% (Szczepaniak, Nurenberg et al. 2005). 
The changes in hepatic triglyceride content (HTGC) in both groups 
combined are shown in figure 1. There was no significant change during the first 
period and during the second period there was a +24.3±35.1% (mean±SD) 
increase in absolute values from 7.77% to 9.65% (p<0.001).   
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Figure 1. Hepatic triglyceride content (HTGC) in both groups combined 
during the study, n=32, mean ± SEM. 
 
Analysing the HTGC outcomes by group, during the first period there 
were no significant changes in either group’s HTGC. In the second period 
significant increases occurred but the changes again were matched between the 
groups. The changes relative to the baseline value in the second period for both 
groups were +22.8% (p=0.02) with fructose, and +25.5% (p=0.01) with glucose. 
Those with a baseline HTGC greater than 15% did not develop a greater HTGC 
with monosaccharide overfeeding. 
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*
*
1st period                     2nd period
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Figure 2. Hepatic triglyceride content (HTGC) before and after two weeks of 
a high fructose or high glucose intake. (*=p<0.05 from baseline in that 
group), mean ± SEM. 
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Figure 3a-d. Changes in individual subject hepatic triglyceride content (HTGC) 
during the study in the two groups during the two periods. (A – fructose 1st 
period, B – glucose 1st period, C – fructose 2nd period, D glucose 2nd period) 
 
  Whole 
cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
First 
period 
Baseline 7.61±5.3 7.20±5.6 7.98±5.2 0.69  
0.65 week 2 7.72±4.43 7.50±4.1 7.92±4.8 
Second 
period 
baseline 7.77±5.08 7.45±5.5 8.04±4.8 0.75  
0.73 week 2 9.65±4.64*** 9.15±4.5* 10.09±4.8* 
 
Table 1. The effect of 2 weeks of a high fructose or glucose intake on 
percentage hepatic triglyceride content (HTGC), mean ± SD. (In comparison 
to the baseline value, *=p<0.05, **=p<0.01, ***=p<0.001) 
 
The observed changes in HTGC were partially explained by changes in 
weight during the first period but not during the second as shown in table 2.  
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 R p 
Whole cohort (n=32) 1st period 0.54 0.002** 
2nd period 0.18 0.34 
Fructose (n=15) 1st period 0.56 0.03* 
2nd period 0.41 0.13 
Glucose (n=17) 1st period 0.54 0.03* 
2nd period -0.03 0.90 
 
Table 2. Association between changes in weight and changes in HTGC. (2-
tailed Pearson correlation, *=p<0.05, **=p<0.01) 
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Figure 4. Association between changes in weight and HTGC in all 32 subjects 
during the first period. 
 
There was an association noted between fasted serum triglyceride 
concentrations and HTGC which was most pronounced at the first baseline 
assessment, as shown in table 3. 
 
  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
1st period Baseline 0.51** 0.29 0.76*** 
Week 2 0.21 0.09 0.26 
2nd period Baseline 0.35* 0.33 0.38 
Week 2 0.42* 0.36 0.47 
 
Table 3. Association between fasted serum triglycerides and HTGC at the 
initial baseline. (* =p<0.05, ** =P<0.01, ***p<0.001) 
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Figure 5. Association between fasted serum triglyceride concentrations and 
HTGC in all subjects at the initial assessment.  
 
5.3.2. Liver volume 
 
Liver volumes were unchanged in the first period and increased in both 
groups during the second. 
 
  Whole 
cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
First 
period 
baseline 2.05±0.33 2.09±0.38 2.02±0.28 0.53  
0.96 week 2 2.07±0.28 2.11±0.31 2.04±0.26 
Second 
period 
baseline 2.11±0.31 2.12±0.37 2.10±0.26 0.91  
0.09 week 2 2.21±0.32** 2.28±0.37* 2.14±0.25 
 
Table 4. The effect of 2 weeks a high fructose or glucose intake on liver 
volumes, mean ± SD. (In comparison to the baseline value, *=p<0.05, 
**=p<0.01) 
 
5.3.3. Liver biochemistry 
 
The two groups were well matched in terms of their liver biochemistry at 
baselines of both periods, see table 5. In the whole cohort liver biochemistry 
improved significantly, bar alkaline phosphatase, during the first period. In the 
second period they all significantly worsened. The changes were matched between 
the groups for all, bar alkaline phosphatase during the first period which worsened 
in fructose and was unchanged in glucose. 
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  All (n=32) Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
ALT           
1st period 
(U/L) 
Baseline 28.7±12.3 31±15 27±10 0.31  
Week 1 27.9±11.3 31±13 25±9 0.58 
Week 2 25.3±9.5* 27±11 24±8 0.67 
ALT          
2nd period 
(U/L) 
Baseline 27.0±9.5 27±12 27±7 0.90  
Week 1 32.0±13.3* 37±18** 28±6 0.009 ^^ 
Week 2 32±12** 33±14* 31±10 0.62 
AST           
1st period 
(U/L) 
Baseline 23.9±6.6 24±8 24±5 0.74  
Week 1 23.0±4.8 23±6 23±4 0.79 
Week 2 22.1±4.9* 21±4* 23±5 0.11 
AST          
2nd period 
(U/L) 
Baseline 22.5±5.0 22±5 23±5 0.73  
Week 1 24.9±6.4* 26±8* 24±5 0.21 
Week 2 23.9±5.3 23±5 25±6 0.64 
GGT          
1st period 
(U/L) 
Baseline 35.3±14.8 39±17 32±12 0.14  
Week 1 33.8±14.4 40±17 29±9* 0.09 
Week 2 31.2±14.4** 38±18 25±8** 0.08 
GGT         
2nd period 
(U/L) 
Baseline 33.3±13.5 37±16 30±10 0.13  
Week 1 36.8±20.4 44±27 31±10 0.12 
Week 2 38.0±19.4* 44±24* 32±12 0.17 
Alk Phos    
1st period 
(IU/L) 
Baseline 73.7±16.4 73±16 74±17 0.81  
Week 1 78.6±18.5*** 80±19** 77±18 0.046 ^ 
Week 2 74.8±16.0 77±19** 73±15 0.003 ^^ 
Alk Phos   
2nd period 
(IU/L) 
Baseline 72.1±16.2 72±15 72±15 0.94  
Week 1 79.8±18.1*** 80±18*** 80±19*** 0.61 
Week 2 75.7±16.4** 75±15* 77±18* 0.49 
Table 5. The effect of 2 weeks of a high glucose or fructose intake on liver 
biochemistry, mean ± SD. (In comparison to the baseline value, *=p<0.05, 
**=p<0.01, ***=p<0.001.  Difference between groups in change during 
intervention ^ = p<0.05, ^^ =p<0.01). (ALT = alanine aminotransferase, AST = 
aspartate aminotransferase, GGT = gamma glutamyl transferase, Alk Phos = 
alkaline phosphatase). 
 
Changes in liver biochemistry in the whole cohort (n=32) (again bar 
alkaline phosphatase) were positively associated with changes in weight (table 6), 
and only weakly associated with changes in HTGC (table 7).  
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Table 6. Association between changes in liver biochemistry and changes in 
weight (2-tailed Pearson correlation, *=p<0.05, **=p<0.01, ***=p<0.001) 
 
  
Table 7. Association between changes in liver biochemistry and changes in 
HTGC (2-tailed Pearson correlation, *=p<0.05).  
 
5.3.4. Hepatic inflammation 
 
There was no change in hepatic inflammation as assessed by serum high-
sensitivity CRP during either period.  
 
Table 8. The effect of 2 weeks of a high fructose or glucose intake on serum 
HS-CRP (mg/L), mean ± SD. 
 
  Whole cohort 
(r) 
Fructose Glucose  
Alt Period 1 0.64** 0.54* 0.66** 
Period 2 0.33 0.20 0.58* 
Ast Period 1 0.52** 0.45 0.62** 
Period 2 0.31  0.19 0.52* 
GGT Period 1 0.25 0.22 0.57* 
Period 2 0.40* 0.67** 0.32 
Alk P Period 1 -0.09 -0.19 0.045 
Period 2 -0.1 -0.19 -0.003 
  Whole cohort 
(r) 
Fructose Glucose  
Alt Period 1 0.44* 0.49 0.42 
Period 2 0.09 -0.03 0.18 
Ast Period 1 0.28 0.43 0.16 
Period 2 0.17 0.08 0.21 
GGT Period 1 0.40* 0.55* 0.25 
Period 2 0.36* 0.22 0.70** 
Alk P Period 1 0.23  0.11 0.30 
Period 2 0.29 -0.12 0.51* 
  Whole 
cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
1st period baseline 1.22±1.29 1.01±1.08 1.40±1.46 0.41  
0.43 week 2 1.20±1.28 0.79±0.84 1.55±1.51 
2nd period baseline 1.44±1.46 1.22±0.97 1.63±1.79 0.44  
0.37 week 2 1.69±2.81 1.13±0.95 2.19±3.75 
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5.3.5. Uric acid 
At study entry fasted uric acid levels were pathologically raised 
(>420µmol/L) in 11 out of the 32 subjects (5 fructose and 6 glucose). In both 
periods, uric acid concentrations increased with fructose and were reduced with 
glucose, though these changes were only significant during the first period. 
 
  Whole 
cohort 
(n=32) 
Fructose 
(n=15) 
Glucose 
(n=17) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
1st period Baseline 408±69 406±60 410±77 0.87 
 
 
0.003 ^^ Week 1 406±72 432±76 384±62** 
Week 2 406±73 428±65 388±77** 0.004 ^^ 
2nd period baseline 388±92 406±79 371±102 0.29  
0.45 Week 1 394±71 420±59 370±74 
week 2 393±82 429±57 362±90 0.10 
 
Table 9. The effect of 2 weeks of a high fructose or glucose intake on fasted 
serum uric acid (µmol/L), mean ± SD. (In comparison to the baseline value, 
**=p<0.01.  Difference between groups in change during intervention ^^ 
=p<0.01). 
 
5.3.6. Hepatic 31P metabolite profiles 
There was signal failure in 4 subjects. Overall there was minimal change 
in the metabolite profiles during the study. Pi increased during the second period 
to an equal extent in both arms. PDE increased during the second period with 
glucose and reduced with fructose.  
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   Whole 
cohort 
(n=28) 
Fructose 
(n=14) 
Glucose 
(n=14) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
g-ATP 1st 
period 
baseline 254±83 239±63 270±99 0.34  
0.96 week 2 259±83 245±79 273±87 
2nd 
period 
baseline 257±82 237±75 274±84 0.23  
0.65 week 2 261±97 251±81 271±111 
Pi 
 
1st 
period 
baseline 223±69 223±72 223±68 0.99  
0.48 week 2 231±70 242±80 219±60 
2nd 
period 
baseline 209±65 209±69 210±62 0.96  
0.81 week 2 241±84* 236±80 246±90 
PME 1st 
period 
baseline 287±86 281±78 292±97 0.75  
0.83 week 2 276±87 267±100 285±76 
2nd 
period 
baseline 297±122 301±130 285±118 0.73  
0.67 week 2 281±93 283±109 279±79 
PDE 
 
 1st 
period 
baseline 556±154 525±158 586±149 0.30  
0.84 week 2 610±185 587±183 633±191 
2nd 
period 
baseline 630±192 638±224 614±163 0.75  
0.01^ Week 2 649±241 533±207 756±226* 
 
Table 10. Fasted hepatic 31P metabolite peak areas before and after 2 weeks 
of a high fructose or glucose intake (nil units), mean ± SD. (In comparison to 
the baseline value, *=p<0.05.  Difference between groups in change during 
intervention ^ =p<0.05). 
 
There were no consistent changes of 31P metabolite ratios during the study. 
The changes in Pi and ATP to Pi ratio were not associated with changes in uric 
acid or weight.  
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   Whole 
cohort 
(n=28) 
Fructose 
(n=14) 
Glucose 
(n=14) 
Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
PME / 
ATP 
1st 
period 
baseline 1.41±1.21 1.22±0.36 1.58±1.66 0.43  
0.71 week 2 1.40±1.27 1.25±0.79 1.54±1.61 
2nd 
period 
baseline 1.45±1.28 1.30±0.46 1.54±1.72 0.62  
0.45 week 2 1.39±1.26 1.18±0.41 1.58±1.69 
PDE / 
ATP 
 
1st 
period 
baseline 2.45±1.06 2.22±0.44 2.66±1.41 0.28  
0.59 week 2 2.71±1.27 2.59±1.00 2.82±1.50 
2nd 
period 
baseline 2.71±1.14 2.63±0.41 2.73±1.52 0.82  
0.37 week 2 3.12±1.52 2.78±1.56 3.36±1.45* 
PDE / 
PME 
1st 
period 
baseline 2.01±0.47 1.92±0.53 2.09±0.40 0.35  
0.45 week 2 2.30±0.60* 2.30±0.58 2.29±0.65 
2nd 
period 
baseline 2.16±0.97 1.89±0.76 2.47±1.03 0.10  
0.77 week 2 2.55±0.78 2.28±109 2.79±0.65 
g-ATP 
/ Pi 
 
1st 
period 
baseline 1.20±0.43 1.10±0.19 1.29±0.58 0.25  
0.58 week 2 1.19±0.54 1.03±0.27 1.35±0.69 
2nd 
period 
baseline 1.28±0.39 1.16±0.27 1.38±0.46 0.13  
0.30 Week 2 1.13±0.36 1.12±0.36 1.13±0.38 
 
Table 11. Fasted hepatic 31P metabolite ratios before and after 2 weeks of a 
high fructose or glucose intake, mean ± SD. (In comparison to the baseline 
value, *=p<0.05.) 
 
5.4. Discussion 
5.4.1. Summary of findings 
The intervention resulted in only a handful of isolated differences detected 
between the groups. During the isoenergetic period fructose resulted in a greater 
uricaemia than glucose. This observation has been widely shown previously and is 
attributed to their differing pre triose metabolic feedback inhibition. Interestingly 
there were no associated 31P MRS metabolite profile differences. Two other 
differences occurred between the groups, with a greater alkaline phosphatase 
concentration with fructose in the isoenergetic period, and a greater PDE peak 
area with glucose in the hyperenergetic period and a smaller PDE peak area with 
fructose. These isolated and unrelated findings appear to be of no consequence. 
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During the first period there were no changes in HTGC, whereas there was 
an increase of 24% in HTGC relative to baseline values during the second period. 
This change was matched in both groups. Changes in weight were strongly 
associated with changes in HTGC in the first period, and less so during the 
second. The HTGC values were strongly associated with the serum triglyceride 
concentrations.  
The trends for alkaline phosphatase did not reflect those of the other liver 
enzymes measured. The reasons for this are uncertain. The rest of the liver 
biochemistry improved during the first period and worsened during the second 
with no difference between the groups. The absolute effects were small but 
statistically significant. Changes in liver enzymes were associated with changes in 
weight and HTGC. In spite of the changes in transaminase levels there were no 
changes in C reactive protein concentrations.  
Uric acid concentrations increased with fructose and reduced with glucose, 
particularly during the first period. However there were no real changes in fasted 
hepatic 31P metabolite profiles or ratios during the study.  
 
5.4.2. HTGC findings 
The cohort had a markedly high HTGC value at study entry. Indeed it was 
greater than that predicted in the power calculation (7.6±5.3% vs. 4.4±3.2%). The 
power calculation value was derived from a previously reported large cohort of 
Caucasian men in Dallas, USA (Browning, Szczepaniak et al. 2004).  Indeed the 
cohort of Browning and colleagues had almost identical BMI and waist profiles to 
that recruited to this current study, and so the aetiology of the current greater 
HTGC values is unclear. Potential factors include the younger age and lack of 
regular vigorous exercise in the current cohort. Alcohol abuse was an exclusion 
for the current study and only reported in 6% of the Dallas cohort. Ultimately the 
greater mean HTGC and broader standard deviation in the observed population 
will have weakened the study’s true power.  
The isoenergetic period maintained weight and HTGC, so a high 
monosaccharide diet in the presence of energy balance has no impact on liver fat. 
There was a trend for HTGC to increase in fructose and for it to decrease in 
glucose, though the changes were far from significant. The absolute difference in 
changes between these two groups was 0.36%. This does not appear to be a type 2 
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error as if we do a power calculation based on an 80% power and a significance of 
<0.05 to detect these changes then we would have had to recruit: 
(4*(1.96+0.84)2 * 5.32 ) / (0.362) = 6,797 volunteers 
At 90% power the numbers needed to recruit are 9,112 volunteers.  
The trend in the first period for fructose to induce a greater HTGC was 
reversed by glucose during the second period. As a result this study is 
overwhelmingly negative for there being a true difference between fructose and 
glucose overfeeding in HTGC changes. It bears remembering that the 
reproducibility of these HTGC measures using 1H MRS is high, with an inter-
examination co-efficient of variation of 7.0% (Thomas, Hamilton et al. 2005). 
The aetiology for the increase in HTGC during the second period as 
opposed to the first is presumed to be its positive energy balance. Curiously there 
was no association between weight change and HTGC changes during the second 
period. As previously discussed in chapter 1, Kechagias and colleagues overfed 
18 healthy male and female volunteers by twice their predicted requirements and 
restricted their exercise (Kechagias, Ernersson et al. 2008). Over 4 weeks the 
subjects had a mean weight gain of 9.5%. Serum ALT increased by 215%, and 
HTGC by 155%. So a total body weight gain of 1% in the Kechagias study 
resulted in a 16% increase in HTGC, whereas in this current study a 1% weight 
gain resulted in a 28% increase in HTGC. These ratios are strikingly similar. The 
reason behind the apparently higher ratio in this study is unclear but it may be due 
to its pure monosaccharide overfeeding. Indeed the contribution of sugar to 
overall energy intake in the Kechagias study only increased from 15.7% to 18.6%. 
In further support of this theory, in Kechagias’ study the intake of sugars was the 
only nutrient change that was associated changes in liver injury according to the 
maximal ALT values (r=0.62, p=0.006).  
The finding that there was no difference in HTGC with glucose or fructose 
overfeeding is not what many would have predicted. Fructose has been turned into 
a pariah nutrient with many believing that it turns ‘everything to fat’. Indeed 6 
review articles on the interactions between fructose and hepatic lipid metabolism 
were published in 2010. This is despite scant controlled clinical evidence that 
fructose and glucose metabolism differ in terms of lipid metabolic outcomes 
(Tappy, Le et al. 2010).  
This study was started after the publication of two similar papers 
comparing fructose and glucose overfeeding with the primary outcome measure 
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being HTGC. Unfortunately for me neither study was registered on the clinical 
trials website and so I was unaware of their existence. Fortunately both studies 
have significant limitations which are discussed in-depth on section 1.10.5. In 
brief, the paper by Ngo Sock et al. compares outcomes from three differing intake 
patterns over 7 days in men: namely a weight maintenance intake; or the same 
intake with additional 35% fructose, or glucose. The data presentation is very 
unclear and there are no baseline analyses despite the short washout periods of 2-3 
weeks. Silbernagel et al. report a small mixed sex study with 10 in each arm, food 
was not supplied and there were no interim visits. After 4 weeks the fructose 
group’s weight change was only 0.2±0.6kg (SEM) (p=0.40), indeed several 
seemed to lose weight. Whereas weight gain seemed to be universal in the glucose 
arm as the changes were +1.7±0.4kg (p=0.001). So as a result the fructose arm 
appears to be isoenergetic and the glucose hyperenergetic. 
Both studies enrolled slim, healthy, insulin sensitive subjects. They 
showed marked increases in HTGC which were matched between the groups. 
Neither of the papers had any real explanation for the absence of a difference 
between fructose and glucose and HTGC. Silbernagel and colleagues accepted it 
as a true outcome. Ngo Sock and colleagues stated that the HTGC changes in their 
study were smaller than their group had previously found (52% versus 79%) with 
similar amounts of fructose overfeeding (Le, Ith et al. 2009), and that the inter-
individual variability may have been a factor. As a result they do not conclude 
that glucose and fructose have the same hepatic lipid outcomes.  
My current findings compliment these prior findings and show that there is 
no difference in a high fructose versus high glucose intake on hepatic lipid stores 
and biochemical enzyme tests. My paper extends the prior studies by recruiting a 
larger cohort with a differing phenotype, namely centrally overweight males with 
a pre-existing tendency to sub-clinical insulin resistance, dyslipidaemia and 
hyperuricaemia. Indeed it is such a cohort who may be predicted to be most 
vulnerable to overfeeding. From a methodological perspective the presence of 
baseline, as well as post intervention, data aid the transparency of the findings’ 
interpretation. The supply of monosaccharides in an isoenergetic as opposed to 
merely energy overfeeding setting means that the separate metabolic challenges in 
these phases can be assessed. The weight changes reflected the differing energy 
delivery phases and were balanced between both groups. The supply of foodstuffs 
provided complete intake control and energy balance during the first period, such 
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that the only factor that differed was the monosaccharide. Changes in HTGC were 
non-significant in the isoenergetic period and matched in the hyperenergetic 
period such that the findings can only be viewed as being the consequence of 
energy as opposed to nutrient overfeeding. The strong associations between the 
hepatic and serum triglyceride values reinforce the reliability of my assessment 
process. 
The liver volumes also reflected the changes in HTGC, with no changes in 
the first period and a matched increase in both groups during the second. The 
aetiology of this increased liver volume is uncertain but is likely to reflect 
increased liver triglyceride and glycogen storage. 
 
5.4.3. Liver biochemistry and CRP 
Liver biochemistry improved in all parameters bar alkaline phosphatase in 
this first period. The reasons for this are unclear. They are crude and poor markers 
of overall liver ‘health’ but it would tend to suggest that the subject’s livers 
improved during this period. This is a curious finding as HTGC and serum 
triglycerides were unchanged, whereas HOMA (a marker of hepatic insulin 
resistance) worsened in those taking fructose. This improved liver biochemistry 
may be explained by the nutritional quality of the provided foodstuffs being 
greater than habitual intakes. The supplied diet clearly changed many nutrients, it 
reduced intakes of fat and increased carbohydrate intakes whilst potentially 
changing the intakes of many micronutrients. Altered alcohol intakes may have 
had a role, but the reduction in Gamma GT was no greater than the reduction in 
ALT or AST. The absolute changes in liver biochemistry are small and so are not 
felt to warrant over-interpretation. There were no changes in C-reactive protein 
levels, which have been shown to be associated with liver enzymes, visceral 
adiposity and the presence of NASH (Kerner, Avizohar et al. 2005; Verrijken, 
Francque et al. 2010; Fierbinteanu-Braticevici, Baicus et al. 2011). 
Liver biochemistry worsened during the overfeeding period and this was 
associated with the marked weight gain that occurred during this period. Of note 
the liver biochemical changes in the Kechagias study were much more dramatic 
than in this study (Kechagias, Ernersson et al. 2008). Kechagias and colleagues 
were unable to be certain as to why such high ALT values were noted in their 
study but they felt that it was by ‘nutrient induced enzyme induction’. It may well 
be that their dramatic overfeeding caused overwhelming metabolic stress resulting 
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in the hepatic compensatory threshold being exceeded. Unfortunately this is 
merely speculation as the authors have not released any non-esterified fatty acid, 
triglyceride, uric acid or inflammatory marker data despite my personal invitation 
for them to do so (Johnston, Aithal et al. 2009). 
 
5.4.4. Uric acid 
A significant proportion of the cohort had hyperuricaemia at baseline. 
Hyperuricaemia results from either an increased production, or decreased 
excretion, of uric acid. In health, diet has a key role in uric acid balance. High 
intakes of alcohol, purine rich foods or fructose increase uric acid production, 
whereas a ketogenic diet reduces its excretion. As to whether hyperuricaemia is a 
causative, or merely an associated, factor in cardiometabolic and renal disease 
development is widely debated. The majority feel that it forms merely an 
association due to it being a marker of a high risk lifestyle (Kanbay, Afsar et al. 
2011). Interestingly uric acid concentrations have been recently shown to be 
greater in children with NASH than without (Vos, Ryan et al. 2011). 
The aetiology of fructose induced hyperuricaemia was described in section 
1.10.3.2. To summarise, the initial steps of fructose catabolism involve hepatic 
ATP consumption which results in an increased formation of adenine nucleotides. 
These are degraded to form uric acid (Tran, Yuen et al. 2009). The rate of these 
steps is strictly limited for glucose via feedback from phosphofructokinase. As a 
result a high fructose intake is associated with hyperuricaemia and hence gout 
(Choi and Curhan 2008; Choi, Ford et al. 2008). However, as sucrose is the main 
dietary source of fructose a high fructose diet also involves a high glucose intake. 
As a result these population based studies cannot demonstrate that this is a 
fructose-specific effect. Indeed there are scant long-term studies comparing the 
uric acid outcomes following a high fructose or glucose intake. 
In the acute setting hyperuricaemia has been described following 
overfeeding with fructose (Tran, Jacot-Descombes et al. 2010), though not as a 
fructose-specific effect (Teff, Grudziak et al. 2009). In long term studies 
hyperuricaemia with fructose has only been reported in studies lacking an energy 
control (Le, Ith et al. 2009), and resulting in a non-significant trend in comparison 
to glucose (Ngo Sock, Le et al. 2010; Silbernagel, Machann et al. 2011). As a 
result this is the first study to my knowledge that clearly demonstrates a difference 
in uricaemia following a high fructose or glucose intake. There was a trend for an 
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increase in uric acid with fructose and reduction with glucose in both periods. 
This was only significant in the first period when all intakes were controlled for. 
During this period however the main change was a reduction in uric acid with 
glucose as opposed to an increase with fructose. Following identical fructose and 
glucose intakes there would be predicted to be a higher rate of pre triose 
metabolism with fructose than glucose due to the lack of feedback inhibition. This 
would result in a greater uricaemia with fructose than glucose as the pre triose 
metabolism of both results in ATP consumption, forming adenine nucleotides 
which are degraded to uric acid (Tran, Yuen et al. 2009). 
The reasons for the observed reduction in uric acid with glucose are 
unclear. During that period both food and monosaccharides were supplied. It is 
possible that this reflects a washout of fructose in the normal diet of the glucose 
arm or a glucose-specific effect. Changes in purine or alcohol intakes should have 
affected both groups equally. Microdiet software does not present data on purine 
intakes and so the purine content of the supplied food is not known. In the glucose 
group habitual intakes of fructose contributed 4.8% of energy. During the first 
period this fell to 2.3%. So there was some degree of fructose washout.  
 
5.4.5. Hepatic 31P metabolite profiles 
31P MRS analyses were performed in order to further assess hepatic ATP 
and uric acid metabolism. There were no consistent patterns of metabolite changes 
during the study. There was an increase in Pi during the overfeeding period 
presumably as a result of increased glucose and/or fructose metabolism. The 
absence of any other 31P MRS findings conflicts with the current uric acid 
findings and the previously described acute responses to fructose overfeeding 
(Segebarth, Grivegnee et al. 1991; Boesch, Elsing et al. 1997; Cortez-Pinto, 
Chatham et al. 1999). The current lack of changes will most likely reflect that the 
assessments were made in the fasted (at least 10 hours post fructose) state as 
opposed to the immediately postprandial phase. It seems likely that the observed 
changes in plasma uric acid reflect the less transitory changes in their levels than 
hepatic 31P metabolite profiles. One would predict tight regulation of ATP 
metabolism with a return to baseline as soon as the acute disturbance is removed, 
which would be predicted to occur within 10 hours of exposure to fructose, 
though this is speculation. Uric acid is not so critical to the central functioning of 
cells and so disturbances likely to be less rapidly reverted. It would have been 
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fascinating to have performed postprandial 31P analyses as these may have been 
altered and exaggerated by induction of fructokinase with fructose. 
 
5.5. Conclusions 
The study resulted in only a handful of differences between the groups, all 
of which appear to be unrelated. During the isoenergetic period fructose resulted 
in a greater uricaemia and serum level of alkaline phosphatase than glucose, and 
the hepatic PDE peak areas differed during the second period. No differing 
hepatic metabolism pattern emerged between fructose and glucose. In contrast 
there were significant differences noted in both groups. The isoenergetic period 
merely resulted in improved liver biochemistry in both groups. In contrast the 
hyperenergetic period was associated with increases in liver lipid, volume, 
biochemistry and Pi content in both groups. So there was a clear metabolic 
challenge to the liver during this period which was equal with both fructose and 
glucose. As a result the clear messages are that over a two week period glucose or 
fructose overfeeding are not different, and they only impact on the liver in the 
presence of energy excess. The lack of an alternative nutrient comparator in this 
study however means it cannot be resolved as to whether the changes observed 
are solely the effects of energy overfeeding, or energy overfeeding specific to 
monosaccharides.  
The strengths of this chapter lie within the numerous and in-depth 
assessments that were made of hepatic metabolism and function. The combination 
of liver lipid, volume, biochemistry and inflammatory markers provided a global 
assessment which is further strengthened by the whole body metabolism, insulin 
resistance and non-hepatic lipid data of the previous two chapters. As such it can 
be viewed as a comprehensive and definitive assessment.  
The key limitation of this work is the lack of histological assessment of 
liver tissue. Such an assessment is not ethically possible within a healthy 
volunteer research setting. In its absence however only indirect inferences can be 
made on the hepatic inflammatory and fibrotic influences of the interventions. 
Another limitation was the timing of the 31P MRS assessments. There are 
dramatic alterations in liver parameters in response to a fructose infusion as 
assessed by 31P MRS. All 31P MRS measurements were made in the fasted state. It 
would be fascinating to perform such assessments in the postprandial or post 
fructose infusion state following a high glucose or high fructose diet. This has 
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never been done before, but it would aid assessments of the degree of enzyme 
induction by overfeeding.  
At present there are no controlled data that demonstrate a difference 
between fructose and glucose intakes on hepatic metabolism. As such advice on 
‘low fructose diets’ in NAFLD are entirely unjustified. The impact of 
monosaccharide and energy overfeeding is however very clearly demonstrated by 
this study, and so further work needs to be made assessing the outcomes of low 
monosaccharide intakes in patients with NAFLD. 
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Chapter 6. The effect of n-3 PUFA supplementation on hepatic fatty acid 
metabolism in non-alcoholic fatty liver disease 
 
6.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the pathological 
consequence of excessive lipid storage within the liver. The aetiology of NAFLD 
appears to be multifactorial, though it is primarily associated with central obesity 
and insulin resistance. Despite all fatty acids being ultimately derived from dietary 
intakes, NAFLD lacks a clear dietary association. Some studies have characterised 
NAFLD as having a relative deficiency of the long chain n-3 PUFAs in the 
patients’ diets, plasma and livers. Biological plausibility of these observations is 
reinforced as hepatic lipid metabolism is potentially improved by n-3 PUFAs. 
Suggested mechanisms include the promotion of insulin sensitivity, anti-
inflammatory immunomodulation and beta-oxidation, combined with the 
reduction of de novo lipogenesis. Not all of these effects have been conclusively 
demonstrated outside the hepatocyte cell line or animal model experience. 
Clinical studies in NAFLD have been performed and shown divergent outcomes, 
though many have lacked robust assessment protocols. This study aimed to assess 
the impact of n-3 PUFA supplementation in patients with clear evidence of 
NAFLD using a robust assessment process. 
 
6.2. Method 
6.2.1. Subject identification  
Adult NAFLD patients were identified from a hospital liver biopsy database in 
University Hospitals Nottingham, UK. I reviewed all liver biopsies over the 
preceding 3 years. All patients aged greater than 18 years and with a liver biopsy 
report suggestive of NAFLD then had a case note review to ensure that they had 
previously undergone detailed investigations to exclude alternative diagnosis. In 
addition, I excluded the following-  
1. Significant hepatic architectural distortion on biopsy with bridging fibrosis or 
cirrhosis 
2. The presence of a further hepatic diagnosis  
3. Excessive alcohol intake defined as self-reported intakes greater than 21 units 
per week in men, and 14 units per week in women. 
4. Poorly controlled diabetes (HbA1C > 7.0% (Skyler, Bergenstal et al. 2009)) 
 200  
5. Use of insulin replacement therapy or insulin sensitising therapies such as a 
thiazolidinedione, or gliclazide. 
6. Initiation, or changes in the dose, of lipid altering medication within the 
preceding 3 months, such as a HMG CoA  reductase inhibitor, fibrate or 
systemic steroids. 
7. Fat malabsorption  
8. Use of n-3 polyunsaturated capsules (including cod liver oil) in the preceding 
4 months.  
9. Predicted life expectancy less than 2 years. 
10. Contraindications to magnetic resonance imaging. 
Architectural distortion was excluded due to its influence on regional hepatic 
chemical composition. A four month wash-out period of polyunsaturated fatty 
acids has been previously shown to be adequate to return plasma erythrocyte 
membrane fatty acid concentrations to normal (Cao, Schwichtenberg et al. 2006). 
Poorly controlled diabetes was excluded as significant changes in diabetic control 
could influence the assessment outcomes.  
 
6.2.2. Subject recruitment 
Patients with biopsy proven NAFLD without any identified exclusion 
criteria were contacted by post with a covering letter signed by the hepatologist 
overseeing the clinical management of the patient, a study information sheet, a 
reply form and envelope. Patients used the reply form to indicate interest, or 
decline involvement in the study. The reply form was returned to me stating either 
an interest or not in participating in the study. Those expressing an interest were 
then contacted by telephone and an initial meeting arranged. A single reminder 
was sent to those who did not return the initial reply slip. 
 
6.2.3. Overview of  method  
The initial screening assessment entailed a discussion of the study protocol 
and any issues or questions identified by the subjects or investigator. The subjects 
then underwent a semi-structured medical and physical assessment which was 
performed solely by me. This assessed past medical and surgical history, usage of 
medication, alcohol and supplements.  
Subjects who were appropriate and willing to participate signed three 
consent forms. As per Good Clinical Practice one consent form was kept by the 
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subject, one inserted into their healthcare records (along with a patient 
information sheet), and the final consent form was placed in the study files. The 
flow chart for the study is shown below in figure 1. The assessments performed at 
baseline and post-intervention were identical. Eighty one were screened in order 
to recruit the 58 patients. 12 were unsuitable for an MRI scan (8 had internal 
foreign objects, 4 had a waist greater than 125cm), 4 reported current excessive 
alcohol intakes, 3 had recent changes in lipid altering medication, 3 were current 
users of n-3 PUFAs, and 1 withdrew consent due to fears of the MRI scanner.  
58 NAFLD patients
Baseline assessment
MR scan, venesection, clinical
Randomise
29 patients
3 months
Daily sunflower oil capsules
29 patients
3 months
Daily 3.5g EPA and DHA
Post-intervention assessment
MR scan, venesection, clinical
 
Figure 1. Overview of the n-3 PUFA study in those recruited 
 
6.2.3.1. Clinical assessments 
Resting blood pressure was measured three times by a Dinamap Carescape 
V100 (General Electric Healthcare, UK) with the subjects in a relaxed quiet 
environment, and the mean value is presented. Weight and height were measured 
by the calibrated scales and telescopic column scale of a SECA 704 (SECA 
Hamburg, Germany). Waist, hip and mid arm muscle circumference were 
measured by the use of a  nonextensible, flexible tape measure, and triceps 
skinfold thickness by a single calibrated set of callipers (Holtain Ltd., Dyfed, 
Wales) with a constant pressure of 10g/mm2. I performed all of these measures 
myself.  
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6.2.3.2. Venesection 
Whole blood was collected, after an overnight fast, into two BD vacutainer 
SST tubes with no additives. The SST tubes were stored for 30 minutes to allow 
for sample clotting.  One tube was centrifuged for 10 minutes at 4000 rpm and at 
4oC. The resultant serum was separated from the red blood cells, placed in 
labelled eppendorf vials and frozen at –80oC prior to analysis. The non 
centrifuged SST tube was submitted fresh to the University hospital’s laboratory 
for analysis of liver biochemistry and lipids. 
 
6.2.3.3. MR assessment 
These were performed fasted using a Philips Achieva 3.0 Tesla, whole 
body system (Philips Medical Systems) in the Sir Peter Mansfield MR Centre, 
Nottingham. 
 
6.2.3.3.1. Hepatic triglyceride quantification 
The collection and analysis protocol was the same as that in chapter 5.2.1. 
 
6.2.3.3.2. Hepatic fatty acid indexes quantification 
To determine the indexes of hepatic fatty acid saturation, unsaturation and 
polyunsaturation a water-suppressed, respiratory triggered, PRESS sequence was 
used. It involved the same parameters as for hepatic triglyceride quantification, 
however the number of acquisitions at each echo time was doubled in order to 
further increase signal to noise ratio.  
The resultant spectra were individually phase corrected and realigned 
using jMRUI (Java-based MR user interface) (Naressi, Couturier et al. 2001) 
before averaging. Spectra were then processed using QUEST (part of jMRUI 
software), as described previously by Johnson et al. and formulae detailed in 
section 2.6.1. (Johnson, Walton et al. 2008). 
 
6.2.4. Randomisation 
Following successful assessments, the subjects then received their 
randomly allocated oil capsules and instructions on taking them. Randomisation 
to active or placebo capsules was performed by a simple non-stratified internet 
based programme run by the University’s clinical trials unit. The outcome of the 
random allocation for each subject was communicated to the pharmacy 
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department from the clinical trials unit. The capsules were labelled in an identical 
fashion for all the subjects, and contained information as to what the two potential 
options for the contents were. As a result, double blinding was attempted to be 
maintained throughout the study. The presence or absence of a fish oil taste was 
unavoidable, although it was only described by a few of the subjects. This 
potential loss of blinding in some volunteers did not influence the outcome 
analysis as all the outcomes were purely objective. 
 
6.2.5. Profile of the capsules 
The active capsules were a fish oil concentrate in a 1000mg Efamax 
capsule (Efamol ltd, Leatherhead, UK), and the placebo capsules were 1000mg 
oleic-enriched sunflower (Efamol ltd, Leatherhead, UK). Both capsules were of an 
identical size, shape and colour and bound in gelatine. Vitamin E is added to fish 
oils for stabilisation, and so an identical dose was added to the placebo. Such 
regular intakes of vitamin E supplements have been shown to be safe and with no 
known clinical outcomes at such a dose (Pocobelli, Peters et al. 2009). Certificates 
of analysis were provided by the manufacturing company, and the fatty acid 
profiles are demonstrated in table 1. There was 24 IU of vitamin E per capsule and 
hence 120 IU were consumed in both arms per day. 
 Active Placebo  
Saturated  35 77 
Monounsaturated  149  820 
Polyunsaturated  797 98 
n-3 polyunsaturated  746 1 
n-6 polyunsaturated  48 97 
n-9 polyunsaturated  3 0 
Short chain n-3 PUFA 9 1 
Short chain n-6 PUFA 7 97 
Long chain n-3 PUFA 737 0 
Long chain n-6 PUFA 41 0 
Oleic acid 44 816 
Vitamin E 16 16 
 
Table 1. Content of the active and placebo capsules in mg per capsule. 
 
6.2.6. Post intervention assessment 
After three months the clinical, MRI and venesection process was 
repeated. In addition, capsule-related side effects were screened for in a subject-
completed questionnaire, and any reported side effects were discussed between 
 204  
the lead investigator and the subject. Subjects were reimbursed their travel 
expenses for each assessment visit, but received no other financial remuneration.  
 
6.2.7. Serum analyses 
Serum insulin and non-esterified fatty acids were quantified by the 
methods previously described in sections 4.2.2. and 3.6.8. respectively.  
 
6.2.7.1. Serum fatty acid profile analysis by gas chromatography 
A step-wise process measured the relative contributions of the differing 
fatty acids to the serum PC fatty acid content. The first step extracted the fatty 
acids from the serum then the extract was fractionated to collect 
phosphatidylchoine. The fatty acids were then converted to volatile methyl esters, 
which were identified using gas chromatography. This allowed determination of 
the proportionate contribution of each fatty acid to the total content. This is further 
detailed below: 
1. Lipid extraction from the serum 
The serum sample vials were thawed at room temperature and the lipids 
extracted using chloroform and methanol. This was done by pippeting 0.4ml of 
serum from the labelled vial into a correspondingly labelled tube, and first adding 
0.4 ml of 0.9% NaCl. Next 0.1 ml of internal standard (1mg/ml in 
chloroform:methanol 2:1) was added to each sample, followed by 5ml 
chloroform: methanol (2:1+BHT 50mg/l), and finally 1ml of 1M NaCl was added. 
The tubes were then capped and vortexed for 15 seconds. The samples were then 
centrifuged (10 min, 2000 rpm, room temperature). The lower layer of the sample 
was aspirated and transferred into a new tube, where it was evaporated to dryness 
under nitrogen at 40oC. 
2. Fractionation of serum total lipid extract using solid phase extraction (SPE) 
The extract was dissolved in 1 ml chloroform and separated using solid 
phase extraction with an aminopropyl-silica column. The sample was loaded onto 
the column and triacylglycerol and cholesterol ester were eluted with 2ml 
chloroform and discarded. The phosphatidylcholine fraction was then eluted with 
2 ml chloroform:methanol 60:40 And the elutant evaporated under nitrogen.  
3. Transmethylation to produce fatty acid methyl esters (FAME) 
0.5ml of toluene and 1 ml of methanol containing 2% sulphuric acid were 
added to the dried samples. The samples were capped, and mixed gently for 10 
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seconds. Following this they were incubated on a heat block at 500C for two 
hours. Tubes were then allowed to cool and then 1ml of neutralising agent (0.5M 
K2CO3, 0.25M KHCO3) and 1ml of hexane was added. Samples were then vortex 
mixed for 5 seconds and centrifuged (2 minutes, 1000 rpm, room temperature). 
The upper layer was aspirated and transferred to a new labelled glass tube. The 
samples were then evaporated to dryness under nitrogen at 40oC.  
The dried sample extract was re-VXVSHQGHG LQȝORIKH[DQHDQGYRUWH[PL[HG
for 5 seconds. The hexane and sample mix was transferred into a labelled Gas 
&KURPDWRJUDSK\ YLDO DQG D IXUWKHU ȝO ZDV DGGHG WR WKH WXEHV 7KLV ZDV
vortexed for 5 seconds and transferred to a vial and stored at -80oC. 
4. Gas Chromatography of FAME 
Fatty acid methyl esters (FAME) were analyzed using a Hewlett Packard 
6890 series Gas Chromatography system (Hewlett Packard, Basingstoke, UK). 
The Gas Chromatography system was fitted with a BPX-70 30m x 0.22mm 
column, which had a coating of 0.25um (SGE Analytical Science, Milton Keynes, 
UK). The FAME were diluted in 150 µL of hexane, 1 µL of which was injected 
onto the column using an Agilent 7683 series autosampler (Agilent Technologies 
UK Ltd., WRNLQJKDP8.7KHLQMHFWRULQOHWWHPSHUDWXUHZDVÛ&DQGKHOLXP
was used as the carrier gas with a pre-column split ratio of 50:1 and a head 
pressure of 21.89 psi. The methyl esters were separated by the following 
temperature program: the oven was initiDOO\ KHDWHG WR Û& DQG KHOG IRU 
PLQXWHV DQG WKH WHPSHUDWXUH WKHQ LQFUHDVHG WR Û& DW Û& SHU PLQXWH 7KH
FAMEs were identified by the comparison of retention time against known 
standards (in house standard mix and PUFA-3 Menhaden Oil standards, Supelco, 
Dorset, UK). 1,2,-dipentadecanoyl-sn-glycero-3-phosphocholine (Avanti Polar 
Lipids, inc, USA) was used as the internal standard.  
A flame ionisation detector within the gas chromatograph detected 
FAMEs. The individual FAMEs differ in their chemical and physical properties, 
and hence they were separated within the column. The rate at which they passed 
through the column’s detector and their amount was noted and transferred to 
chromatograms. The chromatograms were plotted and analysed using Hewlett 
Packard Chemstation software package (Hewlett Packard, 1999). The fractional 
contribution of each fatty acid in relation to the total fatty acid content was 
calculated and converted into percentages of the total amount of fatty acid within 
the sample. 
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6.2.8. Ethical and research and development approval 
Nottingham Research and Ethics Committee one approved the study on the 11th of 
March 2008, and Nottingham University Hospital’s Research and Development 
department gave approval on the 27th of June 2008. No substantial amendments 
were required to the original protocol. 
 
6.2.9. Power calculation  
There were no prior human n-3 PUFA studies using MR spectroscopy as 
their primary outcome measure which could aid sample size determination. Both 
thiazolidenediones and n-3 PUFAs share 33$5Ȗ DFWLYLW\ DQG XVH RI D
thiazolidenedione resulted in a 39% reduction of hepatic triglyceride as quantified 
on 1H MRS after three months (Mayerson, Hundal et al. 2002). Prior human n-3 
PUFA studies had shown significant ultrasound reductions by 35% (Hatzitolios, 
Savopoulos et al. 2004) and 64% (Capanni, Calella et al. 2006).  As a result a 
mean reduction of 30% in the intervention group was predicted with no mean 
change in the control group. 57 participants were calculated to be the minimum 
required using a two-sided p-value of 0.05 and power of 90%. A baseline steatosis 
of 11.5% and standard deviation of 4.0 was assumed, as shown in prior MR 
studies of Caucasians (Browning, Szczepaniak et al. 2004; Thomas, Hamilton et 
al. 2005). 
 
6.2.10. Statistical analyses 
All data are presented as the mean ± standard deviation (SD). 
Comparisons between baseline values were done by the independent samples T 
test. The Student’s T test was used for paired data. Analysis of the significance of 
change between the two groups at two paired assessments was done by an 
independent samples T test of the absolute change between the two assessments in 
both groups. Associations were tested for by 2-tailed Pearson correlations. 
Discrete data were analysed by Chi squared analyses. 
 
6.3. Results 
6.3.1. Baseline clinical data 
43 men and 15 women were recruited. During the 3 month follow up there 
was a single drop out, which was in the n-3 PUFA group. This was due to a 
change in personal circumstances as opposed to the intervention or assessment 
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process. Post randomisation the biopsies were reviewed by an independent liver 
pathologist. Two biopsies were felt to have inadequate steatosis in order to be 
truly labelled as having NAFLD, all the others were felt to be diagnostic for 
NAFLD. As a result the final analysis is of the 55 patients whose baseline 
demographic and clinical features are presented in table 2. Of the 55 patients, 42 
were male, 20 treated for hypertension, 16 on long-term dyslipidaemia therapy, 6 
diabetic, 1 diet treated and 5 on metformin. 
 
 n-3 PUFA, n=28 Placebo, n=27 p 
Age (years) 49 ± 9 52 ± 12 0.20 
Male  21/28 21/27 0.81 
Weight (kg) 91.2 ± 16.4 87.0 ± 15.5 0.34 
BMI 30.3 ± 4.6 29.1 ± 3.8 0.29 
Waist (cm) 106.0 ± 11.7 103.0 ± 10.6 0.32 
Waist : hip ratio 1.03 ± 0.06 1.02 ± 0.07 0.62 
Triceps skinfold thickness (cm) 2.73 ± 1.16 2.64 ± 0.92 0.75 
Mid arm muscle circumference (cm) 34.5 ± 3.4 33.4 ± 3.8 0.24 
Systolic BP (mmHg) 142 ± 13 142 ± 13 0.80 
Diastolic BP  (mmHg) 84 ± 10 80 ± 7 0.10 
On hypertensive therapy 11/28 9/27 0.65 
Diabetic  2/28 4/27 0.36 
Alcohol intake (units per week): 7 ± 7 9 ± 8 0.28 
 
Table 2. Baseline clinical, demographic and anthropometric data on the two 
groups. (mean±SD).  
 
The cohort was typical for NAFLD being predominantly male, middle 
aged, and centrally overweight. The two groups were evenly balanced in terms of 
clinical and demographic features at baseline.  
Compliance was assessed historically and by counting returned capsules. 
The reported compliance rates were 97% in both groups, p=0.91.  
 
6.3.2. Side effects 
Mild gastrointestinal symptoms attributed to the capsules were more 
common in the treatment group (6/28), as opposed to the placebo group (1/27) 
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(p=0.049). None reported symptoms that they classified as severe, and all reported 
willingness to take such capsules again in the future. 
 
6.3.3. Serum fatty acid profile outcomes 
The two groups were essentially matched for their serum fatty acid 
profiles at baseline, see table 3. There was a slightly greater EPA and n-3 PUFA 
content in the treatment group at baseline.  
During the intervention there were no changes in the fatty acid profile in 
the placebo arm except for oleic acid. Whereas the treatment group had a 
significant reduction in the relative contributions of n-6 PUFAs, including 
arachidonic acid, and an increase in n-3 PUFAs including EPA and DHA.  
 
Table 3. Percentage of serum fatty acid profiles from individual fatty acids 
and their classes at baseline and at three months in the active and placebo 
groups. (ARA = arachidonic acid). (mean±SD). 
 
 
 n-3 PUFA Placebo Difference 
between 
baseline 
values (p) 
Absolute 
change 
between 
groups 
(p) 
Baseline 3 month p Baseline 3 month p 
Saturated 44.5±1.1 44.4±1.1 0.54 44.2±1.0 44.2±1.1 0.81 0.33 0.77 
Monounsaturated 13.5±2.1 13.6±2.1 0.66 13.5±2.4 13.1±1.4 0.40 0.94 0.34 
Oleic acid 9.8±1.4 9.3±1.3 0.004 10.1±1.8 10.6±1.5 0.02 0.97 <0.001 
Polyunsaturated 42.0±2.2 41.9±2.3 0.89 42.2±2.7 42.7±1.9 0.38 0.72 0.44 
n-6 PUFA 35.1±5.9 30.6±2.8 <0.001 35.8±5.7 36.2±2.4 0.83 0.35 0.003 
ARA 9.1±1.8 8.0±1.7 <0.001 9.1±2.1 9.0±2.3 0.28 0.96 <0.001 
n-3 PUFA 6.9±2.1 11.3±2.4 <0.001 6.4±1.2 6.5±1.3 0.98 0.08 <0.001 
n-6:n-3 5.3±1.5 2.9±1.2 <0.001 5.8±1.1 5.8±1.2 0.98 0.15 <0.001 
EPA 1.6±0.9 4.2±2.0 <0.001 1.2±0.5 1.2±0.5 0.80 0.04 <0.001 
DHA 3.4±1.1 4.5±0.9 <0.001 3.1±0.8 3.2±0.9 0.96 0.38 <0.001 
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Figure 2. Percentage contribution of oleic acid, arachidonic acid (ARA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to total serum 
fatty acid content pre and post intervention in the n-3 PUFA group (A) and 
the placebo (B). (As compared to baseline value *=p<0.05, **=p<0.0, 
***=p<0.001). (mean ±SEM). 
 
6.3.4. Hepatic and metabolic outcomes  
The groups were well matched at baseline. The biochemical findings are 
typical for NAFLD with an elevated ALT (normal range being 0-45 U/L in men 
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and 0-35 U/L in women), and a high ALT to AST ratio. There is evidence of mild 
systemic insulin resistance and dyslipidaemia with an elevated fasted triglyceride 
and total cholesterol.  
At 3 months there were no significant changes between the groups. There 
was a trend for a greater reduction in HTGC and alkaline phosphatase with n-3 
PUFA, and an increase in insulin concentrations.  
 
 n-3 PUFA Placebo Difference 
between 
baseline 
values (p) 
Absolute 
change 
between 
groups (p) 
Baseline 3 month p Baseline 3 month p 
HTGC (%) 9.3±5.2 8.7±5.5 0.25 10.8±6.0 11.2±6.1 0.41 0.33 0.16 
ALT (U/L) 54±24 49±19 0.21 55±25 51±36 0.45 0.86 0.89 
AST (U/L) 37±10 36±10 0.72 40±14 40±19 0.99 0.31 0.85 
GGT (U/L) 105±103 95±89 0.33 96±109 86±87 0.25 0.74 0.95 
Alk P (U/L) 105±42 95±32 <0.01** 91±27 89±24 0.58 0.16 0.10 
Cholesterol (mmol/L) 5.6±0.9 5.5±1.1 0.51 5.5±1.4 5.4±1.3 0.43 0.61 0.96 
Triglyceride (mmol/L) 2.0±1.0 1.7±0.7 0.02* 2.2±1.7 2.1±1.2 0.77 0.69 0.25 
Glucose (mmol/L) 5.5±0.5 5.4±0.7 0.59 5.9±1.6 5.8±1.5 0.48 0.18 0.89 
Insulin (mIU/L) 10.3±6.0 12.4±7.9 0.04* 10.2±9.4 10.1±7.1 0.89 0.98 0.10 
HOMA-IR 2.5±1.5 2.9±1.7 0.053 2.9±3.3 2.7±2.3 0.58 0.60 0.12 
NEFA (mmol/L) 344±132 387±238 0.18 404±148 449±153 0.15 0.12 0.96 
Adipose-IR 21±19 29±26 <0.01** 28±39 28±26 0.98 0.42 0.12 
Table 4. Hepatic and metabolic measures at baseline and three months in the 
n-3 PUFA and placebo groups. (HTGC = hepatic triglyceride concentration, 
ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = 
gamma glutamyl transferase, Alk Phos = alkaline phosphatase, NEFA = non-
esterified fatty acids, Adipose-IR = Adipose tissue insulin resistance (NEFA 
(mmol/L) x fasted plasma insulin (pmol/L)). (mean±SD). 
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Figure 3. HTGC in all pre and post n-3 PUFA or placebo, n=55 
(mean±SEM). 
 
The baseline HTGC findings are surprisingly low given that this was a 
study in patients with known NAFLD. The reliability of this data however is 
reinforced by the association between the HTGC values and measures of obesity, 
insulin resistance and liver enzymes, see table 5.  
 
 
 
 
 
 
 
 
Table 5. Correlations between HTGC and markers of obesity, liver enzymes 
and insulin resistance in the whole cohort, n=55. 
 
6.3.5. Hepatic fatty acid profiles 
Due to technical issues with the MRI fatty acid profile analyses, data are 
only available for 49 patients, 27 in n-3 PUFA group and 22 in the placebo group. 
 r Significance 
Weight 0.43 0.001 
BMI 0.46 <0.001 
Waist 0.42 0.001 
ALT 0.26 0.06 
HOMA-IR 0.34 0.01 
 212  
These values were matched at baseline. In accordance with the serum data in table 
3, there were no changes in the profile of fatty acid classes during the intervention 
 
 n-3 PUFA Placebo Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
Baseline 3 month p Baseline 3 month p 
Saturated 95.5±1.7 95.7±1.2 0.63 95.8±1.3 95.3±2.6 0.41 0.53 0.32 
Monounsaturated 4.5±1.7 4.3±1.2 0.63 4.2±1.2 4.7±2.6 0.41 0.53 0.32 
Polyunsaturated 1.3±0.5 1.4±0.6 0.64 1.5±0.8 1.9±2.7 0.61 0.47 0.66 
Table 6. Hepatic fatty acid percentage profiles as quantified by 1H MRS 
(n=27 for n-3 PUFA, and n=22 for placebo). (mean±SD). 
 
6.3.6. Effect of baseline steatosis on outcomes 
The accepted 1H MRS cut-off value for a normal HTGC is less than 5.5% 
(Szczepaniak, Nurenberg et al. 2005). It was not predicted that recruited patients 
would have a normal HTGC value. Post-hoc analyses comparing the 12 patients 
with a normal baseline HTGC and the 43 patients with an elevated HTGC found 
no significant differences in terms of age, anthropometry, or insulin sensitivity, 
liver and lipid biochemistry, see table 7. There was a tendency for those with an 
abnormal HTGC to have a greater body mass index.  
 
 Normal HTGC, 
n=12 
Abnormal HTGC, 
n=43 
P 
Age (years)  52±11 50±10 0.56 
Sex (n male) 8 34 0.37 x 
Alcohol (weekly units) 8±8 8±8 0.93 
Diabetic 1 5 0.74 x 
Weight (kg) 81.3±18.2 91.3±14.8 0.054 
BMI (kg/m2) 27.7±3.7 30.3±4.2 0.058 
Waist (cm) 100.5±11.4 105.7±11.0 0.16 
Waist to hip ratio 1.01±0.07 1.04±0.06 0.16 
ALT (U/L) 51.1±23.8 55.5±24.3 0.58 
AST (U/L) 40.1±13.0 38.4±12.3 0.68 
GGT (U/L) 142.7±113.5 88.6±100.6 0.12 
Alk P (U/L) 118.8±56.7 92.0±25.1 0.14 
Cholesterol (mmol/L) 6.0±1.1 5.4±1.2 0.14 
Triglycerides (mmol/L) 2.2±1.4 2.1±1.4 0.84 
HOMA-IR 1.9±1.2 2.9±2.8 0.22 
NEFA (mmol/L) 390±170 368±135 0.65 
Table 7. Comparison of those patients with and without an abnormal HTGC 
at baseline. (x= chi-squared.) (mean±SD). 
 
 213  
6.3.6.1. Findings in those without steatosis at baseline 
Of the 12 patients with a normal baseline HTGC, 7 received n-3 PUFAs 
and 5 placebo. At baseline these two sub-groups did not differ in terms of their 
clinical, anthropometric or biochemical data, as shown in table 8. There were no 
significant changes within or between the two groups, apart from serum 
triglycerides which increased with placebo.  
 
 n-3 PUFA, n=7 Placebo, n=5 Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p) 
 Baseline 3 months p  Baseline 3 months p 
HTGC 3.34±1.46 4.95±2.94 0.14 3.00±1.22 3.97±1.36 0.25 0.69 0.62 
Weight 83.7±20.1 85.0±20.5 0.15 77.9±16.6 78.8±16.3 0.48 0.61 0.71 
ALT 54.1±26.4 43.4±18.3 0.28 46.8±21.9 57.6±69.7 0.69 0.62 0.39 
AST 42.3±12.2 36.6±6.5 0.22 37.0±15.0 44.2±32.2 0.65 0.52 0.36 
GGT 185.6±125.1 122.7±64.3 0.11 82.6±65.2 94.2±95.7 0.58 0.13 0.11 
Alk P 134.3±69.4 108.0±51.2 0.06 97.2±25.0 102.0±19.9 0.69 0.29 0.09 
Cholesterol 5.7±0.8 5.7±1.4 0.90 6.4±1.5 6.1±0.94 0.47 0.26 0.46 
Triglycerides 2.6±1.6 1.8±0.9 0.10 1.5±0.9 2.1±1.2 0.03 0.21 0.02* 
Glucose 5.4±0.5 5.3±0.4 0.57 5.4±1.3 5.1±0.8 0.31 0.99 0.69 
Insulin 7.1±4.9 8.9±3.3 0.27 8.7±5.2 9.5±2.4 0.77 0.61 0.72 
HOMA-IR 1.7±1.2 2.1±0.8 0.33 2.1±1.3 2.1±0.3 0.98 0.60 0.55 
NEFA 314±126 323±229 0.88 496±179 458±106 0.67 0.06 0.57 
Table 8. Hepatic and metabolic measures at baseline and three months in the 
n-3 PUFA and placebo groups of those with normal HTGC at baseline. 
(mean±SD). 
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Figure 4. HTGC in those with a normal baseline HTGC assessment pre and 
post n-3 PUFA or placebo, n=12. (mean±SEM) 
 
6.3.6.2. Findings in those with steatosis at baseline 
Of the 43 with an abnormal baseline HTGC, there were no clinical or 
anthropometric baseline differences between those receiving n-3 PUFA and 
placebo. 
  
 n-3 PUFA, 
n=21 
Placebo, 
n=22 
P 
Age 47±9 53 ±11 0.07 
Sex (n male) 16/21 18/22 0.72x 
Alcohol (weekly units) 8.9±1.6 6.6±1.7 0.33 
Diabetic (n) 1/21 3/22 0.32x 
Weight (kg) 93.7±14.7 89.1±14.8 0.32 
BMI (kg/m2) 31.1±4.7 29.6±3.6 0.25 
Waist (cm) 107.5±11.7 103.9±10.3 0.28 
Waist to hip ratio 1.04±0.06 1.03±0.07 0.72 
 
Table 9. Characteristics of the two groups of patients with steatosis at 
baseline. (x= chi-squared test). (mean±SD). 
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At baseline the two groups were also well matched in terms of liver fat 
content, liver biochemistry and lipids, see table 10. However, these two subgroups 
did respond differently to the intervention. There was a 12.2% relative reduction 
of HTGC in the n-3 PUFA group from the original value, and an increase of 2.2 % 
in the placebo group, p=0.046. Conversely there were opposing outcomes for 
GGT. Within the groups there were improvements in ALT with placebo and 
alkaline phosphatase with n-3 PUFA, though no significant decrease in serum 
triglycerides.  
 
 n-3 PUFA, n=21 Placebo, n=22 Difference 
between 
groups at 
baseline (p) 
Absolute 
change 
between 
groups (p)
 Baseline 3 months p  Baseline 3 months  p 
HTGC 11.3±4.3 9.9±5.6 0.02* 12.6±5.1 12.9±5.4 0.63 0.39 0.046* 
Weight 93.7±14.7 93.9±14.4 0.60 89.1±14.8 89.1±14.5 0.91 0.32 0.62 
ALT 53.9±23.5 51.1±19.5 0.49 57.1±25.6 49.8±26.4 0.02* 0.68 0.37 
AST 35.3±9.4 36.4±11.5 0.58 41.3±14.1 39.6±15.0 0.29 0.11 0.26 
GGT 78.2±80.8 85.7±95.2 0.09 98.5±117.5 84.6±87.7 0.11 0.52 0.03* 
Alk P 94.6±23.1 90.3±22.1 0.03* 89.5±27.2 86.2±23.8 0.30 0.51 0.78 
Cholesterol 5.6±1.0 5.5±1.1 0.40 5.2±1.4 5.2±1.3 0.78 0.31 0.53 
Triglycerides 1.8±0.6 1.6±0.7 0.10 2.3±1.9 2.1±1.2 0.40 0.25 0.97 
Glucose  5.5±0.5 5.4±0.8 0.78 6.0±1.7 5.9±1.6 0.75 0.17 0.98 
Insulin 11.3±6.0 13.5±8.6 0.08 10.6±10.2 10.3±7.9 0.75 0.77 0.11 
HOMA-IR 2.8±1.5 3.2±1.8 0.11 3.0±3.7 2.8±2.5 0.56 0.75 0.16 
NEFA 354±136 409±242 0.16 383±136 447±164 0.07 0.50 0.85 
 
Table 10. Hepatic and metabolic measures at baseline and three months in 
the n-3 PUFA and placebo groups of those with abnormal HTGC at baseline. 
(mean±SD). 
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Figure 5. HTGC in those with an elevated baseline HTGC assessment pre 
and post n-3 PUFA or placebo, n=43. (mean±SEM) 
 
6.4. Discussion 
6.4.1. Summary of findings 
The intervention resulted in significant alterations of serum fatty acid 
profiles between the groups, which were in line with the capsules’ contents. These 
changes however failed to translate, in the whole group, to any detected metabolic 
or hepatic changes beyond a reduction in serum triglyceride. Amongst those with 
steatosis on biopsy and at 1H MRS there was an isolated reduction in HTGC with 
n-3 PUFA and a reduction in GGT with placebo.  
At study entry the two groups were well matched for all parameters bar a 
slightly greater serum EPA concentration in the treatment group. The cohort was 
typical for NAFLD in terms of central obesity, male predominance, abnormal 
liver enzymes, dyslipidaemia and insulin resistance. Not all however had steatosis 
according to their initial 1H MRS assessment.  
Both groups gained weight, though this tended to be greater in the 
treatment group. There was a greater incidence of mild gastrointestinal symptoms 
in the n-3 PUFA than placebo arm. The placebo resulted in an isolated increase in 
oleic acid in the serum fatty acid profile, whereas within the treatment group there 
was an increase in the serum n-3 PUFA proportion and a reduction in n-6 PUFA.  
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Within the groups of the whole cohort there were no changes in hepatic 
lipid or biochemical assessments with placebo. In contrast n-3 PUFA treatment 
was associated with a non-significant reduction in HTGC and ALT, and with a 
significant reduction in alkaline phosphatase and serum triglycerides. Serum 
insulin concentrations however increased with n-3 PUFAs and there was greater 
adipose tissue insulin resistance and a tendency towards greater whole body 
insulin resistance. Strong associations were made between these outcomes and 
changes in weight. As a result the greater weight gain in the treatment arm may 
have influenced many of the outcomes. 
Those with a normal HTGC at study entry tended to have a lower weight 
and BMI. Amongst these there were no significant changes either within or 
between the groups. In those with an abnormal baseline HTGC, post hoc analyses 
demonstrated a significant reduction in HTGC with n-3 PUFA capsules. This was 
not associated however with any other significant improvement in liver enzymes 
or metabolic parameters over placebo.  
 
6.4.2. Issues with the recruitment process 
In routine clinical practice many patients are diagnosed as having NAFLD 
without a liver biopsy. This clinical diagnosis is made on the basis of abnormal 
liver biochemistry in the absence of an alternative explanation following clinical 
assessment and a ‘parenchymal screen’. Such patients can however have 
alternative diagnoses (Skelly, James et al. 2001), and so the requirement for all 
patients to have had a prior liver biopsy strengthens this study. Unfortunately the 
histological diagnosis of NAFLD is not without its controversies. Alcoholic liver 
disease can be difficult to distinguish clinically or pathologically from NAFLD 
(Yeh and Brunt 2007). The inter-observer agreement of NAFLD histology is 
limited with a kappa value of between 0.23 and 0.65 depending on the parameter 
assessed (Gawrieh, Knoedler et al. 2011).  
The patients in this study were recruited after biopsy assessments from 
several pathologists, some who were not specialists in hepatic pathology. The 
failure to have a central histological assessor of the biopsies before recruitment 
was a missed opportunity. It does however have prior precedent, with a recent 
major NAFLD histology study finding that on central review many patients 
already recruited lacked the histological criteria to enter the study (Sanyal, 
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Chalasani et al. 2010). Due to one patient dropping out and two not meeting the 
diagnostic criteria for NAFLD the cohort entailed 55 patients as opposed to 58.  
 
6.4.3. Compliance 
Compliance was assessed by counting returned capsules and further 
validated by serum fatty acid analyses. Historically very high rates of capsule 
consumption were reported and few capsules were returned. Objectively there was 
an increase in the combined serum EPA and DHA content in 25 of 28 in the active 
group and of oleic acid in 20 of 27 in the placebo group. This suggests high 
compliance rates in both the active and placebo arms, especially as the placebo 
will have only moderately increased total daily intakes as will now be discussed. 
The only study to quantify habitual EPA and DHA intakes in NAFLD 
patients estimated 434mg per day (Allard, Aghdassi et al. 2008). The five n-3 
PUFA capsules would have increased this by 3,455mg per day, a nearly 8-fold 
increase, such that an increase in serum concentrations would be universally 
expected. Daily intakes of oleic acid in NAFLD have not been specifically 
published. It is however known that NAFLD patients consume 58g per day of 
monounsaturated fatty acids (Musso, Gambino et al. 2003), and that oleic acid 
contributes to around 90% of monounsaturated fatty acid intakes in healthy adults 
(Hunter, Rimm et al. 1992). Hence the capsules would have only resulted in an 
increase of oleic acid intakes by 8%, so an increase in 20 out of 27 patients seems 
acceptable. 
 
6.4.4. Disagreement between histological and 1H MRS findings 
Not all patients had an elevated hepatic triglyceride count as assessed by 
1H MRS at study entry. The reasons for this remain unclear. There was a time lag 
between biopsy and study recruitment, though the maximal time difference was 3 
years and none reported to be actively losing weight at the time of recruitment. 
The time interval may however have allowed for NAFLD disease progression, 
regression, or indeed a new hepatic disease to develop. This is a limitation, but the 
primary endpoint was defined as the 1H MRS findings not factors related to the 
original histology, and the histology was not a component of the subsequent 
analyses.  
Although the two assessment techniques of liver biopsy and 1H MRS do 
complement each other they also differ in what they assess. As discussed in 
 219  
chapter 2, histopathologists quantify liver biopsy fat content as the percentage of 
hepatocytes with visible fat droplets, whereas 1H MRS determines the fractional 
volume of fat within the liver (Schwenzer, Springer et al. 2009). Consequently the 
values determined by 1H MRS are consistently lower than histopathological 
values (Cotler, Guzman et al. 2007; McPherson, Jonsson et al. 2009). Confusion 
can however arise as both techniques generate scores with a percentage value. The 
absolute difference between both techniques is a factor of  approximately 1.8 
(Longo, Pollesello et al. 1995). So it is possible that some may not fulfil the 1H 
MRS criteria for steatosis whilst fulfilling the pathological criteria. 
 
6.4.5. Duration and nature of intervention and placebo 
In order for the study to be truly blinded there needed to be an oil within 
the placebo capsule. No fatty acids are fully biologically inert, though oleic acid is 
a substantial part of the standard diet and has been shown to be relatively 
metabolically benign. A similar preparation of oleic enriched sunflower oil was 
previously used as a placebo at 3.9g/day (4.08g/day in this study) for 12 weeks 
(Lambert, Goedecke et al. 2007). It resulted in no change in weight, body 
composition, insulin resistance or lipid profiles. As such it appeared to be a valid 
placebo. There were no changes in the placebo group serum fatty acid profiles 
with the exception of oleic acid itself.  
Normal values for EPA or DHA serum fatty acid concentrations are not 
published. As a result it is difficult to interpret the cohort’s baseline values. There 
was however a significant increase in serum EPA and DHA content in the 
treatment group. Indeed the proportion of patients who had at least a 50% rise in 
their serum EPA and DHA concentrations at 3 months was 19/28 vs. 2/27 in the 
placebo group, and 12/28 vs. 0/27 had more than a 100% rise. This was associated 
with a reduction in serum n-6 PUFA content. So it is clear that there was a marked 
change in serum polyunsaturated fatty acid status with the treatment capsules. 
Ultimately it was the hepatic, as opposed to serum, fatty acid profile, and 
indeed content, that the intervention aimed to alter. As discussed in chapter 1 
there are scant data on the timescale for hepatic incorporation of oral n-3 PUFAs. 
The only evidence available described a 3-fold increase in hepatic EPA content 
following 5 days of 3.7g of EPA and DHA (Senkal, Haaker et al. 2005). Due to 
the delivery of similar amounts of EPA and DHA (3.5g/day) for 3 months and the 
marked increase in serum EPA and DHA content, it seems reasonable to assume 
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that hepatic EPA and DHA content increased with the intervention. The 1H MRS 
fatty acid profile analyses were designed to detect changes in total PUFA status. 
No changes were detected, though total serum PUFA status did not change either. 
As opposed to serum analyses, the 1H MRS technique was not able to quantify 
hepatic n-3 or n-6 PUFA sub-fractional status. 
The addition of vitamin E to capsules is necessary to stabilise fish oils. 
Identical amounts were present in both capsules. The daily dose was 15% of that 
used in the PIVENS study and for an eighth of the duration (Sanyal, Chalasani et 
al. 2010). The vitamin E arm in the PIVENS study had improved NASH features 
in 34% more patients than placebo. In this study it seems unlikely that the small 
amounts of vitamin E supplied impacted significantly on the outcomes, especially 
as there have been previous negative studies using the same amount as in the 
PIVENS study for 3 and 12 months (Kugelmas, Hill et al. 2003; Bugianesi, 
Gentilcore et al. 2005).  
 
6.4.6. Potential impact of weight change on study outcomes 
The reasons for the differing weight gain tendency between the capsules 
are unclear. Dietary and activity records were not taken. The capsule energy 
content of both groups was identical at 45kcal per day. Over the 12 weeks the 
patients received 3,780kcal from the capsules. It is estimated that dietary intake 
needs to increase by around 7,000kcal to gain a kilogram of fat (Katan and 
Ludwig 2010). As a result the weight change in the n-3 PUFA group of 0.5kg is in 
line with that predicted. What is interesting is that the placebo group gained less 
weight (0.1kg). This was not significantly different but it may itself have 
influenced the metabolic outcomes. One possibility for the difference between the 
groups is that those taking the n-3 PUFA consumed other foodstuffs around the 
time of taking the capsules so as to limit any gastrointestinal side effects or tastes. 
Such data were not collected and so this is merely speculative.  
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 Group  r P 
 
HTGC 
All 0.44 0.001 
n-3 PUFA 0.59 0.001 
Placebo 0.29 0.14 
 
ALT 
All 0.27 <0.05 
n-3 PUFA 0.36 0.06 
Placebo 0.21 0.30 
 
Triglycerides 
All 0.25 0.064 
n-3 PUFA 0.20 0.31 
Placebo 0.36 0.06 
 
HOMA-IR 
All 0.21 0.13 
n-3 PUFA 0.36 0.06 
Placebo 0.07 0.73 
 
Table 11. Associations between weight change and changes in hepatic and 
serum triglycerides, liver enzymes and insulin resistance. 
 
Weight change was strongly associated with changes in HTGC and liver 
enzymes and tended to be associated with changes in insulin resistance and serum 
triglycerides, see table 11. It is therefore likely that it was a factor that negatively 
influenced outcomes in the intervention group. Adjusting for it would however 
have been a mistake as this was a clinical trial attempting to generate clinical data. 
If the potential beneficial effects of a therapy are negated by a side effect, then the 
side effect should not be ignored. That said weight gain is not a frequently 
reported finding in prior n-3 PUFA supplementation studies. The experience in 
NAFLD is limited and clearly more data is needed in this area.  
 
6.4.7. Hepatic outcomes 
The primary outcome measure for the study was HTGC. There was a trend 
for a reduction in the whole group with n-3 PUFA and this was significant in 
those with an elevated HTGC at study baseline. As this was a post-hoc subgroup 
analysis the study cannot be viewed as being positive. Though a greater reduction 
amongst those with steatosis than those without has been previously reported 
(Cussons, Watts et al. 2009). However the magnitude of change in HTGC was not 
dramatic in this study and there were scant associated metabolic changes. It is 
however strongly suggestive that a larger study with patients with elevated 
baseline HTGC may be positive.  
It is noteworthy that amongst the whole cohort there was a trend, in both 
groups, for a general improvement in liver biochemistry and lipids. This was 
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never significant in the placebo group. The aetiology of this general improvement 
is unclear. Potential explanations include a beneficial effect of the intervention 
and placebo capsules, regression to the mean phenomenon, or a change in lifestyle 
behaviour as a result of being intensively observed in a clinical study – the 
Hawthorne effect (Brody and Miller 2011). Of the individual enzymes, ALT and 
AST are traditionally viewed as being a more significant marker of liver injury in 
NAFLD, and there was no change in these. Alkaline phosphatase was 
significantly reduced in the treatment group whereas there was little change in the 
placebo group. The role for alkaline phosphatase as a marker of NAFLD has been 
explored and suggested as a marker for NASH by a single paper, though there 
seems to be little other corroborative data for this story (Pantsari and Harrison 
2006). Within the subgroups of those with and without an abnormal HTGC at 
baseline there were no additional trends for overall change in liver enzymes with 
the intervention or placebo.  
6.4.8. Metabolic outcomes  
Fasted serum triglycerides were significantly reduced in the active group 
as has been widely shown by prior clinical experience in the non NAFLD setting 
(Hartweg, Farmer et al. 2007). This was a weight independent effect. 
Systemic and adipose IR tended to worsen in the n-3 PUFA group. This was due 
to an increase in fasted insulin with no real change in glucose or NEFA 
concentrations. Such a rise was an unexpected finding. Potentially n-3 PUFAs 
have insulin sensitising effects via PPAR gamma agonism, though this has never 
been shown to have a clinical effect. No mechanistic data were collected that 
could fully explain the aetiology of the development of insulin resistance. Weight 
gain was greater in the treatment than placebo group and this tended to correlate 
with a change in the HOMA-IR value, r=0.36 (p=0.06). As such the greater 
weight gain in the treatment group may in part explain this unpredicted outcome.  
 
6.5. Conclusions 
This study failed to demonstrate a difference in hepatic lipid content following 
n-3 PUFA treatment in patients with NAFLD. This overall finding has to be 
tempered however by the expectation that all patients would have a raised HTGC 
at study entry. Amongst those with an elevated baseline HTGC there was a 
reduction in HTGC, though the magnitude of reduction was small and it was an 
isolated finding. 
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The strengths of this study are: 
1. Its double blind design, meticulous entry criteria, robust assessment process, and 
the high dose of n-3 PUFA prescribed.  
2. All subjects needed histological evidence of NAFLD, as assessed by a single 
expert histopathologist. 
3. Patients on insulin sensitising therapies were excluded.  
4. The assessment of HTGC using a powerful magnetic field, coupled with serum 
and hepatic lipid profiling aided the interpretation of the findings.  
 
The study does however have limitations: 
1. There was no histological assessment of liver tissue pre and post intervention. 
This meant that assessments of hepatic inflammation and fibrosis could not be 
made.  
2. The duration of 3 months may not have been adequate enough to fully test the 
hypothesis. That said, a previous 8 week study assessing liver fat with 1H MRS, in 
a smaller cohort of people with polycystic ovarian syndrome, and using smaller n-
3 PUFA doses than the current study, had positive outcomes (Cussons, Watts et 
al. 2009).  
3.  Not all patients had steatosis at study entry. This appears to have impacted on the 
outcome, as the findings were positive in those with steatosis.  
4.  Patients were not prospectively identified and so there may have been disease 
regression or progression in between the time of their biopsy and study entry. 
 
The conflicting findings between the whole group and the subgroup with steatosis 
mean that this is not a conclusive study. There are several ongoing studies in this 
area registered on the clinicaltrials.gov website. So this study will add to what in 
the future will be a considerable body of evidence.  
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Chapter 7. Final summary 
 
Non-alcoholic fatty liver disease is the hepatic consequence of obesity and 
insulin resistance. The vast majority of such patients are overweight or obese and 
as such lifestyle induced weight loss is currently the only approved therapy for 
NAFLD (AGA 2002). There is however only a single paper that validates this 
approach (Promrat, Kleiner et al. 2010), and it has been shown to be very difficult 
to meaningfully achieve weight loss (Huang, Greenson et al. 2005). Histological 
improvement in steatohepatitis has been shown with insulin sensitising medical 
therapies. Unfortunately these improvements appear to revert following therapy 
cessation and such therapies have been associated with an increased 
cardiovascular risk. Liver targeted anti-inflammatory therapies are currently under 
development though none are imminently expected.  
The management of obesity and its associated complications is a major 
healthcare challenge. In later life the presence of obesity results in a 2 to 3-fold 
increased mortality due to an increased incidence of cardio-metabolic and 
malignant disease (Adams, Schatzkin et al. 2006). The global epidemic of obesity 
is therefore predicted to have an exponential impact on the future health of society 
and hence health care services. This has resulted in nutrient intakes and dietary 
patterns being politicised, with responsibilities increasingly transferred from the 
individual to organisations and governments. Such bodies are ultimately keen to 
please the public whose opinions are commonly led by lay journalism and 
individuals such as Jamie Oliver. The public is also vulnerable to manipulated 
information originating from the food and pharmaceutical industries. Whilst much 
of the current efforts are to be praised it does increase the pressure on the 
scientific community to ensure that the driving forces for nutritional change are 
fully informed and valid.  
The message of ‘eat less, do more’ is rarely effective in terms of weight 
loss. Recently there has been an attempt to reduce energy intakes by branding 
whole foods as being either ‘good’ or ‘bad’ on the basis of their energy and 
macronutrient profile (Brand-Miller, McMillan-Price et al. 2008). This branding 
has been promoted by the food industry which has further developed the concept 
with the development of ‘nutraceuticals’. So a supermarket visit is rapidly being 
transformed into a visit to a scientific laboratory, with the experiment being your 
long-lasting health (van Kleef, van Trijp et al. 2005). It is implied that the only 
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limits to such health benefits are your culinary skills, wallet, taste buds and 
penchant for ‘bad foods’. The dangers of simplistic classifications of good versus 
bad foods are that it confuses the public and overtly vilifies certain foodstuffs. 
Denmark, for example, has recently imposed tax increases of 25% on ice cream, 
chocolate and sweets (Wilkins 2010). Whilst sweets lack any real nutritional value 
the same cannot be said for chocolate or ice cream. Although there are clear 
benefits behind the drive to highlight foods based on their individual nutrient and 
energy profiles, this misses the message that an overall balanced intake is more 
important than its individual constituents.  
To date there is a clear limitation in medical advice given to NAFLD 
patients – ‘eat less or do more’. The majority of patients are significantly 
overweight and hence already aware of their personal benefits of heeding such 
advice irrespective of the presence of liver disease. Critically the mechanisms to 
safely achieve this are unclear and long-term support limited within most 
healthcare systems. Until cirrhosis develops most are relatively asymptomatic, 
and so the diagnosis of NAFLD appears to result in little real motivation to 
change lifestyles. Recently there has been a suggestion that such an energy-
focused strategy should be promoted even in compensated overweight cirrhotics 
(Berzigotti, Garcia-Tsao et al. 2011). This was a post-hoc analysis of a 
prospectively collated cohort of cirrhotic patients with a variety of aetiologies. It 
observed a greater rate of decompensation in patients that were overweight or 
obese than normal weight, as assessed by body mass index. The authors 
speculated that weight loss may reduce the rate of decompensation. The safety of 
this apparently logical and simple conclusion needs to be first assessed before it 
becomes routine practice, as was highlighted in my communication with the 
journal (Johnston, Dolman et al. 2011). I raised concerns over the potentially 
detrimental effects of prolonged fasting or intense aerobic exercise in cirrhosis. 
Plank and colleagues demonstrated that total body protein status is greatly 
improved by nocturnal nutritional supplements than by use of energy-matched 
daytime supplementation in cirrhosis (Plank, Gane et al. 2008). Furthermore, very 
low calorie diets and carbohydrate restriction may pose unique risks in cirrhosis 
by inducing hepatic stressors, namely an increased demand for endogenous 
gluconeogenesis and increased requirement to catabolise ketone bodies. There are 
limited data on a cirrhotic liver’s ability to cope with such insults. Increasing 
exercise is ordinarily an attractive weight loss strategy but in cirrhosis there is 
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impaired endogenous gluconeogenesis and hence there is a potential risk of 
aerobic exercise induced hypoglycaemia (DeLissio, Goodyear et al. 1991). 
Nutrient manipulation has the potential to be a safer, more acceptable and 
complementary approach to weight loss in NAFLD, especially those with 
advanced disease. Such strategies are generally well tolerated and accepted, with 
individual changes having an additive effect on metabolic outcomes (Lewis, 
Hammett et al. 1981).  
My studies were designed to identify the impacts of altering intakes of 
specific nutrients in hepatic lipid metabolism. The issues were whether altering 
intakes of certain macronutrients promotes the development of NAFLD, or can 
treat established disease. These studies have a clear translation into public health 
messages. The studies detailed in this thesis assessed the effects of fructose, one 
of the most notorious nutrient ‘baddies’, and omega 3 fatty acids, a ‘goody’. 
Hence there has been a lot of interest and expectation in this work. The resultant 
messages are not as clear-cut and simple as pressure groups would like. The 
greater uric acid concentration with fructose supports the observation of its lack of 
pre triose metabolic control. It was however the post triose metabolism that was 
the key interest of this study, with the primary outcome being hepatic lipid 
content. There was no difference between fructose and glucose in this respect. It is 
clear that combined energy and monosaccharide overfeeding has a significant 
impact on hepatic metabolism, though the lack of alternative nutrient comparators 
(e.g. fat) means that these cannot be viewed as monosaccharide specific. 
Supplementing n-3 PUFAs reduced serum but not hepatic triglycerides and made 
no other impacts on metabolic status. So this provides no evidence for altering 
macronutrient, as opposed to energy, intakes.  
There has been much publicity both in scientific and lay press resulting in 
considerable anxiety surrounding the fructose content of a modern diet. Despite 
there being no evidence that outcomes from high fructose corn syrup differ from 
sucrose there are numerous campaigns to ban its use in the United States. There is 
scant robust data demonstrating that fructose and glucose result in differing 
clinical outcomes. This has recently been acknowledged by one of the leading 
fructose researchers, Luc Tappy, who stated that the only convincing difference is 
the greater serum triglycerides with fructose (Tappy, Le et al. 2010).  There is 
clear evidence however that overall sugar intakes are increasing and this has been 
associated with the development of obesity (Johnson, Segal et al. 2007). So efforts 
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should be addressed at reducing intakes of all sugars as opposed to an individual 
component. The specific demonisation of fructose appears to be largely 
unjustified and hence unhelpful from a public health perspective. 
The background data implicating a high intake of fructose with NAFLD 
aetiology is derived from some circumspect observations. Firstly, NAFLD 
patients have occasionally been shown to have a higher fructose intake than 
controls (Ouyang, Cirillo et al. 2008). This may not be a fructose-specific effect 
however as there is a strong association between the fructose and glucose content 
of foodstuffs. Secondly, clinical studies have reported features associated with 
NAFLD such as insulin resistance and dyslipidaemia developing with a high 
fructose intake. There are several uncontrolled studies reporting this (Faeh, 
Minehira et al. 2005; Le, Ith et al. 2009), and only one controlled study that 
supports this (Stanhope, Schwarz et al. 2009).  
Prior to the initiation of this thesis there were no controlled studies that 
compared the hepatic outcomes of fructose versus glucose overfeeding. Two 
recent papers, both with significant limitations, have reported a similar finding to 
this study, with no hepatic differences between glucose and fructose short term 
overfeeding in terms of liver lipid content or biochemistry (Ngo Sock, Le et al. 
2010; Silbernagel, Machann et al. 2011). This current study adds to these similar 
outcomes in terms of triglyceride in the serum, liver or muscle; systemic, adipose 
and hepatic insulin resistance; hepatic volume and 31P metabolites; whole body 
substrate oxidation; and cardiovascular profile.  
State of the art assessment tools were used to form a full metabolic profile 
or picture in this thesis. It was the first to study hepatic outcomes in healthy yet 
overweight individuals. The cohort was precisely defined using standard clinical 
assessments, making it easier for others to reproduce the findings. The next key 
strength was that it assessed the outcomes in both an isoenergetic and 
hyperenergetic setting. The provision of all foodstuffs during the isoenergetic 
period ensured complete control over nutrient intakes and hence improves the 
robustness of those findings. Weight maintenance was achieved and so a high 
fructose or glucose intake was achieved without a concurrently high energy 
intake. No prior hyperinsulinaemic euglycaemic clamp data has been published in 
this area (the gold standard for assessing insulin resistance). This was the first 
long-term hepatic 31P assessment study, and the first long-term study on 
cardiovascular health using any assessment greater than a sphygmomanometer.  
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The major limitations of this fructose versus glucose study are that it was 
only performed in men, and that there was no cross-over between the groups. This 
limits the generalisability of the findings and the analyses of the inter-
monosaccharide outcome response. The relatively short-term nature of the 
intervention means that the possibility of an effect with a longer dietary alteration 
cannot be excluded. There was an explicit power calculation made for the primary 
outcome measure, but none for the numerous secondary outcomes assessed. As a 
result many of these potentially could be affected by a type 2 error, and over 
interpretation of the data as a whole could be an error. Such over interpretation is 
more of an issue for false positive than negative findings, and there are few 
positive differences between the groups in the fructose versus glucose study. This 
is a challenging area of study design. Hepatic lipid metabolism does not occur in 
isolation from the global metabolic status. Hence the assessment and presentation 
of the primary outcome, liver triglyceride, would be relatively meaningless 
without data on weight, substrate oxidation, liver biochemistry, serum 
triglycerides, and insulin resistance as an absolute minimum. I believe that the 
additional parameters paint a fuller picture, including explanatory data and 
assessment for potential confounders, and are not merely a ‘fishing exercise’ as 
critics may suggest. This is therefore both an interventional study and an 
assessment of mechanisms. Ideally each parameter should be individually 
powered for though this process is not feasible or indeed reliable itself. 
Fructose and glucose are not normally consumed in vastly differing 
amounts, and so the study did not reproduce potential natural intake patterns from 
whole foods. The addition of a group consuming sucrose would have aided 
interpretation of the data from that of inter-nutrient assessments to a nutrient 
versus whole food assessment. Indeed there is some suggestion that fructose 
behaves metabolically differently when bound to glucose in sucrose, though this 
has been rarely shown and the explanation for this is uncertain (Bizeau and 
Pagliassotti 2005). Equally, the addition of an energy balanced high lipid or 
protein group would have facilitated macronutrient comparisons. These 
assessments need to be performed in future studies. 
In NAFLD patients a low energy diet (~1300kcal/day), with standard 
macronutrient patterns, has recently been shown to reduce hepatic triglyceride to a 
lesser extent than a low carbohydrate diet (~25g/day) (Browning, Baker et al. 
2011). The main problem with this study is that not all foods were provided and 
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hence energy was not explicitly controlled for between the groups. Of note the 
two groups lost similar amounts of weight and only differed in their HTGC 
reduction.  
The lack of hepatic differences between fructose and glucose means that 
future work should focus on the hepatic effects of high or low intakes of 
carbohydrates versus other macronutrients in a rigorously energy controlled 
setting. No such work has been previously done.  
Just as there are pressures to reduce fructose intakes, there are equal 
pressures to increase the population’s n-3 PUFA intakes which are currently 
markedly lower than recommended guidelines. The ideal mechanism to achieve 
such changes in intake remains uncertain (Givens and Gibbs 2008). Oily fish and 
capsules could be promoted, but such advice is unlikely to be heeded by those 
who would most benefit, and there are limited fish stocks globally. Whole 
foodstuff enrichment with n-3 PUFAs is possible but fraught by losses due to fatty 
acid oxidation during food storage and preparation (Taneja and Singh 2011). This 
is of interest not only to the food industry but also the pharmaceutical industry 
who promote the health benefits of n-3 PUFAs even when robust evidence is still 
lacking. A recent article in Nature Medicine quoted a scientist as stating of n-3 
PUFAs and heart disease that “there are clearly benefits. It’s a matter of isolating 
exactly what (the benefits) are, and we haven’t managed to do that yet” (Hersher 
2012). This opinion contrasts with several recent meta-analyses showing no 
benefits with n-3 PUFAs in high risk cardiovascular patients in terms of mortality, 
sudden cardiac death or cardiovascular re-stenosis (Filion, El Khoury et al. 2010; 
Chen, Cheng et al. 2011).  Both of these meta-analyses assessed randomised data 
on over 30,000 patients. The dwindling scientific support for n-3 PUFA 
supplementation is in stark contrast to their ever increasing consumption by the 
public (Hersher 2012). 
The background data linking n-3 PUFA status and NAFLD comes from 
dietary assessments and analyses of lipid profiles in NAFLD liver biopsy tissue. 
These describe a depletion of the long chain n-3 PUFAs (Araya, Rodrigo et al. 
2004; Puri, Baillie et al. 2007; Allard, Aghdassi et al. 2008). However the story is 
not as simple as that as these analyses have also shown a reduction in arachidonic 
acid. This relative depletion of both n-6 and n-3 PUFAs may come from NAFLD 
associated alterations in diet, fatty acid synthesis from precursor, complex lipid 
metabolism resulting in either less cellular incorporation or greater release, be the 
 230  
result of systemic or local inflammation, or alterations in lipid peroxidation driven 
by oxidative stress. Whatever the mechanism the potential for hepatic benefit with 
n- 38)$ VXSSOHPHQWDWLRQ LV JLYHQ ELRORJLFDO SODXVLELOLW\ E\ WKHLU 33$5Į DQG
PPARJ agonism (Gonzalez-Periz, Horrillo et al. 2009). Rodent and non-
randomised clinical studies with limited assessment techniques have suggested 
that supplementation with n-3 PUFAs is beneficial in NAFLD in terms of hepatic 
triglyceride reduction (Capanni, Calella et al. 2006; Gonzalez-Periz, Horrillo et al. 
2009).  
The study described in this thesis did not demonstrate such a beneficial 
effect of n-3 PUFA supplementation in patients with NAFLD.  There was a trend 
for a reduction in hepatic triglycerides with n-3 PUFAs, and so the study may be 
criticised for being underpowered in terms of the number of patients or that the 
duration of supplementation was inadequate. At present one can neither prove nor 
refute this argument. There was a significant increase in serum n-3 PUFA fatty 
acid content and a reduction in serum triglycerides implying that the supplements 
were altering lipid metabolism. The tendency for weight to increase and insulin 
resistance to develop in this study may have negated any potential benefits.  
  The n-3 PUFA study recruited a rigorously defined cohort who all had 
histological evidence of NAFLD. Secondly, hepatic triglyceride content was 
quantified using 3-Tesla 1H MR spectroscopy as opposed to ultrasound – a 
markedly more sensitive tool. Thirdly, double blind randomisation was performed 
with a valid placebo. Assessments of serum and hepatic fatty acid profiles along 
with fasted assessments of insulin resistance aided outcome interpretation. 
  There are many current studies registered that aim to assess the effects of 
n-3 PUFA supplementation. A full picture of the role of n-3 PUFAs in NAFLD 
will therefore shortly be available.  
Ultimately the exquisite sensitivity of the liver to nutrient intakes was 
highlighted by the 0.8% gain in weight in the fructose / glucose study resulting in 
a 24% increase in liver lipid. This affirms the notion that dietary energy intakes 
have a profound influence on hepatic metabolism, but there is no evidence from 
this thesis that this influence is macronutrient specific.  
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